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Abstract
Rationale for the Thesis
One o f the most important steps in the design o f a clinical trial is the estimation o f the 
sample size. For example for a superiority trial, where the data are expected to take a 
Normal form, the sample size (to achieve a stated power) would be based on a given 
clinically meaningful difference and an estimate o f the population variance. This 
estimate o f the population variance is traditionally based on the assumption o f a known 
sampling variance when in reality this is unknown and has to be estimated. The variance 
estimate would be derived from an earlier similarly designed study (or a combination 
from several previous studies) and its precision would depend on its degrees o f 
freedom. There is a need therefore for methods to be developed to deal with the 
problem of estimating sample size with imprecisely estimated variances.
Outcome of the Thesis
This thesis provides solutions for the calculation of sample sizes that allow for the 
imprecision o f the estimates used in the calculations. It also shows how the traditional 
formulae give sample sizes that are too small.
The solutions given are for the calculation o f sample sizes for different types o f trial 
(superiority, non-inferiority, equivalence, bioequivalence and trials for a given 
precision) and different forms of data (Normal, binary and ordinal).
For Normal data a solution that uses the non-central t-distribution is given, while for 
binary and ordinal data numerical methods are proposed. For non-inferiority and 
equivalence trials with a binary outcome it is demonstrated that simple Bayesian 
methods add value to calculations.
Conclusions
Standard sample size calculations are shown to have limitations. The main limitation 
being that no account is made o f the imprecision o f the estimates used in the 
calculations. Methods are described in this dissertation that account for these 
limitations.
It is hoped the results would be useful to any researcher calculating a sample size for a 
prospective clinical study.
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1. CHAPTER 1 -  INTRODUCTION
This chapter describes the background o f randomised controlled clinical trials and the 
main factors that should be considered in their design. The description o f the issues 
associated with clinical trial design will made in the context of a regulated 
pharmaceutical setting. The different types o f clinical trial, for different objectives, will 
then be described in detail. It will be highlighted how these different objectives impact 
on study design with respect to derivation o f formulae for sample size calculations.
The chapter will then describe, through a real example, the limitation of conventional 
sample size calculations and how these limitations may be assessed a priori when 
designing a trial. Finally, the chapter will describe the motivation for the PhD.
1.1. Background to Randomised Controlled Trials
Since the first ‘modem’ randomised clinical trial was reported [Medical Research 
Council, 1948], clinical trials have become a central component in the assessment of 
new therapies. They have contributed to improvements in healthcare as measured by an 
increase in life expectancy by an average o f three to seven years and relief o f poor 
quality o f life related to chronic disease by an average o f five years [Chalmers, 1998; 
Bunker, Frazier and Mosteller, 1994].
The primary objective o f any clinical trial is to obtain an unbiased and reliable 
assessment o f a given regimen response independent of any known or unknown 
prognostic factors i.e. they ensure that there is no systematic difference between 
treatments. Clinical trials are therefore designed to meet this primary objective [Julious 
and Zariffa, 2002]. They do this first by ensuring, as near as possible, that the patients 
studied in the various regimen arms are objectively similar with reference to all 
predetermined relevant factors other than the regimens themselves (e.g. in terms o f 
disease severity, demography, study procedures etc). Second, by making sure that the 
assessment of the regimen response is independent o f a given subject’s regimen and 
finally through inclusion o f an appropriate control to quantify a given regimen response. 
To ensure the primary objective is met Julious and Zariffa [2002] described how the 
essential principles o f clinical trial design can be summarised in terms o f the ABC of 
‘Allocation’ at random, ‘Blinding’ and ‘Control’ group with these principals holding 
regardless o f the type trial.
1.2. Types of Clinical Trial
When planning a trial one essential step is the calculation o f a sample size as studies 
that are either too small or too large may be judged unethical [Altman, 1980]. For 
example, a study that is too large could have met the objectives of the trial before the 
actual study end had been reached, and so some patients may have unnecessarily 
entered the trial. A trial that is too small will have little chance of meeting the study 
objectives, and patients may be put through the potential trauma of a trial for no
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tangible benefit. This chapter, based on the work o f Julious [2004a], will now discuss 
in detail the computation of sample sizes appropriate for:
1. Superiority trials.
2. Equivalence trials.
3. Non-inferiority trials.
4. As good as or better trials.
5. Bio-equivalence trials.
6 . Trials to a given precision.
A distinction therefore is drawn to emphasise differences in trials designed to 
demonstrate ‘superiority’ and trials designed to demonstrate ‘equivalence’ or ‘non­
inferiority’. This is discussed with an emphasis on how differences in the null 
hypothesis can impact on calculations. The ICH guidelines ICH E3 [1996] and ICH E9 
[1998] provide general guidance on selecting the sample size for a clinical trial. The 
ICH E9 [1998] guideline states that:
“The number o f subjects in a clinical trial should always be large enough to provide a 
reliable answer to the questions addressed. This number is usually determined by the 
primary objective o f the trial ....The method by which the sample size is calculated 
should be given in the protocol together with any quantities used in the calculations 
(such as variances, mean values, response rates, event rates, differences to be 
detected).”
This thesis is primarily written on the premise that just two treatments are to be 
compared in the clinical trial and two study designs will be discussed: parallel group 
and cross-over designs.
With a parallel group design subjects are assigned at random to the two treatments to 
form two treatment groups. It is hoped at the end of the trial that the two groups are the 
same in all respects other than the treatment received so that an unbiased assessment of 
treatment affect can be made.
With a cross-over trial all subjects receive both the treatments but it is the order that 
subjects receive the treatments which is randomised. The big assumption here is that 
prior to starting the second treatment all subjects return to baseline and that the order 
which subjects receive treatment does not affect their response to treatment. Cross-over 
trials cannot be used therefore in degenerative conditions, where subjects get worse over 
time. Also, they are more sensitive to bias than parallel group designs [Julious and 
Zariffa, 2002].
The assumption in the dissertation is that there is just one primary outcome to be 
compared and that there are not multiple endpoints. Koch and Ganksy [1996] give an
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overview on the topic of multiple endpoints whilst the CPMP [2002] have issued 
guidelines.
1.3. A ssessing Evidence from  Trials
Since it is rarely possible to collect information on an entire population, the aim o f 
clinical trials (in the context of the dissertation) is to use information from a sample to 
draw conclusions (or make inferences) about the population o f interest. This inference is 
facilitated through making assumptions about the underlying distribution o f the 
measurement such that an appropriate theoretical model can be applied to describe how 
the measurement in the population as a whole from the sample.
Note it is usual a priori to any analysis to make an assumption as to the underlying 
distribution of your measure. These assumptions are then to be investigated through 
various plots and figures for the observed data.
In the context o f this dissertation the population is a theoretical concept used for 
describing an entire group. One way o f describing the distribution o f a measurement in 
a population is by use of a suitable theoretical probability distribution.
1.3.1. The Normal Distribution
The Normal, or Gaussian distribution (named in honour o f C.F.Gauss, 1777-1855, 
German mathematician) is the most important theoretical probability distribution.
The distribution curve of data which are Normally distributed has a characteristic shape; 
it is bell-shaped, and symmetrical about a single peak (Figure 1.1). The Normal 
distribution is described completely by two parameters, the mean (p) and the standard 
deviation (o). This means that for any Normally distributed variable, once the mean and 
variance (cr)  are known (or estimated), it is possible to calculate the probability 
distribution for that population.
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Figure 1-1. The Normal distribution
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1.3.2. The Central Limit Theorem
The central limit theorem (or the law of large numbers) states that given any series o f 
independent, identically distributed random variables, their means will tend to a Normal 
distribution as the number of variables increases. Put another way, the distribution o f 
sample means drawn from a population will be Normally distributed whatever the 
distribution of the actual data in the population as long as the samples are large enough.
Each mean estimated from a sample is an unbiased estimate o f the true population mean 
and using the Central Limit Theorem one can infer 95% of sample means will lie within 
1.96 standard deviations of the population mean. As we do not usually know the 
population mean the more important inference is that with the sample mean we are 95% 
confident that the population mean will fall within 1.96 standard deviations o f the 
sample mean.
The Normal distribution and the Central Limit Theorem are important as they underpin 
much of the subsequent statistical theory outlined both in this and subsequent chapters. 
This is because although only Chapter 2 discusses calculations for clinical trials where 
the primary outcome is anticipated to take a Normal form, approximation to the Normal 
distribution (and what to do when Normal approximation is inappropriate) is important 
to subsequent chapters on Binary (Chapters 3 and 4) and Ordinal (Chapter 5) data.
To illustrate the Central Limit Theorem, consider the random numbers 0 to 9. The 
distribution of these numbers in a random numbers table would be uniform. That is to 
say that each number has an equal probability o f being selected and the shape o f the 
probability density function of theoretical distribution is represented by a rectangle. 
According to the Central Limit Theorem, if  you were to select repeated random samples 
o f the same size from this distribution, and then calculate the means o f these different 
samples, the distribution of the means would be approximately Normal and this 
approximation would improve as the size of each sample increased. Figure 1.2a 
represents the distribution of the sample means for 500 simulated samples o f size 5.
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Even with such a small sample size the approximation to the Normal is remarkable, 
whilst repeating the experiment with samples o f size 50, improves the fit to the Normal 
distribution (Figure 1.2b).
Figure 1-2. Distribution of means from 500 samples
a: Samples of size 5, mean=4.64, sd=1.29 b: Samples o f size 50, mean=4.50, sd=0.41
7.02.0 3.0 4.0 5.0 6.0 8.0 3.0 4.0 5.0 7.0 8.06.01.0 2.0
In reality, as one usually only take a single sample, we can use the Central Limit 
Theorem to construct an interval within which we are reasonably confident the true 
population mean will be included i.e. through calculation of a confidence interval.
Application of the Central Limit Theorem is frequently made, even when non- 
parametric approaches are being undertaken. It is not unknown when bootstrapping (to 
calculate confidence interval) for the bootstrap distribution of the mean to take a 
Normal form. This is because for all practical purposes one is repeating the exercise 
described for Figure 1.2.
1.3.3. Frequentist Approaches
The descriptions o f the issues associated with clinical trial design in this dissertation are 
made in the context of a regulated pharmaceutical setting. In this context trials are 
assessed through a priori declaring a null hypothesis, depending on the objective of the 
trial, and then formally testing this null hypothesis through the empirical trial data.
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/ .3.3.1. Hypothesis testing and Estimation
Consider the hypothetical example o f a study designed to examine the effectiveness of 
two treatments for migraine. In the study patients are randomly allocated to two groups 
corresponding to either treatment A or treatment B. It may be that the primary objective 
o f the trial is to investigate whether there is a difference between the two groups with 
respect to migraine outcome; in this case we could carry out a significance test and 
calculate a P-value (hypothesis testing). Alternatively it may be that the primary 
objective is to quantifying the difference between treatments together with a 
corresponding range of plausible values for the difference; in this case we would 
calculate the difference in migraine response for the two treatments and the associated 
confidence interval for this difference (estimation).
1.3.3.2. Hypothesis Testing
Figure 1.3 describes the steps in the process o f hypothesis testing. At the outset it is 
important to have a clear research question and know what the outcome variable to be 
compared is. Once the research question has been stated, the null and alternative 
hypotheses can be formulated. The null hypothesis (H0) usually assumes that there is no 
difference in the outcome of interest between the study groups. The study or alternative 
hypothesis (Hi) usually states that there is a difference between the study groups.
Figure 1-3. Hypothesis testing: the main steps
Make a decision
Set null hypothesis
Obtain test statistic
Carry out significance test
Set study (alternative) hypothesis
Compare test statistic to 
hypothesized critical value
In lay terms the null hypothesis is what one is investigating whilst the alternative is 
what one wishes to show. Later in the chapter there will be a discussion o f the main
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types of trial objectives and their hypotheses. For example, for a superiority trial when 
comparing a new migraine therapy against control what one is investigating is whether 
there is no difference between treatments. One therefore wishes to show is that this null 
hypothesis is false and demonstrate that there is a difference at a given level o f 
significance.
In general, the direction of the difference (for example: that treatment A is better than 
treatment B) is not specified, and this is known as a two sided (or two tailed) test. By 
specifying no direction one investigates both the possibility that A is better than B and 
the possibility that B is better than A. If a direction is specified this is referred to as a 
one sided test (one tailed) and one would be evaluating only whether A is better then B 
as possibility o f B being better than A is o f no interest. There will be further discussion 
o f one tailed and two tailed tests when describing the different types of trial later in the 
chapter.
A common misunderstanding about the null and alternative hypotheses, is that when 
carrying out a statistical test, it is the alternative hypothesis (that there is a difference) 
that is being tested. This is not the case -  what is being examined is the null hypothesis, 
that there is no difference between the study groups; one conducts a hypothesis test in 
order to establish how likely (in terms of probability) it is that we have obtained the 
results that we have obtained, if  there truly is no difference in the population.
For the migraine trial, the research question o f interest is:
‘For patients with chronic migraines which treatment fo r  migraine is the most 
effective?’
There may be several outcomes for this study, such as the frequency o f migraine 
attacks, the duration of individual attacks or the total duration o f attacks. Assuming one 
is interested in reducing the frequency o f attacks, then the null hypothesis, H0, for this 
research question is:
‘ There is no difference in the frequency o f  attacks between treatment A and 
treatment B groups ’
and the alternative hypothesis, Hi, is:
‘ There is a difference in the frequency o f  attacks between the two treatment 
groups'.
Having set the null and alternative hypotheses the next stage is to carry out a 
significance test. This is done by first calculating a test statistic using the study data. 
This test statistic is then compared to a theoretical value under the null hypothesis in 
order to obtain a P-value. The final and most crucial stage of hypothesis testing is to 
make a decision, based upon the P-value. In order to do this it is necessary to 
understand first what a P-value is and what it is not, and then understand how to use it 
to make a decision about whether to reject or not reject the null hypothesis.
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So what does a P-value mean? A P-value is the probability o f obtaining the study results 
(or results more extreme) if the null hypothesis is true. Common misinterpretations of 
the P-value are that it is either the probability o f the data having arisen by chance or the 
probability that the observed effect is not a real one. The distinction between these 
incorrect definitions and the true definition is the absence o f the phrase when the null 
hypothesis is true. The omission o f ‘when the null hypothesis is true’ leads to the 
incorrect belief that it is possible to evaluate the probability o f the observed effect being 
a real one. The observed effect in the sample is genuine, but what is true in the 
population is not known. All that can be known with a P-value is, if there truly is no 
difference in the population, how likely is the result obtained (from the sample). Thus a 
small P-value indicates that difference we have obtained is unlikely if  there genuinely 
was no difference in the population -  it gives the probability o f obtaining the study 
results (or results more extreme) (difference between the two study samples) if  there 
actually is no difference in the population.
In practice, what happens in a trial is that the null hypothesis that two treatments are the 
same is stated i.e. A=B or A-B=0. The trial is then conducted and a particular 
difference d is observed where A-B=d. Due to pure randomness even if the two 
treatments are the same you would seldom observe A-B=0. Now if d is small (say a 1% 
difference in the frequency of attacks) then the probability of seeing this difference 
under the null hypothesis is very high say P=0.995. If a larger difference is observed 
then the probability of seeing this difference by chance is reduced, say d=0.05 then the 
P-value could be P=0.562. As the difference increases therefore so the P-value falls 
such that a d=0.20 may equate to a P=0.021. This relationship is very simply (i.e as 
linearly) illustrated in Figure 1.4 as d increases then the P-value (under the null 
hypothesis) fall.
Figure 1-4. Illustration of the relationship between the observed difference and the 
P-value under the null hypothesis
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It is important to remember that a P-value is a probability and its value can vary 
between 0 and 1. A ‘small’ P-value, say close to zero, indicates that the results obtained 
are unlikely when the null hypothesis is true and the null hypothesis is rejected. 
Alternatively, if the P-value is ‘large’, then the results obtained are likely when the null 
hypothesis is true and the null hypothesis is not rejected. But how small is small? 
Conventionally the cut-off value or two sided significance level for declaring that a 
particular result is statistically significant is set at 0.05 (or 5%). Thus if the P-value is 
less than this value the null hypothesis (of no difference) is rejected and the result is 
said to be statistically significant at the 5% or 0.05 level (Table 1.1). For the example 
above, if  the P value associated with the mean difference in the number o f attacks was
0.01, as this is less than the cut-off value o f 0.05 one would say that there was a 
statistically significant difference in the number o f attacks between the two groups at 
the 5% level.
Table 1-1. Statistical Significance
One say that our results are 
statistically significant if 
the P-value is less than the 
significance level (a), 
usually set at 5%
P < 0.05 P^).05
Result is Statistically significant Not statistically 
significant
Decide That there is sufficient 
evidence to reject the null 
hypothesis and accept the 
alternative hypothesis
That there is insufficient 
evidence to reject the
~  l
One cannot say that the 
null hypothesis is true, 
only that there is not 
enough evidence to 
reject it
The choice o f 5% is somewhat arbitrary and though it is commonly used as a standard 
level for statistical significance its use is not universal. Even where it is, one study that 
is statistically significant at the 5% level is not usually enough to change practice; 
replication is required. For example to get a regulatory license for a new drug usually 
two statistically significant studies are required at the 5% level which equates to a single 
study at the 0.00125 significance level. It is for this reason that larger ‘super’ studies are 
conducted to get significance levels that would change practice i.e. a lot less than 5%.
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Where the setting o f a level of statistical significance at 5% comes from is not really 
known. Much o f what one refers to as statistical inference is based on the work o f R. A. 
Fisher (1890-1962) who first used 5% as a level o f statistical significance acceptable to 
reject the null hypothesis. One theory is that 5% was used because Fisher published 
some statistical tables with different levels o f statistical significance and 5% was the 
middle column (another is that 5 is the number o f toes on Fisher’s foot which maybe is 
just as plausible).
An exercise to do, with students say, in order to demonstrate empirically that 5% is a 
reasonable level for statistical significance is to toss a coin and tell the students whether 
a head or a tails has been observed. But keep saying heads. After around 6 tosses one 
asks the students when they stopped believing we were telling the truth. Usually about 
half would say after 4 tosses and half after 5. The probability of getting 4 heads in a row 
is 0.063 and the probability of getting five heads in a row is 0.031; hence 5% is a figure 
about which most people would intuitively start to disbelieve an hypothesis!
The significance level o f 5% has to a degree become a tablet o f stone. To such a degree 
that it is not unknown for P-values to be presented as P=0.04999999 as P must be less 
than 0.05 to be significant and written to 2 decimal places P=0.05 is considered to 
present far less evidence for rejection of the null hypothesis than P=0.04999999.
Though the decision to reject or not reject the null hypothesis may seem clear cut, it is 
possible that a mistake may be made, as can be seen from the shaded cells o f Table 1.2. 
For example a 5% significance level means that we would only expect to see the 
observed difference (or one greater) 5% of the time under the null hypothesis. 
Alternatively one can rephrase this to state that even if the two treatments are the same 
5% of the time we will conclude that they are not and we will make a Type I error. 
Therefore, whatever is decided, this decision may correctly reflect what is true in the 
population: the null hypothesis is rejected, when it is fact false or the null hypothesis is 
not rejected, when in fact it is true. Alternatively, it may not reflect what is true in the 
population: the null hypothesis may be rejected, when it is fact true which would lead us 
to a false positive and making a Type I error, (a); or the null hypothesis may not be 
rejected, when in fact it is false. This would lead to a false negative, and making a Type 
II error, (0). Acceptable levels of the Type I and Type II error rates are set before the 
study is conducted. As mentioned above the usual level for declaring a result to be 
statistically significant is set at a two sided level o f 0.05 prior to an analysis i.e. the type 
I error rate (a) is set at 0.05 or 5%. In doing this we are stating that the maximum 
acceptable probability of rejecting the null when it is in fact true (committing a type 1 
error, a  error rate) is 0.05. The P-value that is then obtained from our analysis o f the 
data gives us the probability of committing a Type I error (making a false positive 
error).
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Table 1-2. : Making a decision
The null hypothesis is actually:
Decide to: False True
Reject the null hypothesis Correct Type 1 Error (a) *
The P value. This is the 
probability o f  
concluding that there is 
a difference, when in 
fact there is no 
difference, i.e. the 
probability o f  making a 
false positive m istake
Not reject the null hypothesis Type 2 Error (0) Correct
This represents a well powered study o 
that is able to detect a difference when 
there truly is a difference
The probability that a study will be able to detect a difference, of a given size, if  one 
truly exists is called the Power of the study and is the probability o f rejecting the null 
hypothesis when it is actually false (probability of making a Type II error, (3). It is 
usually expressed in percentages, so for a study which has 90% power, there is a 
probability of 0.9 of being able to detect a difference, o f a given size, if  there genuinely 
is a difference in the population. An underpowered study is one which lacks the ability, 
i.e. has very low power, to detect a difference when there truly is a difference. The 
concepts of power and Type I and II errors will be dealt with further in a later in this 
chapter and throughout the dissertation as these are important components o f sample 
size calculation.
1.3.3.3. Estimation
Statistical significance does not necessarily mean the result obtained is clinically 
significant or o f any practical importance. A P-value will only indicate how likely the 
results obtained are when the null hypothesis is true. It can only be used to decide 
whether the results are statistically significant or not, it does not give any information 
about the likely size of the clinical difference. Much more information, such as whether 
the result is likely to be of clinical importance can be gained by calculating a confidence 
interval. Although earlier in the chapter discussion about the 95% confidence interval 
was in the context o f the mean, it is possible to calculate a confidence interval for any 
estimated quantity (from the sample data), such as the mean, median, proportion, or 
even a difference. It is a measure of the precision (accuracy) with which the quantity of 
interest is estimated (in the case of the migraine trial, the quantity o f interest is the mean 
difference in the number of migraine attacks).
Technically, the 95% confidence interval is the range of values within which the true 
population quantity would fall 95% of the time if the study were to be repeated many 
times. Crudely speaking, the confidence interval gives a range of plausible values for 
the quantity estimated; although not strictly correct it is usually interpreted as the range 
o f values within which there is 95% certainty that the true value in the population lies.
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For the migraine example the mean difference in the number of attacks between the 
groups, was 3 attacks per month with 95% confidence interval for this difference o f 1.2 
to 4.8 attacks per month. Thus, whilst the best available estimate of the mean difference 
was 3 attacks per month, it could be as low as 1.2 or as high as 4.8 attacks per month, 
with 95% certainty. As the confidence interval excludes 0 one can infer from the 
observed trial that it is unlikely that there is no difference between treatments. In fact as 
one has calculated a 95% confidence interval one can deduce that the statistical 
significance is less than 5%. The actual P-value associated with this difference was
0.01 and given that it is less than 5% one can conclude that the difference is statistically 
significant at the 5% level.
As confidence intervals are so informative and from them one can infer statistical 
significance as well as quantify plausible values for the population effect there is a 
growing consensus that only confidence intervals should be reported for studies. In this 
chapter also precision based trials are described where the design and analysis are based 
around confidence intervals. However, it is unlikely that P-values will ever be 
eliminated as a way to quantify differences.
1.3.3.4. Statistical and Clinical Significance
Discussion so far dealt with hypothesis testing and estimation. However, in addition to 
statistical significance, it is useful to consider the concept of clinical significance. 
Whilst a result may be statistically significant, it may not be clinically significant 
(relevant/important) and conversely an estimated difference that is clinically important 
may not be statistically significant. For example consider a large study comparing two 
treatments for high blood pressure; the results suggest that there is a statistically 
significant difference (P=0.023) in the amount by which blood pressure is lowered. 
This P-value relates to a difference o f 3mmHg between the two treatments. Whilst the 
difference is statistically significant, it could be argued that a difference o f 3mmHg is 
not clinically important. This is supported but the 95% confidence interval o f 0.5 to 
4.5mmHg. Hence, although there is a statistically significant difference this difference 
may not be sufficiently large enough to convince anyone that there is a truly important 
clinical difference.
This is not simply a trivial point. Often P-values alone are quoted and inferences about 
differences between groups are made based on this one statistic. Statistically significant 
P-values may be masking differences that have little clinical importance. Conversely it 
may be possible to have a P-value greater than the magic 5% but for there to be a 
genuine difference between groups: absence of evidence does not equate to evidence o f 
absence.
The issue of clinical significance is particular important for non-inferiority and 
equivalence trials, discussed later in the chapter, where margins are set which 
confidence intervals must preclude. P-values are seldom quoted. These margins are 
interpreted in terms of clinically meaningful differences.
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1.3.4. Bayesian Approaches
The discussion to date has been in the context of frequentist based trials where a null 
hypothesis is set up front; an experiment is conducted and based on the strength o f the 
evidence observed the null hypothesis is ‘accepted’ or ‘rejected’. The decision as to 
whether accept or reject is based on the P-value and the confidence intervals. This 
frequentist approach is the basis o f all pharmaceutical regulatory trials which are the 
motivation for this dissertation.
The frequentist approach in some ways is somewhat naive however. Prior to the start o f 
the pivotal (basis for license) phase III program more than 50 trials may have been 
initiated or completed and yet this additional work is not included in the interpretation 
of the final trial(s).
In simple terms Bayesian approaches do account for this additional work (or beliefs) by 
setting priors before the start of a study. Once the trial has been completed the observed 
data are combined with the priors to form a posterior distribution for the treatment 
response. From this posterior distribution (95%) credibility intervals can then be 
calculated for the true value. This credibility interval provides a range in which there is 
a 95% chance the true value will lie.
First time into man studies are good examples to illustrate the utility o f Bayesian 
methods. Table 1.3 gives the scheduled doses for an escalating dose first time into man 
study across 5 cohorts.
Table 1-3. Schedule doses in a hypothetical first time into man study
Cohort Scheduled Doses
1 Placebo, lmg, 2mg or 5mg
2 Placebo, 1 Omg, 20mg or 40mg
3 Placebo, 80mg, 150mg or 300mg
4 Placebo, 500mg, 750mg or l,500mg
5 Placebo, 2,500mg, 5,000mg or 7,500mg
If a person naive to drug development was asked to select a cohort to enter the study 
they’d probably choose cohort 1. When pushed they’d likely say because these are the 
lowest (and hence safest) doses. Someone familiar with drug development would 
choose cohort 4 or even cohort 5. When asked they’d say because the safety 
information from the other cohorts for what is a completely new chemical entity in man 
would have been received from the other cohorts by then, so with this prior knowledge 
a later cohort would be best. This same argument would be the retort for cohort 1 
naively having the lowest doses as it is not known for certain a priori that these doses 
are the lowest as these are merely predictions. As the methodology that does these 
predictions, allometric scaling, is little more complex than what could be managed by a
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9 year old with a ruler, it is not unknown for the first cohort to start with the maximum 
dose with subsequent cohort doses adjusted in light of this observed data.
Note in the context of drug development “first time into man” is not a sexist 
nomenclature as usually new chemical entities do use healthy males in the very early 
studies (except for treatments, such as hormone therapies, to be solely for women). The 
reason for this is that these studies will usually start up to a year before reproductive 
toxicity data becomes available to allow the entry o f fertile female volunteers. In fact it 
could be argued there is an evolutionary order to drug development as rats are the tox 
species for men and men are the tox species for women.
Figure 1-5. Posterior densities for log AUC at 60mg for an untested subjected
Prior to start After 2mg
After 25mg After 50mg
The intuitive application of Bayesian methods is highlighted in Figure 1.5 taken from 
Whitehead, Zhou, Patterson et al [2001], This figure gives the posterior distribution for 
60mg in a dosing cohort prior to any doses being given; and after 2mg, after 25mg and 
after 50mg. The prior information for the initial posterior is obtained initially from pre- 
clinical or other sources. As data comes in new posterior densities are derived, taken as 
a weighted sum of the prior and observed data. A consequence is the more the data one 
has the better the estimates -  as evidenced by the narrowing of the posterior 
distribution. Figure 1.6 gives an illustration of the procedure. The Bayesian methods in 
this context are therefore quantifying how intuitively first time into man studies are 
applied.
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Bayesian methods in the context of assessing toxicity in early oncology trials are 
routinely applied [O’Quigley, Pepe and Fisher, 1990; O ’Quigley and Shen, 1996].
Figure 1-6. Assigning subjects to dose
subjects randomise 
Jo dose or placebo
)ose selected using 
prior information
pdate the dose dat 
on subjects
Predict the dose 
response
Make decision
Stop Continue
A further example of the application of simple Bayesian methods in clinical 
development is given in Chapter 6 where Bayesian methods are applied in designing 
clinical development plans [Julious and Swank, 2005].
A final example is given Table 1.4 where Bayesian methods were applied to frame a 
go/no go decision [Owen, 2002]. Here the decision was in terms o f the probability o f 
achieving the safety profile based on Phase II data in Phase III. The table was used as 
an illustration o f the number of adverse events one could see on active over those on 
placebo to achieve this profile.
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Table 1-4. Maximum number of adverse events observed on active to ensure with 
90% certainty that the difference from placebo is less than 5%
Active Sample Size
Given Number o f Adverse Events on Placebo (n=200)
0 1 2 3 4 5 6 7 9
200 5 6 7 8 8 9 10 10 11
150 3 4 4 5 5 6 6 7 7
100 1 2 2 2 3 3 3 4 4
As a rule Bayesian methods are routinely applied throughout a drug development 
program except for the final quantification of proof -  which would be a frequentist 
P-value. This is because as well as first time into man studies Bayesian methods are be 
applied in pharmacokinetic modelling [for example see: Judson, Peiming, Peng, 
Verweij, Racine and Donato di Paulo, 2005]; safety assessment [Cowell, Dawid, 
Hutchinson, Roden and Spiegelhalter, 1992]; application o f decision science [Julious 
and Swank, 2005]; safety monitoring [Fayers, Ashby, and Parmar, 1997]; go/ no go 
decisions [Owen, 2002] and dose response assessment [for example see: Krams, Lees, 
Hacke, Grieve, Orgogozo and Ford, 2003;. Lunn, Wakefield and Racine-Poon, 2001]. 
Although there are a number of texts discussing the Bayesian design and analysis of 
trials [Spiegelhalter, Abrams, Myles, 2004; Spiegelhalter, Freedman and Parmer, 1995; 
Joseph, du Berger, and B'elisle, 1997; Pham-Gia and Turkkan, 1992] and at a basic 
level [Spiegelhalter, Myles, Jones, and Abrams, 1999] Bayesian methods tend to not be 
applied as the definitive assessment of proof in a regulatory setting. Until SAS launches 
a procedure PROC BAYES this situation is likely to remain the same.
The dissertation will reflect the current realities as although Bayesian methods will be 
applied throughout, the assumption will be that the formal assessment of proof will be 
through a frequentist hypothesis test.
1.4. Superiority Trials
In a superiority trial the objective is to determine whether there is evidence o f a 
difference in the comparison of interest between the regimens with reference to the null 
hypothesis that the regimens are the same. The null (Ho) and alternative (Hi) 
hypotheses may take the form:
H0: The two treatments have equal effect with respect to the mean response ( juA = juB). 
Hf. The two treatments are different with respect to the mean response (juA ^  /uB).
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In the definition o f the null and alternative hypotheses yWAand ju^ refer to the mean 
response on regimens A and B respectively. In testing the null hypothesis there are two 
errors one can make:
I. Rejecting H0 when it is actually true.
II. Retaining H0 when it is actually false.
As described earlier in the chapter these errors are usually referred to as Type I and 
Type II errors [Neyman and Pearson, 1928, 1933, 1936 and 1938]. The aim o f the 
sample size calculation is to find the minimum sample size for a fixed probability o f 
Type I error to achieve a value o f the probability of a Type II error. The two errors are 
commonly referred to as the regulator’s (Type I) and investigator’s (Type II) risks and 
by convention are fixed at rates of 0.05 and 0.10 or 0.20 respectively. The Type I and 
Type II risks carry different weights as they reflect the impact of the errors. With a 
Type I error medical practice may switch to the investigative therapy with resultant 
costs whilst with a Type II error medical practice would remain unaltered.
In general, one usually thinks not in terms of the Type II error but in terms of the power 
o f a trial (1-probability o f a Type II error), which is the probability o f rejecting the H0 
when it is in fact false. Key trials should be designed to have adequate power for 
statistical assessment of the primary parameters. The Type I error rate is usually taken 
as standard for a superiority trial is 5%. The power that is becoming-to be considered as 
standard is 90% with the minimum considered being 80%. It is debatable as to which 
level of power one should use although it should be noted that, compared to a study 
with 90% power, with just 80% power one is doubling Type II error for only a 25% 
saving in sample size.
As an aside it was Neyman and Pearson who introduced the concept o f the two types of 
error, the Type I and Type II, in the 1930s. The labelling o f these two types o f error 
was arbitrary though as the authors simply listed the two types of error that could be 
made as sub bullets which were numbered with the prefixes of I and II. Subsequently 
the authors then referred to the errors as errors o f Type I and errors of Type II. If these 
sub bullets had had different labelling, o f A and B say, then statistics would have had a 
different nomenclature.
The purpose of the sample size calculation is hence to provide sufficient power to reject 
H0 when in fact some alternative hypothesis is true. For the calculation one must have a 
pre-specified value, for difference in the means, for the alternative hypothesis, ‘d ’ 
[Campbell, Julious and Altman, 1995]. The amount d is chosen as a clinically 
important difference or effect size and is the main factor in determining a sample size. 
Reducing the effect size by half will quadruple the required sample size [Fayers and 
Machin, 1995]. Usually the effect size is taken from clinical judgement and/or is based 
on previous empirical experience in the population to be examined in the current trial.
Formally the aim is to calculate a sample size suitable for making inferences about a 
certain function of given model parameter, /j  , f( ju )  say. For data that take a Normal
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form f ( n )  will be //A i.e. the difference in means o f two populations A and B. 
Now let S be a sample estimate o f / ( ^ ) .  Thus S is defined as the difference in the
sample means. As one is assuming that the data from the clinical trial are sampled from 
a Normal population, then, using standard notation, S~N( Var (S ) ), giving
^ > - * ( 0 ,1).
■JVar(S)
A basic equation can now be developed in general terms from which a sample size can 
be estimated. Let a  be the overall type I error level, with a/2 o f this type I error equally 
assigned to each tail of the two tailed test, and let Z,_a ., denote the (l -  a  12) 100% o f a
standard Normal distribution.
Thus, an upper 2-tailed, a  -level critical region for a test o f f ( / j )  =0 is
! |^ > Z,_Q 2JVar(S)}.
For this critical region against an alternative that f( /u )  = d, for some chosen d, to have 
power (1-/5)% one requires
d - Z t_/>JVar(S) = Z l_a 2JV ar{s) ,  (1.3.1)
where p  is the overall Type II error level and Z ^ i s  the 100(1-/5)% point o f the
standard Normal distribution. Thus, in general terms for a 2-tailed, a  -level test one 
requires
Var(S)= — d~  -5. (1.3.2)
\ ^ \ - P  + \ - a  ! 2 )
where Var (S) will be unknown and depends on the sample size. Once Var(S) is written 
in terms o f sample size, the above expressions can be solved to give the sample size.
1.4.1. Estimation of the Variance for Calculations
In this section and in subsequent sections one of the most important components in the 
sample size calculation is the variance estimate used in the calculations. This variance 
estimate is usually estimated from retrospective data sometimes from a number o f 
studies. To assess the relative quality of the variance one should consider the following 
aspects of the trial from which the variance is obtained [Julious, 2004a]
1. Design: is the study design ostensibly similar to the one you are designing? On 
the basic level are the data from a randomised controlled trial - observational or 
other data may have greater variability. If you are undertaking a multi-centre 
trial is the variance estimated too from a similarly designed trial? Were the 
endpoints similar to those you plan to use -  not just the actual endpoints but
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were the times relative to treatment o f both the outcome of interest and the 
baseline similar to you own? If there is likely to be missing data in the study 
was the same imputation method as you plan to use used?
2. Population: is the study population similar to your own? The most obvious 
consideration is to ask whether the demographics were the same but if  the 
clinical trial conducted was a multi centre trial was it conducted in similar 
countries? Different countries may have different types of care (e.g. different 
concomitant medication) and so may have different trial populations. Was the 
same type of patient enrolled (the same mix of mild and moderate; the same 
season)? Was it conducted covering the same seasons (relevant for conditions 
such as asthma)?
3. Analysis: was the same statistical analysis undertaken? Not just the question of 
whether the same statistical test was used for the analysis but were the same 
covariates fitted into the model? Were the same summary statistics used?
The quality of the estimate o f variance will obviously influence the strategy of an 
individual clinical trial and the question of variance estimation for sample size 
calculations will be returned to throughout this dissertation
1.5. Equivalence Trials
In certain cases the objective is not to demonstrate superiority but to demonstrate that 
two treatments have no clinically meaningful difference, i.e. they are equivalent. The 
null (Hi) and alternative (Ho) hypotheses may take the form:
Ho: The two treatment differences are different with respect to the mean response 
( M a  *  M b ) -
H i: The two treatments have equal effect with respect to the mean response ( juA = fuB). 
Usually these hypotheses are written in terms of a clinical difference, d, and become:
H 0 : M a - M b o r  M a - M b ^ + d  •
H j :  - d  <  m a ~ M b <  + d  •
The statistical tests of the null hypotheses are an example of an intersection-union test 
(IUT), in which the null hypothesis is expressed as a union and the alternative as an 
intersection. In order to conclude equivalence, one needs to reject each component o f 
the null hypothesis.
Note that in an IUT, each component is tested at level a  giving a composite test, which 
is also of level a  [Berger and Hsu, 1996].
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A common approach with equivalence trials is to test each component o f the null 
hypothesis with a t test - called the Two One-Sided Test (TOST) procedure. In practice, 
this is operationally the same as constructing a ( 1-2a ) 100% confidence interval for f(//)
where equivalence is concluded provided that each end of the confidence interval falls 
completely within the interval (~d,+d) [Jones, Jarvis, Lewis et al, 1996].
Note as each test is carried out at the a  level o f significance then, under the two null 
hypotheses, the overall chance o f committing a type I error is less than a  [Senn, 1997,
2001]. Hence, the TOST, and (1-2a) 100% confidence interval, approach, is 
conservative. There are enhancements that can be applied but they are o f no practical 
importance for formally powered clinical trials [Senn, 1997, 2001]. As a consequence 
the TOST approach will only be discussed for equivalence trials (and bioequivelence 
trials later). Figure 1.7 highlights how equivalence can be demonstrated through 
confidence intervals.
Figure 1-7. An illustration of average equivalence between two populations
•__/  ma__ La
Equivalence Region
Reject that the
difference is
S -d  with Type I
error of 2.5%
and
R eject that the
difference is
* +d with Type I
error of 2 5%
Figure 1.8 shows how confidence intervals are used to test the different hypotheses in 
superiority and equivalence trials. The special case o f bioequivalence is covered in 
Section 1.8.
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Figure 1-8. An illustration of difference between equivalence, non-inferiority and 
superiority
S u p e r i o r  ( s t a t i s t i c a l l y )
Control B etter 
E q u iv a le n t  (c l i n i c a l l y )
0 T re a tm en t B etter
C ontrol B etter _ 
N o n - in f e r io r  (c l i n i c a l l y )  .
0 A T re a tm e n t B etter
C ontrol B etter _ \ 0 T re a tm en t B etter
* A is  v a r ia b le
ICH E10 [2000] goes into some detail in the description of equivalence trials, and the 
related non-inferiority trials (discussed in Section 1.5) whilst ICH E9 [1998] and ICH 
E3 [1996] discuss the appropriate analysis of such trials.
In this section the sample size formulae will initially be derived
I. For the general case of inequality between treatments (i.e. f( ju )  = A )
II. Adopting the same notation and assumptions as in Section 1.4
III. Under the assumption that the equivalence bounds - d and d are symmetric about 
zero
This section will then move on to the special case of no treatment difference replacing 
(i) with:
I. For the special case of no mean difference (i.e. f(/^)=0).
1.5.1. General Case
As with Section 1.3 one requires
4 = 4 4  ~ a,(o-i ) -y/Var(S)
Hence, the(l - 2 a )  100% confidence limits for a non-zero mean difference would be 
S - A +  Z,_a jV a r  S .
To declare equivalence the lower and upper confidence limit should be within ±d
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S  -  A -  Z,_a jV a r  (5) > - d  and S -  A + Z,_a J V a rJs )  < d
Thus, for the two one sided test procedure (TOST) with this critical region there are two 
opportunities under the alternative hypothesis to have a Type II error for some chosen d 
and power (l-(3)
A + d -  Z,_A ^Var(S) = Z,_a VVar(S) and A - d - ZM, VVar(S) = -Z,_a ar(S) (1.4.2)
where /?, and /?2are the probability of a Type II error associated with each one sided 
test from the TOST procedure and /3 = /?, + p 2. Hence, one requires
= it ;  7~cT + Z .-a a n d  Z l - f t  = ' / „  / . a  - z . - -  (1A 3)
Alternatively, Senn (1997) considers the calculation o f the Type II error in terms o f the 
power and hence has a slightly different nomenclature. However, they are equivalent.
1.5.2. Special Case of No Treatment Difference
With symmetric equivalence bounds one requires 
5 + Z,_„ -JVar S ,
Thus, to declare equivalence one should have 
S -  Z x_a -yJVar (s) > - d  and S + Z,_a -JVar (s )  < d .
With the TOST procedure the Type II error for some chosen d and power (1~P) will 
come from
d -  Z,_„ ^ Var(S)  = Z,_a VVar(S) and - d - Z ,^  VVar(S) = -Z,_a VVar(S) .
Hence,
d_
-JVar(S)
7  = _____   7
1 - P ' 2  171 \~a ’
giving
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1.5.3. Choice of Type I Error and Equivalence Limit
1.5.3.1. Choice o f  Type I  Error
Strictly speaking when undertaking two simultaneous one tailed tests setting a=0.05 
would maintain an overall Type 1 error rate o f 5%. However, the choice o f the Type I 
error is a controversial issue. The convention for equivalence trials is to set the Type I 
error rate at half o f that which would be employed for a two sided test used in a 
superiority trial i.e. a=0.025. That is, giving a Type I error rate o f 2.5% [ICH E9, 
1998]. However, setting the Type I error rate for equivalence trials at half that for 
superiority trials could be considered consistent. This is because although in a 
superiority trial one has a two sided 5% significance level in practice for most trials in 
effect what one has is a one sided investigation with a 2.5% level o f significance. The 
reason for this is that one usually has an investigative therapy and a control therapy and 
it is only statistical superiority of the investigative therapy that is of interest.
Through the rest of the sections on equivalence and non-inferiority trials the assumption 
will be that a=0.025 and that 95% confidence intervals will be used in the final 
statistical analysis - although remember as discussed in this chapter in section 1.4 that 
the type I error is actually a little less than 2.5%.
The issue of setting an appropriate Type I error level will be discussed again in the 
section on bioequivalence later in this chapter.
1.5.3.2. Choice o f Equivalence Limit
The discussion on setting equivalence limits in this section can also be generalised to 
non-inferiority trials discussed in the proceeding section. As with the choice o f the 
Type I error the setting of the non-inferiority/equivalence limit is a controversial issue. 
The limit is defined as the largest difference that is clinically acceptable such that a 
larger difference than this would matter in clinical practice [CPMP, 2000]. This 
difference also cannot be “greater than the smallest effect size that the active (control) 
drug would be reliably expected to have compared with placebo in the setting o f the 
planned trial” [ICH E10, 2000].
However, beyond this there is not much formal guidance. Jones, Jarvis, Lewis et al 
[1996] have recommended that the choice of limit be set at half the expected clinically 
meaningful difference between the active control and placebo. There is no hard 
regulatory guidance although the CPMP [1999] in a concept paper originally stated that 
for non-mortality studies it might be acceptable to have an equivalence limit “o f one 
half or one third o f the established superiority o f the comparator to placebo, especially if 
the new agent has safety or compliance advantages”. Although in the draft notes for 
guidance that followed the CPMP [2004] have moved away from such firm guidance 
and state, “Historically, it has been common to select as delta (a) proportion o f the 
difference between comparator and placebo. Such an approach does not necessarily 
ensure superiority over placebo and there is no clinical rationale to support it”. The
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CPMP now talk o f having a margin that ensures that there is “no important loss o f 
efficacy” caused through switching from reference to test and that the margin could be 
defined from a “survey o f practitioners on the range of differences that they consider to 
be unimportant”.
Generally, the definition of the acceptable level o f equivalence or non-inferiority is 
made with reference to some retrospective superiority comparison to placebo [Hung, 
Wang, Lawrence et al, 2003; D ’Agostino, Massaro and Sullivan, 2003; Wiens, 2002]. 
Methodologies for indirect comparisons to placebo have been discussed in detail by 
Hasselblad and Kong [2001]. In this context the definition of the non-inferiority and 
equivalence limits should address the following steps [Wiens, 2002; D ’Agostino, 
Massaro and Sullivan, 2003; Julious, 2004a].
1. One must be confident that the active control would have been different from 
placebo had one been employed.
2. One should be able to determine that there is no clinically meaningful difference 
between investigative treatment and the control.
3. Through comparing the investigative treatment to control one should indirectly 
be able to determine that it is superior to placebo.
Steps 1. and 3. are important as there is a view that non-inferiority and equivalence 
trials reward “failed” studies i.e. if one conducted a poor trial where it would not have 
been possible to demonstrate the active control to be superior to placebo then a poor 
investigative therapy may slip through, through comparison to this control. However, 
Julious and Zariffa [2002] point out that this may not be the case as poor studies are 
poor for most objectives due to their higher statistical variability.
In summary therefore one can infer that the clinical difference used for the limits of 
equivalence and non-inferiority will be smaller than the difference used for placebo 
controlled superiority trials. There also is no generic definition for its setting -  its 
definition will need to be defined on a study by study basis with consultation with the 
appropriate agencies and experts.
1.6. Non-Inferiority Trials
In certain cases the objective of a trial is not to demonstrate that two treatments are 
different or that they are equivalent but rather to demonstrate that a given treatment is 
not clinically inferior compared to another i.e. that a treatment is non-inferior to another. 
The null (H0) and alternative (Hi) hypotheses may take the form:
Ho: A given treatment is inferior with respect to the mean response.
Hi: The given treatment is non-inferior with respect to the mean response.
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As with equivalence trials these hypotheses are written in terms o f a clinical difference, 
d, which again equates to the largest difference that is clinically acceptable [CPMP, 
2000]:
Ho: Ma ~M b* ~d  ■
Hi: n A- n B> - d .
ICH E3 [1996] and ICH E9 [1998] go into detail on the analysis o f non-inferiority trials 
whilst ICH E10 [2000] goes into detail as to the definition o f d.
In order to conclude non-inferiority, one needs to reject the null hypothesis. In terms of 
the equivalence hypotheses in Section 1.5 this is equivalent to testing just one o f the two 
components o f the TOST procedure and reduces to a simple one-sided hypothesis test. 
In practice, this is operationally the same as constructing a (1-2a) 100% confidence 
interval and concluding non-inferiority provided that the lower end of this confidence 
interval is above -d . Figure 1.9 highlights how non-inferiority can be demonstrated 
through confidence intervals and Figure 1.8 shows how confidence intervals are used to 
test the different hypotheses in superiority, equivalence and non-inferiority trials.
Figure 1-9. An illustration of average non-inferiority between two populations
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Adopting the same notation and under the same assumptions as in Section 1.5 but with 
/ ( / / )  = -A  and the additional assumption that the non-inferiority bound is -d, the lower 
(l -  2a)  100% confidence limit is
S - A - Z , _ a J V a r S . (1.5.1)
To declare non-inferiority the lower end o f the confidence interval should lie above -d  
S - A - Z , _ „  J n i r \ s ) > - d .  (1.5.2)
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For this critical region one therefore requires a (l -/?) 100% chance that the lower limit 
lies above -d. Hence,
(1.5.3)
giving
Var (5) = — ^
( Z .- .+ Z , - , ) 2
(1.5.4)
1.7. As Good as or Better Trials
For certain clinical trials the objective is to demonstrate either that a given treatment is 
not clinically inferior or that it is clinically superior when compared to the control i.e. 
that the treatment is “as good as or better” than the control. Therefore two null and 
alternative hypotheses are being investigated in such trials. First the non-inferiority null 
and alternative hypotheses:
Ho: A given treatment is inferior with respect to the mean response ( /uA < juB).
Hi: The given treatment is non-inferior with respect to the mean response ( fuA > juB).
If this null hypothesis is rejected then a second null hypothesis is investigated:
H0: The two treatments have equal effect with respect to the mean response ( / /A = /uB).
Hj: The two treatments are different with respect to the mean response ( juA ^  /j b ).
Practically these two null hypotheses are investigated through the construction o f a 95% 
confidence interval to investigate where the lower (or upper as appropriate) bound lies. 
Figure 1.8 highlights how the two separate hypotheses for superiority and non­
inferiority are investigated.
“As good as or better” trials are really a sub-category o f either superiority or non­
inferiority trials. However, in this dissertation this class o f trials are put into a separate 
section to highlight how as good as or better trials combine the null hypotheses of 
superiority and non-inferiority trials into one closed testing procedure whilst 
maintaining the overall Type I error [Morikawa and Yoshida, 1995; Bauer and Kieser, 
1996; Julious, 2004a],
To introduce the closed testing procedure this section will first describe the situation 
where a one-sided test of non-inferiority is followed by a one-sided test o f superiority. 
The more general case where a one sided test of non-inferiority is followed by a two 
sided test of superiority is then described.
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In describing “as good as or better” trials this thesis draws heavily on the work o f 
Morikawa and Yoshida [1995], The CPMP [2000] have recently issued a points to 
consider document.
1.7.1. A Test of Non-Inferiority and One Sided Test of Superiority
The null (H l0) and alternative (HI i) hypotheses for a non-inferiority trial can be written 
as:
H l 0: M a ~ / 4 b < - d .
HIi:  n k - M b  > ~ d -  
Which alternatively can be written as 
H l0: Ma - M b  + d  
H Ii: jja ~ /uB + d  > 0.
Whilst the corresponding null (H20) and alternative (H2i) hypotheses for a superiority 
trial can be written as
H20: Mk ~ M b S O .
H2 i :  M a - M b > ° -
What is clear from the definitions of these hypotheses is that if H20 is rejected at the a  
level then H l0 would also be rejected. Also, if H 10 is not rejected at the a  level then 
H20 would also not be rejected. This is because f jA -  juB + d > juA -  /uB. Hence, both
H l0 and H20 are rejected if they are both statistically significant; neither H l0 and H20 
are rejected if H 10 is not significant; only H 10 is rejected if only H l0 is significant.
Based on these properties a closed test procedure can be applied to investigate both non­
inferiority and superiority whilst maintaining the overall Type I error rate without a  
adjustment. To do this the intersection hypothesis H20 n H l 0is first investigated
which, if rejected, is followed by a test o f H l0 and H20. In this instance 
H20 n H l 0 = H l0 and so both non-inferiority and superiority can be investigated
through the following two steps [Morikawa and Yoshida, 1995].
First investigate the non-inferiority through the hypothesis H l0. If H 10 is rejected then 
H20 can be tested. If H 10 is not rejected then the investigative treatment is inferior to 
the control treatment.
If H20 is then rejected in the next step one can conclude that the investigative treatment 
is superior to the control. Else if H20 is not rejected then non-inferiority should be 
concluded.
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1.7.2. A Test of Non-Inferiority and Two Sided Test of Superiority
The null (H30) and alternative (H31) hypotheses for a two-sided test o f superiority can 
be written as:
H30: Ha =Mb -
H 3 i :  jUA < f i B or / / A > f iB .
Which is equivalent to two one-sided tests at the a/2 level of significance -  summing to 
give an overall type I error of a  - with the investigation o f H20 against the alternative o f 
H2i and the following hypotheses:
H4„: / /A > / r B.
H4,: n A <<“ b-
In applying the closed test procedure in this instance it is apparent that the intersection 
hypothesis H l0 n H 3 0 is always rejected as it is empty and so both H l0 and H30 can be
tested. Due to there being no intersection the following steps can be applied steps 
[Morikawa and Yoshida, 1995]:
1. If the observed treatment difference is greater than zero and H30 is rejected then H l0 
is also rejected and one can conclude that the investigative treatment is superior to 
control.
2. If the observed treatment difference is less than zero and H30 is rejected and H l0 is 
not then the control is statistically superior to the investigative treatment. If H l0 is 
also rejected then the investigative drug is worse than the control but is not inferior 
(practically though this may be difficult to claim).
3. If H30 is not rejected but H l0 is, then the investigative drug is non-inferior compared 
to the control.
4. If neither H l0 nor H3C) are rejected then one must conclude that the investigative 
treatment is inferior to control.
Note that when investigating the H l0 and H30 hypotheses, using the procedure 
described above, H3U will be tested at a two sided a  level of significance whilst H l0 will 
be tested at a one-sided a/2 level of significance. Thus, the overall level o f significance 
is maintained at a
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1.8. Assessment of Bioequivalence
Earlier in the chapter trials were described where one wished to demonstrate that the 
two therapies are clinically equivalent. In equivalence trials the comparators may be 
completely different, in terms of route o f administration or even actual drug therapies, 
but what one wishes to determine is whether they are clinically the same. However, in 
bioequivalence trials the comparators are ostensibly the same - one may have simply 
moved manufacturing sites or had a formulation changed for marketing purposes. 
Bioequivalence studies are therefore conducted to show these two formulations o f the 
drug have similar bioavailability -  the amount o f drug in the bloodstream. The 
assumption in bioequivalence trials is that if the two formulations have equivalent 
bioavailability then one can infer that they have equivalent therapeutic effect for both 
efficacy and safety. The pharmacokinetic bioavailability is therefore a surrogate for the 
clinical endpoints. As such one would expect the concentration time profiles for the test 
and reference formulations to be super-imposable, see Figure 1.10 for an example, and 
the two formulations to be clinically equivalent.
Figure 1-10. An example of pharmacokinetic profiles for test and reference 
formulations
Cmax
Tmax
AUC
In bioequivalence studies, therefore, one can determine whether in vivo the two 
formulations are bioequivalent by assessing whether the concentration time profiles for 
the test and reference formulations are super-imposable [Senn, 1998]. Assessing if  the 
rate and extent o f absorption are the same usually does this. The pharmacokinetic 
parameter AUC (area under the concentration curve) is used to assess the extent o f 
absorption and the parameter Cmax (maximum concentration) is used to assess the rate 
o f absorption. Figure 1.10 gives a pictorial representation o f these parameters. If the 
two formulations are bioequivalent then they can be switched without reference to 
further clinical investigation and can be considered inter-changeable.
The null and alternative hypotheses are similar to those for equivalence studies:
H0: The test and reference formulations give different drug exposures (juT * juR).
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Hj: The test and reference formulations give equivalent drug exposure (//r = juR).
Similarly to other types o f trials the objective o f a bioequivalence study is to test the 
null hypothesis to see if the alternative is true. The ‘standard’ bioequivalence criteria 
demonstrate that average drug exposure on the test is within 20% o f the reference on the 
log scale [FDA 2000, 2001; CPMP, 1998]. Thus, the null and alternative hypotheses 
can be rewritten as:
H0: Ut I ^ r ^0-80  or /JT/juR >1.25.
Hi: 0.80 < H j / n R < 1.25 .
One can declare two comparator formulations to be bioequivalent if one can 
demonstrate that the mean ratio is wholly contained within 0.80 to 1.25. To test the null 
hypothesis one undertakes two one-sided tests at the 5% level to determine whether 
fur / n R < 0.80 or jut/ mr ^ 1.25. If neither o f these tests hold then one can accept the 
alternative hypothesis of 0.80 < ///^  < 1.25 . As one is performing two simultaneous
tests on the null hypothesis, both o f which must be rejected to accept the alternative 
hypothesis, the type I error is maintained at 5%. Similar to equivalence trials discussed 
earlier in this chapter the convention is to represent the two one-sided tests as a 90% 
confidence interval around the mean ratio o f ^ T/ /JR which summarises the results o f 
two one-tailed tests. Figure 1.11 highlights how average bioequivalence between two 
formulations can be demonstrated through 90% confidence intervals.
Figure 1-11. An illustration of average bioequivalence between two formations
o.ao 1.25
and
R ejec t th a t the  
ratio it  * 1.25 
with Type I 
error of 5%
In summary, a test formulation of a drug is said to be bioequivalent to its reference 
formulation if the 90% confidence interval for the ratio test:reference is wholly 
contained within the range 0.80 to 1.25, for both AUC and Cmax. As both AUC and 
Cmax must be equivalent to declare bioequivalence there is no need to allow for 
multiple comparisons.
R eject that the 
ratio is s  0  80 
with T ype I error 
of 5%
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Note this example raises the issue of loss of power when one has multiple endpoints. 
Here both AUC and Cmax needed to hold to declare bioequivalence and so the type I 
error is not inflated. However, such “and” comparisons may affect the type II error, 
depending on the correlation between the endpoints, as there is twice the chance to 
make a type II error which can impact on the power. [Koch and Ganksy, 1996; CPMP,
2002]. The most extreme situation would be for two independent “and” comparisons 
where the type II error is doubled. However, here AUC and Cmax are highly correlated 
and as one selects the highest variance from the two to calculate the sample size this 
means that any increase in the type II error could be offset by the fact that for either of 
AUC or Cmax the power is greater than 90% for the calculated sample size.
For compounds with certain indications other parameters, such as Cmin (defined as the 
minimum concentration over a given period) or Tmic (defined as time above a 
minimum inhibitory concentration over a given period), may also need to be assessed.
Note, the criteria for acceptance of bioequivalence may vary depending on factors such 
as which regulatory authority’s guidelines are being followed and the therapeutic 
window of the compound being formulated and so the ‘standard’ criteria may not 
always be appropriate.
The methodology described in this section can also be applied to other types of in vivo 
assessment such as the assessment o f a food [FDA, 1997]; drug interaction [CPMP 
1997, FDA 1999] or special populations [FDA 1998, 1999]. The criteria for acceptance 
for other types of in vivo assessment may vary depending on the guidelines [FDA 1999] 
or a priori clinical assessment [CPMP 1997, FDA 1997, 1999].
It may be worth noting the statistical difference between testing for equivalence and 
bioequivalence with reference to investigating the null hypothesis. In equivalence trials 
the convention is to undertake two one-sided tests at the 2.5% level, which in turn are 
represented by a 95% confidence interval; in a bioequivalence trial two one-sided tests 
at the 5% level are undertaken, which are represented by a 90% confidence interval. 
Thus, in bioequivalence trials the overall type I error is 5% - twice that o f equivalence 
trials where the overall type I error is 2.5%.
1.8.1. Justification for Log Transformation
The concentration-time profile for a one compartment intravenous dose can be 
represented by the following equation:
c(t) = Ae, 'l,) ,
where t is time, A is the concentration at t=0 and A is the elimination rate constant 
[Julious and Debamot, 2000]. It is evident from this equation that drug concentration in 
the body falls exponentially at a constant rate X. A test and reference formulation are 
super-imposable, therefore only when c r (t) = c R ( t ) . On the log scale this is equivalent 
to log(AT)-X 1 = log(A R)-A R which for /Lr = TR (which a priori one would expect)
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becomes log(AT) = log(AR). Thus, on the log scale the difference between two curves 
can be summarised on an additive scale and indeed it is upon this scale that such 
pharmacokinetic parameters as the rate constant, X, and the half life, are derived [Julious 
and Debamot, 2000]. This simple rationale also follows through for statistics used to 
measure exposure (AUC) and absorption (Cmax) as well as the pharmacokinetic 
variance estimates [Lacey, Keene, Pritchard et al, 1997; Julious and Debamot, 2000]. 
Hence, unless there is evidence to indicate otherwise, the data are assumed to follow a 
log-Normal distribution and hence the default is to analyse loge AUC and loge Cmax.
The differences on the loge scale (test-reference) are then back-transformed to obtain a
ratio. It is the back transformed ratio and its corresponding 90% confidence interval 
which is used to assess bioequivalence.
1.8.2. Rationale for Using Coefficients of Variation
All statistical inference for bio-equivalence trials is undertaken on the log scale and 
back transformed to the original scale for interpretation. Thus, the within-subject 
estimate of variability on the log scale is used both for inference and sample size 
estimation. With the interpretation of the mean effect on the original scale it is good 
also to have a measure of variability also on the original scale. A measure o f variability 
usually is the Coefficient of Variability (CV) as for log-Normally distributed data the 
following exact relationship between the CV on the arithmetic scale and the standard 
deviation, o, on the log scale holds [Dilletti, Hauschke and Steimijans, 1991; Julious 
and Debamot, 2000]
CV = ^(e*' - l )  .
For small estimates of cr2 [a  < 0.30] the CV can be approximated by 
CV = a .
which relies on the first two terms of the Taylor series expansion of exp(cr). Thus, 
both the measure o f effect and its variability can both be interpreted on the original 
scale. The derivation of this is result is based on the following relationships for the log- 
Normal distribution [Julious and Debamot, 2000]
where n  and a 2 relate to the mean and variance respectively on the log-transformed 
scale and m and s the corresponding mean and variance on the non-transformed scales 
and hence
C F = ^  = 
m
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1.8.3. Individual and Population Bioequivalence
The assessment of bioequivalence as defined in this chapter is based on average 
bioequivalence in which only the formulation means are required to be equivalent. New 
paradigms for bioequivalence based on population and individual bioequivalence have 
also be been proposed [Schall and Williams, 1996; Hauck and Anderson, 1992] for 
which there are regulatory guidelines [FDA, 2001]. These alternative approaches also 
involve formulation variabilities as well as their means in the assessment 
bioequivalence. To calculate a sample size recommendations have been made based on 
simulations [FDA, 2001].
The merits of the concepts of individual and population bioequivalence are debatable 
and some authors have questioned the concepts [Senn, 2001]. There are a number o f 
reasons for this. For first is that for two formulations A and B; in a study it could be 
possible to declare A to have individual or population bioequivalence with B while the 
converse is not true.
The second reason is that there is no hierarchy to the assessments. If in a study 
individual bioequivelence was declared between two formulations it is not then possible 
to automatically be enable to conclude population bioequivalence and average 
bioequivalence. In fact it is possible to be able to conclude individual bioequivalence 
and yet have a point estimate outside o f the standard average bioequivalence bounds o f 
(0.80, 1.25).
The final reason is turning the arguments for individual and population bioequivalence 
assessment around. The justification for their use is that they allow for an assessment o f 
switchability and prescribability of two formulations which have greater clinical 
meaning. This may apply if the study conducted is in a patient population with clinical 
endpoints. However, bioequivalence studies are conducted in healthy volunteers using 
surrogate endpoints (pharmacokinetics) and so the argument pertaining to 
“switchability” and “prescribability” fail.
1.9. Estimation to a Given Precision
In the previous sections of the chapter calculations have been described with reference 
to some clinical objectives such as the demonstration o f equivalence. However, often a 
preliminary or pilot investigation is conducted where the objective is to provide 
evidence of what the potential range of values is with view to doing a later definitive 
study [Wood and Lambert. 1999; Day, 1988; Julious and Patterson, 2004; Julious 
2004a]. Such studies may also have sample sizes based more on feasibility than formal 
consideration [Julious, 2005d].
In given drug’s development, it may be the case that reasonably reliable estimates of 
between-subject and of within-subject variation for the endpoint of interest in the
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reference population are available, but the desired magnitude in the treatment difference 
of interest will be unknown. This may be the case, for example, when considering the 
impact of an experimental treatment on biomarkers [Biomarkers Definitions Working 
Group, 2001] or other measures not known to be directly indicative o f clinical outcome 
but potentially indicative of pharmacological mechanism of action. In this situation, 
drug and biomarker development will be in such an early stage that no pre-specified 
treatment difference will be of interest nor either will statistical testing of any observed 
treatment difference. In such exploratory or ‘learning’ studies [Sheiner, 1997], what is 
proposed in this dissertation is that the sample size be selected in order to provide a 
given level of precision in the study findings, not to power in the traditional fashion for 
a (in truth unknown) desirable and pre-specified difference of interest.
For such studies, rather than testing a hypothesis, it is more informative to give an 
interval estimate or confidence interval for the unknown f (^ ) .
Recall that (l - a )  100% confidence interval for f (^ )  has half-width
Hence, if one is able to specify a requirement for w and write Var (S) in terms o f ‘n ’ 
then the above expression can be solved for n. It should be noted though that if  the 
sample size is based on precision calculations, then the protocol should clearly state this 
as the basis for the size of the study.
A similar situation occurs when the sample size is determined primarily by practical 
considerations. In this case one may quote the precision of the estimates obtained based 
on the half-width of the confidence interval, and provide this information in the 
discussion of the sample size. Again it must be clearly stated in the protocol that the 
size of the study was determined based on practical, and not formal, considerations.
The estimation approach also could be useful where one wishes to quantify a possible 
effect across several doses, or to power on a primary endpoint overall but also to have 
sufficient precision in given subgroup comparisons. The former of these may be a 
neglected consideration for clinical trials even though there is some regulatory 
encouragement as the CPMP [2002] Points to Consider on Multiplicity Issues in 
Clinical Trials states:
“Sometimes a study is not powered sufficiently for the aim to identify a single 
effective and safe dose but is successful only at demonstrating an overall positive 
correlation of the clinical effect with increasing dose. This is already a valuable 
achievement. Estimates and confidence intervals are then used in an exploratory 
manner for the planning of future studies.”
Indeed in early trial for the same sample size as doing a larger study where a single dose 
is powered against placebo one could undertake a well-designed study based on the 
precision approach with several doses estimated against placebo.
( 1.8 . 1)
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In an alternative use for the exploratory use o f confidence intervals Julious [Julious, 
2004c] highlights how non-overlapping 84% confidence intervals around individual 
means equates to a significance level o f 5% for the difference between means. This 
result could be used if one has several doses across time points to explore possible 
differences between groups (not accounting for multiplicity).
1.10. Conventional Calculations and Their Limitations
Subsequent chapters in this thesis will in turn go through the conventional sample size 
calculations for each of the different types o f clinical trial described in the previous 
sections of this chapter for Normal, binary and ordered categorical data.
One potential issue with conventional calculations is that they all usually rely on 
retrospective data to quantify the variance to be used in the calculations. Even for 
binary data a retrospective control prevalence will feed into a variance estimate. If this 
variance is therefore estimated imprecisely then it would impact on the calculations. 
Calculations at the moment do not allow for this imprecision.
To highlight the issues around using imprecise variance estimates in the following sub­
section a worked example will be given, which was introduced by Julious [Julious, 
2004b]. In the scheme of things this example is quite an important one as it is the 
genesis for most the consequent work that has formed the basis of this thesis.
The issues raised by this one study led to work on how to prospectively consider the 
sensitivity of the sample size to the assumptions about the variance (which will be 
discussed in detail throughout this dissertation) and to work on adaptive designs 
(including sample size re-estimation), a brief discussion of which will be given in 
Chapter 6 .
The conclusion to this work are proposed new methodologies developed within this 
dissertation for the calculation of sample sizes, which takes account of the imprecision 
o f the variance estimate.
1.10.1. Worked Example
A bioequivalence study was conducted to compare a test and reference formulation. 
Such bioequivalence studies are conducted to show that two formulations o f the drug 
have similar bioavailability. As discussed in Section 1.7 the assumption in 
bioequivalence trials is that if two formulations have equivalent bioavailability then one 
can infer that they have equivalent therapeutic effect, for both efficacy and safety.
For the worked example the ‘standard’ bioequivalence criteria were used a priori  such 
that bioequivalence was to be declared if the average drug exposure on the test ( p T) 
was within 20% of the reference { p R) on the log scale [FDA, 2000, 2001; CPMP,
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1998]. Thus, a priori it was determined that bioequivalence could be concluded if the 
90% confidence interval for p r / p R is completely contained within (0.80, 1.25).
The planned study design was a two period cross-over trial (AB/BA) with AUC and 
Cmax being used to assess bioequivalence. As both AUC and Cmax must both be 
bioequivalent to declare bioequivalence there was no issue with multiplicity (although 
as discussed earlier when discribing bioequivalence studies there may be implications 
for the type II error). An estimate o f the within-subject variability was available from 
previous studies, CVw=30%, and the mean true ratio of p T/ p R was assumed to be 
unity. The total sample size was calculated to be 39 subjects or 20 per sequence (AB or 
BA). In the trial 48 subjects were recruited to ensure 40 completed (to allow for drop 
outs). The study was completed and the results are presented in Table 1.5
Table 1-5. Results of the example bioequivalence study
N Ratio 90% C.I. CVw%
AUC 45 1.10 (0.94, 1.29) 47
Cmax 47 1.05 (0.92, 1.21) 41
From these results bio-equivalence it seems can be declared for Cmax but not for AUC. 
Thus, as both AUC and Cmax must hold to be able to declare bioequivalence it was 
concluded that the study had failed and the two formulations were not bioequivalent. 
However, there was some evidence that the two formulations were bioequivalent - the 
point estimates for the mean ratios o f both AUC and Cmax were within 0.80 to 1.25.
One factor that seemed to have caused the problems was the unexpectedly high 
variances. Within subject CVw’s of 47% and 41% were observed for AUC and Cmax 
respectively compared to 30% used in the sample size calculations. There was one 
marked outlier in the analysis but even after excluding this outlier the CVw’s were 42% 
and 38% for AUC and Cmax respectively. There was no reason to exclude this subject 
from the analysis and the final analysis was presented including all subjects.
As one might imagine these results caused a great deal of contemplation upon their 
reporting. Especially as no study is an island for, as well as the cost of a failed study, 
there was an impact in timelines on the development of the asset, which were dependent 
upon the results of this study. Thus, there was a double impact of having to conduct 
another (far larger) study and also having to wait for these study results.
1.10.2. Sensitivity Analysis
In the study given in the worked example two studies, given in Table 1.6, were used to 
obtain a variability estimate.
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Table 1-6. Within subject coefficients of variability with their corresponding 
degrees of freedom (DF) observed in two previous studies prior to the study 
undertaken in the worked example for the primary endpoints of AUC and Cmax
AUC Cmax
CVw(%) df CVw(%) D f
Study 1 33% 13 20% 13
Study 2 24% 15 23% 15
Pooled 29% 28 27% 28
The maximum pooled estimate o f variance, as measured by the CV, observed from 
these two studies was 29% for AUC which was rounded up to 30% for calculations. 
What was not considered in the calculations at all was the fact that this estimate o f the 
CV was made with just 28 degrees of freedom. The assumption in the calculations 
therefore was that the variance used in the calculations was the population variance. 
However, what was not undertaken a priori was any sensitivity analysis o f the study 
design to the assumptions around the sample variance. On this issue ICH E9 [1998] 
makes the following comment, where the emphasis is that o f the author:
“The method by which the sample size is calculated should be given in the protocol, 
together with the estimates o f any quantities used in the calculations (such as
variances, mean values, response rates, event rates, difference to be detected) It is
important to investigate the sensitivity of the sample size estimate to a variety of 
deviations from these assumptions ”
The investigation of the sensitivity of the trial design to the assumptions about the 
variance is relatively straightforward to investigate and could have been done using the 
degrees of freedom of the variance estimate used in the calculations [Julious, 2004b]. 
First o f all, one needs to calculate the sample size conventionally using an appropriate 
variance estimate. Next, using the degrees of freedom for this variance and the chi- 
squared distribution, one can calculate the upper one tailed 95th percentile for the 
variance
From these pooled estimates and corresponding degrees of freedom Table 1.7 could 
have been constructed and the maximum plausible estimate for the CV, taken as the 95th 
percentile, would be 38%. If this CV for the AUC was observed and not the 30% used 
in the calculations then the study would still have had 70% power. Thus, the study was 
reasonably robust to deviations about the variance estimate.
Table 1-7. Sensitivity analysis about the coefficients of variability (%) observed in 
two previous studies
CVw 95th Power
for 95th
AUC 29% 38 70%
Cmax 27% 35 16%
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There are a couple of points worth noting though. First, the actual CV observed in the 
study was greater than that estimated as the 95th percentile from the sensitivity analysis. 
Indeed the variance estimates for Cmax and AUC, excluding the outlying subject, fell 
on the 99th percentile based on the previous studies. This fact demonstrates that, 
although it would be nice to be wise after the event, no one has a crystal ball and that, 
by definition, one will always encounter unexpected variances.
The second point to highlight is that although the planned study was robust to 
deviations in the assumptions about the variance it was hit with the double whammy of 
an unexpected large variance and an unexpectedly large regimen difference -  as the 
study was designed assuming no difference between treatments (a ratio of 1.00 ) when a 
ratios of 1.10 (for AUC) and 1.05 (for Cmax) were observed.
1.10.3. Calculating the Sample Size Accounting for the Imprecision in the
Variance Estimate
As highlighted in the previous section, the pooled within-subject CVw used in the 
sample size calculations was 30% estimated with 28 degrees o f freedom. Chapter 2 
describes for bioequivalence studies the methodology for sample size calculation that 
would account for the fact that the variance used in the sample size calculation was 
estimated with just 28 degrees of freedom. Accounting for this imprecision would 
equate to a total sample size estimate of 44 subjects or 22 per sequence (AB or BA). To 
account for dropouts 54 subjects in total would need to be recruited to ensure 44 
completed. Thus, accounting for the imprecision in the variance would increase the 
sample size by 10%. If this proportional increase in the sample size had been applied 
then one may have expected 48 and 52 subjects to be evaluable for the comparisons of 
AUC and Cmax respectively. Thus, with a 10% proportional increase in the sample 
size the 90% Cl for AUC would have become 0.94 to 1.28 and Cmax would have 
become 0.92 to 1.20.
1.10.4. Moving Beyond the Conventional Calculations - Motivation for Further 
Work
The worked example given in the previous sub-section was both a good and bad one. 
Good in that it highlights the issues associated with imprecise variability estimates and 
the subsequent costs if this imprecision is ignored -  as with conventional calculations. 
Bad in that it does not allow one to be wise after the event and say “if on ly ....”. 
However, the worked example does highlight the motivation for the work in this PhD as 
it demonstrates how an imprecisely estimated variance used in a sample size calculation 
can have a substantial impact on a study -  particularly if this imprecision is not allowed 
for in the sample size calculation.
The issue of imprecise variability estimates is one that is most associated with early 
phase clinical trials, where, by definition, there is little clinical experience o f a 
compound in man with comparatively few subjects available to provide estimates o f the 
variability for the first formally powered study. It should be highlighted though that the
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work could be generalised to later phase trials. For example, where a novel endpoint is 
being used for the first time within a company and the information on variability may be 
limited. Alternatively, when one is undertaking a later phase trial in a sub population 
where there may be little variability data available for the specific sub population.
In addition the logic of the issues o f imprecise variability estimates for Normally 
distributed data can be extended to other forms of data such as that o f binary (Chapters 
3 and 4) and ordinal (Chapter 5) where the respective variability estimates would come 
from the anticipated control responses based on retrospective data for the binary or 
ordinal outcome of interest. The solution is not so straightforward for binary or ordinal 
data, however, the thesis will also discuss the solutions to these particular problems 
also.
Finally the thesis will finish with an investigation o f issues generic to all forms o f trial 
independent of the type of data (Chapter 6 ). Included in this chapter will be an 
investigation into issues such as adaptive designs, clinical development plans and 
computer intensive methods with respect to their impact on sample size calculation.
66
2 . C H A P T E R  2 -  S A M P L E  S I Z E  C A L C U L A T I O N S  F O R
C L I N I C A L  T R I A L S  W I T H  N O R M A L  D A T A
2.1. Introduction
This chapter describes the calculations for clinical trials where the expectation is that 
the data will take a plausibly Normal form. This chapter will discuss the standard 
sample size calculations for trials where the objective is to determine: superiority; 
equivalence; non-inferiority; estimation to a given precision and bioequivalence. These 
calculations will be described for both cross-over and parallel group designed studies. 
Much of the description of the standard calculations comes from Julious [Julious, 
2004a]. This chapter will then describe how to undertake sensitivity analyses around 
the sample size calculations when designing the trial. Finally it will introduce 
calculations for the estimation of the sample size, which account for the degrees o f 
freedom of the sample variance used in the calculations.
2.2. A im s o f the Chapter
The main issues to be covered in this chapter are:
• To describe the standard sample size calculations for data anticipated to take a 
Normal form and how the different clinical trial objectives impact on these 
calculations.
• To highlight the limitation of standard calculations with respect to the 
assumptions about the sample variance used in the calculations.
• To introduce methodologies for undertaking sensitivity analyses, with respect to 
the sample variance.
• To derive a methodology for sample size calculation that takes account o f the 
imprecision in the sample variance.
• To discuss the impact of design factors, such as covariates or repeated measures, 
on sample size calculations.
• To describe how Bayesian methods could be applied to explore and account for 
the assumptions in the sample size calculations.
2.3. Superiority Trials
2.3.1. Parallel Group Trials
2.3.1.1. Sample Sizes Estimated Assuming the Population Variance to be Known
As discussed in Chapter 1, in general terms for a 2-tailed, a  -level test one requires
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Var (S)=--------   7 , (2.2.1)
( Z ^ + Z ^ . j ) -
K or(s ) = ^  + ^  = ^ i . ^ ! ,  (2 .2 .2 )
n A n B r nA
where <r2 is the population variance estimate and n B = m A Note: (2.2.2) is minimised
when r = 1 for fixed n. Substituting (2.2.2) into (2.2.1) gives the standard sample size 
result which does not allow for the imprecision about the variance [Brush, 1998; 
Lemeshow, Hosmer, Klar et al, 1990]
m _  ( r +  +  Z | _a t )2g ^  ^ ^
rd 2
Note that in this section, and throughout the chapter for parallel group trials with 
Normal data, the assumption will be made that the variances in each group are equal i.e. 
that <rA — <j 2b = ct 2. This assumption is referred to as homoscedasticity. There are 
alternative formulae for the case o f unequal variances [Schouten, 1999; Singer, 2001] 
and Julious [2005a] has described how the assumptions o f homogeneity impacts on 
statistical analysis.
When the clinical trial has been conducted and the data have been collected and cleaned 
for analysis it is usually the case that for the analysis the population variance, a 2, is 
considered unknown and a sample variance estimate, s 2, is used instead of a 2. As a 
consequence of this a t-statistic as opposed to a Z-statistic is used for inference. This 
fact should be represented in the sample size calculation rewriting (2.2.3) so that t- as 
opposed to Z-values are used. Hence, if the population variance is considered unknown 
for the analysis the following could be used
anA > - ------ — ^ --- 1 ~ . (2.2.4)
rd~
As nA appears on both the left and right side o f (2.2.4) it is best to rewrite the equation 
in terms of power and then use an iterative procedure to solve for nA
(2.2.5)
where 0(») is the defined as the cumulative density function of N(0,1). However, it is 
not just a simple case of replacing Z values with t values for the case of when a sample 
variance is being used in the analysis. In this situation the power should be estimated 
from a cumulative t-distribution as opposed to a cumulative Normal [Senn, 1993; 
Brush, 1988; Chow, Shao and Wang, 2002; Julious 2004a]. The reason for this is that 
by replacing a 2 with 52 (2.2.5) becomes
1 - 0  =  0
\r +1 )<r
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\~J3 = P I rnAd 2
(r + 1)5 2  1 - a  2, nA ( r  +  l ) - 2
where P(») denotes a cumulative distribution defined below. This equation can in turn 
be rewritten as
\ -  P = P
y[rn^d  : \ l ( r  + l)cr
V T ' TS~ <j -
- t
by dividing top and bottom by a 2. Thus, one has a Normal over a square root o f an 
independent chi-squared (divided by its degrees o f freedom), which is a t-distribution. 
More specifically, in fact, as the power is estimated under the alternative hypothesis, 
and that under this hypothesis d *  0 , the power should hence be estimated from a non­
central t distribution with degrees of freedom nA(r+ l)-2 and non-centrality parameter
yJrnA/(r  + l)cr2 [Senn, 1993; Brush, 1988; Chow, Shao and Wang, 2002; Kupper and
Hafner, 1989; Julious 2004a]. Thus, (2.2.5) can be rewritten as
(
1 - a  2.n . ( r  +  1 ) - 2 , n,(r  + 1) — 2 ,
rnAd ‘
(r + 1)0^
(2 .2 .6)
where probt(», n 4(r + 1) — 2 , yjrn^d2/ ( r  + l ) a 2) denotes the cumulative distribution 
function of a Student's non-central t distribution with nA(r + 1) -  2 degrees of freedom
and non-centrality parameter ^rn  4d 2 / ( r  + 1)<t2 Note here, the notation,
probt(«, nA(r + 1) — 2 , *JrnAd 2/ ( r  + 1 )<t 2 ), is the same as that used in the statistical 
package SAS notation. Note also that when d=0 then one has a standard t distribution.
Practically one could use (2.2.3) for the initial sample size calculation and then calculate 
the power for this sample size using (2 .2 .6 ), iterating as necessary to the required power 
is reached. To further aid in these calculations a correction factor o f 2’1_a/2/4  can be
added to (2.2.3) to allow for the Normal approximation [Guenther, 1981; Campbell, 
Julious and Altman, 1995; Julious 2004a]
(r + n f c . j  + Z ,.. , ) v  Z,;„ 2
rd~
(2.2.7)
For quick calculations the following formula to calculate sample sizes, with 90% power 
and a two-sided 5% type 1 error rate, can be used
10.5a2 (r + 1)
d 2 r
(2 .2 .8)
or for r= 1
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21a2n. — — — 
 ^ d 2
Equations (2.2.7) and (2.2.8) are close solutions to (2.2.6), giving estimates only one or 
two lower and thus provide quite good initial estimates. Equation (2.2.5) is closer to
(2.2.6) mainly giving the same result and occasionally underestimating by just 1. Table 
2.1 gives sample sizes using (2 .2 .6 ) for various standardised differences ( 8  = d l a ) .
Table 2-1. Sample sizes for one group, nA (nB=nA) in a parallel group study for 
different standardised differences and allocation ratios for 90% power and a two 
sided type I error of 5%
Allocation ratios
8 1 2 3 4
0.10 2103 1577 1402 1314
0.20 527 395 351 329
0.30 235 176 157 147
0.40 133 100 89 83
0.50 86 64 57 53
0.60 60 45 40 37
0.70 44 33 30 28
0.80 34 26 23 21
0.90 27 21 18 17
1.00 23 17 15 14
2.3.1.2. Worked Example
An investigator wishes to design a hypertension trial with equal allocation between 
groups where the clinical effect of interest is a reduction in blood pressure compared to 
control of 4mmHg (d). The expected standard deviation in the population in which the 
trial is to be undertaken is 20mmgHg ( a ). Thus, the standardised difference equates to 
8 -  d / a  = 4 /2 0  = 0.20. For the Type I and Type II errors fixed at 5% and 10% 
respectively, (2.2.8) gives 526. Using this sample size to initiate iterations in (2.2.6) 
one gets the following steps:
Iteration n Power
1 526 0.8993
2 527 0.9004
Thus, the sample size required is 527 subjects in each arm o f the trial and a total sample 
size of 1054. Alternatively one could look up the standardised effect of 0.20 in Table
2 .2 , which gives the same sample size.
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Table 2-2. Sample sizes for one group, nA (nB=nA) in a parallel group study for 
different standardised differences with 90% power and a two sided type I error of 
5% along with the power corresponding to the 95th percentile of the variance for 
difference degrees of freedom
Degrees o f  Freedom
d n 5 10 15 20 25 30 40 50 75 100 200
0.10 2103 0.34 0.53 0.62 0.67 0.70 0.72 0.75 0.77 0.80 0.82 0.84
0.20 527 0.34 0.53 0.62 0.67 0.70 0.72 0.75 0.77 0.80 0.82 0.85
0.30 235 0.34 0.53 0.62 0.67 0.70 0.72 0.75 0.77 0.80 0.82 0.85
0.40 133 0.34 0.53 0.62 0.67 0.70 0.72 0.75 0.77 0.80 0.82 0.85
0.50 86 0.34 0.53 0.62 0.67 0.70 0.73 0.76 0.78 0.80 0.82 0.85
0.60 60 0.34 0.53 0.62 0.67 0.70 0.73 0.76 0.78 0.80 0.82 0.85
0.70 44 0.34 0.53 0.62 0.67 0.70 0.72 0.75 0.77 0.80 0.82 0.85
0.80 34 0.34 0.53 0.62 0.67 0.70 0.72 0.75 0.77 0.80 0.82 0.85
0.90 27 0.34 0.53 0.62 0.67 0.70 0.72 0.75 0.770 0.80 0.82 0.85
1.00 23 0.35 0.55 0.64 0.69 0.72 0.74 0.77 0.79 0.82 0.83 0.86
2.3.1.3. Sensitivity Analysis about the Variance Used in the Sample Size Calculations
The sensitivity of the trial design to the variance is relatively straightforward to 
investigate and can be done using the degrees o f freedom of the variance estimate used 
in the calculations. This concept was described by Julious [2004b]. First o f all, one 
needs to calculate the sample size conventionally using an appropriate variance 
estimate. Next, using the degrees o f freedom for this variance and the chi-squared 
distribution, one can calculate the upper one tailed 95th percentile, say, for the variance 
using the following formula
s~p( 9 5 ) < - ^ — s l .  (2.2.9)
Xo.95.df
Then this upper estimate o f the variance can be used in (2.2.6), to investigate the power. 
This would give an assessment o f the sensitivity o f the study to deviations from the 
variability assumptions, by investigating a study's power to an extreme plausible value 
that the variance could take.
Table 2.2 gives the sample size per group required for different standardised differences 
for a parallel group superiority trial along with the sensitivity o f these sample sizes to 
the 95th percentile of the variance for different degrees o f freedom. From Table 2.2 it 
seems that to ensure 50% and 80% power with the 95th percentile about the variance 
one would require 10 and 75 degrees of freedom respectively.
2.3.1.4. Worked Example
The investigator as in the earlier worked example wishes investigate the sensitivity o f a 
hypertension trial with respect to the variance used in the calculations. Recall the mean 
reduction of interest was 4mmHg (d) that, with an expected standard deviation in the
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population o f 20mmgHg (c r), gives a standardised difference o f 0.20 and hence a target 
sample 527 subjects in each arm. However, the estimate o f the population variance 
used in the calculation was only from a relatively small pilot investigation, which had 
just 10 degrees o f freedom for the sample variance. From (2.2.9) one can calculate an 
upper one tailed estimated of the variance -  and consequent standard deviation -  from 
the 95th percentile. This estimate could be taken as a high plausible value for the 
variance. With such few degrees o f freedom an upper estimate o f the standard deviation 
is relatively high at 31.85mmHg. Putting this standard deviation into (2.2.6), with the 
sample size fixed at 527, one would expect to have power o f 53% if the standard 
deviation observed was nearer to 31.85mmHg than the 20mmHg used in the original 
calculations.
Alternatively one can use Table 2.2. With 10 degrees of freedom for the variance one 
can see that a high plausible variance estimate would give one 53% power - the same as 
calculations in the previous paragraph.
2.3.1.5. Optimising the Variance Estimates
What is apparent from what has been described in this section so far is that the more 
degrees o f freedom about the variance one has the less sensitive calculations are to 
assumptions about the variance. This is as one would expect. However, often when 
calculating a sample size a great deal of information is thrown away. One approach that 
is common when calculating sample sizes is to tabulate all the variances estimated from 
previously observed studies and then take the maximum of these variances. Another is 
to calculate a crude arithmetic mean across the studies to obtain an overall estimate. 
Both these approaches may be appropriate if the variances originate from studies of 
similar size; however, in many instances the studies are of diverse sample size with 
diverse estimates of the variance. The most extreme variance estimates are also often 
those from the smallest studies and thus by taking the maximum or by taking the 
arithmetic mean one may be giving undue weight to the studies with the poorest 
estimate of the variance.
If there are several studies with variance estimates available then it is recommended that 
an overall estimate of the population variance is obtained from the following formula 
[Julious 2004b]
k
;=1
where k is the number of studies, s 2 is the variance estimate from the i th study and dft
is the degrees of freedom about this variance. The pooled variance estimate, s 2p is the
minimum variance unbiased estimate of the population variance and is estimated with 
the following degrees of freedom
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df f = Z d f ,
( =  1
(2.2.11)
This estimate o f the variance has a number o f obvious advantages. The main advantage 
is that appropriate weight is given to the variances with the smallest and largest degrees 
of freedom. Another advantage is that by combining the variance estimates one is 
maximising the degrees of freedom about the overall estimate.
Note the assumption in these calculations is that the variances are all estimates o f the 
sample population variance. If there is true heterogeneity between variances then 
different would need to be considered. The issue of heteroscadicity o f trials will be 
discussed in Chapter 6 .
2.3.1.6. Calculations Taking Accounting of the Imprecision of the Variance Used in the 
Sample Size Calculations
Sample size determination is now reconsidered in the context o f Normally distributed
observations with common variance a 2. However, as previously highlighted, typically
2 2 
a  would be unknown but the choice of sample size, which depends crucially on a  , has
to be decided before any observations in the prospective trial have been made. This
impasse is overcome with an assumption about a 2. The simplest approach is just to
assume that a  is known and takes an ‘assumed value' which is the basis for traditional
sample size formulae discussed previously in this chapter. In reality the 'assumed value'
is obtained from an estimate s2 of a 2 from previous similarly designed studies using the
same endpoint.
This section addresses the issue that the traditional sample size formulae do not take 
account o f the uncertainty about a 2. It is assumed that the estimate s2 o f a 2 is o f the 
'standard' type so that the ratio (ms2) / a 2 would have a chi-squared distribution with a 
known number of degrees of freedom, m. In particular this implies that s2 is an 
unbiased estimate of cf\ The most common situation is revisited where the sample size 
must be decided before any data are observed in the planned trial. The context o f this 
problem was introduced by Julious [2004b] and the methodology described by Julious 
and Owen [Julious, 2002a; Julious and Owen, 2006]
The sample size and power calculations are based on an estimate of a 2 but once the 
prospective study is complete any tests of hypotheses would be based entirely on the 
'current' estimate of variance from the study data alone.
The context considered throughout this section, as throughout the chapter, is that o f a 
two arm parallel group study with a given fixed ratio r for the numbers of patients in the 
two arms, n patients in one arm and rxn patients in the other arm so there is a total of 
N =(l+r)nA patients. Choice of nA for a parallel study is made according to the criteria 
explained above for testing Ho versus Hi. In this context the best linear unbiased 
estimate 0 o f 0 would be adopted,
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0  =  X A ~ x b (2 .2 . 12)
which has variance (r+l)<T/(rn^) so 0 is distributed Normal(0, (r+J)cr/(rn4)). When 
the prospective trial is run and analysed there will be a standard estimator a  o f a  and
hence the following ratio follows a Student's t distribution on nA(r+l)-2 degrees of 
freedom,
Hence for a given type I error level, a , a 2-tail a  -level critical region for a test o f the 
null hypothesis, 0 = 0 , would be given by
where, for 0 < P < 1, tp,v denotes the value such that prob(T < tp,v ) = P where T has a 
standard Student's t-distribution on v degrees o f freedom. However, at the time o f the
region (2.2.14) are unknown. Traditionally the determination o f nA is made on the basis
where O denotes the cumulative distribution function (c.d.f.) of a standard Normal
Here (2.2.16) is equivalent to (2.2.6) discussed earlier in the chapter. This is a simpler 
result than (2 .2 .6 ) although at a practical level they give the same sample size 
(occasionally underestimating by 1). The implication o f using (2.2.16) will be 
discussed later. Note that here and throughout the following arguments d , a  , f3 and r
are fixed with the power dependent on nA and a  .
In the spirit o f the 'usual' argument, since a 2 is in fact unknown it is replaced by s2 in
(2.2.16) and then this expression is set greater than or equal to the desired power 1-0 . 
This results in the 'traditional' result, given earlier in this chapter, for (the integer) nA to 
achieve a power of at least 1 - 0
e-e
(2.2.13)
(2.2.14)
power calculation d 2 is of course unknown and hence the boundaries o f the critical
o f the following argument. If c r were known then (2.2.14) would become
(2.2.15)
and if 0 = d then for given a  this would occur with probability
distribution. Let us call T'(d) the ’true' power of the study for given nA and a 2. Hence, 
the power for given n ^  and cT is given by
(2.2.16)
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(r + + t,_fl 2./N(r+I)^2)2 5
r d 1
(2.2.17)
As noted previously, however, that as nA appears on both sides of this inequality it is 
obtained by iteration and a good starting value for this iteration can be obtained by 
replacing t|-a.2,nA(r+n-2 in (2.2.17) by Zi_a.-2, the corresponding percentile for the standard
Normal distribution, so nA would be chosen to be the least integer exceeding nA where 
(r + l)(z. „ + Z,
n,  =   v ’ (2.2.18)
rd~
For the moment ignoring the constraint of nA to integer values, if n would satisfy
(2.2.17) exactly then the true power o f the study would be (by substitution into (2.2.16))
vF (J) = 0
r d ‘ (/" + l)s {tX a 2 j , A(r + ] ) ~ 2  Z \ - p )
(r + l)cr rd' 1 -  a  ■ 2 ,  /i - ( r  + 1 ) -  2
hence,
'? (d )  = 0
a -a 2 . n A ( r  +  1 ) - 2
(2.2.19)
Here (2.2.19) gives power as a function of d, nA, r, s, a  a  and /?. 4/(d ) is now
something slightly different giving the power obtained when nA is chosen in order to 
achieve a power using an estimate of the standard deviation in place of the population 
value. It is logically different from (2.2.16) as nA is forced to satisfy (2.2.17) from 
which (2.2.19) is derived.
Note that d does appear in the right hand side o f (2.2.19) although of course nA depends 
implicitly on d though (2.2.17) and (2.2.16) from which (2.2.19) is derived. In fact o f 
interest now is the anticipated power for a given sample size (nA) for fixed d, r, a  and
p -
Note also that in the special case where cf is assumed known, s~ = a  (which can be 
thought of as corresponding to m =  oo) and it can be seen that in this case the right hand 
side o f (2.2.19) reduces to 1-p exactly.
In general however the power vp(d) is a random variable because s“ is a random 
variable. This in turn implies that nA and hence tx_a , „ ..•* are random variables too.
In order to assess the way this affects the choice of n an expression for the expected 
power is required
E(^P) = E{E('F | /, a (2.2.20)
where the outer expectation is with respect to t]_a 2 ;| lr+!)_2 • Now, if Y ~ ' I p c l j m  then 
for any constants a and b then the expectation of (2.2.19) is [Ellison, 1964]
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E[<£>(bY - a ) ]  = probt(b,m,a) (2.2.21)
Similar to earlier in the chapter here probt(»,w ,a) denotes the cumulative distribution 
function of a Student's non-central t distribution with m degrees o f freedom and non­
centrality parameter a. To prove the result given in (2.2.21) some notation is first 
introduced. Let R and W denote random variables, then E(R\W) is defined to be the
random variable h(W) where h(w) = E(R |W= w). Also E{E(R |W)} is defined to be 
E[h(W)]. Now, to evaluate the left hand side o f (2.2.21) the problem can be thought of 
as a special case o f trying to determine
EfO(bY-Z)], (2 .2 .2 2 )
where Y = ^ % 2m / m and Z ~ N { ^ 0 2) independently of Y and b can take any value for 
some £ and 0~ to be chosen. Note that later in this section Y will be set as Y = s i  a  . 
It can be shown that for two random variables R and W
E[R]-E{E[R|W ]}, (2.2.23)
provided only that these expectations exist [Rao, 1965]. What one wishes to establish 
now is the result
E[<$(bY-Z)\ = P{X <bY - Z ) , (2.2.24)
where X is a standard Normal independent o f bY-Z. Setting the random variable W 
equal to W=bY-Z then by generalised addition law of probability one requires
P ( X  < W ) =  f P ( X  <  w | W  = \ v ) f  .
J H'
Since X is independent of W one requires 
P{ x  < w ) =  f p ( x  < w) f  (\v)dw
J H'
= f 0(vr)/(u')*ftv
Jw
Going back to (2.2.24) the event o f focus X<bY-Z may now be expressed in an 
equivalent form
+ Z b
 <  — .
< p Y  <p
This event is equivalent for any (p>0 . Now choose cp=V(l+02), since with that choice 
Y + Z
N
<P \ < P  j
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Finally one invokes the definitive characterisation o f a random variable T (m ,£ ) with a 
non-central t distribution having m degrees o f freedom and non-centrality parameter
S  = V1 + 6 2 ofT(5,m)=U/Y where U and Y are independent with U~N(5,1) and Y is
defined as Y = ^ x l  / m . Hence one requires (X+Z)/[Ycp]~T(^/cp,m). Finally, for the
special case o f setting -Z=-£,=a and 0 2 -  0 , and for any value of a and b one requires
£0{(6T  - a }  = probt[6 , /w, a ] . (2.2.25)
Now, since ms2/ a 2 ~ xl, it follows from this and (2.2.20) that
E(^F I 6 - a 2.«,,(/•♦ I)-2 ) = Pr°bt(t\ -a 2,n 4(r + 1) 2 ^1 -■// ’ 6 a 2,n , ( r + I)- 2 ) ’ (2.2.26)
The inequality,
probt(Zi_p+a,m,a)<l-p, (2.2.27)
is valid for any value a > 0 o f the non-centrality parameter, for any 0<p<0.5 and all 
degrees o f freedom m >1. To prove this result, apply the (monotonically increasing) 
inverse function tinv(», m , a) o f probt{*,m,a) , to each side o f (2.2.33) so that one can 
state that (2.2.33) is true if and only if
Zi.p+a<tinv(l-p,m,a). (2.2.28)
Note, that again the notation tinv(*m,a) agrees with the notation used in SAS.
As the right hand side of (2.2.28) is monotonically decreasing in the degrees of freedom 
m (for fixed 0<P<0.5 and a>()) the result follows since the right side will tend to the left 
hand side as m tends to go.
Hence if n is chosen to satisfy (2.2.17) it follows from (2.2.26), (2.2.27) and (2.2.28) 
that the expected power is less than its target
E(4/ ) <\ -  p . (2.2.29)
Hence (2.2.26) suggests that the deficit in the expected power associated with the finite 
precision of s when the choice of sample size is given by (2.2.17) may be corrected by 
choosing nA to satisfy [Julious, 2002a; Julious and Owen, 2006]
1 -  probt
f   ~ r  >rn xi
T,m,t
y (r +1)5' I a  2. n , ( rr  1) 2
J
> \ - p .  (2.2.30)
Hence the following result is indicated if
^ (r + ])s2[ th n { \ - / } ,m , t l a (2 2 3 0
rd'
then
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E ( ' ¥ ) > \ - 0 (2 .2 .32)
To prove this assertion note that the exact form o f (2.2.16) is
(2.2.33)
and hence if n satisfies (2.2.31 then
' V > < X > [ ( s l a ) t m v ( \ - (2.2.34)
Applying (2.2.21) to (2.2.34) for the expectation conditional on t implies that 
E(NP | probl{linv( 1 -  ,
and the inequality (2.2.32) follows on noting the identity 
obt{tinv( \ = 1 - / ?.
Note that, similar to the standard derivation given earlier in this chapter, the relevant 
condition (2.2.31) is an inequality (rather than equality) because n may only take an 
integer value. Thus for given power 1-/3, the sample size n would be chosen to be the 
least integer value satisfying (2.2.31). Note also an approximate solution for nA is given 
with Z i-a /2 replacing ti-a 2,nA(r+n-2 in (2.2.31) so that n would be chosen to be the least
integer exceed n A where
n\ = . (2.2.35,
rd'
This equation may be thought of as a version o f (2.2.18) which has been adjusted for 
uncertainty about the unknown true sampling standard deviation a.
As relationships (2.2.30) and (2.2.31) both have to be solved by iteration for a given 
power equation (2.2.35) can be used to provide initial values to start the iteration. From 
simple empirical observation it seems that an expected power o f at least 1-P is ensured 
through adding 1 to the sample size obtained from (2.2.35).
Exact sample size solutions satisfying (2.2.31) for the case r =1 (equal arms) are given 
in Table 2.3 for 5% significance (a=0.05) and 90% power (p=0.1) and a range o f values 
o f degrees of freedom m and a standardised difference defined as, d/s. The last row o f 
the table corresponds to m=oc and gives the 'traditional' value corresponding to the 
assumption that a 2 is known. This row is calculated from (2.2.4) (and (2.2.17)).
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Table 2-3. Sample sizes estimated for different standardised differences and 
degrees of freedom, m, about s2 from (2.2.30) and from simulations (in brackets). 
The final line with "infinite" degrees of freedom is from (2.2.4) and the assumption 
that the -population variance is being used. The type I error is set at a two sided 
level of 5% and the type II error is set at 10%
Standardised Difference
m 0.05 0.10 0.25 0.50 0.75 1.00
10 10933(10939) 2734 (2751) 439 (439) 111 (111) 50 (50) 29 (29)
25 9327 (9331) 2333 (2335) 374 (374) 95 (95) 43 (43) 25 (25)
50 8853 (8865) 2214 (2217) 355 (355) 90 (90) 41 (41) 23 (23)
75 8702(8700) 2176 (2182) 349 (349) 88 (88) 40 (40) 23 (23)
100 8627(8631) 2158 (2159) 346 (347) 88 (88) 40 (40) 23 (23)
200 8516 (8523) 2130 (2132) 342 (342) 86 (86) 39 (39) 23 (23)
500 8451 (8453) 2114 (2114) 339 (339) 86 (86) 39 (39) 22 (22)
oc 8407 2103 337 85 39 22
It is worth noting when considering the approximate formula for nA of (2.2.35) and
(2.2.18) that the ratio of these depends on a , p and m but not on r, s or d. Some values 
are given in Table 2.4. This table could be used to provide multiplication or inflation 
factors when standard formulae are used to calculate the sample size, such as (2.3.3), 
(2.2.4) or (2.2.6), to account for the imprecision in the variance.
Inflation Factor (IF) = (r + l)s : tinv(\ -  p ,  m, Z ]_a 2)f (2.3.36)
Note the sample sizes from (2.2.30) converge to (2.2.4) as nA gets large. Earlier in this 
chapter, using (2 .2 .6 ), the sample sizes were also derived from a non-central t 
distribution. However, as (2.2.30) converges to (2.2.4) there will be instances for large 
m where (2.3.40) gives a sample size one smaller than (2.2.6). For the inflation factors 
though as Z,_a not t]_a 2n<{r+])_, is used (2.2.6) becomes (2.2.4). Hence, the inflation
factors hold regardless o f the original sample size calculation as they are large sample 
results.
To further confirm the above sample sizes, from (2.2.30), simulations were undertaken 
in the Interactive Matrix Language (IML) in SAS [1985]. In undertaking the 
simulations for a given sample size, n, and standardised difference (<d / s ), a sample 
variance was first generated with m degrees o f freedom and then the power was 
calculated using expression (2.2.16). For a given sample size and degrees of freedom 
this was repeated 10,000 times and the average power was calculated across all the 
simulations. The sample size was then iterated until the average power was over 90% 
for the given standardised difference. This process was undertaken for different degrees 
o f freedom and for different standardised differences. The simulations confirm the 
results from (2.2.31) and are given in brackets in Table 2.3.
79
Table 2-4. Multiplication factors for different levels of two sided significance, type 
II error and degrees of freedom
m P
Significance Level ( a  )
0.010 0.025 0.050 0.100
5 0.05 2.232 2.145 2.068 1.980
0.10 1.819 1.761 1.711 1.652
0.15 1.614 1.571 1.533 1.489
0.20 1.482 1.449 1.419 1.385
0.50 1.122 1.120 1.117 1.114
10 0.05 1.488 1.454 1.425 1.392
0.10 1.346 1.322 1.301 1.276
0.15 1.268 1.249 1.233 1.214
0.20 1.215 1.200 1.187 1.172
0.50 1.056 1.055 1.054 1.053
25 0.05 1.172 1.160 1.150 1.139
0.10 1.126 1.117 1.109 1.101
0.15 1.100 1.092 1.086 1.079
0.20 1.081 1.075 1.070 1.065
0.50 1.021 1.021 1.021 1.021
50 0.05 1.083 1.077 1.072 1.067
0.10 1.061 1.057 1.053 1.049
0.15 1.049 1.045 1.042 1.039
0.20 1.040 1.037 1.034 1.032
0.50 1.010 1.010 1.010 1.010
75 0.05 1.054 1.051 1.047 1.044
0.10 1.040 1.037 1.035 1.032
0.15 1.032 1.030 1.028 1.026
0.20 1.026 1.024 1.023 1.021
0.50 1.007 1.007 1.007 1.007
100 0.05 1.040 1.038 1.035 1.033
0.10 1.030 1.028 1.026 1.024
0.15 1.024 1.022 1.021 1.019
0.20 1.020 1.018 1.017 1.016
0.50 1.005 1.005 1.005 1.005
2.3.1.7. Comment
The solution to the problem of accounting for the imprecision of the variance used in 
sample size calculations provided in this dissertation assumes that the source of 
variation in the estimate o f the variance is pure sampling variation. In practice true 
variances could differ from trial to trial by more than this suggests and so there is a 
potential limitation to the solution. However, it should be noted that the proposed 
solution is an improvement on what is commonly done at the moment, where the 
problem is ignored altogether. Also, the potential limitations become less important
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when one considers that the main issue discussed in this dissertation is the situation 
where the variance estimates are take from small trials. For such trials pure random 
variability will be a major component o f the overall variability.
The issue of heteroscadicity of trials will be discussed in Chapter 6 .
2.3.1.8. Worked Example
Suppose the investigator from the worked examples given earlier wished to account for 
the imprecision in the sample variance estimate in the design o f the trial. Remember the 
clinical effect of interest is a reduction in blood pressure compared to control o f 4mmHg 
(d) with an observed standard deviation from a pilot study 20mmgHg (s) estimated with 
10 degrees o f freedom. Thus, the standardised difference equates to 
5 = d / cr = 4 /2 0  = 0.20. For the Type I and Type II errors fixed at 5% and 10% 
respectively Table 2.4 gives a multiplication factor 1.301 for 10 degrees o f freedom. 
Previously the sample size, assuming the variance in the calculations to be a population 
variance, was estimated using (2.2.6) at 527 patients in each arm of the trial. To 
account for the imprecision in the sample variance therefore one needs to increase the 
sample size estimated earlier by 30% to 745 patients per arm. An inversion o f this 
argument would be to say that by assuming that the standard deviation was a population 
estimate the sample size could be considered to be underestimated by 30%. This 
underestimation o f the sample size would result in a reduction in the anticipated power 
by 6% to 84%.
It may seem an unrealistic scenario to undertake a large study where the calculations are 
based on such few degrees around the variance. However, it is not an unknown 
occurrence. Chapter 1 gave a worked example where not only was the individual trial 
sensitive to the assumptions made about the variance used in the sample size 
calculations but the entire clinical program (which was dependent on the results on the 
individual trial). Chapter 6 has a discussion on adaptive designs and sample size re­
estimation which should be considered for such situations.
2.3.1.9. Bayesian Methods
On an intuitive level if prior information is being used to power a study then it leads one 
to think of Bayesian methods. In Chapter 6 it will be highlighted how (2.2.36) can be 
extended to the case where an interim analysis is to be used to re-estimate the variance 
and hence re-calculate the sample size [Julious, 2004e]. This was an extension o f the 
work of Zucker et al [1999, 2002, 2004] who had previously undertaken the calculation 
through numerical methods. In Chapter 6 it will be highlighted how these numerical 
methods give the same result as the calculations using a non-central t-distributions 
[Julious, 2004e].
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Zucker et al [1999, 2004] also highlighted how the sample size re-estimation problem 
(and analogously the problem in this dissertation) can be thought o f in terms o f a 
predictive power calculation with a Jeffrey’s prior for the variance. However, this 
approach also utilises numerical methods to solve -  however, these methods do match 
the results in this chapter [Julious, 2004e].
Bayesian methods will be discussed later in this chapter for the situation where a non­
zero mean difference may be anticipate for equivalence, non-inferiority and 
bioequivalence trials. Also, Bayesian methods will be discussed in detail in subsequent 
chapters on binary data.
2.3.2. Cross-over Trials
2.3.2.1. Sample Sizes Estimated Assuming the Population Variance to be Known
For the analysis o f cross-over trial data this chapter will concentrate on the case where 
an analysis of variance is the primary analysis, fitting terms for subject, period and 
treatment. The assumption is that one is undertaking an AB/BA cross-over trial 
although the methodology described can be extended to a pair wise comparison in a 
multi-period cross-over trial (with appropriate adjustment to the degrees o f freedom). 
The within subject residual errors are assumed to be sampled from a Normal 
distribution. This approach is equivalent to the period-adjusted t-test [Senn, 1993].
2.3.2.2. Paired t-tests and Period Adjusted t-tests
The difference between a period adjusted t-test and a standard paired t-test is that for a 
paired t-test one simply places the observed individual effects on the two treatments in 
two columns -  ignoring any ordering. For each subject a treatment difference is 
calculated and consequently a mean of these differences, d , equivalent to /uA -  fuB, and
a standard deviation o f the differences <Jd . The test statistic is thus d4n!<Jd which is
compared to the t distribution on n-1 degrees o f freedom.
In a period adjusted t-test for each treatment sequence (AB or BA) a mean difference is 
calculated, d 4B , equivalent to f.iA -  f.iB, and dBA , equivalent to /nB -  /uA . Assuming that 
the allocation to each sequence, n 4B = nB4 = n /2 , and the within sequence variances, 
<7j = <Jd/i) = a ] , are equal then the mean difference of interest, (dAB - d BA) / 2 , has the
variance <Jd(\ n 4B +1 n 4B) / 4 = crd/yfn . Thus, the test statistics is
1 2 (d AB -  d s t ) 
cr, Vn
which is compared to the t distribution on n-2 degrees o f freedom.
If there is truly no period effect,
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and thus one would have an equivalent test to a paired t-test but with one less degree of 
freedom.
2.3.2.3. Sample Size Calculations
To estimate a sample size for a cross-over trials as well as quantifying the within subject 
estimate of the difference in treatment means that is of interest, the effect size, one also 
needs an estimate of the within- (intra-) subject standard deviation crM.. The within-
subject standard deviation is taken from the residual line of an ANOVA model and 
quantifies the expected variation among repeated measurements on the same individual 
[Julious, Campbell and Altman, 1999]. With an estimate of both the within subject 
standard deviation and the effect size (2 .2 .1) can again be solved as per a parallel group 
study
where n here is the total sample size. Note that the allocation ratio has not been used as 
per (2.2.3) as in a cross-over trial the meaning of r would be the allocation ratio per 
treatment sequence AB and BA. The assumption here is that subjects will be equally 
assigned to each sequence. If a sample variance is to be used in the analysis then one 
can rewrite (2.2.36) as
Similarly to parallel group trials, when the population variances is considered unknown 
for the statistical analysis, under H i: d * 0  the Type II error (and hence the power) 
should be calculated under the assumption of a non-central t distribution with degrees of
(2.2.36)
n > (2.2.37)
which in turn can be rewritten in terms o f power to solve iteratively for n
(2.2.38).
freedom n-2 and non-centrality parameter ^fnd2/ 2 a l  [Senn, 1993; Kupper and Hafner, 
1989, Julious, 2004a]. Thus, (2.2.44) can be rewritten as
In the same manner to a parallel group study one can add a correction factor o f Z,_a , 2 /2
to (2.2.36) to allow for the Normal approximation, and use this for initial calculations in
(2.2.39) [Guenther, 1981]
n=  ^ Z i .^ + Z  (2.2.40)
d 2 2
For quick calculations one can adapt (2.2.36) for the calculation o f sample sizes with 
90% power and a two-sided 5% type I error rate
21a 2
n = — (2. 2. 41)
d 2
As with the parallel group equivalents (2.2.40) and (2.2.41) give slightly lower results 
than (2.2.39), while also compared to (2.2.39), (2.2.38) will mostly give the same 
sample size -  occasionally underestimating by 1. Table 2.5 gives sample sizes using
(2.2.39) for various standardised differences ( 8  = d I a  ).
Table 2-5. Total sample sizes for a cross-over study for different standardised 
differences for 90% power and two sided type I error rate of 5%.
s n
0.10 2104
0.20 528
0.30 236
0.40 134
0.50 87
0.60 61
0.65 52
0.70 45
0.80 35
0.90 29
1.00 24
The total sample sizes for cross-over trials are nearly the equivalent to that for one arm 
of parallel group studies, for each standardised difference (S ) .  The slight differences 
are accounted for by the different degrees of freedom used in (2.2.6) and (2.2.39). 
Practically, though, they are the same. It should be noted, however, that the 
standardised differences in Tables 2.1 and 2.5 represent different quantities. The 
within- subject variance in a cross-over trial can be derived from a 2 = a 2 (1 -  p ) , where
a 2 is the population variance from a conventional parallel group design and p  is the
Pearson correlation coefficient estimated between two measures on the same subject. For 
a relatively modest correlation of 0.5, the within-subject variance would be half the 
population variance, and as a consequence the equivalent standardised difference would 
be 40% larger in a cross-over compared to a parallel group study. Parallel group and
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cross-over trials will only have an equivalent standardised difference for a zero 
correlation.
2.3.2.4. Worked Example
An investigator wishes to design a hypertension trial similar to that in the section on 
parallel group trials where the clinical effect o f interest is a reduction in blood pressure 
compared to control of 4mmHg (d). The expected within-subject standard deviation in 
the trial population the trial is expected to be half that of the between-subject standard 
deviation at 8mmgHg (<r). Thus, the standardised difference equates to 
5  = d l a  -  4 /8  = 0.50. For the Type I and Type II errors fixed at 5% and 10% 
respectively Table 2.5 gives a total sample size o f 87.
2.3.2.5. Sensitivity Analysis About the Variance Used in the Sample Size Calculations
As with parallel group trials the sensitivity of the sample size estimate in a cross-over 
trial is relatively straightforward to investigate. Equation (2.2.9) can be used with an 
estimate of the within subject population variance.
Table 2.6 gives the total sample size required for different standardised differences for a 
cross-over superiority trial along with the sensitivity o f these sample sizes to the 95th 
percentile of the variance for different degrees o f freedom. From Table 2.6 it seems, 
like with the parallel group trials, that to ensure that 50% and 80% power with the 95th 
percentile about the variance one would require 10 and 75 degrees o f freedom 
respectively.
2.3.2.6. Worked Example
Following on from the worked example given earlier -  a hypertension trial similar to 
that where the clinical effect o f interest is a reduction in blood pressure o f lOmmHg (d). 
Suppose that the within-subject standard deviation, of 20mmgFlg ( a ) ,  was estimated 
with 20 degrees of freedom then from Table 2.9 with an estimated sample size o f 87 for 
the trial one would have 67% power if the actual variance was nearer the plausibly high 
value.
85
Table 2-6. Total sample sizes for a superiority cross-over trial for different 
standardised differences with 90% power and 5% type I error rate along with the 
power corresponding to the 95th percentile of the variance for different degrees of 
freedom
6 n
Deerees o f  Freedom
5 10 15 20 2,5 30 40 50 75 100 200
0.10 2104 0.34 0.53 0.62 0.67 0.70 0.72 0.75 0.77 0.80 0.82 0.84
0.20 528 0.34 0.53 0.62 0.67 0.70 0.72 0.75 0.77 0.80 0.82 0.85
0.30 236 0.34 0.53 0.62 0.67 0.70 0.72 0.75 0.77 0.80 0.82 0.85
0.40 134 0.34 0.53 0.62 0.67 0.70 0.72 0.75 0.77 0.80 0.82 0.85
0.50 87 0.34 0.53 0.62 0.67 0.70 0.73 0.76 0.78 0.80 0.82 0.85
0.60 61 0.34 0.53 0.62 0.67 0.70 0.73 0.76 0.78 0.80 0.82 0.85
0.70 45 0.34 0.53 0.62 0.67 0.70 0.72 0.75 0.77 0.80 0.82 0.85
0.80 35 0.34 0.53 0.62 0.67 0.70 0.72 0.75 0.77 0.80 0.82 0.85
0.90 29 0.35 0.55 0.63 0.68 0.71 0.74 0.77 0.79 0.81 0.83 0.86
1.00 24 0.35 0.55 0.63 0.68 0.72 0.74 0.77 0.79 0.82 0.83 0.86
2.3.2.7. Calculations taking Account o f the Imprecision o f the Variance Used in the 
Sample Size Calculations
To account for the imprecision of the variance used in the sample size calculations the 
results for parallel group trials can be generalised to give the following formula
n >
2sl[tinv(\ -  f3, m, tx_a : ^ : )f
d 2
(2.2.42)
Where n is the least integer value for (2.2.42) to hold. One can rewrite (2.2.42) in terms 
o f power to obtain the following result
1 -  p  = 1 -  probt 'nd~? f" (2.2.43)
Replacing the t-statistic with a Z-statistic gives one the following result
n = 2 s ; [ / m v ( l - / 7 , m , Z , . g 2 ) J
d 2
(2.2.44)
which allows one to have a direct estimate o f the sample size and also gives an initial 
value for iterations for (2.2.42).
Exact sample size solutions satisfying (2.2.42) are given in Table 2.7 for 5% 
significance (a=0.05) and 90% power (p=0.1) and a range of values o f degrees of 
freedom m and a standardised difference defined as, d/s. The last row of the table 
corresponds to  m = oo and gives the 'traditional' value corresponding to the assumption 
that a 2 is known from (2.2.38).
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Table 2-7. Sample sizes estimated for different standardised differences and 
degrees of freedom from (2.2.42). The final line with "infinite” degrees of freedom  
is from (2.2.38) and the assumption that the population variance is being used.
The type I error is set at a two sided significance level of 5% and the type II error 
is set at 10%
Standardised Difference
m 0.05 0.10 0.25 0.50 0.75 1.00
10 10934 2735 439 111 51 30
25 9328 2333 375 95 44 25
50 8854 2215 356 91 41 24
75 8703 2177 350 89 41 24
100 8628 2158 347 88 40 24
200 8517 2131 343 87 40 23
500 8451 2114 340 86 40 23
oc 8408 2103 338 86 39 23
As with parallel group trials multiplication factors derived from (2.2.44) and (2.2.36) 
can be obtained to assist in trial design. As these depend only a , p and m (but not on r, 
s or d) these ratios are the same as, and are given in, Table 2.4.
2.4. E quivalence Trials
2.4.1. Parallel Group Trials
2.4.1.1. Sample Sizes Estimated Assuming the Population Variance to be Known
2.4.1.2. General Case
Recall from Chapter 1 that the total Type II error (define as /? = /?, + /?2) is derived 
from the following result
7  _  ~ d - A 7  _  d - A - z , (2.3.1)
For equivalence trials for the general case where the expected true mean difference is 
not fixed to be zero the sample size cannot be derived directly. This is because the total 
Type II error is the sum of the Type II errors associated with each one-tailed test. As is 
the case with superiority trials Var(S) can be defined as
Var (S ) = ^  + ^
n A n H
r  +  1 <j
n ,
(2.3.2)
From this, and the fact that the following can be used to derive the Type II
error (and power)
! - /?  = (!> f((/C - P B) ~ d f rnA
(/- + l)cr
Z, '( ( /T  - p B) + d f r n l 
(r + l)cr:
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The sample size cannot be derived directly; instead one has to iterate until a sample size 
is reached which gives the required Type II error (and power). If the variance is to be 
considered unknown for the statistical analysis (2.3.4) can be used
\ - p  = <x> (it*a - rnA 
( r  +  1) c t :
+ o
( r  +  1)<72
-t I 2 (2.3.3)
As with superiority trials it is best to assume a non-central t-distribution to calculate the 
Type II error and power. Under the assumption of a non-central t-distribution the power 
can be calculated using the following [Owen, 1965; Diletti, Hauschke, Steinijans, 1991; 
Julious, 2004a]
1 “ /? -  probt(— /, u „|(r.1) : , ^ ( r  + l ) - 2 , r : )-probt(f, a n<{r,{) : ,nA(r + 1 ) - 2 , r , ), (2.3.4)
where r, and r 2 are non centrality parameters defined as
r, =_ ((/U  - M B) +  d ) 4 ^ h  and = ((/',« ~  f - h ) ~
+ 1)<t2 V(r + 1)cr2
For quick calculations, and to provide an initial value for the sample size in the 
iterations, an estimate o f the sample size can be obtained from the following
n,  = (2.3.5)
This provides reasonable approximations for case of /uA-  /j b > 0 , especially when the 
mean difference approaches d. For very quick calculations, for 90% power and Type I 
error o f 2.5%, the following formula can be used
1 0 .5 c r (r  + l) 
((/U  ’
(2.3.6)
or for r= 1
2 1 o "n,  = (2 .3 .7 )
2.4.1.3. Special Case of No Treatment Difference
For the special case o f no treatment difference, /j a -  f iB = 0 , (2.3.3) can be rewritten to 
obtain a direct estimate of the sample size
" ' J r  + l ( 2 3 g )
r d "
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For case of the variance considered unknown for the statistical analysis, (2.3.8) can be 
written in terms of
(r + 1)ct: (z
(2.3.9)
Equation (2.3.9) can be rewritten to give power in terms of the sample size
/
1 -  /? = 2 0  4 -  - t
(r +  l)c r  "
(2.3.10)
V
and, similarly to (2.3.4), under the assumption of a non-central t-distribution, the power 
can be derived from
-\{r + l ) a 2
For quick calculations, for 90% power and Type 1 error o f 2.5%, the following formula, 
similar to (2.3.6) can be used
The quick equations give reasonable estimates o f the sample size, underestimating by 
one or two, and thus provide reasonable initial values for (2.3.4) and (2.3.11). It was 
worth noticing the difference between (2.3.12) and (2.3.13) compared to (2.3.6) and
(2.3.7). The difference in the coefficients (10.5 and 21 compared to 13 and 26) is to do 
with the non-symmetric allocation o f the Type II error if the population mean is non­
zero. Table 2.8 gives sample sizes for equivalence trials using (2.3.4).
1 -  p  = 2probt(- tx1 - a  , /i j (r + 1 )  - 2  ’,nA(r + l) - 2 , r ) - l , (2.3.11)
where r  is defined as
T =
n 13cr(r + l) 
d 2r
(2.3.12)
or, for r= l,
2 6 a 2
(2.3.13)
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Table 2-8. Sample sizes (nA) for one arm of a parallel group equivalence study with 
equal allocation (r=l) for different standardised equivalence limits and true mean 
differences (as a percentage of the equivalence limit) for 90% power and type I 
error rate of 2.5%
Percentage Mean Difference
d 0% 10% 15% 20% 25%
0.10 2600 2762 2980 3306 3741
0.20 651 691 746 827 936
0.30 290 308 332 369 417
0.40 164 174 188 208 235
0.50 105 112 121 134 151
0.60 74 78 84 93 105
0.70 55 58 62 69 78
0.80 42 45 48 53 60
0.90 34 36 38 42 48
1.00 27 29 31 35 39
2.4.1.4. Worked Example
An investigator wishes to design a hypertension trial where the objective is to 
demonstrate equivalence between the two treatments. The largest clinically acceptable 
effect for which equivalence can be declared is a change in blood pressure o f 4mmHg 
(d). There is to be equal allocation between groups. The true mean difference between 
the treatments is thought to be zero and the expected standard deviation in the 
population in which the trial is to be undertaken is 25mmHg (cr). Thus, the 
standardised equivalence limits equate to ± 5 = ±d / cr = ±5/25 = ±0.20. For the Type I 
and Type II errors fixed at 2.5% and 10% respectively Table 2.8 gives a sample size of 
651 patients in each arm of the trial.
Suppose the true mean difference is thought to be ImmHg. This equates to 20% o f the 
standardised equivalence limits and would inflate the sample size to 827 patients in each 
arm o f the trial.
2.4.1.5. Sensitivity Analysis About the Variance Used in the Sample Size Calculations
As with superiority trials described earlier in this chapter the sensitivity of the sample 
size estimate to the variance used in the calculations is relatively straightforward to 
investigate. Equation (2.2.9) can be used to estimate a plausibly large value for the 
population variance and from this the sensitivity o f the study (assessed as a loss in 
power) to this high variance.
With equivalence trials however, one has the further factor to investigate o f the 
sensitivity o f calculations about the true mean difference. If one has assumed no 
difference when it was truly non-zero then this will have an effect on the power o f the 
study.
Table 2.9 gives the sample size per group required for different standardised 
equivalence limits for a parallel group equivalence trial along with the sensitivity of
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these sample sizes to the 95th percentile o f the variance (for different degrees o f 
freedom) and different mean differences (assuming the mean difference is zero).
Table 2-9. Sample sizes per arm for a parallel group equivalence trial for different 
standardised equivalence limits with 90% power and 2.5% type I error rate along 
with the power corresponding to the 95th percentile of the variance for different 
degrees of freedom and different mean differences
Sample 
d Size
True
Mean
Diff
(%)
Degrees o f  Freedom
10 25 50 75 100 500 00
0.05 10397 0 0.24 0.57 0.70 0.75 0.78 0.85 0.90
5 0.24 0.57 0.70 0.75 0.77 0.85 0.89
10 0.23 0.56 0.68 0.73 0.76 0.83 0.88
15 0.22 0.54 0.66 0.70 0.73 0.80 0.85
20 0.22 0.51 0.62 0.67 0.69 0.76 0.81
25 0.20 0.47 0.58 0.62 0.64 0.72 0.77
0.10 2600 0 0.24 0.57 0.70 0.75 0.78 0.85 0.90
5 0.24 0.57 0.70 0.75 0.77 0.85 0.89
10 0.23 0.56 0.68 0.73 0.76 0.83 0.88
15 0.22 0.54 0.66 0.70 0.73 0.80 0.85
20 0.22 0.51 0.62 0.67 0.69 0.76 0.81
25 0.20 0.47 0.58 0.62 0.64 0.72 0.77
0.15 1157 0 0.24 0.57 0.70 0.75 0.78 0.85 0.90
5 0.24 0.57 0.70 0.75 0.77 0.85 0.89
10 0.23 0.56 0.68 0.73 0.76 0.83 0.88
15 0.22 0.54 0.66 0.70 0.73 0.80 0.85
20 0.22 0.51 0.62 0.67 0.69 0.76 0.81
25 0.20 0.47 0.58 0.62 0.64 0.72 0.77
0.20 651 0 0.24 0.57 0.70 0.75 0.78 0.85 0.90
5 0.24 0.57 0.70 0.75 0.77 0.85 0.89
10 0.23 0.56 0.68 0.73 0.75 0.83 0.88
15 0.22 0.54 0.66 0.70 0.73 0.80 0.85
20 0.21 0.51 0.62 0.66 0.69 0.76 0.81
25 0.20 0.47 0.58 0.62 0.64 0.72 0.77
0.25 417 0 0.24 0.57 0.70 0.75 0.78 0.85 0.90
5 0.23 0.57 0.70 0.75 0.77 0.85 0.89
10 0.23 0.56 0.68 0.73 0.75 0.83 0.88
15 0.22 0.53 0.66 0.70 0.73 0.80 0.85
20 0.21 0.51 0.62 0.66 0.69 0.76 0.81
25 0.20 0.47 0.58 0.62 0.64 0.72 0.77
From Table 2.9 it seems that assuming a trial has been designed with 90% power:
• With 25 degrees of freedom, if the true variance was nearer to the 95th 
percentile then one would have 50% power. With 100 degrees of freedom then 
if the true variance was nearer to the 95th percentile then one would have 80% 
power. Both calculations assume there is no mean difference.
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• If one's variance estimate was close to the true variance then even if the true
mean difference was 20% of the standardised equivalence limit then one would
still have 80% in the study.
• With moderate degrees o f freedom a study is reasonably robust to deviations in
the assumptions either about the true mean or the variance but less so to
deviations in both simultaneously.
2.4.1.6. Worked Example
In the worked example given earlier a sample size o f 651 was calculated for a 
standardised equivalence limit of 0.20. Now suppose the variance used in the 
calculations was estimate with 25 degrees of freedom then from Table 2.9 Table 2.10 
could be built as an investigation o f the sensitivity o f the study.
Table 2-10. Worked example of a sensitivity analysis for an individual equivalence 
study.
True Difference (%) Power
0 0.57
5 0.57
10 0.56
15 0.54
20 0.51
25 0.47
The values in each cell are the calculated powers of the study for the different scenarios.
2.4.1.7. Calculations Taking Account o f the Imprecision of the Variances Used in the 
Sample Size Calculations
2.4.1.8. General Case
Extending the arguments from superiority trials. To account for the degrees o f freedom 
of the sample variance used in the calculations the following equation could be used to 
calculate the power
l - / ?  = p r o b t ( - r , , w „„Ar,u 2) -  probt (r, , m , t x „  __2 ), (2.3.14)
where r, and r 2 are the absolute standardised equivalence limits defined as defined as
I ( M a - V b ) -  V ™ 7  A \ ( Ma ~  M b )  +  d \r, = J - = = !=------- and r , = J . .  .
y]{r + \ ) s2 ' yj(r + \) s2
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To calculate the sample size one would need to iterate to find the minimum value that 
would give the required power from (2.3.14).
For non zero treatment differences (i.e. for /aA — n B > 0 ) most o f the Type Two error 
would be coming from just one tail and hence the power could be estimated from
1 -  p  = 1 -  probt
\ l (r + l ) s 2
, rnj 1 -  a ,n A ( r t I ) -  2 (2.3.15)
Which when written in terms of n becomes 
(r + l ) j2[r/>iv(l -  /?, m, tl) 2 J
" ,  £ (2.3.16)
Replacing the t-statistic with a Z-statistic and (2.3.15) can in turn be approximated from 
the following equation to give a direct estimate of the sample size
(r + \)s2[tinv(\-/3,m,  Z,.a )f (2.3.17)
This direct estimate could be used to provide initial estimates o f the sample size for
(2.3.14).
2.4.1.9. Special Case of No Treatment Difference 
For the special case of no treatment difference the power can be estimated from 
l - / ?  = 2 p r o b t ( r , li(„ IH, ) - l ,  (2.3.18)
where r  is defined as
_ -  yfn Ard 
y](r + \)s2
which when written in terms of n becomes
( r +  \)s2\tinv(\ -  0  2 , m,  t. ..
n >  ------ L-----V . (2.3.19)
rd2
Replacing the t-statistic with a Z-statistic and (2.3.19) can in turn be approximated from
the following equation to give a direct estimate of the sample size.
+ (2.3.20)
rd~
93
Tables 2.11 and 2.12 are produced for the special case o f no mean difference between 
treatments. Table 2.11 gives the sample sizes for different degrees o f freedom and 
standardised equivalence limits.
Table 2-11. Sample sizes estimated for different standardised equivalence limits 
and degrees of freedom from (2.3.14). The final column with "infinite" degrees of 
freedom is from (2.3.3) and the assumption that the population variance is being 
used. The type I error is set at a two one-sided significance level of 2.5% and the 
type II error is set at 10%
d
Degrees o f  f  reedom
10 25 50 75 100 500 00
0.10 3705 2990 2787 2723 2692 2618 2600
0.20 927 748 698 682 674 655 651
0.30 413 333 311 304 300 292 290
0.40 233 188 175 171 169 165 164
0.50 149 121 113 110 109 106 105
0.60 104 84 79 77 76 74 73
0.70 77 62 58 57 56 55 54
0.80 59 48 45 44 43 42 42
0.90 47 38 36 35 34 33 33
1.00 38 31 29 28 28 27 27
Table 2.12 gives the multiplication factors, compared to assuming one has the 
population variance, for various degrees o f freedom and Type I and II errors. Similar to 
superiority trials (2.3.20) converges to (2.3.10), however, the multiplication factors can 
be used regardless of the original formula for calculations.
2.4.1.10. Worked Example
Returning to the worked example given earlier for a standardised equivalence limit of 
0.20 with 25 degrees o f freedom for the variance Table 2.11 gives a sample size o f 748. 
This compares to sample size of 651 calculated assuming one had the population 
variance for calculations - a potential under estimation of the sample size of 16%.
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Table 2-12. Multiplication factors for different levels of one sided significance, type 
II error and degrees of freedom
m 0
Significance Level (a)
0.010 0.025 0.050 0.100
5 0.05 2.649 2.509 2.385 2.238
0.10 2.167 2.068 1.980 1.875
0.15 1.929 1.850 1.780 1.696
0.20 1.776 1.711 1.652 1.581
0.50 1.367 1.337 1.311 1.278
10 0.05 1.611 1.562 1.520 1.470
0.10 1.463 1.425 1.392 1.353
0.15 1.382 1.351 1.323 1.290
0.20 1.328 1.301 1.276 1.248
0.50 1.166 1.153 1.141 1.127
25 0.05 1.208 1.192 1.178 1.162
0.10 1.163 1.150 1.139 1.125
0.15 1.137 1.126 1.116 1.105
0.20 1.119 1.109 1.101 1.091
0.50 1.062 1.058 1.053 1.058
50 0.05 1.099 1.091 1.085 1.077
0.10 1.078 1.072 1.067 1.060
0.15 1.066 1.061 1.056 1.051
0.20 1.058 1.053 1.049 1.044
0.50 1.031 1.028 1.026 1.024
75 0.05 1.065 1.060 1.056 1.051
0.10 1.052 1.047 1.044 1.040
0.15 1.044 1.040 1.037 1.033
0.20 1.038 1.035 1.032 1.029
0.50 1.020 1.019 1.017 1.016
100 0.05 1.048 1.044 1.041 1.038
0.10 1.038 1.035 1.033 1.030
0.15 1.033 1.030 1.028 1.025
0.20 1.029 1.026 1.024 1.022
0.50 1.015 1.014 1.013 1.012
2.4.1.11. Calculations Taking Account of the Imprecision of the Mean and Variance 
Used in the Sample Size Calculations
As well as being sensitive to the assumptions around the variance the sample size 
calculations are also sensitive to the assumptions around the assumed mean difference. 
The more the mean difference deviates away from the assumptions in the calculations 
(and nearer the margins) the greater the reduction in power. If one has an estimate of 
the mean difference ( - x B) from a previous study then one could use the standard error 
around this mean difference (se(7xt - x B) )  when estimating the sample size.
For the general case *4-.vB*o the power for a given sample size can be estimated 
(through numerical integration) from
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\ - p =  £  o.ooi*
probt
-  probt 
probt
-  probt
yfrn , ((*., -  x H ) + Z , s e { x A -  x„ ) - d  j
!(r + l ) s :
( rrn A((*, - x H) + Z se(x , - x H) + d )
\ j(r  + \ ) s2
yf-/», ((*, -  x „ ) + Z p. o m se{:xA - x H) - d )  
yj(r + \ ) s2
J rn  4 (v,, ~ x H) + Z rtl)MUs e (xA - x H) + d ) 
y[(r +1 ) s 2
I™*'.
(2 .3 .21)
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where the sample size required is the minimum value which gives the required sample 
size. z p is the value from the Normal distribution that equates to the percentile p.
This result however is practically unappealing as the only way for a sample size to be 
easily estimable is for the cases where equivalence has already been demonstrated i.e. 
all plausible values for the mean difference fall within the equivalence margin. 
Practically to allow for possible mean differences between treatments one should first 
investigate the sensitivity of the trial to the assumptions about the mean difference (all 
trials will still have 80% power if one assumes no mean difference for the calculations 
but the true mean difference is 20% of the equivalence margin). If the trial is quite 
sensitive to the mean difference assumption then the calculations should maybe be 
repeated allowing for a small mean difference between treatments.
2.4.1.12. Calculations Taking Account o f the Imprecision of the Mean and Variance Used 
in the Sample Size Calculations -  A Bayesian Approach
In this section it will be demonstrated how simple Bayesian methods could be employed 
to estimate sample sizes allowing for imprecision in the mean and variance. The 
rationale for this section is not to give a detailed exposition of Bayesian methodology 
but to detail how this methodology may be applied.
The context o f the methodology with the situation in hand is to interrogate sample sizes 
where an equivalence study is to be planned and a mean difference, d l = x 1 - x B, has
previously been observed. In the prospective trial being designed inference is to be 
made about the ‘true’ difference o.
For the given sample size what needs to be determined is the probability of observing a 
given difference, (i , or greater for e given that dx has already been observed i.e.
P r o b( 0  > c / J j , ) •
Note, the methodology described in the previous subsection, (2.3.1.11), could be 
considered to be sample calculations calculated under a Bayesian framework but with a 
non-informative prior distribution for 0 .
What is to be undertaken now is an investigation o f calculations where the assumption 
is that there is prior knowledge about the mean difference that will be used. Simply, for
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a hypothesis H suppose that prior to observing data D one believed H with probability 
P(H) then after observing D one should believe H with probability (from Bayes’ rule)
P(H|D)=P(D|H)P(H)/P(D). (2.3.22)
For inference about an unknown continuous parameter, 0, what one is interested in is 
how would our belief about 0 change. If the prior is expressed in the density p(0) and if  
subsequently data x are observed then the posterior distribution is expressed in the 
density, p(0|x), where the Bayes’ rule for densities is
p(0|x)ocA.(x|0)p(0), (2.3.23)
where X(x|0) is the likelihood function. Note the constant o f proportionality is chosen 
so that it integrates to 1 and the likelihood function is considered defined for the whole 
range (though may be zero for parts of it).
For Normal data o f the form
Xi,X2,...Xn~N(0,a2), (2.3.24)
where one wishes to obtain inference about 0 for given a 2 one has the following prior
0~N(po,<JO2), (2.3.25)
The Normal family is conjugate in this case (both the prior and the posterior have the 
same distribution). The Bayesian updating rules for the case described in this section 
can be defined as follows.
2.4.1.13. Prior Response
Prior values for the mean difference and population standard deviation are defined as d{) 
(i.e. for r,-.vs) and So respectively. These values can be subjective values taken as 
beliefs about the mean difference.
2.4.1.14. Anticipated Response
The anticipated mean difference and population standard deviation are defined as^  and 
j, respectively. These values are taken as objective values observed in a previous 
clinical trial. Hence s^{r+\)/ni is an estimate of the standard deviation around the mean 
where r is the allocation ratio between groups.
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2.4.1.15. Posterior Response
With the anticipated and prior responses the posterior distribution can be calculated 
through a weighted sum of the prior and anticipated responses. The posterior estimate 
o f the variance around the mean, s2, is defined as
(2.3.26)
and the posterior estimate of the mean difference, d,,, is defined as
< = A i L +4 ' n
K *f (/• + !)
(2.3.27)
From these posterior values a density distribution for prob(6 < dt | d ,) can be defined 
such that a probability of observing r/ , or greater, for a given dn would be
d„ -  d. (2.3.28)
or alternatively for prob{6 < dt \ d x)
p ro b{ 6  > d \ d l ) = O
d. - d . .
From this result a mean difference d for given percentile p can be estimated and put 
into the following result for the general case x t - x B *o, to estimate the power for a given 
sample size.
]-/? = £ 0.00l.r
I ( Vrn J I \ d r n A\ci~d )
probt -  ,m, -t, t | , I - probtl — ~r-----------— , mj , |rW
L I ^{r + \)s- .....  1
J f yjrn , ( - d - d 
probtl ------, m,-t.
)
(r+ l)r'
- probt
yj{r *■ l)r 
'frn A{d - d  ,
, (2.3.29)
where the sample size is estimated through numerical integration and iteration.
Note that for this Bayesian approach if 5 is set to a very large value (2.3.29) will 
approach (2.3.21) described earlier as
+  ' 4 (-r  + 1 U ' - l  a n d  ,/, - 4 d ’ + - I 1-'™—  U , / , -
( j , ( r  + l) s ' )  (  rn ) ( s +
In the context of the problem here elementary Bayesian procedures can enhance insights 
into the reliability o f inferences. As well as using empirical observation, beliefs about 
the results that are anticipated can be used in sample size calculations. The invocation 
o f a prior could provide an opportunity to the explore robustness (sensitivity) o f 
calculations. For example you may be more sceptical in your priors than results 
previously observed. This more sceptical subjective prior could be used to calculate 
posterior probabilities and hence sample size calculations.
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As with the result discussed in section (2.3.1.11) there is no great practical application 
o f (2.3.39). Bayesian inference around the mean response will be discussed in greater 
detail in Chapter 4 for binary data.
2.4.2. Cross-over Trials
The methodologies and assumptions for an equivalence trial with a cross-over design 
are the same as those for parallel group equivalence trials (for the methodologies) and a 
superiority cross-over trials (for assumptions about the parameters). This subsection 
will therefore only go briefly through the sample size calculations for an equivalence 
trial with a cross-over design.
2.4.2.1. Sample Size Estimated Assuming the Population Variance to be Known
2.4.2.2. General Case
The Type II error (and power) can be estimated from
\
+ cr>
\ 2a:
(2.3.30)
If the variance is to be considered unknown for the statistical analysis then (2.3.22) can 
be rewritten as
1 - / ?  = <P ( ( ( / '  < - p B) - d f n
\
+ (D
\
V 2 c r : 1 u 
V ’ J v V 2 a ; /
l ’ (2.3.31)
and under the assumption of a non-central t-distribution the power [Owen, 1965; Diletti, 
Hauschke, Steinijans, 1991] can be estimated from
1 - P  = p r o b t ( - - 2 , r, )-probt(r,  -  2 , r , ),
where r, and r , are defined as
(2.3.32)
r, = ((/'.< - V B) + d'hfn ^  r _ ((/',i - f ‘s ) - d ) 4 n
1 (7 .
For quick calculations the sample size can estimate from
(2.3.33)
and for very quick calculations, for 90% power and Type I error o f 2.5%, one can use 
the following
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n = ^  r r .  (2.3.34)
((Ma - M B) - d Y
2.4.2.3. Special Case of No Treatment Difference
For the special case o f /uA -  fuB = 0 a direct estimate o f the sample size can be 
estimated from
2(71 (z. + Z. V
n = —  V , (2.3.35)
which, if  the variance is to be considered known for the statistical analysis, can be 
rewritten as
n = 2 _ J
d-
Equation (2.3.28) can be rewritten as
\ -  P  =  2 0 1, (2.3.37)
which in turn, under the assumption of a non-central t-distribution, can also be rewritten 
as
1 -  P  = 2probt(- t ^ a „ -  2 , r ) - 1, (2.3.38)
where r  is defined as 
-  yfndx =
For quick calculations, for 90% power and Type I error of 2.5%, the result formula can 
be used
n = ^ y .  (2.3.39)
d 2
As with parallel groups the quick equations give reasonable estimates of the sample 
size, underestimating the sample size by just one or two subjects, and thus provide 
reasonable initial values for iterations. Table 2.13 gives sample sizes using (2.3.32) for 
various standardised equivalence limits ( S = d/<j )  and mean differences.
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Table 2-13. Total sample sizes (n) for cross-over equivalence study for different 
standardised equivalence limits and true mean differences (as a percentage of the 
equivalence limit) for 90% power and type I error rate of 2.5%
d
Percentage Mean Difference
0% 10% 15% 20% 25%
0.10 2601 2763 2981 3307 3742
0.20 652 692 747 828 937
0.30 291 309 333 370 418
0.40 165 175 189 209 236
0.50 106 113 122 135 152
0.60 75 79 85 94 106
0.70 56 59 63 70 79
0.80 43 46 49 54 61
0.90 35 37 39 43 49
1.00 29 30 32 36 40
2.4.2.4. Sensitivity Analysis About the Variance Used in the Sample Size Calculations
Table 2.14 gives the total sample size required for different standardised equivalence 
limits for a cross-over equivalence trial along with the sensitivity o f these sample sizes 
to the 95th percentile of the variance (for different degrees of freedom) and different 
mean differences (assuming the mean difference is zero).
The inference and conclusions from the table are virtually identical to those for parallel 
group trials.
2.4.2.5. Calculations Taking Account of the Imprecision of the Variance Used in the 
Sample Size Calculations
2.4.2.6. General Case
To account for the degrees of freedom of the within subject sample variance the 
following equation could be used to calculate the power.
1 - p  = probt (-  r 2, m - t i a ) -  probt (r, , m, t t_a n_2) (2.3.40)
where r, and are the absolute standardised equivalence limits defined as defined as
. |(^-t ~ ^ n )  + d\yfn
r, = ----------= ------------- and r, = -------------- .
' V2s .
To calculate the sample size one needs to iterate to find the minimum value that would 
give the required power from (2.3.40).
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Table 2-14. Total sample sizes for a cross-over equivalence trial for different 
standardised equivalence limits with 90% power and 2.5% type I error rate along 
with the power corresponding to the 95th percentile of the variance for different 
degrees of freedom and different mean differences
d
Sample
Size
True
Mean
D iff
(%)
Degrees o f  Freedom
10 25 50 75 100 500 00
0.05 10398 0 0.24 0.57 0.70 0.75 0.78 0.85 0.90
5 0.24 0.57 0.70 0.75 0.77 0.85 0.89
10 0.23 0.56 0.68 0.73 0.76 0.83 0.88
15 0.23 0.54 0.66 0.70 0.73 0.80 0.85
20 0.22 0.51 0.62 0.67 0.69 0.76 0.81
25 0.20 0.47 0.58 0.62 0.64 0.72 0.77
0.10 2601 0 0.24 0.57 0.70 0.75 0.78 0.85 0.90
5 0.24 0.57 0.70 0.75 0.77 0.85 0.89
10 0.23 0.56 0.68 0.73 0.76 0.83 0.88
15 0.23 0.54 0.66 0.70 0.73 0.80 0.85
20 0.22 0.51 0.62 0.67 0.69 0.76 0.81
25 0.20 0.47 0.58 0.62 0.64 0.72 0.77
0.15 1158 0 0.24 0.57 0.70 0.75 0.78 0.86 0.90
5 0.24 0.57 0.70 0.75 0.77 0.85 0.89
10 0.23 0.56 0.68 0.73 0.76 0.83 0.88
15 0.23 0.54 0.66 0.70 0.73 0.80 0.85
20 0.22 0.51 0.62 0.67 0.69 0.76 0.81
25 0.20 0.47 0.58 0.62 0.64 0.72 0.77
0.20 652 0 0.24 0.57 0.70 0.75 0.78 0.86 0.90
5 0.24 0.57 0.70 0.75 0.77 0.85 0.89
10 0.23 0.56 0.68 0.73 0.76 0.83 0.88
15 0.23 0.54 0.66 0.70 0.73 0.80 0.85
20 0.22 0.51 0.62 0.67 0.69 0.76 0.81
25 0.20 0.47 0.58 0.62 0.64 0.72 0.77
0.25 418 0 0.24 0.57 0.70 0.75 0.78 0.86 0.90
5 0.24 0.57 0.70 0.75 0.77 0.85 0.89
10 0.23 0.56 0.68 0.73 0.76 0.83 0.88
15 0.23 0.54 0.66 0.70 0.73 0.80 0.85
20 0.22 0.51 0.62 0.67 0.69 0.76 0.81
25 0.20 0.47 0.58 0.62 0.64 0.72 0.77
For non-zero treatment differences (i.e. for //., -  Mb > 0 )  the power could be estimated 
from
1 -  P  -  1 -  probt
V2.v.
j n j . (2.3.41)
Which when written in terms of n becomes 
m, )f
n >
{(Ma ~ Mb) ~ d f
(2.3.42)
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Replacing the t-statistic with a Z-statistic and (2.3.42) can in turn be approximated from
n = 2 , ; M l - / ? , m . Z , - j r  (2 3 43)
{ ( M a ~  M n ) - d \
This direct estimate could be used to provide initial estimates o f the sample size for 
(2.3.40).
2.4.2.7. Special Case of No Treatment Difference 
For the special case of no treatment difference the power can be estimate from 
1 - P = 2probt{r ,m-t\  a n , ) - 1 ,  (2.3.44)
where r  is defined as 
yfndT =
4 2 s w
Which when written in terms of n becomes
2si\tinv( 1 -  J3 2, m,t. , )f
n > - ^ ± -----^ H , (2.3.45)
d 2
Replacing the t-statistic with a Z-statistic and (2.3.45) can in turn be approximated from
d '
Table 2.15 gives the sample sizes for different degrees o f freedom and standardised 
equivalence limits. For cross equivalence trials, as with superiority trials, the 
multiplication factors only depend on the Type I and II errors and the degrees of 
freedom and are the same as for parallel group trials given in Table 2.12
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Table 2-15. Sample sizes estimated for different standardised equivalence limits 
and degrees of freedom from (2.3.32). The final column with " infinite” degrees of 
freedom is from (2.3.41) and the assumption that the within subject population 
variance is being used. The type I error is set at a two one-sided significance level 
of 2.5% and the type II error is set at 10%
Degrees o f  Freedom
d 10 25 50 75 100 500 00
0.10 3706 2991 2788 2724 2693 2619 2601
0.20 928 749 698 682 675 656 652
0.30 414 334 311 304 301 293 291
0.40 233 189 176 172 170 165 164
0.50 150 121 113 111 109 107 106
0.60 105 85 79 77 77 75 74
0.65 90 73 68 66 66 64 63
0.70 78 63 59 57 57 55 55
0.80 60 49 45 44 44 43 42
0.90 48 39 36 36 35 34 34
1.00 39 32 30 29 29 28 28
2.4.2.8. Calculations Taking Account o f the Imprecision of the Mean and Variance Used 
in the Sample Size Calculations
For the general case o f x t - x b the power for a given sample size can be estimated 
(through numerical integration) from
\ - [3 = £  0.00U
p r o b t
-  p r o b t  
p r o b t
-  p ro b t
4 n ((.vA - x B) + Z „ s e (x 4 -  x B ) - d )
Vn((.vA -  x B ) + Z se(x , -  x B ) + d)
,m,t\ (2.3.47)
where the sample size required is the minimum value which gives the required sample 
size. z„ is the value from the Normal distribution that equates to the percentile p. As
with parallel group trials there is little practical application o f this result.
2.4.2.9. Calculations Taking Account of the Imprecision of the Mean and Variance Used 
in the Sample Size Calculations -  A Bayesian Approach
In this section the Bayesian methods described for parallel group data will be extended 
to cross-over data.
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2.4.2.10. Prior Response
Prior values for the mean difference and within subject population standard deviation 
are defined as </o (i.e. for pA- p B) and S i) respectively. As with parallel group data these
values can be subjective values taken as beliefs about the mean difference.
2.4.2.11. Anticipated Response
The anticipated mean difference and within subject population standard deviation are 
defined as^  and s respectively. These values are taken as objective values observed
in a previous clinical trial. Hence Jis„,/« is an estimate o f the within subject standard 
deviation around the mean.
2.4.2.12. Posterior Response
With the anticipated and prior responses the posterior distribution can be calculated 
through a weighted sum of the prior and anticipated responses. The posterior estimate 
o f the within subject population variance around the mean, ^  , is defined as
(2.3.48)
and the posterior estimate of the mean difference, ^  , is defined as
(2.3.49)
From these posterior values a density distribution for prob(0 < dj \ d ,) can be defined 
such that a probability of observ ing j  , or greater, for a given <■/ would be
p r ob { 9  > d . \d | ) = <t> (2.3.50)
or alternatively for prob(0 < d t \ d ])
p r ob { 9  > d \ d \ ) = O
From this result a mean difference </ for given percentile p can be estimated and put 
into the following result for the general case V| *o, to estimate the power for a given 
sample size
where the sample size is estimated through numerical integration and iteration.
2.5. N on-Inferiority Trials
2.5.1. Parallel Group Trials
2.5.1.1. Sample Size Estimated Assuming the Population Variance to be Known 
From Chapter 1 one requires
i d  — A ) 2
Var (S) =
( Z \ - a
(2.4.1)
and as with superiority and equivalence trials Var(S) can be defined as 
r + 1 a 2Var (5 ) =
r n
which can be substituted in to (2.4.1) (replacing A with fu4 - / u B) giving a direct 
estimate o f the sample size
(r + l)cr(z,_/? +Z[_a):
(2.4.2)
Rewriting (2.4.2) to give power for a give sample size results in
((Ma - / ' * ) - o' ): ™,,
(r + 1)<t
-Z ,
The equivalent for the case when the variance is considered unknown for the analysis is
\ - P  = 0 ((/C -  Mb) ~ d f rn A
y ( r  +  l ) c r
- t r a . /i | (/ + I) - 2 (2.4.3)
As with the sections on equivalence and superiority trials it is best to calculate the 
power under the assumption of a non-central t-distribution [Julious, 2004a]
1 ~ P  = 1 -probt(r, + l ) - 2 , r ) , (2.4.4)
where r  is defined as
(it*a - P n ) - d )4™,
^ ( r  + \)cr2
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For quick calculations, for 90% power and Type I error o f 2.5%, the following formula 
can be used
10.5o-: (r + l)
In the case o f r=l (2.4.5) resolves to
(2 A 6 )
The quick equations give reasonable estimates o f the sample size, although with slight 
underestimation. Table 2.16 gives sample sizes using (2.4.4) for various standardised 
non-inferiority limits (<5 = d/cr)  and standardised mean differences assuming equal
allocation between groups.
Table 2-16. Sample sizes (nA) for one arm of a parallel group non-inferiority study 
with equal allocation for different standardised non-inferiority limits and true 
mean differences (as a percentage of the non-inferiority limit) for 90% power and 
type I error rate of 2.5%
Percentage Mean Difference
d -25% -20% -15% -10% -5% 0% 5% 10% 15% 20% 25%
0.10 1346 1461 1590 1738 1908 2103 2330 2596 2910 3285 3737
0.20 338 366 399 436 478 527 584 650 729 822 935
0.30 151 164 178 194 213 235 260 290 325 366 417
0.40 86 93 101 110 121 133 147 164 183 207 235
0.50 55 60 65 71 78 86 95 105 118 133 151
0.60 39 42 46 50 54 60 66 74 82 93 105
0.70 29 31 34 37 40 44 49 54 61 68 78
0.80 23 24 26 29 31 34 38 42 47 53 60
0.90 18 20 21 23 25 27 30 34 37 42 48
1.00 15 16 17 19 21 23 25 27 31 34 39
One feature to highlight in Tables 2.16 and 2.20 (described in the next section on cross­
over trials) is the asymmetric effect on the sample size for different values o f the true 
mean difference. In equivalence trials as one has two, usually symmetric, margins, 
when one moves away from a zero mean difference in any direction the sample size is 
inflated. However, in non-inferiority trials the sample size is inflated only if the true 
mean difference moves towards the non-inferiority margin. If it is expected that the true 
mean difference is in favour of the comparator regimen (compared to control) then the 
sample size is significantly reduced.
This asymmetric effect o f the mean difference on the sample size should be considered 
when designing non-inferiority trials as even only a small expected mean difference in 
favour o f the comparator could have a marked effect on the sample size.
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2.5.1.2. Worked Example
An investigator wishes to design a hypertension trial where the objective is to 
demonstrate that one treatment (an investigative therapy) is non-inferior to another (a 
standard therapy). The largest clinically acceptable effect to be able to declare non­
inferiority is a change in blood pressure of 5mmHg (d). The true mean difference 
between the treatments is thought to be zero with an expected standard deviation in the 
trial population of 25mmHg ( a ). There is to be equal allocation between groups. Thus, 
the standardised non-inferiority limits equate to - 5  -  - d  I a  = -5 /2 5  = -0 .20 . For the 
Type I and Type II errors fixed at 2.5% and 10% respectively Table 2.16 gives a sample 
size of 527 patients in each arm of the trial.
Suppose, though, that one believes that the investigative therapy is a little superior to 
the standard such that the true mean difference is thought to be ImmHg. This inflates 
the distance one expects the mean to be away from the non-inferiority margin by 20% 
and would reduce the sample size required to 366 patients in each arm o f the trial.
2.5.1.3. Sensitivity Analysis About the Variance Used in the Sample Size Calculations
As with superiority and equivalence trials described earlier (2.2.9) can be used to 
estimate a plausibly large value for the population variance. As with equivalence trials 
however, one also needs to investigate the sensitivity o f calculations to the assumption 
about the true mean difference. If one has assumed no difference when it was truly non­
zero then this will have an effect on the power o f the study. Unlike equivalence trials 
the adverse affect on the power is not symmetric and if there is a difference in favour o f 
the investigative treatment there will be a positive effect on the power. This section will 
only investigate negative effects.
Table 2.17 gives the sample size per group required for different standardised non­
inferiority limits for a parallel group equivalence trial along with the sensitivity o f these 
sample sizes to the 95th percentile of the variance (for different degrees o f freedom) and 
different mean differences (assuming the mean difference is zero).
From Table 2.17 it seems that assuming a trial is designed with 90% power:
• That to ensure that the study has at least 50% or 80% power, if the true variance 
is nearer the 95th percentile, then the variance estimate would require at least 10 
and 75 degrees of freedom respectively -  assuming that there was no mean 
difference.
• If one's variance estimate was close to the true variance then even if the true 
mean difference was 15% of the standardised non-inferiority limit (against the 
investigative treatment) then one would still have 80% power in the study.
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Table 2-17. Sample sizes per arm for a parallel group non-inferiority trial for 
different standardised non-inferiority limits with 90% power and 2.5% type I 
error rate along with the power corresponding to the 95th percentile of the 
variance for different degrees of freedom and different mean differences
d
Sample
Size
True
Meai
Diff
(%)
n
Degrees o f  Freedom
10 25 50 75 100 500 00
0.05 8407 0 0.53 0.70 0.77 0.80 0.82 0.87 0.90
5 0.49 0.65 0.73 0.76 0.78 0.83 0.87
10 0.45 0.61 0.68 0.71 0.73 0.79 0.83
15 0.41 0.56 0.63 0.66 0.68 0.74 0.79
20 0.37 0.51 0.58 0.61 0.63 0.69 0.74
25 0.33 0.46 0.53 0.56 0.57 0.63 0.68
0.10 2103 0 0.53 0.70 0.77 0.80 0.82 0.87 0.90
5 0.49 0.65 0.73 0.76 0.78 0.83 0.87
10 0.45 0.61 0.68 0.71 0.73 0.79 0.83
15 0.41 0.56 0.63 0.66 0.68 0.74 0.79
20 0.37 0.51 0.58 0.61 0.63 0.69 0.74
25 0.33 0.46 0.53 0.56 0.57 0.63 0.68
0.15 935 0 0.53 0.70 0.77 0.80 0.82 0.87 0.90
5 0.49 0.65 0.73 0.76 0.78 0.83 0.87
10 0.45 0.61 0.68 0.71 0.73 0.79 0.83
15 0.41 0.56 0.63 0.66 0.68 0.74 0.79
20 0.37 0.51 0.58 0.61 0.63 0.69 0.74
25 0.33 0.46 0.53 0.56 0.57 0.63 0.68
0.20 527 0 0.53 0.70 0.77 0.80 0.82 0.87 0.90
5 0.49 0.65 0.73 0.76 0.78 0.83 0.87
10 0.45 0.61 0.68 0.71 0.73 0.79 0.83
15 0.41 0.56 0.63 0.66 0.68 0.74 0.79
20 0.37 0.51 0.58 0.61 0.63 0.69 0.74
25 0.33 0.46 0.53 0.56 0.57 0.64 0.68
0.25 338 0 0.53 0.70 0.77 0.80 0.82 0.87 0.90
5 0.49 0.65 0.73 0.76 0.78 0.83 0.87
10 0.45 0.61 0.68 0.71 0.73 0.79 0.83
15 0.41 0.56 0.63 0.66 0.68 0.74 0.79
20 0.37 0.51 0.58 0.61 0.63 0.69 0.74
25 0.33 0.46 0.53 0.56 0.57 0.64 0.68
2.5. /. 4. Worked Example
Revisiting the worked example earlier. Suppose the sample variance used in 
calculations was estimated with 10 degrees o f freedom. Table 2.17 demonstrates that a 
high plausible value for this variance would have 53% power with the same sample 
size. If the true mean difference was 10% of the non-inferiority limit, against the 
investigative treatment, the power of the study would be reduced to 83%.
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2.5.1.5. Calculations Taking Account o f the Imprecision of the Variance Used in the 
Sample Size Calculations
To account for the imprecision o f the sample variance used in the sample size 
calculations the results given in the section on superiority trials can be generalised to 
give the following result
„  > (r + l)$; [/im’(l -  P, m. t („!)-; ) ! (2 4 7)
rk ^ A ~  Ma) ~d) 1
where the sample size required is the least integer value for (2.4.7) to hold. One can 
rewrite (2.4.7) in terms of power to obtain the following result
1 - P  = 1 -  p r o b t ( z - , m , ,),  (2.4.8)
where r  is defined as
((Ma - M B) - d]4rn~tT =
yj(r + \ )s2
Replacing the t-statistic with a Z-statistic gives one the following result 
(r + 1 )r[;» iv (l- /? ,m ,Z |_ a , ) f
r({„A- M . ) - d y
which allows one to have a direct estimate o f the sample size and also gives an initial 
value for iterations for (2.4.7). Tables 2.18 and 2.19 are produced for the special case o f 
no mean difference between treatments.
Table 2-18. Sample sizes estimated for different standardised non-inferiority limits 
and degrees of freedom from (2.4.7). The final column with "infinite" degrees of 
freedom is from (2.4.3) and the assumption that the population variance is being 
used. The type I error is set at a one-sided significance levels of 2.5% and the type 
II error is set at 10%
D
Degrees o f  freedom
10 25 50 75 100 500 00
0.10 2734 2333 2214 2 176 2158 2114 2103
0.20 685 584 555 545 540 529 527
0.30 305 260 247 243 241 236 235
0.40 172 147 140 137 136 133 133
0.50 111 95 90 88 88 86 85
0.60 77 66 63 62 61 60 60
0.70 57 49 46 46 45 44 44
0.80 44 38 36 35 35 34 34
0.90 35 30 29 28 28 27 27
1.00 29 25 23 23 23 22 22
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Table 2.18 gives the sample sizes for different degrees o f freedom and standardised 
equivalence limits. Table 2.19 gives the multiplication factors, compared to assuming 
one has the population variance, for various degrees o f freedom and Type I and II 
errors. These multiplication factors can be used to inflate a sample size to account for 
the imprecision in the variance.
Table 2-19. Multiplication factors for different levels of one sided significance, type 
II error and degrees of freedom
Significance Level ( a )
m P 0.010 0.025 0.050 0.100
5 0.05 2.167 2.068 1.980 1.875
0.10 1.776 1.711 1.652 1.581
0.15 1.582 1.533 1.489 1.436
0.20 1.457 1.419 1.385 1.344
0.50 1.120 1.117 1.114 1.111
10 0.05 1.463 1.425 1.392 1.353
0.10 1.328 1.301 1.276 1.248
0.15 1.254 1.233 1.214 1.192
0.20 1.204 1.187 1.172 1.154
0.50 1.055 1.054 1.053 1.053
25 0.05 1.163 1.150 1.139 1.125
0.10 1.119 1.109 1.101 1.091
0.15 1.094 1.086 1.079 1.071
0.20 1.076 1.070 1.065 1.058
0.50 1.021 1.021 1.021 1.020
50 0.05 1.078 1.072 1.067 1.060
0.10 1.058 1.053 1.049 1.044
0.15 1.046 1.042 1.039 1.035
0.20 1.037 1.034 1.032 1.028
0.50 1.010 1.010 1.010 1.010
75 0.05 1.052 1.047 1.044 1.040
0.10 1.038 1.035 1.032 1.029
0.15 1.030 1.028 1.026 1.023
0.20 1.025 1.023 1.021 1.019
0.50 1.007 1.007 1.007 1.007
100 0.05 1.038 1.035 1.033 1.030
0.10 1.029 1.026 1.024 1.022
0.15 1.023 1.021 1.019 1.017
0.20 1.019 1.017 1.016 1.014
0.50 1.005 1.005 1.005 1.005
2.5.1.6. Worked Example
Returning to the worked example given earlier for a standardised non-inferiority limit o f 
0.20 with 10 degrees o f freedom for the sample variance estimate Table 2.18 gives a 
sample size of 685. This compares to sample size o f 527 calculated assuming one had
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the population variance for calculations - a potential under estimation o f the sample size 
o f 30%
2.5.1.7. Calculations Taking Account o f the Imprecision of the Mean and Variance Used 
in the Sample Size Calculations
Similarly to equivalence trials as well as being sensitive to the assumptions around the 
variance the sample size calculations are also sensitive to the assumptions around the 
assumed mean difference. As the mean difference deviates away from the assumptions 
in the calculations there is a consequent effect on the power. However, this effect is not 
symmetric. If one had underestimated an effect in favour o f the investigative treatment 
then one may have a study that is overpowered. On the other hand if one had 
underestimated an effect against the investigative treatment then one may have an 
underpowered study.
With an estimate o f the mean difference ( x t ~xB) from a previous study and an estimate 
o f the standard error around this mean difference G e(^-.rfl)) an estimate of the sample 
size can be obtained. For the special case x4 -  * *o the power for a given sample size 
can be estimated (through numerical integration) from
0 WX
\ ~ P =  £  0.001.V
r. oooi
where the sample size required is the minimum value which gives the required sample 
size. As with equivalence trials discussed earlier this result however is practically 
unappealing.
- probt
i rnA i(.v4 -  x B) + Z „se(xA -  x B) -  d\
, m,t.
-  probt ,m,t
(2.4.10)
2.5.1.8. Calculations Taking Account o f the Imprecision of the Mean and Variance Used 
in the Sample Size Calculations -  A Bayesian Approach
The prior, anticipated and posterior responses would be calculated as per parallel group 
equivalence trials. Hence, a mean difference d for given percentile p can be estimated
and put into the following result for the general case * - x B *o, to estimate the power for
a given sample size.
- ' yfrn , \d d\  ') [ J r n  , \d , -  d\
\ ~ [ ) =  0 . 0 0 l.r 2 - p ro b t  — .= n n (j-li . j probtj — , m , t l
{ \ ' ( r -+  1 ).v ' i yj(r + \ ) s '
(2.4.12)
2
where the sample size is estimated through numerical integration and iteration.
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2.5.2. Cross-over Trials
2.5.2.1. Sample Size Estimated Assuming the Population Variance to be Known
The equivalent sample size formula to (2.4.2) for cross-over trials is
i g :{z u^ z iJ
n =
((Ma
which when rewritten in terms o f power becomes
\ - P  = <D z,
2 a .
(2.4.12)
(2.4.13)
The equivalent formula replacing the Z-statistics with the t-statistic is
((Ma »
2 a 2
- t l - a r . n - (2.4.14)
As with parallel group designs it preferable to calculate the Type II error (and power) 
under the assumption of a non-central t-distribution and thus (2.4.14) is rewritten as 
[Julious 2004a]
\ - P  = \ -  probt(t, -  2. r).
where r  is defined as
(2.4.15)
r = ((/% W V "
For quick calculations, for 90% power and Type I error o f 2.5%, the following formula 
can be utilised
2 1 a .
n = (2.4.16)
As with parallel group sample size estimation the quick equations give reasonable, 
although slightly under, estimates of the sample size. Table 2.20 gives sample sizes 
using (2.4.15) for various standardised equivalence limits ( S  = d / a )  and standardised 
mean differences assuming equal allocation between groups.
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Table 2-20. Total sample sizes (n) for a cross-over non-inferiority study with equal 
allocation for different standardised non-inferiority limits and true mean 
differences (as a percentage of the equivalence limit) for 90% power and type I 
error rate of 2.5%
d
Percentage Mean Difference
-25% -20% -15% -10% -5% 0% 5% 10% 15% 20% 25%
0.10 1347 1462 1591 1739 1909 2104 2331 2597 2911 3286 3738
0.20 339 367 400 437 479 528 585 651 730 823 936
0.30 152 165 179 195 214 236 261 291 326 367 418
0.40 87 94 102 111 122 134 148 165 184 208 236
0.50 56 61 66 72 79 87 96 106 119 134 152
0.60 40 43 47 51 55 61 67 75 83 94 106
0.70 30 32 35 38 41 45 50 55 62 69 79
0.80 24 25 27 30 32 35 39 43 48 54 61
0.90 19 21 22 24 26 29 31 35 38 43 49
1.00 16 17 19 20 22 24 26 29 32 35 40
2.5.2.2. Sensitivity Analysis About the Variance Used in the Sample Size Calculations
Table 2.21 gives the total sample size required for different standardised non-inferiority 
for a cross-over trial along with the sensitivity o f these sample sizes to the 95th 
percentile o f the variance (for different degrees o f freedom) and different mean 
differences (assuming the mean difference is zero). The inference and conclusions from 
the table are virtually identical to those for parallel group trials.
2.5.2.3. Calculations Taking Account of the Imprecision of the Variance Used in the 
Sample Size Calculations
To account for the imprecision of the variance used in the sample size calculations the 
results for parallel group trials can be generalised to
(2.4.17)
[it*A -  I*B) ~ d Y
where n is the least integer value for (2.4.17) to hold. One can rewrite (2.4.17) in terms 
o f power
1 — [3 -  1 -  probt f "IC/T, - / ' * ) -  d=----------:  I u . n  2
V  '  «  J
(2.4.18)
Replacing the t-statistic with a Z-statistic gives one the following result 
n 2s;[fmv(| - /7 ,m , Z>„ ,) f  (2.4.19)
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which allows one to have a direct estimate o f the sample size and also gives an initial 
value for (2.2.17).
Table 2-21. Total sample sizes for a cross-over non-inferiority trial for different 
standardised non-inferiority limits with 90% power and 2.5% type I error rate 
along with the pow er corresponding to the 95th percentile of the variance for 
different degrees of freedom and different mean differences
True
Mean
Sample D iff  Degrees o f  Freedom
d Size (%) 10 25 50 75 100 500 00
0.05 8408 0 0.53 0.70 0.77 0.80 0.82 0.87 0.90
5 0.49 0.65 0.73 0.76 0.78 0.83 0.87
10 0.45 0.61 0.68 0.71 0.73 0.79 0.83
15 0.41 0.56 0.63 0.66 0.68 0.74 0.79
20 0.37 0.51 0.58 0.61 0.63 0.69 0.74
25 0.33 0.46 0.53 0.56 0.57 0.63 0.68
0.10 2104 0 0.53 0.70 0.77 0.80 0.82 0.87 0.90
5 0.49 0.65 0.73 0.76 0.78 0.83 0.87
10 0.45 0.61 0.68 0.71 0.73 0.79 0.83
15 0.41 0.56 0.63 0.66 0.68 0.74 0.79
20 0.37 0.51 0.58 0.61 0.63 0.69 0.74
25 0.33 0.46 0.53 0.56 0.57 0.63 0.68
0.15 936 0 0.53 0.70 0.77 0.80 0.82 0.87 0.90
5 0.49 0.65 0.73 0.76 0.78 0.83 0.87
10 0.45 0.61 0.68 0.71 0.73 0.79 0.83
15 0.41 0.56 0.63 0.66 0.68 0.74 0.79
20 0.37 0.51 0.58 0.61 0.63 0.69 0.74
25 0.33 0.46 0.53 0.56 0.57 0.63 0.68
0.20 528 0 0.53 0.70 0.77 0.80 0.82 0.87 0.90
5 0.49 0.65 0.73 0.76 0.78 0.83 0.87
10 0.45 0.61 0.68 0.71 0.73 0.79 0.83
15 0.41 0.56 0.63 0.66 0.68 0.74 0.79
20 0.37 0.51 0.58 0.61 0.63 0.69 0.74
25 0.33 0.46 0.53 0.56 0.57 0.64 0.68
0.25 339 0 0.53 0.70 0.77 0.80 0.82 0.87 0.90
5 0.49 0.65 0.73 0.76 0.78 0.83 0.87
10 0.45 0.61 0.68 0.71 0.73 0.79 0.83
15 0.41 0.56 0.63 0.66 0.68 0.74 0.79
20 0.37 0.51 0.58 0.61 0.63 0.69 0.74
25 0.33 0.46 0.53 0.56 0.57 0.64 0.68
Table 2.22 give the sample sizes required using (2.4.17) for different standardised non­
inferiority limits and degrees of freedom. For multiplication factors see Table 2.19. As 
these factors depend only on the Type I error, Type II error and degrees o f freedom they 
are the same for both parallel and cross-over trials.
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Table 2-22. Sample sizes estimated for different standardised non-inferiority limits 
and degrees of freedom from (2.4.17). The final column with "infinite" degrees of 
freedom is from (2.4.14) and the assumption that the population variance is being 
used. The type I error is set at a one-sided significance level of 2.5% and the type 
II error is set at 10%
Degrees o f  Freedom
d 10 25 50 75 100 500 00
0.10 2734 2333 2214 2176 2158 2114 2103
0.20 685 584 555 545 540 529 527
0.30 305 260 247 243 241 236 235
0.40 172 147 140 137 136 133 133
0.50 111 95 90 88 88 86 85
0.60 77 66 63 62 61 60 60
0.70 57 49 46 46 45 44 44
0.80 44 38 36 35 35 34 34
0.90 35 30 29 28 28 27 27
1.00 29 25 23 23 23 22 22
2.5.2.4. Calculations Taking Account of the Imprecision of the Mean and Variance Used 
in the Sample Size Calculations
Similarly to parallel group trials with an estimate o f the mean difference ( ^  ~ x B )  from a
previous study and an estimate of the standard error around this mean difference 
(s<?(.v4- x B))  an estimate of the sample size can be obtained. For the general case of 
the power for a given sample size can be estimated (through numerical 
integration) from
1-/1= £  O.OOl.v
2 - probt 
-  probt
'n(\xA -  xB) + Z,se(xA -  xB ) -  d\
■ ,m,t,
v
<n/xi - x B) + Zr,itmse(x, - x B) - d
42s,
12
(2.4.19)
where the sample size required is the minimum value which gives the required sample 
size.
2.5.2.5. Calculations Taking Account of the Imprecision of the Mean and Variance Used 
in the Sample Size Calculations -  A Bayesian Approach
As with parallel group non-inferiority trials described earlier the priors, anticipated and 
posterior responses are defined as for equivalence trials. Hence, the power, for given n, 
can be calculated from
'L22* i n\ d  , - i/I ' | vnj<7 . -  ,/ |  ^  (2.4.20)
^ 7  0 . 0 0  l . v j  2  -  p r o b t  ;
I
—  -  J  p r o b t  -  j - - - . -  , m , i t
v 2 r   I 1 v V
where the sample size is estimated through numerical integration and iteration.
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2.6. As G ood as or Better Trials
To calculate the sample size required for an "as good as or better" trial one should apply 
the methodologies described in Sections 2.2 (Superiority) and 2.4 (Non-inferiority). For 
example a parallel group trial to investigate a one sided test of non-inferiority and a two 
sided test of superiority; designed to about a standardised clinically meaningful 
difference for superiority o f 0.20 and a standardised non inferiority margin o f 0 .2 0 . 
With the Type I error fixed at 5% for the test o f superiority and 2.5% for the test o f non­
inferiority and the Type II error fixed at 10%. From Table 2.1 for superiority one would 
require 527 patients in each arm. Whilst from Table 2.16 for non-inferiority, assuming 
no treatment difference, again one would require 527 patients per arm.
Note that here one is making the big, probably unrealistic, assumption that the 
standardised non-inferiority limit and the standardised difference are the same.
On the face of it then one can switch between non-inferiority and superiority whilst 
maintaining the Type I error for no great cost in the sample size. However, if  in the 
example above, to test non-inferiority one wished to allow for the fact that there may be 
a true mean difference between the two groups against the investigative therapy. If this 
mean difference equated to 20% of the standardised non-inferiority limit it would inflate 
the sample size, mutatis mutardis, to 822 patients per arm.
A more realistic scenario to the one described in the previous paragraph is one where 
the non-inferiority margin is a fraction o f the clinically meaningful difference. The 
sample size required to investigate non-inferiority would hence be a factor more than 
required to investigate superiority - the factor being the ratio o f the clinically 
meaningful difference over the non-inferiority margin squared. In this circumstance, 
given that one also is investigating superiority, it may be appropriate to power for non­
inferiority assuming a small difference between the two groups in favour of the 
investigative therapy.
A further consideration in as good as or better trials is the choice of data set to have as 
primary -  which adds a further complication. For a superiority trial the primary data set 
would be that based on intention to treat (ITT); for a non-inferiority trial the primary 
data set would be both the per protocol data set (PP) and the ITT [CPMP, 2000].
2.7. B ioequivalence Trials
In a reversal to the ordering of previous sections the calculations for cross-over trials 
will be described before parallel group trials. The reason for this is that cross-over trials 
are the most common designs for bioequivalence studies.
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2.7.1. Cross-over Trials
2.7.1.1. Sample Sizes Estimated Assuming the Population Variance to be Known
2.7.1.2. General Case
The derivation o f the sample size equations is similar to that for equivalence trials. For 
the general case where the expected true mean difference is not fixed to be unity the 
sample size cannot be directly derived. One instead has to iterate until a sample size is 
reached which gives the required Type II error and power.
To calculate the power for the two one-sided test procedure at the 5% significance level 
where the bioequivalence acceptance limits are (0.80, 1.25) for any given value for the 
true ratio, p T / p R , the following formula can be used
\ - P  = 0
((log ( / ' r  H r ) -  log(l .25 )) : / I  7
i  " 2a: 1
+ O (log( / / r / / f i ) - l o g ( 0 . 8 0 ) 2Ai _  2 , ( 2 .6 . 1)
where crH, is the within-subject variability on the log scale and n is the total sample size. 
Replacing the Z-statistic with the t-statistic and (2.6.1) can be rewritten as
( l o g ( / / ,  > , ) - l o g ( 1.25))' n t + ) (lo g ( / / ,  7 ^ ) - l o g ( 0 . 8 0 ) J n _ ^
\ - a . n -  2
J
(2 .6 .2 )
As with superiority, equivalence and non-inferiority trials discussed earlier in this 
chapter it is best to calculate the power using a non-central t-distribution the power, as 
outlined by Owen [1965], rewriting (2.6.1) to the following formula [Owen, 1965; 
Diletti, Hauschke, Steinijans, 1991; Julious, 2004a],
1 - p  = probt(- ,n -  2 , r 2) -  probt(f,. a n 2,n -  2 , r , ), (2.6.3)
where r, and r 2 are non centrality parameters defined as
sfn (log(//7. p R) -  log(0.80)) 4n  (log( ^ T ) -  log(l .25))
r, = ---------------- p==---------------- and r, = —---------
2cr; j 2 a ; .
An estimate of the sample size fo r/ / 7 //.iR greater than unity can be obtained from the 
following
n=  — l  + (2 .6 .4 )
(log(//,. / /J -!o g (1 .2 5 ))
which can be used to provide an initial value for the iterations. This equation provides 
reasonable approximations for p ,  I p R * 1 , especially when the mean ratio becomes 
large relative to (0.80 to 1.25) as in such circumstances most of the Type II error comes 
from one test o f two one sided tests. For quick calculations, for 90% power and a 
Type I error o f 5%, the following can be used
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Obviously for true ratios less than unity log(l .25) should be replaced by log(0.80).
2.7.1.3. Special Case of the Mean Ratio Equalling Unity
For the special case where the expected true mean difference is expected to be unity the 
sample size can be directly derived from the following formula
By replacing the Z-statistic with the t-statistics (2.6.6) can be rewritten to give the 
sample size as
Estimating the power from a non-central t-distribution, (2.6.3) can be rewritten to
Equation (2.6.6) can be used to obtain initial estimates o f the sample size to use in
(2.6.8). For quick calculations for 90% power, 5% Type I error rate and 20% 
acceptance criteria one could use
Table 2.23 gives sample size estimates using (2.6.3) for different CVs, mean ratios and 
acceptance criteria 10% (0.90 to 1.11), 15% (0.85 to 1.18), 20% (0.80 to 1.25) etc for a 
Type 1 error rate o f 5% and 90% power. The simpler equations provide good estimates 
o f the total sample size, underestimating the sample size by one or two, and hence good 
initial values for iteration.
(2 .6 .6 )
(2.6.7)
In turn this can be rewritten as
1 -  P  = 2probt( - 1 (2 .6 .8 )
where r  is the non centrality parameters defined as
N»(log(1.25))
n = 433a^ . (2.6.9)
Table 2-23. Total sample sizes (n) for bioequivalence cross-over study for different 
CVs, levels of bioequivalence and true mean ratios for 90% power and type I error 
of 5%
CV (%) Ratio
Levels o f  Bio-equivalence
10% 15% 20% 25% 30%
20 0.80 163 40
0.85 18 45 20
0.90 207 50 22 13
0.95 232 56 2 14 10
1.00 78 34 1 12 9
1.05 j "> 54 2 14 10
1.10 151 43 20 12
1.15 99 33 16
1.20 405 62 24
25 0.80 163 40
0.85 185 45 20
0.90 2073 50 22 13
1.00 232 56 25 14 10
1.05 78 34 19 12 9
1.05 212 54 24 14 10
1.10 151 43 20 12
1.15 99 33 16
1.20 405 62 24
30 0.80 356 85
0.85 403 96 41
0.90 454 108 46 25
0.95 507 121 52 29 18
1.00 170 73 39 25 17
1.05 463 116 51 28 18
1.10 329 92 42 24
1.15 214 69 33
1.20 888 135 50
35 0.80 477 113
0.85 540 128 54
0.90 608 145 61 33
0.95 679 162 69 38 24
1.00 227 97 52 32 22
1.05 620 155 67 37 24
1.10 440 123 55 31
1.15 287 92 44
1.20 1190 180 67
40 0.80 612 144
0.85 694 164 69
0.90 780 185 78 42
0.95 871 207 88 48 30
1.00 291 124 66 41 27
1.05 796 198 86 47 30
1.10 565 157 71 39
1.15 367 118 56
1.20 1527 231 86
Note the “standard” bio-equivalence criteria are o f a 20% difference on the log scale 
(0.80 to 1.25) but these need not always be used. For a drug with a narrow safety
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window (with respect to dose) a narrower margin may be used; while for in-vivo 
assessment (drug-interactions, food effect) wider margins may be used -  for example 
for food effect studies a margin o f (0.70 to 1.43) for Cmax [FDA, 1997].
2.7.1.4. Replicate Designs
For compounds with high variability the standard AB/BA can require very large sample 
sizes, especially if the mean ratio is not expected to be unity. One type of design, which 
can partially overcome this problem, are replicate cross-over designs. By adding an 
extra arm to the study such that the sequences are ABB/BAA one can reduce the sample 
size by 25% compared to a standard AB/BA design; while an ABBA/BAAB design can 
reduce the sample size by 50% [Liu, 1995]. This option may not be practical for certain 
compounds, for example those with a long half-life, but it is a possible solution for 
compounds with high pharmacokinetic variability.
Another type of replicate design is a two period replicate design AA/AB/BA/BB -  also 
known as Balaam’s Design [Jones and Kenward, 2003]. This design allows for an 
intra-subject estimate o f variability for a given compound without increasing the 
number of periods beyond two (more than two periods may not be practical). To 
consider the effect such a design has on the sample size one must consider the 
derivation o f the total variance a 2 = a 2 + a l ,  where a l  is the within-subject 
component o f variation and cj2b is the between subject component of variation. Both
these variance components can be estimated from previous cross-over trials with the test 
and reference compounds. Now suppose a b = k a 2w it can be shown, assuming an equal
allocation to each sequence, that the sample size required for a two period replicate 
design can be derived by multiplying the sample size for standard AB/BA design as 
follows [Julious, 2004a]
The derivation number of this formula comes initially from imagining that the AB/BA 
and AA/BB sequences are from a cross-over trial and a parallel group trial respectively 
with n/4 subjects assigned to each sequence. For each sequences the following total 
variance can thus be derived for the "parallel group" sequences
If these sequences were from a parallel group study one would effectively take the 
average o f the two sessions to compared A and B and so from (2.8.5) given later in the
4(2k + l)cr^ which equals w, say. Now for the "cross-over" AB/BA sequences, the total 
variance can be derived as
(2 .6 . 10)
4 a 2 4 a 2 h —
n n
chapter a 2 = a 2b + o U  2 and with a 2b = k a \  this the variance becomes
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4 cr.‘
which equals vv2 say. Now to combine the cross-over and parallel sequences into one 
overall variance one could use the following formula borrowed from meta-analysis 
methodology [Whitehead and Whitehead, 1991, Julious, 2004a]
( 2 i V
i - H
Thus, the overall variance is [Julious, 2004a]
+
4o-; 4a;,(2k + \)
2 a l (2 k  + \) 
n{k + 1)
From any of the sample size formulae given in this chapter it is evident that one 
increases the sample size directly proportional to any increase in the variance. If one is 
planning a simple AB/BA cross-over trial the overall variance would be 2<jlJn . Thus, 
the ratio o f the variances is thus
2a;(2k  + l) n _ {2k + \)
«( / :  +  !)  2 c r  (A +  l )
and so the increase in sample sizes for doing a replicate cross-over is 
/ 2A +  1
AA AB BA BB k +1 AB BA
and (2 .6 .10).
To verify this result 10,000 simulations for a fixed sample size of 48 and for various k 
were undertaken. Each simulation simulated AB/BA and AB/BA/AA/BB cross-over. 
The analysis for each simulation was done with all subjects entered into PROC MIXED 
with subject entered as random. Table 2.24 gives the results.
Table 2-24. Multiplication factors for different values of k for a two period 
replicate cross-over design
k 2k + 1 
k + \
Simulation
2 1.67 1.65
4 1.80 1.78
6 1.86 1.85
8 1.89 1.88
10 1.91 1.90
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What is evident both from the table above and (2.6.10) that for a two period replicate 
design will always require more subjects than a standard AB/BA requiring the same 
sample size only for k=0. However, no matter how larger k becomes it will only require 
twice as many subjects at most. This is because as k becomes large virtually all the 
information, in the comparison o f the mean ratio, comes from the AB/BA sequences 
and with twice as many subjects there will be as many people in these sequences as in a 
standard AB/BA design.
2.7.1.5. Worked Example
A bioequivalence trial to compare a test with reference formulation needs to be 
designed. The standard bioequivalence criteria will be used to demonstrate that the 
average drug exposure on the test is bioequivalent to the reference i.e. 0.80 to 1.25. The 
within-subject standard deviation is expected to be 0.25 (=<JW) and the mean ratio is
expected to be unity {juT/ptR = 1). The standard deviation o f 0.25 equates to a within 
subject CV of 25%. The study design will be an AB/BA two period crossover. From 
Table 2.23 it can be seen that one would need a minimum evaluable sample size of 28 
subjects. Practically this would equate to at least 28 subjects in total or 14 subjects on 
each sequence (AB and BA) maybe with approximately 20% more subjects added to the 
sample size (i.e. 17 subjects per sequence) to account for drop outs.
If the test formulation is expected, on average, to have exposures 5% greater than the 
reference (fuT//aR =1.05) then the total sample size would increase to 36 subjects (or
18 per sequence).
Suppose though instead of an AB/BA design replicate ABB/BAA or ABBA/BAAB 
designs were being considered for the case where exposures were expected to be 5% 
greater on test compared to reference. If one adapted a 4 period replicate design then 
would would multiply the total sample size calculated earlier by 0.50 to get 36x0.5=18 
subjects in total required. If one adopted a 3 period replicate design then the total 
sample size calculated earlier should be multiplied by 0.75 to get 36x0.75=27 subjects 
in total.
2.7.1.6. Sensitivity Analysis About the Variance Used in the Sample Size Calculations
As with other types of trial described earlier in this chapter (2.2.9) can be used to 
estimate plausibly large value for the population variance. For bioequivalence trials (as 
with equivalence trials), one has the further factor to investigate o f the sensitivity of 
calculations about the true mean ratio. If one has assumed a mean ratio o f unity then it 
will affect the power of the study if this assumption is false.
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Table 2-25. Sample sizes for a bioequivalence study for different mean ratios 
assuming 90% power and 5% type I error rate along with the powers 
corresponding to the 95th percentile of the variance for different degrees of 
freedom and different true mean ratios
CV(%) Ratio
Sample Degrees of  Freedom
Size Ratio 5 10 15 20 25 30 40 50 75 100 00
20 1.00 19 1.00 0.00 0.35 0.50 0.58 0.63 0.67 0.71 0.74 0.78 0.80 0.91
1.05 0.00 0.31 0.45 0.52 0.56 0.59 0.63 0.66 0.70 0.72 0.82
1.10 0.00 0.24 0.33 0.37 0.40 0.42 0.45 0.47 0.50 0.51 0.60
1.15 0.00 0.15 0.20 0.22 0.24 0.25 0.26 0.27 0.28 0.29 0.34
1.05 24 1.05 0.12 0.48 0.60 0.66 0.70 0.73 0.76 0.78 0.81 0.82 0.90
1.10 0.10 0.35 0.43 0.47 0.50 0.52 0.54 0.56 0.59 0.60 0.70
1.15 0.07 0.21 0.25 0.27 0.29 0.30 0.31 0.32 0.34 0.35 0.41
1.10 43 1.10 0.38 0.58 0.66 0.70 0.73 0.75 0.77 0.79 0.82 0.83 0.90
1.15 0.22 0.33 0.38 0.41 0.43 0.45 0.47 0.48 0.51 0.52 0.61
1.15 99 1.15 0.41 0.58 0.66 0.70 0.73 0.75 0.77 0.79 0.82 0.83 0.90
25 1.00 28 1.00 0.00 0.33 0.49 0.57 0.62 0.66 0.70 0.73 0.77 0.80 0.90
1.05 0.00 0.30 0.44 0.51 0.55 0.58 0.62 0.65 0.69 0.71 0.82
1.10 0.00 0.23 0.32 0.37 0.40 0.42 0.44 0.46 0.49 0.50 0.60
1.15 0.00 0.15 0.20 0.22 0.23 0.24 0.26 0.27 0.28 0.29 0.34
1.05 36 1.05 0.12 0.47 0.60 0.66 0.70 0.72 0.76 0.78 0.81 0.82 0.90
1.10 0.09 0.34 0.43 0.47 0.50 0.51 0.54 0.56 0.59 0.60 0.70
1.15 0.07 0.21 0.25 0.27 0.28 0.29 0.31 0.32 0.33 0.34 0.41
1.10 65 1.10 0.37 0.57 0.65 0.70 0.72 0.74 0.77 0.79 0.81 0.83 0.90
1.15 0.22 0.33 0.38 0.41 0.43 0.44 0.46 0.48 0.50 0.52 0.60
1.15 151 1.15 0.40 0.58 0.65 0.70 0.72 0.74 0.77 0.79 0.81 0.83 0.90
30 1.00 39 1.00 0.00 0.33 0.48 0.57 0.62 0.65 0.70 0.73 0.77 0.79 0.90
1.05 0.00 0.30 0.43 0.50 0.55 0.58 0.62 0.65 0.69 0.71 0.81
1.10 0.00 0.23 0.32 0.37 0.39 0.41 0.44 0.46 0.49 0.50 0.59
1.15 0.00 0.15 0.20 0.22 0.23 0.24 0.26 0.27 0.28 0.29 0.34
1.05 51 1.05 0.12 0.48 0.60 0.66 0.70 0.73 0.76 0.78 0.81 0.83 0.90
1.10 0.10 0.35 0.43 0.47 0.50 0.52 0.54 0.56 0.59 0.61 0.70
1.15 0.07 0.21 0.25 0.27 0.29 0.30 0.31 0.32 0.34 0.35 0.41
1.10 92 1.10 0.37 0.58 0.65 0.70 0.72 0.74 0.77 0.79 0.81 0.83 0.90
1.15 0.22 0.33 0.38 0.41 0.43 0.44 0.46 0.48 0.50 0.52 0.61
1.15 214 1.15 0.40 0.58 0.65 0.70 0.72 0.74 0.77 0.79 0.81 0.83 0.90
Table 2.25 gives the sample size per group required for different CVs for a cross-over 
bioequivalence trial (assuming the standard 20% bioequivalence criteria are being used) 
along with the sensitivity of these sample sizes to the 95th percentile of the variance (for 
different degrees of freedom) and different mean ratios. From Table 2.25 it seems:
• That to ensure that 50% and 80% power with the 95th percentile about the 
variance one would require 15 and 100 degrees of freedom.
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• If one's variance estimate was close to the true variance then even if the true 
mean ratio 1.05 one would still have 80% in the study if  designed under the 
assumption o f unity.
• With moderate degrees of freedom a study is reasonably robust to deviations in 
the assumptions either about the true mean or the variance but less so to 
deviations in both simultaneously.
2.7.1.7. Worked Example
Revisiting the example given earlier. Suppose that the CV used in the sample size 
calculations was estimated with just 15 degrees o f freedom. From Table 2.25 it seems 
that for a high plausible value for the CV the study has 49% power. If the true mean 
ratio is really 1.05 as opposed to 1.00 then the study would have 82% power.
2.7.1.8. Calculations Taking of Account the Imprecision of the Variance Used in the 
Sample Size Calculations
2.7.1.9. General Case
Extending the arguments for equivalence trials given earlier in this chapter the sample 
size for a bioequivalence study, taking into account the degrees of freedom about the 
sample variance study, can be derived from
1 - 0 .  probl| -  : I -  probl( ’ <2 -6 - 1 1 )
where s i  is a sample estimate o f the within subject population variance. Replacing the 
t-statistic with the z-statistic and (2 .6 .11) becomes
\ - p .  probtj -  - Z , „ I .  probl
( l o g ! / / ,  , / / „ ) - l o g ( 0 . 8 0 ) ) 2 / i  z
2s]' ’
j .(2.6.12)
A direct estimate o f the sample size can be obtained as an initial estimate for (2.6.11) 
for the expected true mean ratio becomes large, n T/ >1.05. Hence, the following
quick formula can be used to obtain direct initial estimates o f the sample size for the 
general case o f /nr /f.tR * 1
n 2sw[tim{\-  p , d f  (2.6.13)
[log(1.25)-log(//y - ^ ) f
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Table 2-26. Sample sizes for bioequivalence cross-over studies for various CVs and 
degrees of freedom using (2.6.11), for 90% power and 5% type I error rate 
assuming 20% (0.80 to 1.25) bioequivalence limits. The row with "infinite” 
degrees of freedom is from (2.6.2)
Coefficients o f  Variation
Ratio
1.00
1.05
1.10
m 20 25 30 40
5 35 54 76 101 129
10 25 38 54 71 91
15 23 34 48 64 82
20 22 33 46 61 77
25 21 32 44 59 75
30 21 31 43 57 73
40 20 30 42 56 71
50 20 30 41 55 70
75 19 29 41 54 69
100 19 29 40 53 68
00 19 28 39 52 66
5 43 65 91 122 156
10 31 47 67 89 114
15 28 43 60 80 103
20 27 41 58 77 98
25 26 40 56 75 95
30 26 39 55 73 94
40 25 38 54 72 92
50 25 38 53 71 90
75 25 37 52 69 89
100 24 37 52 69 88
00 24 36 50 67 86
5 71 108 153 205 263
10 54 83 117 157 201
15 50 76 108 144 184
20 48 73 104 138 177
25 47 72 101 135 173
30 46 70 99 133 170
40 45 69 97 130 167
50 45 68 96 129 165
75 44 67 95 127 162
100 44 67 94 126 161
00 43 65 92 123 157
2.7.1.10. Special Case of the Mean Ratio Equalling Unity
For the special case of fi, -  f.iR (2.6.11) can be rewritten as
, . f logic soivV)  ^ , (2.6.14)
1  -  f i  =  2 n r o b t  *  .  .  —  - , 4 / , -  t ,  u  „  .  !  -  I
V
which when replacing the t statistic with the Z statistics becomes 
I ) - r  (2.6.15)
Hence, a direct estimate of the sample size can be obtained from
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„  _  -  P 12 ,  d f , Z | .„ ) f
(log(1.25)):
(2.6.16)
Table 2.26 gives estimates of the sample size for bioequivalence cross-over studies 
using the standard 20% bioequivalence criteria.
Table 2-27. Multiplication factors for different levels of one sided significance, type 
II error and degrees of freedom
m 0
Significance Level (a)
0.010 0.025 0.050 0.100
5 0.05 2.649 2.509 2.385 2.238
0.10 2.167 2.068 1.980 1.875
0.15 1.929 1.850 1.780 1.696
0.20 1.776 1.711 1.652 1.581
0.50 1.367 1.337 1.311 1.278
10 0.05 1.611 1.562 1.520 1.470
0.10 1.463 1.425 1.392 1.353
0.15 1.382 1.351 1.323 1.290
0.20 1.328 1.301 1.276 1.248
0.50 1.166 1.153 1.141 1.127
25 0.05 1.208 1.192 1.178 1.162
0.10 1.163 1.150 1.139 1.125
0.15 1.137 1.126 1.116 1.105
0.20 1.119 1.109 1.101 1.091
0.50 1.062 1.058 1.053 1.058
50 0.05 1.099 1.091 1.085 1.077
0.10 1.078 1.072 1.067 1.060
0.15 1.066 1.061 1.056 1.051
0.20 1.058 1.053 1.049 1.044
0.50 1.031 1.028 1.026 1.024
75 0.05 1.065 1.060 1.056 1.051
0.10 1.052 1.047 1.044 1.040
0.15 1.044 1.040 1.037 1.033
0.20 1.038 1.035 1.032 1.029
0.50 1.020 1.019 1.017 1.016
100 0.05 1.048 1.044 1.041 1.038
0.10 1.038 1.035 1.033 1.030
0.15 1.033 1.030 1.028 1.025
0.20 1.029 1.026 1.024 1.022
0.50 1.015 1.014 1.013 1.012
Table 2.27 gives the multiplication factors, compared to assuming one has the 
population variance, for various degrees o f freedom and Type I and II errors assuming a 
mean ratio of unity. This table is in fact the same as Table 2.12 given for equivalence 
trials - although for bioequivalence trials one would choose different Type I errors. 
Table 2.12 (and Table 2.27) can be used regardless of which original sample size 
formula was used.
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2.7.1.11. Worked Example
Revisiting the example given earlier with just 15 degrees o f freedom of the sample 
variance used in calculations one would require 32 subjects in the trial as opposed to 28 
calculated previously. This is an increase in the sample required of 15%.
2.7.1.12. Calculations Taking Account o f the Imprecision of the Mean and Variance 
Used in the Sample Size Calculations
Similarly to equivalence trials with an estimate o f the mean ratio ( . r r / . r * )  from a
previous study and an estimate of the standard error around this mean ratio on the log 
scale ( s e iog(.x:r /x s ) ) an estimate o f the sample size can be obtained. For the special case 
xT / xfg ~~ 1 the power for a given sample size can be estimated (through numerical 
integration) from
i-/? = Y. 000Lr
where the sample size required is the minimum value which gives the required sample 
size. As with equivalence trials this result, however, is practically unappealing.
2.7.1.13. Calculations Taking Account of the Imprecision of the Mean and Variance Used 
in the Sample Size Calculations -  A Bayesian Approach
In this section it will be demonstrated how simple Bayesian methods could be employed 
to estimate sample sizes allowing for imprecision in the mean and variance.
2.7.1.14. Prior Response
Prior values for the mean difference and population within subject standard deviation on 
the log scale are defined as ^  (i.e. for iog (.r7 ) - i o g ( x 7)) and su0 respectively.
2.7.1.15. Anticipated Response
The anticipated mean difference and population within subject standard deviation on the 
log scale are defined as^  and ,V| respectively. These values are taken as objective
values observed in a previously conducted bioequivalence trial.
^ vA»(z.,.yt'log(.Y; ' x K) ~  log(l .25))
2Probt
v
+ 2Probt
'2s-
, m - t  | (2.6.17)
in{Z, .se\og(.t7 x H) -  log(l .25))
i 2
\  2s-
_u n
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2.7.1.16. Posterior Response
With these anticipated and prior responses the posterior distribution can be calculated, 
with the posterior estimate of the population variance around the mean, 52 , is defined as
5.:. =i —-  + —  
2*;,
(2.6.18)
and the posterior estimate of the mean difference, d , is defined as
,0 25,*
(2.6.19)
From these posterior values a density distribution for prob^>d ,|J,) can be defined such 
that a probability o f observing dt, or greater, for a given j  would be
p r o b ( 0  > d t | d , ) = 0 |  — — — (2 .6 .20)
or alternatively for p r o b ( 0 < d ,  :</,
p r o b { 9  > d \ d ]) -  0 |
d, - d . .
From this result a log-mean difference d for given percentile p can be estimated and put 
into the following result for the general case iog(//7 //7 )^o, to estimate the power for a 
given sample size
1 - P =  £  0 . 0 0 l.r
[ \ ‘n (d  -  d)  j |' \ ' n ( d + d)
P r o b t  j — , j + Probt] — - ~ = — , w , / ,
I ‘ !., v2s2
i n  , ( d )  i -Jn , ( d + d )
P r o b t  p =  , m , - t , „ , . | + P r o b t l  p=^=-------, w,r,
V2-5. j  I \ 2 s '
, (2 .6 .21 )
where the sample size is estimated through numerical integration and iteration.
2.7.2. Parallel Group Studies
Although cross-over trials are the 'norm' for the assessment o f bioequivalence 
sometimes, particularly with very long half life compounds, these designs are not 
practical. This section briefly describes the methodology for sample size calculation for 
parallel group bioequivalencc trials.
2. 7.2.1. Sample Size Estimated Assuming the Population Variance to be Known
2.7.2.2. General Case
The power for a bioequivalence trial with acceptance limits of (0.8, 1.25) for given 
values o f the any true ratio is given by
129
where a  is the between-subject variability on the log scale, r is the allocation ratio and 
n j is the sample size in the test group. Replacing the Z-statistic with a t-statistics and 
(2 .6 .22 ) can be rewritten as
1 n J  i 0 o s ( ^ . > * ) - l o g ( 1 . 2 5 ) ) : r« ,  I f ( log( / / ,  l o g ( 0 . 8 0 ) > « 7 )  ’ ( 2 . 6 . 2 3 )
= ( r + 1 )<j: ................ '' ..............  y M v  " " T r V l ^  '' ' .' .......’ p '
and under the assumption of a non-central t-distribution the power is estimated from 
I -  P  = P rob t( -  : , nT (r  + 1) -  2, r , ) -  Probt(/, , ,/»7 ( r  + 1 ) -  2, r, )> ( 2 . 6 . 2 4 )
where r, and r 2 are non centrality parameters defined as
_ J r n T(\og(/ur p K)-log(0 .80)) A _ ^rn~r 0°g(/fr /'>*) ~ log(l-25))
r, —----------------v-.-..- - = -------- _ _ _  ana r2 — , —------= --------------.
yl(r + \)<r2 " ^j(r + \)<j2
As with a cross-over trial a direct estimate o f the sample size for a mean ratio greater 
than unity can be obtained from the following
(r + \)cr2(z. , ,+Z,  J
nT = - f   v W  L^ ,  (2.6.25)
/■(log(/Y, jU„) — log(l.25))‘
and for quick calculations one could use 
17(r -f l)cr2
nT = —7 — . (2.6.26)
r 0°g(/fr l°g(l -25))“
If the mean ratio is expected to be less than unity then replace log(1.25) with log(0.80) 
in (2.6.25) and (2.6.26).
Table 2-28. Sample sizes for one arm of a bioequivalence parallel group study for 
different CVs, levels of bioequivalence and true mean ratios for 90% power and a 
type I error rate of 5%
CV (%) Ratio
Levels o f  Bio-equivalence
10% 15% 20% 25% 30%
30 0.80 356 84
0.85 40 95 40
0.90 453 10 46 25
0.95 506 121 5 28 18
1.00 169 72 3 24 16
1.05 462 115 5 28 17
1.10 328 92 41 23
1.15 21 69 33
1.20 887 134 50
35 0.80 476 112
0.85 540 128 54
0.90 607 144 61 33
0.95 678 161 69 37 23
1.00 226 96 51 31 21
1.05 620 154 67 37 23
1.10 439 122 55 30
1.15 286 92 43
1.20 1189 179 66
40 0.80 611 144
0.85 693 163 69
0.90 779 184 78 41
0.95 871 207 88 48 30
1.00 291 123 66 40 26
1.05 796 198 85 47 29
1.10 564 157 70 38
1.15 367 117 55
1.20 1527 230 85
45 0.80 759 178
0.85 861 203 85
0.90 968 229 96 51
0.95 1082 257 109 59 36
1.00 361 152 81 49 33
1.05 988 245 106 58 36
1.10 700 194 87 47
1.15 455 146 68
1.20 1896 286 105
50 0.80 919 216
0.85 1041 245 103
0.90 1171 277 116 62
0.95 1309 310 131 71 44
1.00 436 184 98 60 39
1.05 1195 297 128 70 43
1.10 847 235 104 57
1.15 551 176 82
1.20 2295 345 127
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2.7.2.3. Special Case o f the Ratio Equalling Unity
When the mean ratio is expected to be unity the sample size can be derived directly 
from
(r + l ) a 2(z ,_0 , + J
nT = --------- 7------- -— ^------- . (2.6.27)
r(log(1.25))-
Replacing the Z-statistic with the t-statistic (2.6.27) can be rewritten as 
M _  ( r  +  1 ) 0 "  ( z , \ ,  p  2 +  a  ,)/ ( , + 1 , - :  J  AO Atij . (2.6.28)
r(log(1.25))-
Equation (2.6.28) can in turn can be rewritten as
/
\ - P  = 2d> (l°g ( l-25))~ rnT I a , / r / ( r . l |(r + 1 )cr
1
J
and under the assumption of a non-central t-distribution the power can be derived from 
1 - p  = 2probt(-  t ^ a nj (r+1)_: ,M '*  +1) -  2 , r ) - 1 ,  (2.6.29)
where r  is the non centrality parameters defined as 
-  l°g(1.25))
T =
•J(r + 1)CF
Equation (2.6.27) can be used for initial estimates o f the sample size to use in (2.6.29). 
For quick calculations of the sample size for 90% power, 5% Type I error rate and 20% 
one could use
10.75(/- + 1)<7: /V .  (2.6.30)
Table 2.28 gives sample size estimates using (2.6.24) for different CVs, mean ratios and 
acceptance criteria 10% (0.90 to 1.11), 15% (0.85 to 1.18), 20% (0.80 to 1.25) etc for a 
Type I error rate of 5%, 90% power and an allocation ratio of one. As with cross-over 
trials the simpler equations provide good estimates for initial calculations.
2.7.2.4. Sensitivity Analysis About the Variance Used in the Sample Size Calculations
As with the cross-over trials described earlier an example table such as Table 2.29 can 
be used to investigate the sensitivity of a parallel group bioequivalence trial. The 
inference from this table is the same as that for cross-over trials.
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Table 2-29. Sample sizes for a parallel group bioequivalence study with different 
mean ratios assuming 90% power and 5% type I error rate along with the powers 
corresponding to the 95th percentile of the variance for different degrees of 
freedom and different true mean ratios
Sample  Degrees o f  Freedom
Ratio Size Ratio 5 10 15 20 25 30 40 50 75 100 00
1.00 98 1.00 0.00 0.33 0.48 0.56 0.62 0.65 0.70 0.73 0.77 0.79 0.90
1.05 0.00 0.30 0.43 0.50 0.55 0.58 0.62 0.65 0.68 0.71 0.81
1.10 0.00 0.23 0.32 0.36 0.39 0.41 0.44 0.46 0.49 0.50 0.59
1.15 0.00 0.15 0.20 0.22 0.23 0.24 0.26 0.27 0.28 0.29 0.34
1.05 128 1.05 0.11 0.47 0.60 0.66 0.70 0.72 0.76 0.78 0.81 0.82 0.90
1.10 0.09 0.34 0.43 0.47 0.50 0.52 0.54 0.56 0.59 0.60 0.70
1.15 0.07 0.21 0.25 0.27 0.28 0.29 0.31 0.32 0.33 0.34 0.41
1.10 235 1.10 0.37 0.58 0.65 0.70 0.72 0.74 0.77 0.79 0.81 0.83 0.90
1.15 0.22 0.33 0.38 0.41 0.43 0.44 0.46 0.48 0.50 0.52 0.60
1.15 551 1.15 0.40 0.58 0.65 0.70 0.72 0.74 0.77 0.79 0.81 0.83 0.90
2.7.2.5. Calculations Taking of Account the Imprecision of the Variance Used in the 
Sample Size Calculations
2.7.2.6. General Case
For a parallel group bioequivalence study the sample size can be derived from
1 -  P  = probt
) -  lug(1.25)V rn, 
\  ( r t l ) r
„  , i / / ' a ) - iog(0 .80)): in,
i [\ (r + \)s-
, (2.6.31)
where 5 2 is a sample estimate of the population variance. Replacing the t-statistic with 
the z-statistic and (2.6.31) becomes
1 -  P  = probt I (logQ'/ / '«}"  lQg(l 251 f  rn_/ df  y prob,|
i V  ( r  +  l ) i -
.(2.6.32)
For juT//JK >1.05 a direct estimate of the sample size can to start iterations can be 
obtained from
n —_ {r+ \)s2[tinv(\-{J.df .Z^ u)j  
r[log(l .25) -  log( //7 / / J ]2
(2.6.33)
2.7.2.7. Special Case of the Mean Ratio Equaling Unity 
For the special case of p T -  jlik (2.6.31) can be rewritten as
1 -  P  = 2probt
(log log( I 25)): r/i7 
(/■ + l)^ -: Af-t, „„
(2.6.34)
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which when replacing the t-statistic with the Z-statistics becomes
/
1 -  P  = 2probt
(log log( l 2 5 ) ) -rn.
(r + 1)j -
(2.6.35)
Hence, a direct estimate o f the sample size can be obtained from
n = 2s j[ t inv ( l - f3 /2 ,d f ,  Z. J f  
(log(1.25));
(2.6.36)
Table 2.30 gives estimates of the sample size for bioequivalence parallel group studies 
using the standard 20% bioequivalence criteria.
Table 2-30. Sample sizes for bioequivalence parallel group studies for various CVs 
and degrees of freedom using (2.6.25), for 90% power and 5% type I error rate 
assuming 20% (0.80 to 1.25) bioequivalence limits. The row with "infinite" 
degrees of freedom is from (2.6.18)
Degrees
o f  Coefficient o f  Variation
Ratio Freedom 30 35 40 45 50
5 101 129 160 193 229
10 71 91 113 136 161
15 63 81 101 122 144
20 60 77 95 115 136
25 58 74 92 111 132
30 57 73 90 109 129
40 55 71 88 106 126
50 55 70 86 104 124
75 53 68 85 102 121
100 53 68 84 101 120
00 51 65 81 98 116
5 121 156 193 233 276
10 88 113 140 169 200
15 80 102 127 153 181
20 76 98 121 146 173
25 74 95 118 142 168
30 73 93 115 140 165
40 71 91 113 136 161
50 70 90 111 135 159
75 69 88 109 132 156
100 68 87 108 131 155
00 67 85 106 128 151
5 20 262 326 394 466
10 15 200 248 300 355
15 14 184 228 276 327
20 13 177 219 265 314
25 13 172 214 259 306
30 13 170 210 254 301
40 13 166 206 249 295
50 12 164 204 246 292
75 12 162 201 242 287
100 12 160 199 241 285
oc 12 157 194 235 278
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Table 2.27 (given earlier for cross-over trials) can be used for multiplication factors, as 
these depend only on degrees of freedom and Type I and II errors.
2.7.2.8. Calculations Taking Account o f the Imprecision of the Mean and Variance 
Used in the Sample Size Calculations
Similarly to cross-over trials with an estimate of the mean ratio and an estimate of the 
standard error around this mean ratio on the log scale GeiogOiy/.?*)) an estimate of the 
sample size can be obtained. For the special case xT /.v* = l the power for a given sample 
size is
r
1 - / ? -  £  0 . 0 0  l.v
p^ \) IKJ!
2Probt
rn, (X/,.vf'log(.v, ’.v.( ) log() .25)) 
v ( r  ♦ I ).v
™  i [ \ rn ..... .  velog(.v :. \H ) -  log(l .25))
2Probt |  J  ----------------------- , m j l
1 (^/•+l).s
(2.6.37)
2.7.2.9. Calculations Taking Account of the Imprecision of the Mean and Variance 
Used in the Sample Size Calculations -  A Bayesian Approach
With the similar derivation as for cross-over bioequivalence studies the following result 
for the general case of iog(.vr '-v*)*o can be used to calculate the power for a given
sample size.
\ ~ p =  £  0 . 0 0 l.r
Jr n  , (d t d  ) 
Probt — -------------,/w.r,
L I V
■Jrn )
)  (  J rn  A(d + d
... |+  Probtl — —■ —--  , m j
Probt
v’V' f Dv
• m d; „ i, : ! ■+ Probt
•J(r+ l)r:
Ad ~ d
y j ( r  +  \ ) s :
 I ) - : -1
,(2.3.38)
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with the sample size estimated through iteration.
2.8. Estim ation to a G iven Precision
2.8.1. Parallel Group Trials
2.8.1.1. Sample Size Estimated Assuming the Population Variance to be Known
As discussed in Chapter 1 a (l -  a )  100% confidence interval for f(//) has half-width
w = Z a 2y[va r { s ) , (2.7.1)
and so defining Var(S) as per equation
Var (S ) = £ l  + ? 1  = L ± 1 . ? 1 ,
n  A n B r  n  A
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one can solve (2.7.1) to give [Brush, 1988; Day, 1988; Desu and Raghavarao, 1990; 
Julious, 2004a; Julious and Patterson, 2004]
_ (r 4- l)Z,2_tt 2 a 2
.4 irw~
(2.7.2)
If the population variance is to be assumed unknown in the statistical analysis (2.7.2) 
can be rewritten as [Julious, 2004a; Julious and Patterson, 2004]
" ,  *
(r + l)'r „ 2 : 0 -:
nv
(2.7.3)
Equation (2.7.3) can be solved iteratively to find a value of nA where the left hand side 
o f the equation is greater than the right. An alternative equation to solve for nA would 
be
0.5 > 0
rn vv‘
(r + l)cr
- t 1 - a  2 . / i , ( r  +  l ) ~ 2 (2.7.4)
Equation (2.7.4) holds as if  one was to rewrite (2.7.4) in terms o f n one would first have
Z0 5 = 0 >
(r + l)cr
and hence (2.7.3). Equation (2.7.4) is in fact the same as (2.2.5), given in the section in 
superiority trials, but with the Type II error set at 0.5 -  although obviously as precision 
trials are not powered they cannot have any Type II error. The practical application o f 
this result is given later in the section on sample sizes where the population variance is 
assumed unknown for calculations.
To allow for the Normal approximation (2.7.2) can have a correction factor added to 
assist in initial calculations [Guenther, 1981; Julious and Patterson, 2004]
+
nv
(2.7.5)
and the following quick formula can be used assuming one wishes to have a 95% 
confidence interval for the precision estimates
Table 2.31 gives sample sizes using (2.7.3) for various standardised widths ( S  = w/cr).  
The simpler equations slightly underestimate the sample size.
Table 2-31. Sample sizes for one group, nA (nB=rnA) in a parallel group study for 
different standardised widths and allocation ratios with 95% confidence intervals 
for the precision estimates
Allocation ratios
5 1 -> 3 4
0.10 770 578 513 481
0.20 194 145 129 121
0.30 87 65 58 54
0.40 50 37 33 31
0.50 32 24 22 20
0.60 23 17 15 14
0.70 17 13 12 11
0.80 14 10 9 9
0.90 11 8 7 7
1.00 9 7 6 6
2.8.1.2. Worked Example
An investigator wishes to design a pilot hypertension trial with equal allocation between 
groups where the objective is to estimate any possible effect on blood pressure of new 
treatment compared to control with precision around the point estimate of ± 2mmHg 
(w). The expected standard deviation in the population in which the trial is to be 
undertaken is 20mmHg (cr). Thus, the standardised width equates to 
S  = d / a  -  2 / 20 = 0.10. Table 2.31 gives a sample size o f 770 patients in each arm of 
the trial.
2.8.1.3. Sensitivity Analysis About the Variance Used in the Sample Size Calculations
When undertaking sensitivity analysis in a study designed to estimate effects to a given 
precision it is not the power one investigates against a high plausible value for the 
variance but the precision itself.
Pecision based studies are usually undertaken early in the development of a compound, 
when, by definition, there is little variability information available. Hence, a sensitivity 
analysis o f the study may be quite important.
Table 2.32 gives sample sizes and precision estimates for high plausible values of the 
variance for different standardised widths. From this table it seems that with few 
degrees of freedom (about the variance used in the calculations) the precision could be 
half that used for the sample size calculations for a high plausible value for the variance.
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Table 2-32. Sample sizes for one group, nA (iib=tiia) in a parallel group study for 
different standardised widths along with the precision for high plausible values for 
the variance
Sample Degrees o f  Freedom
8 Size 5 10 25 50 100
0.10 770 0.21 0.16 0.13 0.12 0.11
0.20 194 0.42 0.32 0.26 0.24 0.23
0.30 87 0.63 0.48 0.39 0.36 0.34
0.40 50 0.84 0.64 0.52 0.48 0.45
0.50 32 1.04 0.80 0.65 0.60 0.57
0.60 23 1.25 0.96 0.78 0.72 0.68
0.70 17 1.46 1.12 0.92 0.84 0.79
0.80 14 1.67 1.27 1.05 0.96 0.91
0.90 11 1.88 1.43 1.18 1.08 1.02
1.00 9 2.09 1.59 1.31 1.20 1.13
2.8.1.4. Worked Example
Revisiting the worked example given earlier where the sample size was estimated to be 
770 patients based a standardised width o f 0.10. Now suppose the variance used in the 
calculations was estimated with 10 degrees o f freedom. From Table 2.32 a high 
plausible value for the variance would have a standardised width of 0.16 -  precision 
60% worse than the standardised width upon which the sample size calculations were 
based.
2.8.1.5. Calculations Taking of Account the Imprecision of the Variance Used in the 
Sample Size Calculations
To account for the imprecision of the variance used in the sample size calculations for 
parallel group precision based trials, (2.7.4), and the results from superiority trials given 
earlier in this chapter, can be generalised to give the following formula
(r + l ) i : [/mv(o.5, m , 0 )f
rd
(2.7.7)
where nA is the least integer value for (2.7.7) to hold. This equation can in turn be 
rewritten as
(
0.5 >1 — probt rnAd 2
(7+1 Ys
■> A tlJ  | a (| : (2.7.8)
Replacing the t-statistic with a Z-statistic gives one the following result
_ (r + \)s2 |//m ’(0.5, m, Z, M : )f 
n'4 ~ r d 2
(2.7.9)
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which allows a direct estimate for the sample size and gives an initial value for 
interations for (2.7.7).
Table 2.33 gives the sample sizes required for 95% confidence interval precision 
estimates and for a range of degrees of freedom, m, and standardised widths, w/s.
Table 2-33. Sample sizes for one group, nA (nB=rnA) in a parallel group precision 
study for different standardised widths and degrees of freedom using (2.7.7) for a 
5% level of significance. Sample sizes with "infinite" degrees of freedom are 
estimated from (2.7.3)
Degrees o f  
Freedom
Standardised Widths
0.05 0.10 0.25 0.50 0.75 1.00
5 3434 860 139 36 17 10
10 3242 812 131 34 16 10
25 3138 786 127 33 16 10
50 3106 778 126 33 16 10
100 3090 774 125 33 15 10
oo 3075 770 125 32 15 9
Table 2.34 gives the multiplication factors for different levels o f statistical significance. 
What is interesting to note is that for precision based studies the impact on the sample 
size is not as great as that for formally powered studies. This could be because power -  
and consequently the distribution under the alternative hypothesis -  does not have to be 
considered for precision based studies. From Table 2.34 at most the impact is to 
increase the sample size by 12%.
Table 2-34. Multiplication factors for different levels of statistical significance
m
Significance Level (a)
0.010 0.025 0.050 0.100
5 1.122 1.120 1.117 1.114
10 1.056 1.055 1.054 1.053
25 1.021 1.021 1.021 1.021
50 1.010 1.010 1.010 1.010
75 1.007 1.007 1.007 1.007
100 1.005 1.005 1.005 1.005
2.8.1.6. Worked Example
Revisiting the worked example given earlier. For a standardised width of 0.10 and with 
10 degrees o f freedom about the variance estimate used in calculations the sample size 
812 patients per arm compared to 770 calculated earlier. A relatively small increase in 
the sample size.
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2.8.1.7. The Problem Reconsidered
The problem of uncertain variance estimates in the variability in context with precision 
based trials was discussed in detail by Grieve [1989, 1990, 1991] drawing on and 
commenting on the work of others [Beale, 1989; Day, 1988; Greenland, 1988; Kupper 
an Hafher, 1989], Here, Grieve highlighted that for (2.7.2) or (2.7.3) one only had a 
50% chance of achieving the desired precision as the variance half the time will be 
greater than that anticipated.
Grieve advocated the following result to work out the sample size
(  2 . .  A
Probability = probchi \v2rn,(n4(r + l ) - 2 )' - ,nA(r + l) - 2
(r 4- 1)/] a 2./i (/•,!)-: cr
(2.7.10)
where probchi(?,nA{r + 1) -  2 ) is a cumulative density distribution (using the same 
notation as SAS) of a x~ distribution on nA(r + l ) - 2  degrees of freedom. The 
probability here is the probability o f the confidence interval having the required 
precision for the variance estimated in the planned trial for a given sample size- it is not 
power. To estimate a sample size one has to iterate until a required level o f probability 
is reached. This result compares with
n t > -(r + .1)?I:g 2 , (2 .7 .11)
r\v~
which was given earlier or
n< > (r ' 1>/ ' " , (2.7.12)
nv'
which is (2.7.11) written in terms of a F-statistics.
Table 2-35. Sample sizes for one group, nA (nB=nA) in a parallel group study for 
different standardised widths and probabilities for 95% confidence intervals for 
the precision estimates
Probabilities
s 0.50 0.80 0.90 0.95
0.05 3076 3122 3146 3166
0.10 771 794 806 816
0.25 125 135 139 143
0.50 33 38 40 42
0.75 16 19 21 22
1.00 10 12 13 14
Table 2.35 gives sample sizes from (2.7.10) for given probabilities and required 
precisions. From visual inspection of this table and Table 2.31 (estimated from 
(2.7.11)) it is clear that for a probability o f 0.5 (2.7.10) gives the same results as (2.7.4)
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-  allowing for a little rounding error. Also from inspection, it seems that to ensure a 
greater probability o f having the required precision it does not require a great increase in 
the required sample size.
Table 2-36. Sample sizes for one group, nA (nB=nA) in a parallel group precision 
study for different standardised widths, probabilities (p) and degrees of freedom  
using (2.7.13) for a 5% level of significance. Sample sizes with "infinite” degrees 
of freedom are estimated from (2.7.11)
Degrees o f ____________________Standardised Widths
p Freedom 0.05 0.10 0.25 0.50 0.75 1.00
0.50 5 3533 884 143 37 17 10
10 3291 824 133 34 16 10
25 3158 791 128 33 15 9
50 3116 780 126 33 15 9
100 3095 775 125 32 15 9
oo 3075 770 124 32 15 9
0.80 5 6561 1642 264 67 31 18
10 4976 1246 201 52 24 15
25 4059 1071 165 43 21 13
50 3710 930 152 40 19 12
100 3499 878 144 39 19 12
oc 3121 837 134 37 18 11
0.90 5 9544 2388 384 97 44 26
10 6319 1582 255 66 31 18
25 4667 1169 190 50 24 15
50 4081 1024 167 45 22 14
100 3737 938 155 42 21 13
00 3472 805 138 39 20 13
0.95 5 13417 3356 539 136 62 36
10 7802 1953 315 81 37 22
25 5262 1318 214 56 27 17
50 4425 1110 182 49 24 15
100 3950 993 164 45 22 14
00 3165 815 142 41 21 13
2.8.1.8. Allowing for the Imprecision in the Variance used in the Sample Size 
Calculations
In an elegant solution Grieve [1991] demonstrated that if there was prior uncertainty 
around the variance used in the precision sample size calculations then the probability 
o f seeing the required precision for a given sample size can be calculated from
(
probability = probf \v2rn (n Ar + 1) -  2) . . . -IV J - - - - - - - -  L ,nA(r + \ ) - 2 , m
O' + l) i^ a 2.„ .(/•*!) : s
(2.7.13)
where probf  (•^n 4{r + 1) - 2 ,m) is a cumulative density distribution (using the same 
notation as SAS) of a F distribution on n A r  + l ) - 2  and m degrees o f freedom. This
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result was originally given without proof by Mood and Snedecor [1946]. Here s 2 is the 
estimate o f the variance from a previous trial being used to plan the current trial, nA is 
the sample size in the trial being planned, n A{r + \ ) - 2  the degrees of freedom of the 
variance in this trial and m is the degrees of freedom of s 2. To solve for n A one iterates
(2.7.13) until the appropriate probability is reached. The sample sizes from (2.7.13) are 
given in Table 2.36. For probabilities o f 0.50 the table should be comparable to Table 
2.33, however, the results from this table are a little conservative in comparison.
2.8.2. Cross-Over Trials
2.8.2.1. Sample Size Estimated Assuming the Population Variance to be Known 
Similarly to the parallel group case one can solve (2.7.1) to give [Julious, 2004a]
where n is the total sample size. If the population variance is to considered unknown in 
the statistical analysis (2.7.14) can be rewritten as [Julious, 2004a]
which can be solved iteratively. Alternatively as with parallel group trials the following 
formula could be used
To allow for the Normal approximation, (2.7.14) can amended to have a correction 
factor [Guenther, 1981; Julious, 2004a]
The following formula can be used assuming one wishes to have a 95% confidence 
interval precision estimates
Table 2.37 gives sample sizes using (2.7.16) for various standardised widths
(2.7.14)
(2.7.15)
(2.7.16)
(2.7.17)
(2.7.18)
( S  = d t o  ). As with parallel group trials the quick formula slightly under estimates the 
sample size.
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Table 2-37. Total sample sizes for a cross-over study for different standardised 
widths with 95% confidence intervals for the precision estimates
S n
0.10 771
0.20 195
0.30 88
0.40 51
0.50 34
0.60 24
0.70 19
0.80 15
0.90 13
1.00 11
2.8.2.2. Sensitivity Analysis About the Variance Used in the Sample Size Calculations
Table 2.38 gives sample sizes and precision estimates for high plausible values o f the 
variance for different standardised widths. The inference drawn from this table is the 
same as for parallel group studies.
Table 2-38. Total sample sizes for a cross-over study for different standardised 
widths along with the precision for high plausible values for the variance
Sample  Degrees o f  Freedom
;nce Size 5 10 25 50 100
0.10 771 0.21 0.16 0.13 0.12 0.11
0.20 195 0.42 0.32 0.26 0.24 0.23
0.30 88 0.63 0.48 0.39 0.36 0.34
0.40 51 0.84 0.64 0.52 0.48 0.45
0.50 34 1.04 0.80 0.65 0.60 0.57
0.60 24 1.25 0.96 0.78 0.72 0.68
0.70 19 1.46 1.12 0.92 0.84 0.79
0.80 15 1.67 1.27 1.05 0.96 0.91
0.90 13 1.88 1.43 1.18 1.08 1.02
1.00 11 2.09 1.59 1.31 1.20 1.13
2.8.2.3. Calculations Taking of Account the Imprecision of the Variance Used in the 
Sample Size Calculations
To account for the imprecision the results from parallel group trials can be generalised 
to give the following formula
n >
cl2
(2.7.17)
This equation can in turn be rewritten as
(
0.5 > probt
rid
v 2s:
— ,m,t 1 a  2.n- (2.7.18)
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Replacing the t-statistic with a z-statistic gives one the following result
2j;.[fim {0.5,m ,Z,.a : )f (2 7 19)
d 2
which allows a direct estimate for the sample size and gives an initial value for 
interations for (2.7.17).
Table 2.39 gives the sample sizes required for 95% confidence interval precision 
estimates and for a range of degrees o f freedom, m, and standardised widths, w/s. The 
multiplication factors for a cross-over trial are the same as those for a parallel group 
study given Table 2.34.
Table 2-39. Total sample sizes for cross-over precision study for different 
standardised widths and degrees of freedom using (2.7.18) for a 5% level of 
significance. Sample sizes with "infinite" degrees of freedom are estimated from  
(2.7.15)
Degrees o f  ______________________  Standardised Widths________________________
Freedom 0.05 0.10 0.25 0.50 0.75 1.00
5 3435 861 140 37 18 12
10 3243 813 133 35 18 11
25 3140 787 128 34 17 11
50 3107 779 127 34 17 11
100 3092 775 126 34 17 11
GO 3076 771 126 34 17 11
2.8.2.4. The Problem Reconsidered
The work o f Grieve [1989, 1990, 1991] can be extended to cross-over trials such that 
the total sample size can be estimated from
Probability = probchi ~n(n -  2 )
\ 2 r t l a  2 . n - 2 °
T , n - i (2.7.20)
Table 2-40. Total sample sizes for a cross-over study for different standardised 
widths and probabilities for 95% confidence intervals for the precision estimates
Probabilities
S 0.50 0.80 0.90 0.95
0.05 3075 3141 3175 3204
0.10 771 803 820 834
0.25 125 138 145 150
0.50 33 40 43 45
0.75 16 20 22 24
1.00 10 13 15 16
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As with parallel group trials to estimate a sample size one has to iterate until a required 
level of probability is reached. Table 2.40 gives sample sizes from (2.7.20) for given 
probabilities and required precisions.
Table 2-41. Total sample sizes for a cross-over study for different standardised 
widths, probabilities (p) and degrees of freedom using (2.7.21) for a 5% level of 
significance. Sample sizes with "infinite" degrees of freedom are estimated from 
(2.7.20)
Degrees o f  Standardised Widths
p Freedom 0.05 0.10 0.25 0.50 0.75 1.00
0.5 5 3533 885 144 38 18 11
10 3292 825 134 35 17 11
25 3159 791 129 34 17 11
50 3117 781 127 34 16 10
100 3096 776 126 33 16 10
oc 3075 771 125 33 16 10
5 6563 1643 266 69 32 20
10 4977 1247 203 54 26 16
25 4061 1019 167 45 23 14
50 3713 933 154 42 21 14
100 3502 881 147 41 21 14
00 3141 803 138 40 20 13
5 9546 2389 385 99 46 28
10 6321 1584 257 68 32 20
25 4670 1172 193 52 26 17
50 4085 1027 171 48 24 16
100 3742 943 159 45 23 15
00 3175 820 145 43 22 15
5 13418 3357 540 138 63 37
10 7804 1955 317 83 39 24
25 5265 1322 217 59 30 19
50 4430 1114 186 52 27 18
100 3956 999 169 49 25 17
OC' 3204 834 150 45 24 16
2.8.2.5. Allowing for the Imprecision in the Variance used in the Sample Size 
Calculations
Extending the parallel group result to allow for prior uncertainty around the variance 
used in the precision sample size calculations then the probability of seeing the required 
precision for a given sample size can be calculated from
Probability = probf
^ u ,:m ( n - 2 ) ^ —------ ,/? -  2 ,/m
(>*+ 1)T„V
(2.7.21)
To solve for n one iterates (2.7.21) to the appropriate probability is reached. Table 2.41 
gives sample size tables using (2.7.21)
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2.9. D esign C onsiderations
2.9.1. Inclusion of Baselines or Covariates
In the analysis o f the results of a clinical trial, the effects o f treatment on the response of 
interest are often adjusted for predictive factors, such as demographic (like gender and 
age) or clinical covariates (such as baseline response), by fitting them concurrently with 
treatment. This section will concentrate on the case where baseline is the predictive 
covariate of interest (although the results are generalisable to other factors), the design 
is a parallel group design and an analysis o f covariance, allowing for the baseline, is to 
be the final analysis. The CPMP have just issued notes for guidance on the design and 
analysis o f studies with covariates [CPMP, 2003]
Frison and Pocock [1992] give a variance formula for various numbers of baseline 
measures
Variance = o
f
i -  p p
\ l + ( p - l ) p
(2 .8 . 1)
Here, p is the Pearson correlation coefficient between observations -  assuming 
compound symmetry - and p is the number of baseline measures taken per individual. 
From this equation a series of correction factors can be calculated [Machin, Campbell, 
Fayers, 1997] which give the variance reduction and consequent sample size reduction 
for different correlations and numbers of baselines. The assumption here is that there is 
balance between treatments and the baseline (or covariate) o f interest. Any imbalance 
will increase the variance from (2.8.1), and consequent sample size [Senn, 1997]. With 
randomisation the imbalance should be minimised however.
From (2.8.1) it is clear that for fixed numbers o f baseline measures the higher the 
correlation the greater the reduction in variance and consequent sample size. For 
example if three baseline measures were to be taken and the expected correlation 
between baseline and outcome is 0.5, the effect would be to reduce the variance to 
0.6250 cr2. However, for the same number o f baseline measures if the expected 
correlation between baseline and outcome is 0.7 then the effect would be to reduce the 
variance to 0.3875 cr2.
Table 2-42. Effect of number of baselines on the variance
Number of 
baselines
Variance
1 0.7500
2 0.6667
3 0.6250
4 0.6000
5 0.5833
6 0.5714
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Another result from (2.8.1) is that for fixed correlation it seems that although there is 
incremental benefit with increasing numbers o f baselines this incremental benefit 
asymptotes at 3 baselines. The results in Table 2.42 demonstrate this giving the 
correction factors for a fixed correlation between baseline and outcome of 0.50 and 
difference numbers of baseline measures.
The results of Frison and Pocock are a little simplistic -  for example they assume that 
the within subject errors are independent [Senn, Stevens and Chaturvedi, 2000]. 
However, they do highlight the advantages o f taking baselines in clinical trials.
The results in this sub-section demonstrate the importance, when estimating the sample 
size, to take the variance estimate from the full model where all covariates are present. 
It also highlights how, if one ignores baseline and covariate information when doing 
sample size calculations, one could potentially be overestimating the sample size. The 
variance allowing for covariates should be used in the sample size equations given in 
previous sections.
2.9.2. Post Dose Measures Summarised by Summary Statistics
Often in parallel group clinical trials, patients are followed up at multiple time points. 
Making use o f all o f the information obtained on a patient has the desirable property of 
increasing the precision for estimating the effects o f treatment. Naturally as the 
precision is increased the variability is decreased and one consequently needs to study 
fewer patients in order to achieve a given power. Suppose one is interested in looking 
at the difference in the average of all o f the post-dose measures
■Ji A =  M b verses H ,  : J i A *  J t B ,
where JiA and JiB represent the means o f the average the post-dose measures in the two 
treatment populations. Frison and Pocock [1992] explored several summary measures 
for this hypothesis. Often in a clinical trial where data are measured longitudinally, it is 
the rate o f change of a particular endpoint which is of interest. For example in 
respiratory trials of chronic lung disease the hypothesis may focus on whether or not a 
treatment changes the annual decline in lung function. Diggle, Liang and Zeger [1994]
describe the hypothesis for such a trial. However, the simplest approach of taking the
summary measure as the simple average of the post-dose assessments for each subject 
and taking the average of these averages across treatments to obtain JiA and JiB is
assumed to be the summary statistic used.
Assuming we have r post-dose measures and that the correlation between those 
measures is p the variance can be calculated as
Variance = a  ^ ' (/' "  , (2.8.2)
r
where a 2 represents the variance o f a given individual post-dose measurement.
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When looking at (2.8.2) it seems that as the correlation between post-dose measures 
increases the variance increases so does the total sample size required. This is because, 
although it may seem counterintuitive, the advantage of taking additional measurements 
decreases as the correlation increases. This fact is due to how the total variance, o  2, is 
constructed [Julious, 2000]
o 2 =<j ; + cr' , (2.8.3)
where o 2 is the within subject component o f variation (as in cross-over trials) and o \  
is the between subject component of variation.
It is important here to distinguish between the within- (intra-) subject and the between- 
(inter-) subject components of variation. The within-subject component of variation 
quantifies the expected variation among repeated measurements on the same individual. 
It is a compound of true variation in the individual. Whilst the between-subject 
component o f variation, quantifies the expected variation of single measurements, from 
different individuals. If only one measurement is made per individual it is impossible to 
estimate c r  and o 2b and consequently only the total variation, given in (2.8.3), can be
estimated
If one knows the between-subject variance and the correlation between the measures the 
within-subject variance can be derived from
o ' f \ - p \  
P j
o : . (2.8.4)
Therefore for known variance components of o 2 and correlation between measures the 
variance that takes account o f the number of post dose measures is defined as
■>
Variance = o \  + . (2.8.5)
r
Thus, the formula (2.8.2) is actually quite intuitive. As for constant r the higher the 
correlation, from (2.8.4), the lower the within-subject variance and, from (2.8.5), the 
lower the total variance and consequent sample size. However, as p increases, and o \
falls, the effect o f taking repeated measures diminishes as o \  already constitutes a
small part of the overall variance.
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Table 2-43. Effect of number of post dose measures on the variance
Number o f post Variance 
dose measures
1 1.0000
2 0.7500
3 0.6667
4 0.6250
5 0.6000
6 0.5833
Equation (2.8.2) also gives the incremental benefit o f taking additional post dose 
measures for fixed correlation. Like with the number o f baselines it seems that although 
there is incremental benefit with increasing numbers o f post dose measures, the 
incremental benefit asymptotes at 4 post dose. The results in Table 2.43 demonstrate 
this giving the correction factors for a fixed correlation between post dose measures o f
0.50 and difference numbers o f post dose measures.
2.9.3. Inclusion of Baseline or Covariates as well as Post Dose Measures 
Summarised by Summary Statistics
As noted in the previous section further savings in sample size can be achieved by 
accounting for baseline as a covariate. Frison and Pocock [1992] define an additional 
variance measure to account for the baseline (or multiple baselines) as a covariate and 
difference numbers of post dose measures. Assuming there are p  baseline visits and r 
post dose visits the variance is defined as
Variance = cr2 \ + ( r - \ ) p PP~
\ + { p - \ ) p
( 2 .8 .6 )
2.10. Sum m ary o f C hapter 2
This chapter described in detail the standard calculations for sample size estimation for 
the most common types of clinical trial w here the data are anticipated to take a Normal 
form. It was highlighted that one o f the main assumptions in these calculations was 
with respect to the variance used in the calculations. This variance is usually a sample 
estimate that is estimated imprecisely and yet in calculations it is usually assumed fixed 
and known.
The chapter described a methodology to investigate the sensitivity of a study to the 
assumptions about the variance used in the sample size calculations. This sensitivity 
analysis was undertaken using the degrees o f freedom for the sample variance and the 
chi-squared distribution to obtain a high plausible value for the variance. Determining 
the loss o f power if the true variance was actually nearer to the high plausible value
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assesses the sensitivity o f the study. It was highlighted how if  the variance was 
estimated with few degrees of freedom then the study was sensitive to assumptions 
about the variance. Recommendations were made as to how to optimise the variance 
estimate.
The chapter then went on to develop a methodology for estimating a sample size that 
accounts for the imprecision in the variance estimate -  assessed through its degrees of 
freedom. It was demonstrated how' having few degrees o f freedom impacts on the 
sample size estimate. For example if one only had 10 degrees o f freedom for the 
variance estimate and was designing a superiority study with 90% power and a two 
sided significance level of 5% one would require 30% more subjects to account for the 
imprecision in the variance. It was further shown that as the degrees of freedom 
increased, the precision of the variance also increased -  impacting on the sample. Such 
that if  one had 100 degrees of freedom or more one could use either the new results 
proposed in this chapter or standard calculations.
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3 .  C H A P T E R  3  -  I N F E R E N C E  A N D  A N A L Y S I S  O F
C L I N I C A L  T R I A L S  W I T H  B I N A R Y  D A T A
3.1. Introduction
Binary outcomes are common endpoints in clinical trials and appear when the outcome 
o f interest is a two point response variable such as presence/absence, alive/dead or 
yes/no. Researchers also often use cut-offs on continuous scales to dichotomise and 
form a binary outcome. In areas such as Quality o f Life the cut-offs for some scales are 
well known and may define patients into various prognostic categories.
Note though that although these cut-offs may assist in interpretation, as will be 
discussed in Chapter 5, a lot of information is discarded if  all the other categories are 
ignored, which can have a knock on in an increased sample size [Julious, George, 
Machin et al, 1997; Campbell, Julious and Altman, 1995].
For such a relatively straightforward response there are many issues associated with 
trials with binary primary outcome. Not least o f these is how to summarise such data. 
Initially this chapter will describe four ways o f summarising binary data:
1. Absolute risk reduction
2. Odds-ratio
3. Relative risk reduction
4. Number needed to treat
The chapter well describe the relative merits of each. These relative merits will be 
discussed in context with the difference types of trial that may be being conducted i.e. 
trials to assess superiority; equivalence and non-inferiority. The emphasis will be on 
assessing summary measures that can be generally used for all types of clinical trial.
For each summary statistic the methodology for the calculation of confidence intervals 
will be discussed. Obviously, when designing a trial a priori  one should know both 
how one will summarise and analyse it. It will be highlighted how the limiting factor 
in making inference is the discrete nature o f binary data - there are only a finite number 
o f responses that may occur for a given sample size.
Particular emphasis will be given to the absolute risk reduction. This is because it is on 
this scale that the discrete (and bounded) nature of binary data is most apparent. Also 
the variance estimates for other summary measures are often dependent on the variance 
estimates on the proportional scale (estimated through Taylor's Series expansions).
The inference about the estimates discussed in this chapter will impact on the sample 
size discussions in Chapter 4. This is due to the sample size methodologies depending 
on the asymptotic properties of the parameters that the study is being powered on.
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Note the objective o f this chapter is not to give a definitive review of confidence 
interval methodology for binary responses but is intended as overview in the context of 
how the inference will affect sample size calculations.
3.2. A im s o f the C hapter
The main issues to be covered in this chapter are as follows
• To describe the summary measures for assessing efficacy for a binary response 
and how these measures are impacted by different clinical trial objectives.
• To review the methodologies for the calculation o f a confidence interval for a 
single binary response.
• To describe the methodologies for the calculations o f confidence intervals for 
the different summary measures for a parallel group trial.
• To explore the asymptotic (and other) properties for the estimates o f response 
and the variance about these responses.
• To make recommendations as to the most appropriate summary measures for 
binary responses.
3.3. A bsolute Risk R eduction
For a clinical trial where the primary outcome is a binary response the data may take the 
form summarised in Table 3.1 where: p A and p B are the responses anticipated on 
treatment A and B respectively; p  the average response across treatments; nA and nB 
are the sample sizes in each treatment group and N is the total sample size.
Table 3-1. Summary table for a clinical trial with a binary outcome
Outcome
Treatment  0_____    1 Sample Size
A 1 -  Pa Pa n A
B Pb Pb n B
Overall Response 1 - p  p = {pA + p b)/2 j\[ = n 4 + nB
The absolute risk reduction is probably the simplest way of summarising binary data. 
One simply takes the risk of the event for each treatment, p A and p B, and takes the 
absolute difference o f these p  , -  p B.
152
One drawback o f working on the proportional scale is that the difference is bounded by 
(-1, 1). This bounding can adversely affect inference -  especially when a response is 
near one of the bounds. The affect o f bounding o f the proportional scale will be 
discussed throughout the chapter.
3.3.1. Absolute Risk Reduction and Clinical Trials
This sub-section will walk through how a study, in terms o f the null and alternative 
hypothesis, would be designed when the absolute risk reduction (or improvement) is 
used as the assessment o f efficacy.
3.3.1.1. Superiority Trials
When designing a superiority trial in terms o f absolute effects, n  4, n B and n  A- n B, the 
null hypothesis ( H 0) and alternative hypothesis ( / / , )  are defined as
H 0 : n A = n a or H 0 : n  t -  n B = 0 .
and
H \ ■' n A ~ 71B = d •
where here d is some pre-define treatment effect that used in sample size calculations.
3.3.1.2. Equivalence Trials
The null and alternative hypotheses for an equivalence trial, on a proportional scale, 
take the form
H 0 \ n  A -  n  B > d  or tta -  n B < - d  ,
H  i : -7t < p A - p B <7r.
As discussed in Chapter 2, this is an example of an intersection-union test (IUT), in 
which the null hypothesis is expressed as a union and the alternative as an intersection. 
This is operationally the same as constructing a (1-2a) 100% confidence interval and to 
conclude equivalence provided that the ends o f the confidence interval fall completely 
within the interval ( - d . + d ) .
3.3.1.3. Non-Inferiority Trials 
On the proportional scale the null and alternative hypotheses take the form
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H 0 • TC A 71 g ^  d  ,
H l \7TA - 7 l B > - d  .
In order to conclude non-inferiority, one needs to reject the null hypothesis. In practice, 
this is the same as constructing a (1-2a) 100% confidence interval and concluding non­
inferiority provided that the lower end o f this confidence interval is above -d  on the 
proportional scale.
3.3.1.4. Choice of Non-Inferiority Limit
The choice o f non-inferiority (and equivalence) limits was discussed generally in 
Chapter 1. However, it is worth re-interrogating this issue for binary data, as it is one of 
the few areas where there is hard regulatory guidance on the issue. The guidance is for 
the antimicrobial therapeutic area where active controlled trials are the norm although 
the issues raised are generic to other therapeutic areas.
Table 3-2. Non-inferiority margins for different control response rates
Response Rate
Non-inferiority Margin
FDA CPMP
>90 -10% 10%
80-89% -15% 10%
70-79% -20% 10%
Table 3.2 gives the non-inferiority margins for different response rates as recommended 
by CPMP [2004] and FDA [1992],
Figure 3-1. Graphical illustration of CPMP and FDA non-inferiority limits
■
CPMP
1
1
J
_______________________1 -------FDA
0 .7 5  0 .80  0 .8 5  0 .9 0  0 .9 5
C o r r p a r a to r  R e s p o n s e  R a t e  j
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What is evident from Table 3.2 is that whilst the CPMP recommend a flat equivalence 
margin the FDA currently recommends a step function according to the anticipated 
control response rate. Table 3.2 is also figuratively described in Figure 3.1.
Having different regulatory guidance has two practical problems first there is the need 
to design a study that sufficiently meets the regulatory requirements of two regions. 
The second is how to design a study -  should it be based on the more stringent 
guidance?
3.3.2. Calculation of Confidence Intervals
3.3.2.1. Single Proportion
This chapter will now discuss the methodology for the calculation of confidence 
intervals, and corresponding inference. The rationale for this discussion is that the 
inference for a single proportion generalises both to the absolute difference in two 
proportions and other binary summaries such as odds-ratios and relative risks. 
Inference about a single proportion is also important when designing a clinical trial, as 
often one only has data for just one arm (usually the control arm). From this one arm a 
response rate is inferred for the other (usually investigative arm). Thus, it is the 
imprecision o f a single proportion to which a study is sensitive as will be discussed in 
Chapter 4.
Table 3-3. Anticipated frequency distributions for different population responses
n 71 -0 .4 71 - 0.5 71 -0 .6
0 0.00004 0.00000 0.00000
1 0.00049 0.00002 0.00000
2 0.00309 0.00018 0.00000
3 0.01235 0.00109 0.00004
4 0.03499 0.00462 0.00027
5 0.07465 0.01479 0.00129
6 0.12441 0.03696 0.00485
7 0.16588 0.07393 0.01456
8 0.17971 0.12013 0.03550
9 0.15974 0.16018 0.07099
10 0.11714 0.17620 0.11714
11 0.07099 0.16018 0.15974
12 0.03550 0.12013 0.17971
13 0.01456 0.07393 0.16588
14 0.00485 0.03696 0.12441
15 0.00129 0.01479 0.07465
16 0.00027 0.00462 0.03499
17 0.00004 0.00109 0.01235
18 0.00000 0.00018 0.00309
19 0.00000 0.00002 0.00049
20 0.00000 0.00000 0.00004
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Inference for a single proportion generalises to other parameters such as relative risk 
and odds-ratios as the standard errors for these parameters may be estimated from the 
standard error o f a single proportion through approximations using the delta method 
[Armitage and Berry, 1987].
To consider the inferences about a single proportion one must go back to basics. 
Table 3.3 gives an illustration of the anticipated frequency distribution for different 
proportions for a fixed sample size o f 20. This is known as a binomial distribution. 
From this table two major points are evident. The binomial distribution although uni- 
modal is only symmetric when n  0.5. For any other value the distribution is skewed. 
The other point is the discrete nature o f the distribution. As the sample size tends to 
infinity the binomial distribution tends towards the Normal [Kendall and Stuart, 1977] 
however, the discreteness of the distribution may question the robustness of this 
assumption for small sample sizes. This assumption will be interrogated throughout the 
chapter.
3.3.2.2. Normal Approximation
Under the Normal approximation the confidence interval for a single proportion is 
defined as
p ± Z x_a;2se{p) ,  (3.2.1)
where s e ( p ) =  ^ p (  1 -  p ) / n  . (3.2.2)
where p is the estimated response from the trial. This method is referred to as the Wald 
method [Newcombe, 1998a]. An empirical investigation o f the asymptotic assumptions 
is given in Figures 3.2 to 3.4. This was done through simulation in SAS [1990]. For 
each sample size 10,000 simulations were undertaken assuming the population 
prevalence rate was 60%. One thing to highlight though in the simulations is that 
except for the large sample sizes there was a degree o f redundancy in these simulations 
due to the discrete (and very finite) distribution being sampled from.
Figure 3.2 gives the Normal probability plot for the simulated proportions. As one can 
see from this plot the simulated proportions do not deviate greatly from the 
approximation to Normal for all the sample sizes. For each simulation the following 
was also calculated
(n-i )Z(i_-z )_:«=(n_,)p(j-p),
7 r ( \ - 7 r )  n  / r ( l - / r )
where p is the estimated response from the simulation and n  is the population 
prevalence (p=0.60) from which each simulation was drawn.
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Figure 3-2. N orm al probability plots for different sam ple sizes for a response 
(/r=0.6) sam pled from  a binomial d istribution
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Figure 3.3 gives chi-probability plots for the ratio o f the simulated sample over the 
population variance for different sample sizes. What is evident from this figure is that 
the approximation to the chi-distribution is quite weak for small sample sizes but 
improves the larger the trial.
Sam ple S ize=  100000Sam ple S ize= 1 0 0 0
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Figure 3-3. Chi-probability plots for different sample sizes for a W ald variance 
(/r=0.6) sam pled from a binomial d istribution
Sample Size=24
1 -
Sample Size=100
Sample Size=1000
Sample Size= 100000
A rationale for Figure 3.3 may be gained from Figure 3.4. This gives a plot o f the 
variance, p(l-p), against an observed proportion, p, for different values o f p. One can 
see from this figure that with p in the centre o f the range (0.3 to 0.7) the variance is 
quite stable. It is only as p approaches the extreme o f the range (0 or 1) that the 
variance differs markedly. Thus, if  p is towards the middle o f the range and is 
imprecisely estimated (i.e. from a small sample size) the consequent plausible range for 
the variance would be comparatively narrow - less than expected if the sample variance 
was for continuous data and followed a chi-squared distribution.
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Figure 3-4. Plot of the variance of a proportional response for different responses
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Finally, Figure 3.5 gives Normal probability plots for the 'standardised' proportions 
defined as the observed simulation proportion (3.2.1) divided by its standard error 
(3.2.2). As with the observed proportions the standardised proportions approximate 
reasonably well to the Normal.
The practical consequence of these and subsequent simulations will be referred to 
through this chapter and in Chapter 4.
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Figure 3-5. Normal probability plots for different sample sizes for a standardised 
proportional response (/r=0.6) sampled from a binomial distribution
Sample Size-24 Sample Size= 100
Sample Size= 100000
Sample Size 1000
3.3.2.3. Normal Approximation with Continuity Correction
To approximate better to the Normal quantiles one can add a continuity correction to the 
confidence interval through addition to the right hand side o f (3.2.2) of 1/(2n)
[Newcombe, 1998a; Fleiss, 1981], Thus, the standard error o f p can be rewritten as
se(p)=  P-(l P) + ~ ,  (3.2.3)
V n 2 n
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and used in (3.2.1) to construct a confidence interval.
Figure 3.6 gives a chi-probability plot for the variance defined from (3.2.3). As with the 
probability plots for none continuity corrected variances the evidence tends to suggest 
that the approximation to the chi-squared distribution is weak if  the sample size is small.
Figure 3-6. C hi-probability plots for different sample sizes for continuity corrected 
W ald variance (/r=0.6) sampled from  a binomial D istribution
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3.3.2.4. Wilson's Score Method
An alternative method for calculating confidence intervals is the score method 
[Newcombe, 1998] first introduced by Wilson [1927]. To calculate the confidence 
interval one solves the following quadratic
2rtP +  z L  2 ± z i-a z f L  2 + 4 n p 0 - p )  2
2( n + z L , )
such that the lower point of the confidence interval is defined as 
2nP + Z l - a  ; - Z v - a  i f , 2 a 1 + 4nP0  ~ P)
2 (n + Z ; a 2 ) ~  ’
and the corresponding upper as
2"P + Z L  l + Z , - a  i f  l a  : +4«p(l -~p)
2(n + Z;_a ,)
Unlike the Wald confidence intervals the Wilson Score method gives asymmetric 
confidence intervals on the proportional scale -  although symmetric ones on the logit 
scale [Newcombe, 1998a].
3.3.2.5. Wilson fs Score Method with Continuity Correction
As with the Wald method Wilson's method also can be calculated with a continuity 
correction [Newcombe, 1998a; Fleiss, 1981]. The continuity corrected score confidence 
intervals can be calculated also by solving a quadratic with the lower bound defined as
(2np + Z|-_a : — 1) — 2T,-„ . y / r  ,, ; - (2 w  + l) n + 4p(n(\  -  p)  + 1)
2(« + Z , .)
and the upper as
(2np + Z-_a , + I) + Z |..U : y Z| „ : + (2n -1 )  n + 4p(n(l  -  p)  -1 )  ^
2(« • Z, . .)
3.3.2.6. Exact Confidence Intervals
The final confidence interval calculations described are "exact" confidence intervals, 
also known as Clopper-Pearson confidence intervals [Clopper and Pearson, 1934]. 
These confidence intervals are calculated by summing each o f the tail probabilities from 
the binomial distribution, given the observed number of cases (k) for the sample size 
(n).
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Defining the individual cell probabilities as
P r ( X  =  k )
W
P k { \ - P )
( n- k ) (3.2.6)
the lower limit of the confidence interval is defined as the lowest cumulative value of p 
such that the lower tail area o f the distribution is no more than a/2. Likewise the upper 
limit is calculated as the point where the cumulative distribution exceeds l-a/2 . 
Formally, the lower point o f a confidence interval is defined as
* f  n \
' =  0  V  * /
whilst the upper point is defined as, 
± [ n\ ' A \ - Pvr " > \ - a i 2 . (3.2.7)
Table 3-4. Frequency and cumulative frequency distributions for a sample size of 
20 and response of 0.60
Cumulative 
n Probability Probability
0 0.00000 0.00000
1 0.00000 0.00000
2 0.00000 0.00001
3 0.00004 0.00005
4 0.00027 0.00032
5 0.00129 0.00161
6 0.00485 0.00647
7 0.01456 0.02103
8 0.03550 0.05653
9 0.07099 0.12752
10 0.11714 0.24466
11 0.15974 0.40440
12 0.17971 0.58411
13 0.16588 0.74999
14 0.12441 0.87440
15 0.07465 0.94905
16 0.03499 0.98404
17 0.01235 0.99639
18 0.00309 0.99948
19 0.00049 0.99996
Table 3.4 illustrates the effect of the sample size on the confidence interval calculation. 
In the example, the sample size was 20 with 12 subjects a prevalence of 0.60. From the
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column of cumulative probabilities the 95% confidence intervals is thus estimated as 
0.35 to 0.80.
The link between the F distribution and the binomial distribution can also be used to 
calculate exact confidence intervals such that the lower bound is defined as [Agresti and 
Coull, 1998; Anderson and Bumstein 1967 and 1968; Casella, 1986; Crow, 1956; Daly, 
1992; Edwardes, 1998; Ghosh, 1979; Blyth, 1983; Korn, 1986; Steme, 1945; Vollset, 
1993]
____________k _______
k + ( n - k  + l)F,_a '
and upper bounds are defined as
__________ k + \__________k + ] + {n.k) Fi_a2ikt2/i 2k ■ (3.2.8)
It is interesting how using tails of the F-distribution has become the "norm" for the 
calculation of exact confidence intervals when a more straightforward calculation can 
be made through a using of tails of a Beta distribution [Julious, 2005b; Daly, 1992; 
Johnson and Kotz 1994a, 1994b, 1994c; Reiczigel, 2003; Newcombe, 1998]. To 
demonstrate this one needs to go back to basics and consider the distribution functions 
o f the F-distribution
,  . a a 2 b b 2 T ( a 2  + b 2 ) r  tp F(x;a,b) = --------------------------  — - -------——  (//,
r(a 2)f(o 2) J» (at+by^-
( o  2 )  2
and the Beta distribution
p B(x;a,b) = [ t a ] ( \ - i ) h ]dt .
From inspection o f these it is apparent that the following relationship holds [Daly, 1992; 
Julious 2005b]
F bBr.a2,b2
p - ° b -Hi h , .. . i
Which when substituted back in (3.2.8) gives lower bound defined as 
1 -  B E T A I N V ( l - a / 2 , n - k  + U ) ,
and upper as
BETAINV(] -  a /2 , A- + 1,« -  k ) . (3.2.9).
A more straightforward nomenclature. The fact that the calculations using the Beta 
distribution are not more commonly used one imagines to be simply a function of the
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fact that F-distribution are more readily available compared to the Beta distribution. 
This should not continue to the present day as BETAINV(•) is a function in packages
such as SAS (even Excel has a similar function) and so the confidence interval 
calculation is operationally straightforward.
It should be noted here, however, that just because the "exact" confidence intervals have 
this flag exact does not make them truly "exact". This is because one only knows the 
true coverage probabilities of these intervals if one knows the true population rate 
[Clayton and Mills, 1993].
3.3.2.7. Comparison of the Different Methods
Table 3.5 give a comparison of the different methods o f calculating the confidence 
intervals for different sizes. For large(ish) sample sizes (100+) there is pretty good 
agreement between the different methods. Even for a relatively small sample size of 50 
to two decimal places the agreement is relatively good. It is with small sample sizes 
that the differences are more apparent with both the Wald confidence intervals giving 
upper bounds greater than one in these examples. As one would expect using the tails 
o f the Beta distribution matches the summing o f tails o f the binomial distribution.
The selection o f the most appropriate confidence interval depends on the objective for 
which the calculation will be used. If one wishes to describe a plausible range of values 
for a given confidence interval then a generic solution would be to quote Wilson 
(continuity or non continuity corrected) confidence intervals. If, however, the objective 
is to rule out a certain value with a pre-specified probability (say for a non-inferiority 
study) then the exact confidence intervals are probably the optimal solution as these will 
provide a lower bound (say) from which one can guarantee to be greater than the pre- 
specified value with a probability less than or equal to some P-value.
3.3.2.8. Difference in Two Proportions
The methods for the calculation o f confidence intervals for the difference in 
independent proportions are similar to those for a single proportion and will be briefly 
discussed now.
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Table 3-5. A comparison of the different methods for calculating confidence intervals
Sample Bionomial Beta Wald Wald (with CC) Wilson Wilson (with CC)
Proportion Size Lower Upper Lower Upper Lower Upper Lower Upper Lower Upper Lower Upper
0.60 20 0.3500 0.8000 0.3605 0.8088 0.3853 0.8147 0.3603 0.8397 0.3866 0.7812 0.3641 0.8007
50 0.4400 0.7400 0.4518 0.7359 0.4642 0.7358 0.4542 0.7458 0.4618 0.7239 0.4520 0.7327
100 0.4900 0.6900 0.4972 0.6967 0.5040 0.6960 0.4990 0.7010 0.5020 0.6906 0.4970 0.6952
500 0.5440 0.6420 0.5556 0.6432 0.5571 0.6429 0.5561 0.6439 0.5565 0.6420 0.5554 0.6430
1000 0.5690 0.6300 0.5689 0.6305 0.5696 0.6304 0.5691 0.6309 0.5693 0.6299 0.5688 0.6304
10000 0.5904 0.6096 0.5903 0.6096 0.5904 0.6096 0.5903 0.6097 0.5904 0.6096 0.5903 0.6096
0.75 20 0.5000 0.9000 0.5090 0.9134 0.5602 0.9398 0.5352 0.9648 0.5313 0.8881 0.5059 0.9046
50 0.6200 0.8600 0.6074 0.8616 0.6300 0.8700 0.6200 0.8800 0.6151 0.8492 0.6045 0.8571
100 0.6500 0.8300 0.6534 0.8312 0.6651 0.8349 0.6601 0.8399 0.6570 0.8245 0.6516 0.8288
500 0.7100 0.7980 0.7096 0.7874 0.7120 0.7880 0.7110 0.7890 0.7102 0.7860 0.7092 0.7869
1000 0.7220 0.7770 0.7219 0.7766 0.7232 0.7768 0.7227 0.7773 0.7222 0.7758 0.7217 0.7763
10000 0.7414 0.7584 0.7414 0.7585 0.7415 0.7585 0.7415 0.7585 0.7414 0.7584 0.7414 0.7584
0.90 20 0.7000 1.0000 0.6830 0.9877 0.7685 1.0315 0.7435 1.0565 0.6990 0.9721 0.6687 0.9832
50 0.8000 0.9800 0.7819 0.9667 0.8168 0.9832 0.8068 0.9932 0.7864 0.9565 0.7741 0.9627
100 0.8300 0.9500 0.8238 0.9510 0.8412 0.9588 0.8362 0.9638 0.8256 0.9448 0.8196 0.9484
500 0.8700 0.9260 0.8703 0.9249 0.8737 0.9263 0.8727 0.9273 0.8706 0.9233 0.8695 0.9242
1000 0.8800 0.9180 0.8797 0.9179 0.8814 0.9186 0.8809 0.9191 0.8798 0.9171 0.8793 0.9175
10000 0.8940 0.9058 0.8940 0.9058 0.8941 0.9059 0.8941 0.9059 0.8940 0.9057 0.8939 0.9058
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3.3.2.9. Normal Approximation
Under Normal approximation the confidence interval for the difference in proportions is 
defined as
P a ~  P b ± Z \ - q i s e ( P A ~  P b ) ,  (3.2.10)
where se(pA - / , , ) =  + . (3.2 .11)
This method is referred to as the Wald method [Newcombe 1998b].
3.3.2.10. Normal Approximation with Continuity Correction
One can add a continuity correction to the confidence interval through addition to the 
right hand side of (3.2.10) of (l n A +1 nB)/ 2 [Newcombe 1998b; Fleiss, 1981] such 
that it takes the form
P a -  P B ± Z \ - a 2s e ( p . . t -  P b )  + ( 1 n A + 1 «fl)/2 • (3.2.12)
3.3.2.11. Wilson's Score Method
The Wilson Score confidence intervals are derived from the following, for the lower 
[Newcombe, 1998b]
l  =  P a ~ P b - S *  
and upper bounds
U = p A - p B - £ ,  (3.2.13)
where
S  =  Z 1 - a  2 y l l A 0  -  l A )  1 n A + H « 0 -  l i B )  1 U B £  -  Z , .  a  ,  ^ U A ( 1  ~  U A ) 1 " a +  1f i O  ~  / )  1 " B •
Here IA and uA are the lower and upper bounds for p  4 and lB and uB are the lower 
and upper bounds for p B obtained from (3.2.4)
3.3.2.12. Wilson's Score Method with Continuity Correction
The Wilson Score continuity corrected confidence intervals are derived as per (3.2.13) 
but with lA, u j , lB and uB (the lower and upper bounds for p A and p B respectively) 
obtained from (3.2.5) instead of (3.2.4).
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3.3.2.13. Exact Confidence Intervals
For two independent proportions p A (rA events in nA subjects) and p B ( rB events in 
nB subjects) the probability function for their difference 6 = p A -  p B can be expressed 
in terms of 6 and a nuisance parameter p B [Agresti.2003; Agresti and Min, 2001; 
Newcombe 1998b]
V (o+p„)"(h-o-pBr - ' (n \nB
U J U J
To obtain the lower and upper bounds for the 95% confidence (3.2.14) could be used 
through iteration to obtain the 2.5th and 97.5th percentile. In truth this confidence 
interval is not exact in the strictest sense, more a permutation type "exact" confidence 
interval [Santer and Snell, 1980].
3.3.2.14. Comparison of the Different Methods
To illustrate the different methods of confidence interval estimation, Table 3.6 was 
constructed to give a comparison of the different methods for fixed proportions 
o f p 4 =0.40 and p B =0.60 ( p  4 -  p B = -0.20) for different sample sizes. What this table 
highlights is that if there is sample o f 50 per group there is little separation between the 
different methods. Even for a sample size o f 20 per group the agreement is relatively 
good.
As with the comparison of the methods earlier in this chapter for a single proportion the 
method to use for a small sample size depends on the rational for the calculation. For 
consistency with the single proportion case a recommendation would be to use the exact 
calculations if there is a value one wished to be ruled out with certain probability and 
Wilson (continuity or non continuity corrected) confidence intervals if a plausible range 
of values needs to be described with an appropriate coverage.
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Table 3-6. A Comparison of the different Methods for Calculating Confidence Intervals for Two Proportions of PA-0.40 and 
Pb=0.60
Sample Exact Wald Wald (with CC) Wilson Wilson (with CC)
Size Lower Upper Lower Upper Lower Upper Lower Upper Lower Upper
10 -0.20 0.70 -0.23 0.63 -0.33 0.73 -0.21 0.53 -0.19 0.50
20 -0.10 0.55 -0.10 0.50 -0.15 0.55 -0.10 0.46 -0.10 0.45
50 0.00 0.38 0.01 0.39 -0.01 0.41 0.00 0.38 0.00 0.37
100 0.06 0.33 0.06 0.34 0.05 0.35 0.06 0.33 0.06 0.33
500 0.14 0.26 0.14 0.26 0.14 0.26 0.14 0.26 0.14 0.26
1000 0.16 0.24 0.16 0.24 0.16 0.24 0.16 0.24 0.16 0.24
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3.4. N um ber N eeded to Treat
The number needed to treat (NNT) is a parameter that has been advocated for binary 
type data. This is because it supposedly gives an estimated effect in terms o f a number 
o f subjects as opposed to more "abstract" probabilities and risks which do not relate so 
directly to day to day practice [Cook and Sackett, 1995].
The number needed to treat (NNT) is defined as
NNT = ----- '------ , (3.3.1)
Pa -  P b
where p A and p B are the proportion of subjects expected to have an event on regimens 
A and B respectively. It is thus the reciprocal of the proportional difference between 
treatments. It is interpreted as the number o f subjects that on average would need to be 
treated on the investigative therapy to prevent one event that otherwise would have 
occurred had the control therapy been given. For example an NNT of 10 means that on 
average after treating each of 10 subjects one would expect to have prevented one event. 
Hence, it is argued that the two proportions, p  4 and p B, have been reduced into a
single parameter to provide an estimate o f the treatment effect.
The published literature indicates there has been an increase in the use of NNT, as 
evidenced in the British Medical Journal where articles quoting the parameter increased 
from one article in 1994 to a peak of 34 in 1998. This has led to some discussion as to 
its merits [Grieve, 2003; Hutton, 2000; Julious, 2002, 2005c; Smeeth, Haines and 
Ebrahim, 1999],
3.4.1. Number Needed to Treat and Clinical Trials
There are a number of issues with using NNT in clinical trials as will be now 
highlighted.
3.4.1.1. Superiority Trials
When designing a superiority trial, one should plan the study with reference to a null 
( H 0) and alternative hypothesis ( / / , ) .  As discussed earlier in this chapter when one is 
thinking in terms of p  ,, p B and p -  p B the null hypothesis is easy to define
H o : 7 r A = * b  o r  H o - n A ~ K b  = 0 ’ 
and
H  j . Tc 4 n B d  ,
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where d is some pre-define treatment effect. However what is the null hypothesis when 
planning to summarise the trial using NNT [Hutton; Julious, 2002, 2005c]
H 0 : NNT  = oo ?
3.4.1.2. Non-Inferiority Trials
NNT has also been advocated to summarise non-inferiority trials and equivalence trials 
[Bender, 2001]. On the face of it for non-inferiority trials there may be some merit to 
the proposal. Remember that on the proportional scale the null and alternative 
hypotheses take the form
H 0 . K A Kg ^ d ,
H { : k A — k b > —d ,
which on the NNT scale equate to 
H 0 : NNT > - \ / d ,
/ / ,  : NNT < - \ / d  .
In order to conclude non-inferiority, one needs to reject the null hypothesis. In practice, 
this the same as constructing a (1 -2a) 100% confidence interval and concluding non­
inferiority provided that the lower end of this confidence interval is above -d  on the 
proportional scale or greater than -1 /d  on the NNT.
For a simple non-inferiority trial this may seem to be operationally straightforward. 
However, as discussed in Chapter 1, such trials are seldom just designed as non­
inferiority trials but as "as good as or better" trials where an appropriate closed testing 
procedure is applied to investigate both superiority and non-inferiority whilst 
maintaining the overall Type I error rate [Morikawa and Yohsida, 1995; CPMP, 2000]. 
As a consequence "as good as or better" trials also incorporate the null and alternative 
hypotheses of superiority trials and hence issues with using NNT for superiority trials 
arise.
3.4.1.3. Equivalence Trials
The null and alternative hypotheses for an equivalence trial on the proportional scale 
may take the form
H 0 : k  A -  k B > d  or k  -  k b < - d  ,
H x\ —d < k a — Kg <d  .
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On the NNT scale the equivalent Null and alternative hypotheses become 
H 0 : NNT < \ /d  or NNT > - \ / d  ,
/ / ,  : - \ / d  < NNT >\ /d  ,
which operationally would equate to constructing a confidence interval and 
demonstrating that it fall completely within the interval (-00 to -1/d) and (1/d to 00)? 
Not what one could argue to be the most easily understood concept.
3.4.2. Confidence Intervals for Number Needed to Treat
This sub-section will discuss the different methods of calculating a confidence interval 
for the NNT. It will start with the standard methodology for calculating confidence 
intervals for the NNT of taking the reciprocal o f the difference in proportions and then 
move onto two other methods the delta method and bootstrapping.
3.4.2.1. Reciprocal of the Confidence Intervals of the Difference in Proportions
Given that NNT is the reciprocal o f p A -  p B the convention is to simply take the 
reciprocal of the confidence interval of p A -  p B to obtain its confidence interval 
[Altman, 1998].
Table 3-7. Table of confidence intervals for the difference in responses (p a = 0.4 and 
Pb^O.IO) and number needed to treat by three methods for different sample sizes
Sample Size
Confidence Intervals
Proportion Reciprocal Method Delta Method Bootstrapping
10 -0.19 to 0.59 -5.26 to 1.69 -4.75 to 14.75 -5.00 to 1.67
25 -0.05 to 0.45 -20.00 to 2.22 -1.25 to 11.25 -24.79 to 2.27
50 0.02 to 0.38 2.63 to 50.00 0.50 to 9.50 2.63 to 49.42
100 0.08 to 0.32 3.13 to 12.50 2.00 to 8.00 3.12 to 12.57
500 0.14 to 0.26 3.85 to 7.14 3.50 to 6.50 3.91 to 7.02
1000 0.16 to 0.24 4.17 to 6.25 4.00 to 6.00 4.19 to 6.25
The problem with this approach is that at first glance confidence intervals are obtained 
that do not contain the point estimate for negative studies. The first two lines of 
Table 3.7 illustrate this (column 3). For example for a NNT point estimate of 5 a 
confidence interval o f -5.26 to 1.69 is obtained. This problem with negative results has 
led to confidence intervals sometimes just being just quoted for positive (statistically 
significant) trials. The interpretation o f negative results is in fact in terms of "to 
infinity and beyond" with confidence intervals for the given example actually being (-00 
to -5.3] and [1.7 to 00) [Altman, 1998] and is due to the fact that the "null" value of a 
NNT  = 00 (and negative trials should contain the null). The two part confidence
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interval does now actually include the point estimate - although interpretation may be a 
bit difficult.
3.4.2.2. The Delta Method
To first reconsider the calculation of the confidence interval for the NNT one should 
first consider how to obtain a variance estimate. For a given function f ( x ) ,  where
x = p 4 - p B and f ( x )  = NN7\  the variance for the number needed to treat can be
defined as [Armitage and Berry, 1987]
var(ATVT) = var(l/ x) = var(l/ (pA - p B))*  v) var(x),
giving [Lesaffre and Pledger, 1999; Schulzer and Mancini, 1996]
var(ATVr) = var(/?, -  p B) / (pA -  p B)A = (N N T )4 var( pA - p B). (3.3.2)
Thus, the standard statistic can be defined as
NNT = 1 (p A ~ p Bf  = Pa - P b (3 3 3)
se(NNT) p A -  p B se{pA -  p B) se{pA -  p B)
Which is identical to the standard statistic for the difference in proportions. One can 
thus calculate the confidence interval for the number needed to treat from,
NNT+/-Z,_„ ,se(NNT)=AW7 ±Z, „ , {NNT)2se(p,  -  p B) ,
which is the same as calculating the Cl for the difference in proportions and multiplying 
it by (NNT )2. This approach is sometimes referred to as the delta method [Matthews, 
2000]. It is just as easy as taking reciprocals to calculate and on the face o f it gives 
more intuitive answers as the confidence interval always includes the point estimate. 
The equivalent confidence interval to the example quoted earlier is -4 .8  to 14.8. In fact 
this confidence interval still has the "to infinity and beyond" interpretation in that it 
should actually be (-ooto -4.8] and (5 to 14.8].
One issue with the Delta method is that as Lesaffre and Pledger [1999] point out, for 
any sample size and any expected proportional difference there is always a non-zero 
probability that the observed proportional difference will equal zero. Hence, for any 
expected proportional difference and sample size the expected value of NNT is infinity 
along with its variance.
3.4.2.3. Bootstrapping
A final approach for calculating confidence intervals is to calculate them using non- 
parametric bootstrap methodology -  extending the work from other areas [Efron and
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Tibshirani, 1993; Keene, 2002; Julious, 2001]. To calculate a bootstrap confidence 
interval a bootstrapping sample, with replacement, is taken from the data. This 
bootstrap sample is of the same sample size as the original data. For each bootstrap 
sample a NNT is calculated. This is repeated a large number of times, 10,000 say, to 
generate a bootstrap distribution for NNT.
The bootstrap distribution of the NNTs is then ordered. As on the NNT scale 1>2>3>... 
etc the data are "reverse" ordered separately for positive and negative simulated values. 
For example for 5 NNTs of 2,-1,-4,3 and 8 the data would be ordered as -1,-4,8,3 and 2. 
After this ordering the percentiles were taken. To calculate bootstrap 95% confidence 
interval the values associated with the 2.5% to the 97.5% percentiles are taken. This 
bootstrap method is known as the percentile method [Efron and Tibshirani, 1993].
It may be worth noting that the apparently unusual ordering o f NNT does occur on other 
scales. For example on the log scale 0.25>0.5>0.75 for observed effects which one 
counters by log transforming to get the data on an arithmetic scale. For NNT one would 
reciprocate the data (i.e. back to the p 4 -  p B scale) to get a conventional arithmetic
ordering.
When calculating a bootstrap confidence interval, bootstrap samples from a finite 
sample size with only two categories of outcome are taken. Thus, a number of ties will 
be expected. As bootstrapping requires the calculation o f the number of NNTs below a 
certain value ties can represent a problem in calculations. To overcome this problem a 
random number is added to each bootstrap p  4 -  p B response prior to the calculation of
the bootstrap NNT. In the examples given here a random number sampled from the 
uniform distribution between (-0.0005, 0.0005) was added to each p A -  p B.
Bootstrapping has been commented on as a way o f calculating a confidence interval for 
NNT by Hutton [2000]. However, Hutton also highlighted the issue of indeterminable 
NNTs for bootstrap samples where p  4 -  p B = 0 . Through adding a small random
number one overcomes this problem through in effect randomly assigning bootstrap 
samples where p  4 -  p B -  0 to either very large positive or negative NNTs.
The equivalent bootstrap confidence interval to the example quoted earlier for methods 
1 and 2 is -5.00 to 1.67. The estimated bootstrap confidence interval for this example is 
quite close to method 1. This bootstrap calculation was undertaken in the Interactive 
Matrix Language in SAS [1985].
3.4.2.4. Comparison of the Different Methods
A simple comparison of the three methods o f calculating the confidence intervals is 
given in Table 3.7. From this table it is evident that one feature of the delta method is 
that the confidence interval is symmetric about the point estimate. Simple reciprocation 
of the proportional difference confidence intervals and bootstrapping give similar 
confidence interval estimates, which differ from the delta method when the sample size
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is small but all three methods start to converge as the sample size gets larger and the 
evidence towards a positive effect increases.
To further compare the three methods of calculating a confidence interval around NNT 
simulations were undertaken in the Interactive Matrix Language in SAS [1985] to 
compare with Table 3.7. As the number needed to treat is an abstract parameter on an 
abstract scale the simulations were done on the proportional scale with a NNT 
calculated for each simulation from the proportional difference. The data were 
simulated the respective treatment responses for each simulation taken as p A =0.40 and
p B =0.20.
One issue with the simulations on the binary scale is that one encounters zero for the 
treatment differences which causes a problem when reciprocating to calculated NNT. 
For the bootstrapping described earlier this problem was overcome through adding a 
very small value to all simulated proportional differences. For this simulation exercise 
the problem was overcome by randomly assigning p A -  p B = 0 to be either a very large 
negative or very large value for NNT. For a given sample size the simulation was 
repeated 10,000 times.
After the simulation for each sample size the data were ordered smallest to largest and 
five percentiles (2.5th, 25th, 50th, 75th and 97.5th) were taken. The 2.5th and 97.5th 
percentile should correspond to the 95% confidence interval. The simulated NNT were 
ordered in the same why as that described for bootstrap samples. The results are given 
in Table 3.8.
Table 3-8. Results from simulations for number needed to treat
Percentile
Sample Size 2.5 25 50 75 97.5
10 -5.00 10.00 5.00 3.33 1.67
25 -25.00 8.33 5.00 3.57 2.27
50 50.00 7.14 5.00 3.85 2.63
100 12.50 6.25 5.00 4.17 3.03
500 6.94 5.49 5.00 4.55 3.90
1000 6.21 5.35 5.00 4.67 4.17
For negative trials the simulations are awry from method 2 but for positive and larger 
trials there is greater agreement. The issue with the simulations though is that each 
NNT was estimated indirectly from the proportional difference, as it would be done 
practically, whilst method 2 provides a confidence interval for NNT assuming that in 
future trials NNT could be directly derived.
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3.4.2.5. Further Issues with Number Needed to Treat
One of the problems with NNT is the fact that it is just one number, which is sometimes 
quoted as an advantage. Usually when one quantifies a treatment effect it is usually in 
context with something. For example in a hypertension trial if  subjects on treatment A 
had a mean diastolic blood pressure of 110 whilst subjects on treatment B had a mean of 
100, a treatment effect of 10 would be observed. In this instance the number 10 has a 
context in terms of the effects observed on the individual treatments. However, what is 
the context of NNT=10? Table 3.9 summarises this point. For different values o f p A 
and p B equivalent values of NNT are derived. As the NNTs are the same one would 
imagine that for each, the effects would be the same. However, an effect of 0.10 in 
terms of p A -  p B ranges from a trebling in the proportion observed to an increase of 
just a third when putting the effect in context with p A and p B . A marked difference in 
interpretation and meaning. To assist in interpretation therefore NNT should not be 
quoted in isolation but in context with p 4, p B and p A —p B [Julious, 2005c] indeed 
due to the issues raised in this Chapter in isolation a NNT should really stand for 
Nonsensical Numeration of Treatment.
Table 3-9. Proportional differences that would give an equivalent estimate for the 
number needed to treat
P a P b P a -  P b NNT
0.05 0.15 0.10 10
0.10 0.20 0.10 10
0.20 0.30 0.10 10
0.30 0.40 0.10 10
3.5. O dds-R atio
The difference between two proportions can also be expressed through the odds ratio 
(OR) which is defined as
o r = Pb0_z 1 A  , (3.4.1)
P a 0 - P b )
Odds of 2:1 would mean that for every 3 subjects on a control regimen, for example, 
one would expect one event i.e. non-events are twice as numerous as events. Odds of 
4:1 on the investigative regimen would mean non-events are four times as numerous. 
An odds-ratio is simply therefore a ratio o f two odds and is an assessment of the 
likelihood of success on one treatment compared to another. Hence, an odds-ratio 
would be 2 indicating non-events relative to events are twice as numerous on the 
investigative regimen compared to control.
One of the main advantages o f the OR is that it is invariant to the definition o f success 
[Olkin, 1998; Walker, 1998]. An analysis based on the OR also easily allows one to
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adjust for covariates such that estimates can be provided that are independent of, but 
adjusted for, any predictive factors o f interest. As an analysis with covariate adjustment 
is often the standard analysis it supports the idea o f the OR being the standard 
parameter.
The log-odds-ratio is also an attractive scale for analysis as it is both unbounded and 
likely to be additive across a wide range.
3.5.1. Odds-Ratios and Clinical Trials
This sub-section will discuss how a study, in terms of the null and alternative 
hypothesis, would be designed where the odds-ratio is the primary assessment of 
efficacy.
3.5.1.1. Superiority Trials
When making inferences with odds-ratios it is much simpler to work on the Log(OR) 
scale then back transform to the original scale. Hence, when working on the odds ratio 
scale the null hypothesis and alternative hypotheses can be defined as
H 0 : Log(OR) = 0 ,
/ / ,  : Log(OR) = d ,
where d is some pre-defined treatment effect used for sample size calculations.
3.5.1.2. Non-Inferiority Trials
For a non-inferiority trial the null and alternative hypothesis would be expressed as the 
following
H 0 : L o g ( O R ) < - d .
/ / ,  : Log(OR) > - d  ,
where d is a pre-define non-inferiority limit.
3.5.1.3. Choice of Non-Inferiority Limit
It is when considering non-inferiority trials (and equivalence trials later) that one sees 
one an advantage of working on the odds-ratio scale. As discussed earlier in the chapter 
there are hard regulatory guidance for the antimicrobial therapeutic area to assess non­
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inferiority as given in Table 3.2. The guidance from the FDA [1992] is currently a 
function dependent on the anticipated control response rate.
This step function does present problems when working with absolute differences. 
Suppose one designed a trial based on an anticipated active response rate of 78% and a 
margin of 20% but one actually observed 82%. This brings one over into the next 
margin level o f 15%. Also, the step function states one can use the same margin 
whether the anticipated response rate is 80% or 89%. One could argue these are 
markedly different response rates.
Working on the odds-ratio scale avoids the problems with the issues with stepped non­
inferiority margin. This is because on the odds-ratio scale a fixed margin would equate 
to different margins on the proportional scale. This has been recognised by a number of 
authors. Garrett [2003] has recommended using a margin of 0.5 on the odds-ratio scale 
whilst Senn [1997] has recommend a margin of 0.55 and Tu [1998] a margin o f 0.43. 
The relative merits of these margins can be seen in Table 3.10 and Figure 3.7.
Table 3-10. Table of differences on the proportional scale that are equivalent to 
different odds-ratios for various anticipated expected responses on one treatment 
arm
Odds-Ratio
Pa 0.40 0.45 0.50 0.55 0.60
0.95 0.066 0.054 0.045 0.037 0.031
0.90 0.117 0.098 0.082 0.068 0.056
0.85 0.156 0.132 0.111 0.093 0.077
0.80 0.185 0.157 0.133 0.113 0.094
0.75 0.205 0.176 0.150 0.127 0.107
0.70 0.217 0.188 0.162 0.138 0.117
0.65 0.224 0.195 0.169 0.145 0.123
0.60 0.225 0.197 0.171 0.148 0.126
0.55 0.222 0.195 0.171 0.148 0.127
0.50 0.214 0.190 0.167 0.145 0.125
Table 3.10 gives the equivalent difference on the proportional scale for different odds- 
ratios and control response rates. Taking the 0.45 column to approximately represent 
the Tu margin one can see the relative merits of each margin particularly at the different 
step points, given in Table 3.2, from the FDA guidance [1992]. The Tu [1998] margin 
gives the closest agreement at the step points to the FDA guidance -  although it equates 
to an 11% margin at the 0.90 step and 17% at 0.80 which are too high. The margin of 
Senn is the most conservative and would guarantee that the difference is no greater than 
15% no matter what the control prevalence is. Finally, the margin of Garrett falls 
between those of Senn and Tu although has the advantage of being a round number. 
Figure 3.7 figuratively demonstrates these points being a repeat of Figure 3.1 although 
with the margins o f Garrett [2003] and Tu [1998] now included.
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Figure 3-7. Graphic illustration of CPMP and FDA non-inferiority limits on the 
proportional scale for fixed odds-ratios
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Incidentally a margin which has never been mentioned is one of 0.47 which gives 
margins that are closest to all the steps without crossing them: for 70% it would equate 
to 17.7%; 80% and 14.7% and 90% and 9.1%.
3.5.1.4. Equivalence Trials
Similarly to the proportional scale the null and alternative hypotheses for an equivalence 
trial may take the form
H q : log (OR) > d  or log(OR) < - d  ,
H l : - d  < log (OR) < d  ,
with margins set similarly to those o f non-inferiority trials described previously.
3.5.2. Calculation of Confidence Intervals
Methods for the calculation of confidence intervals for the odds-ratio will be described. 
Two methods will be discussed in detail. That of Normal approximation (on the log 
scale) and the exact methodology.
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Figure 3-8. Plot of the variance of a log odds ratio for different mean proportional 
responses
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3.5.2.1. Normal Approximation 
Under the Normal approximation the confidence interval for the log(OR) is defined as 
log (OR) ± Z,_a 2se(log(Otf)), (3.4.2)
where the confidence interval on the original odds-ratio scale is obtained by back 
transforming the confidence interval on the log scale. There are a number of ways of 
estimating the standard error for the odds-ratio [McCullagh, 1980] although in this 
chapter will concentrated on just one, defined by Whitehead [1993] as
var (LogOR) = 12
i - X p ;'
V / l /
\ " (3.4.3)
where p , = ( p A + p H)/ 2 and /?, = 1 -  . As will discussed in chapter 5 this formula
can be generalised to more that a 2 point response variable. For just two categories
(3.4.3) becomes
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where 2 p x{ \ - p x) * p A{ \ - p A) + p B( \ - p B) . Thus, the variance for the log(OR) is
proportional to the reciprocal o f the variance for the difference in proportions i.e. 
var{LogOR) <x 1/var{p,  -  p B) .
This relationship is highlighted in Figure 3.8 which gives the variance for log(OR) for 
different mean proportional responses. As one can see from this figure, the variances 
take a U shape in relation to the mean proportional response with a minimum when 
p  -  0.5. This is the opposite to the proportional scale where the variance takes the
maximum at the mid point.
Another feature to highlight is how the variance is relatively stable for a large of the 
range of the mean response (0.3 to 0.7). Only varying greatly as the mean response 
approaches a boundary.
An empirical investigation of the asymptotic assumptions about the variance is given in 
Figure 3.9. The simulation was undertaken in SAS [1990]. For each sample size 10,000 
simulations were undertaken assuming the response rate to be 60% and for each 
simulation the following was calculated
where p  is the estimated mean response from the simulation and n  is the population 
mean prevalence (/r=0.60) from which each simulation was drawn. What is evident 
from this figure is that the approximation to the chi-distribution is quite weak for small 
sample sizes but improves the larger the trial. The empirical investigation suggest that 
the approximation to the chi-squared is slightly better for the variance of the log odds- 
ratio compared to the proportional difference discussed earlier.
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Figure 3-9. C hi-probability plots for different sample sizes for a variance for the 
log(OR) for different mean responses (/r=0.6) sam pled from  a binomial 
distribution
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3.5.2.2. Exact Confidence Intervals
Following the notation in Table 3.11, by conditioning on x a sufficient statistic for the 
odds-ratio can be obtained [Fisher, 1935; Chan, 2003; Dunnett and Gent, 1977]. Hence, 
the probability o f observing an outcome in the top left cell equal to x can be calculated 
from an hypergeometric distribution [Toendle and Frank, 2001; Agresti and Min, 2003; 
Agresti, 2001]
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n \t
P(x;OR)  =
A
* )
nB
n , -  x
OR*
£
V  I
V n
OR'
i=0 A " in, - i
(3.4.4)
Table 3-11. Notation for calculation confidence intervals about an odds-ratio
Number of Number of Total
Successes Failures
Treatment A X nA-X nA
Treatment B Y nB-Y nB
Total ni rb n
In this calculation the assumption is that cell counts follow a multinomial distribution or 
are independent Poisson or are independent binomial, conditioning on the row and 
column marginal totals [Agresti and Min, 2003].
Using this result therefore two one sided confidence intervals, each o f a/2, can be 
calculated through iteration to find
^ P ( x ; O R L.) = a /2  and J^P ( x ,ORL) = a / 2 ,
( . t ):OR(.x)< ORohs ( v ): OR ( v ) > OR
to construct a (1-g)%  confidence interval [Troendle and Frank, 2001]. Note that unlike 
the difference in proportions one can compute exact confidence intervals for odds-ratios 
[Miettinen and Nurminen, 1985]. Where the sum extends across all x, which satisfy the 
condition and are possible for the total ni and nA.
3.5.2.3. Comparison of the Different Methods
Comparison o f the two different methods is given in Table 3.12. Note that although it 
seems that the Normal approximation may be worse at estimating the upper tail o f the 
95% confidence interval this is simply a function of the odds-ratio being best expressed 
on the anti-log scale. On the log scale the Normal approximation has more comparable 
precision for both the upper and lower tail compared to the exact methodology.
As with previous cases in this chapter the Normal approximation gets close to that of 
the exact confidence intervals as the sample size gets larger although for all sample 
sizes it does give a narrower range for the limits. After a sample size per group of 
around 50 the Normal approximation and the exact method are quite close.
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Table 3-12. Table of confidence intervals for different proportions (pA=0.50 and 
Pb=0.33) equating to an odds-ratio of 2 by two methods for different sample sizes 
per group
Sample Size
Confidence Intervals
Normal Approximation Exact
12 0.39 to 10.14 0.29 to 14.61
24 0.63 to 6.30 0.54 to 7.61
48 0.89 to 4.50 0.81 to 4.97
96 1.13 to 3.55 1.07 to 3.74
192 1.33 to 3.00 1.30 to 3.09
384 1.50 to 2.66 1.48 to 2.71
768 1.63 to 2.45 1.62 to 2.47
3.6. Relative Risk
The relative difference between two proportions can also be expressed through simply 
taking their ratio, termed the relative risk (RR)
RR = ^ ~ .  (3.5.1).
P b
One of the main advantages of the relative risk is that it is allegedly easier to interpret. 
However, in absolute terms the same relative risk could be quite markedly different with 
a relative risk of 2 equally be ratios of 0.002/0.001, 0.2/0.1 or 0.80/0.40. This alone can 
cause problems in terms of interpretation (especially rare events) and design as will be 
discussed later.
It is worth noting here the fact one o f the main criticisms made of the odds-ratio (OR), , 
with reference to its interpretation is that it is not a relative-risk [Davies, Crombie and 
Tavaloli, 1998; Sackett, Decks and Altman, 1996; Altman, Deeks and Sackett, 1998; 
Deeks, 1998]. Although the fact that an OR does not equal a RR should not be 
considered a criticism.
The main disadvantage of the RR is that it is not invariant to the definition o f success. 
If the number of events on two respective treatments were 60/120 and 80/120 then the 
relative risk for this would be 0.75. However, if it is the number of none events that is 
o f importance then the relative risk becomes 1.33 (the odds-ratio is 2 no matter what the 
choice of success is).
3.6.1. Relative Risk and Clinical Trials
The issues with using the relative risk in clinical trials will now be highlighted. As with 
odds-ratios, it is the log-relative-risk which is the most attractive scale, to base 
inference.
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3.6.1.1. Superiority Trials
When one is thinking in terms of the relative risk, or as written here log relative risk, the 
null and alternative hypothesis should be express as
H 0 :\og(RR) = 0,
H 0 : log (RR) = d ,
where d is some pre-define treatment effect.
3.6.1.2. Non-Inferiority Trials
For a non-inferiority trial on the relative scale the null and alternative hypotheses take 
the form
H 0 : log (RR) < - d  ,
H x : log (RR) > - d  ,
where d is some predefined non-inferiority limit.
3.6.1.3. Choice of Non-Inferiority Limit
It is in the assessment of non-inferiority trials that the rationale for using the relative 
risk begins to fail. Remember that for an odds-ratio one could set a fixed non-inferiority 
limit, which would have a consistent meaning regardless o f the control response rate. In 
particular Table 3.11 demonstrates that an odds-ratio of 0.5, say, for a non-inferiority 
limit would allow one to meet all the steps in the FDA non-inferiority guidance given in 
Table 3.2.
The relative risk does not share the properties of the odds-ratio. For example a relative
risk of 2.0 would equate to a 35% difference on the proportion scale if active response
rate was 70% but a 40% difference if the active response rate was 80%. Thus, the 
relative risk non-inferiority boundary would need to change for different active response 
rates. Bringing in the need for a step function for non-inferiority limits. This feature 
alone negates the use of the relative risk as a statistic to use in clinical trials.
3.6.1.4. Equivalence Trials
The null and alternative hypotheses for an equivalence trial on the relative scale may 
take the form
H 0 : log (RR) > d  or \og(RR) < - d  ,
185
H x \ - d  < log (RR) < d ,
where d is some pre-defined equivalence limit. Equivalence trials however, share the 
same issues as non-inferiority trials in that the equivalence margin will need to change 
depending on the control response rate.
3.6.2. Calculation of Confidence Intervals
The most common approach is to calculate the confidence interval, under Normal 
approximation, on the log scale using
and then back transforming back to get a confidence interval on the original scale. The 
standard error for the logged relative risk can be taken as
where E A and E B are the observed number of events on treatments A and B 
respectively. The standard error is estimated using the delta method described earlier in 
this chapter. For alternative methods for calculating confidence intervals please see the 
work of Graham, Mengersen and Morton [2003] and Ederer and Mantel [1974].
This chapter described four ways o f summarising binary data:
1. Absolute risk reduction
2. Odds-ratio
3. Relative risk reduction
4. Number needed to treat
Due to the relative merits o f each summary measure in context with the different types 
that may be conducted it is recommended that relative risk and the number needed to 
treat should not be used to summarise individual trials. Instead the summary measures 
of absolute risk and odds-ratio should be used. The odds-ratio from a statistical 
perspective is particularly attractive as it allows for a transition through different non­
inferiority (and equivalence) criteria for a given active control response rate. 
Subsequent chapters will only now discuss the odds-ratio and absolute risk reduction.
\o%(RR) ± Z x_a. 2se(log(/?/?)), (3.5.2)
where se(log(.ftft)) (3.5.3)
3.7. Sum m ary o f C hapter 3
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/ / ,  : - d  < log (RR) < d ,
where d is some pre-defined equivalence limit. Equivalence trials however, share the 
same issues as non-inferiority trials in that the equivalence margin will need to change 
depending on the control response rate.
3.6.2. Calculation of Confidence Intervals
The most common approach is to calculate the confidence interval, under Normal 
approximation, on the log scale using
and then back transforming back to get a confidence interval on the original scale. The 
standard error for the logged relative risk can be taken as
where E 4 and E B are the observed number of events on treatments A and B 
respectively. The standard error is estimated using the delta method described earlier in 
this chapter. For alternative methods for calculating confidence intervals please see the 
work of Graham, Mengersen and Morton [2003] and Ederer and Mantel [1974].
This chapter described four ways of summarising binary data:
1. Absolute risk reduction
2. Odds-ratio
3. Relative risk reduction
4. Number needed to treat
Due to the relative merits o f each summary measure in context with the different types 
that may be conducted it is recommended that relative risk and the number needed to 
treat should not be used to summarise individual trials. Instead the summary measures 
o f absolute risk and odds-ratio should be used. The odds-ratio from a statistical 
perspective is particularly attractive as it allows for a transition through different non­
inferiority (and equivalence) criteria for a given active control response rate. 
Subsequent chapters will only now discuss the odds-ratio and absolute risk reduction.
log(/?/?) ± Z x_a 2se(\og(RR) ) , (3.5.2)
where 5e(log(&K)) (3.5.3)
3.7. Sum m ary o f C hapter 3
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This chapter also discussed the relative asymptotic properties of data, which take a 
binomial form. It highlighted how for large sample sizes binary data have asymptotic 
properties, which from a practical point o f view, means that the approximate 
methodologies agree with the exact methodologies. A consequence o f this is that as 
most clinical trials are relatively large the sample size methodologies assuming 
asymptotic results will hold.
If exact confidence intervals are to be calculated for a single response then this chapter 
recommends that a Beta distribution be used. Operationally these are relatively 
straightforward to calculate and the calculations can be undertaken in most statistical 
packages.
The issue of the asymptotic properties for a binary response estimated from a relatively 
small sample size becomes a concern if retrospective trial data (from a small trial) are to 
be used to design a prospective study. In Chapter 2 it was highlighted how a result 
using the non-central t distribution could be used if a sample variance was to be used in 
the calculations. Here, the data could be assumed to take a Normal form. Part of the 
proof of this result was the fact the ratio of the sample variance over the population 
variance could be assumed to take a chi-squared distribution. In this chapter it was 
highlighted that the sample variance does not follow a chi-squared distribution for 
binary data with small sample sizes. And hence questions whether the result for Normal 
data discussed in Chapter 2 could be extended to binary data. This will be discussed in 
detail in Chapter 4.
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4 .  C H A P T E R  4  -  S A M P L E  S I Z E  C A L C U L A T I O N S  F O R
C L I N I C A L  T R I A L S  W I T H  B I N A R Y  D A T A
This chapter describes the sample size calculations for trials where the primary outcome 
is binary. As discussed in Chapter 3 binary outcomes are common endpoints in clinical 
trials and appear when the outcome of interest is a two point response variable such as 
presence/absence, alive/dead or yes/no.
The sample size calculations will be described for situations where the trial design is 
either parallel group or a cross-over. The conventional calculations will first be 
introduced for each trial design and objective, followed by calculations, which account 
for the imprecision of the estimates.
4.1. Aim s o f the C hapter
The main issues to be covered in this chapter are:
• A description of standard sample size calculations for clinical trials with a binary 
primary outcome.
• A review of methodologies for calculation of sample sizes for cross-over trials
with an assessment of how effect sizes for parallel group studies can be
generalised to cross-over trials.
• An assessment of how the effect of period can impact the design and analysis of 
a cross-over study.
• An investigation (and make recommendations for) the calculation of sample 
sizes for non-inferiority and equivalence trials.
• An assessment of whether methodologies for imprecisely estimated variances
developed for data anticipated to take a Normal form in Chapter 2 can be
extended binary data.
• To investigate methodologies to assess the sensitivity of studies to the 
assumptions made in the sample size calculations.
• To develop numerical methods for the estimation o f sample sizes that account 
for the imprecision in the control response.
• To develop Bayesian methodologies to assess a study’s sensitivity and also to 
account for the imprecision in the estimate of the control response.
• To investigate the effect o f factors such as covariates in the design and analysis 
of studies with a binary response.
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4.2. Superiority Trials
As discussed in Chapter 3 there are a number of ways to summarise binary data for a 
parallel group trial, such as odds-ratios, relative risks, the number needed to treat and 
the absolute difference in the proportions. The two summary statistics that this chapter 
will concentrate on are those o f the odds-ratio and the difference in the proportions.
4.2.1. Parallel Group Trials
4.2.1.1. Sample Sizes with the Population Effects Assumed Known
4.2.1.2. Odds-ratio
For a given binary response, p., and p b are defined as the proportion of responders
expected on each of the two treatment groups, A and B, respectively. Each of these 
expected responses can, in turn, be written in terms of odds, p J ( \ - p A) and 
p B/ ( \ - p B) (each odds is a ratio of responders over non-responders). As a 
consequence an odds-ratio (OR) can be used as assessment o f the treatment difference 
(and effect size for sample size calculations) - where the OR is defined as
o r  = e 4 ^
P b V1 - P a
In a trial where the objective is to determine whether there is evidence of a statistical 
difference between the regimens the null (Ho) and alternative (Hi) hypotheses may take 
the form:
H0: The two treatments have equal effect with respect to the odds-ratio ( OR = 1).
H i: The two treatments are different with respect to the odds-ratio ( OR *  1).
From these null and alternative hypotheses a formula can be constructed to calculate a 
sample size per group [Julious, George, Machin et al, 1997; Julious, Walker, Campbell 
et al, 2000; Campbell, Julious and Altman, 1995; Machin, Campbell, Fayers et al, 1997; 
Whitehead, 1993]. As discussed in Chapter 1, in general terms for a 2-tailed, a  -level 
test the variance of the measure o f effect must satisfy
Var(S)=—  ---------------------------------------------------------------------------- (4.1.1)
( Z 1 - / )  +  Z l - - „  2 )
and the variance of the log-odds-ratio (S^log-odds-ratio in this instance) can be 
approximated by [Whitehead, 1993]
Var (S) = (4.1.2)
i - T p !
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where p, is the average response across treatments for each outcome category (i.e. 
Pj = (p,  ^ + p 2h)/ 2 and p^ = 1 -  p , ) and a  and p are the overall type I and type II errors 
respectively with Z,_a , and Z 1-/? denoting the percentage points of a standard Normal
distribution for these two errors. Here n is the sample size per group. Note that in this 
chapter the assumption will be that there is equal allocation to treatment.
Now by equating (4.1.1) with (4.1.2) one requires 
6[Z, . , + Z , . 0,2] / ( \ o g O R ) :
1 - 1 $ (4.1.3)
/ -  1
4.2.1.3. Proportional Difference
Keeping the data on the proportional scale the treatment difference would be expressed 
in terms of an absolute difference in the proportions defined as p A -  p B. On this scale
the null and alternative hypothesis would be written as:
H0: The two treatments have equal effect with respect to the proportional response
( * A  =  * b ) -
Hi: The two treatments are different with respect to the proportional response
(*A * * b )-
Table 4-1. Sample size estimates for one arm of a parallel group trial for various 
expected outcome responses for a given treatment (pA) and odds-ratios for a two 
sided type I error rate of 5% and 90% power
Odds-Ratio
P a 1.25 1.50 1.75 2.00 3.00 4.00
0.10 5112 1653 914 621 276 184
0.20 2819 900 494 333 146 98
0.30 2105 663 360 242 105 69
0.40 1803 560 300 200 85 56
0.50 1694 517 274 180 75 49
0.60 1725 517 270 176 70 45
0.70 1926 566 290 186 71 44
0.80 2468 709 356 224 81 49
0.90 4278 1199 588 362 121 68
From these a hypotheses a sample size formula - following the same arguments as 
(4.1.1) and (4.1.2) - where an absolute difference is the response of interest can be 
derived [Julious, George, Machin et al, 1997; Campbell, Julious and Altman, 1995; 
Machin, Campbell, Fayers et al, 1997]
190
[Zi-/? +  Z1 - a  2f  (p.-,(1 -  P.4) + Pb0  -  Pb))fl — ± c-------------±-- ----------------------------------
(Pa - P bY
(4.1.4)
Table 4.1 gives a table o f sample sizes for various odds-ratios and responses on a given 
treatment using (4.1.3). Table 4.2 gives the sample sizes using (4.1.4).
Table 4-2. Sample size estimates for one arm of a parallel group trial for various 
expected outcome responses for a given treatment (p.\) and comparator (pe) for a 
two sided type I error rate of 5% and 90% power
£ b
Pa 0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40 0.45
0.10 578
0.15 184 915
0.20 97 263 1209
0.25 63 120 331 1461
0.30 44 79 158 389 1671
0.35 33 54 94 182 437 1839
0.40 25 39 62 106 200 473 1965
0.45 20 29 44 69 115 214 500 2048
0.50 16 23 33 48 74 121 223 515 2091
4.2.1.4. Equating Odds-Ratios with Proportions
Although (4.1.3) and (4.1.4) seem on the face of it to be quite different it can be shown 
that they are approximately algebraically the same [Julious and Campbell, 1996]. This 
comes from the following two results
A A o o
(4.1.5)
1 - I p '
V  (=1
( P i+ p 2y - p i - p \  P iO - p . )  P 1O - P 1) ’
and
2(OR -1)
log (OR)
OR + /
which holds for 0.33 < OR < 3.00 (i.e. for most practical differences when design a 
clinical trial). Thus,
2(OR - 1) = 2(  p  t - p „ ) ____________^ p  . 1 -  p „  j
OR + 1 p A( I - p „  )+  p A (  1 -  p „  ) p , ( l - p , ) ’
Which if substituted back into (4.1.5) gives the result
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n (^1-a 2 +
(  ^ V P|(1-P,)^ _ 2pi(l-P|)('Z,-a 2+Zl-/l)
vA 0 - A ) A  P a - P b ( P a - P b Y
v + z i-„ 2 f  (p A 1 -  p J  + p»(' -  p<))
(p.2 - P » ) 2
Thus, (4.1.3) and (4.1.4) can be used interchangeably depending on preference. Due to 
this property one therefore requires
2 p ,d - P lj z i_a 2 + Z \ . fl) _ 2 (z ,.a , + Z ,..,)2 (4.1.7)
( P a ~ P b f  (log(OZ?))2 p, (1 - /? ,)
Hence, from (4.1.7) the following approximate result can be derived,
\ P a ~ P b | * |log(CW)|(Pi 0  ~ P \ ))> (4.1.8)
and therefore the proportional difference can be written in terms of the odds-ratio and 
the mean overall response.
As a brief note a by-product of the results highlighted in this section is that as a result of
(4.1.8) the null and alternative hypotheses on the proportional scale can be written as:
H0: The two treatments have equal effect with respect to the proportional response
K  -* » l  = 0 -
H i: The two treatments are different with respect to the proportional response 
\*a - X b\ = |log (0 /?)|(^(1 -  n x)).
The practical consequence of these results is that the formulae for the odds-ratio and the 
absolute difference can be used, for all intents and purposes, interchangeably for the 
same effects. This result is particularly useful for non-inferiority and equivalence trials 
to be discussed later in this chapter.
4.2.1.5. Worked Example
An investigator wishes to design a study where the anticipated response on the control 
therapy is 50%. The effect of interest is an odds-ratio of 1.5 in favour o f the 
investigative therapy and the investigator wishes to design the study with Type 1 and II 
errors fixed at 5% and 10% respectively. From Table 4.1 one can see that the sample 
size required would be 517 patients per arm of the trial.
With a response rate of 50% anticipated on control an odds-ratio of 1.5 would equate to 
an investigative response rate of 40% or a 10% reduction. From Table 4.2 one can see 
that the sample size required to detect this difference is 515 patients. This sample size 
is approximately the same as that using the odds-ratio formula.
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4.2.1.6. Sensitivity Analysis about the Estimates o f the Population Effects Used in the
Sample Size Calculations
In Chapter 2 the concept of a sensitivity analysis of a trial design was introduced for 
data anticipated to take a Normal form where the trial’s sensitivity was assessed with 
respect to the variance estimate used in the calculations. For Normal data an upper 
estimate of the variance, estimated from the chi-squared distribution, can be used to 
investigate the sensitivity of the designed study to a plausibly extreme value for the 
variance.
In Chapter 3 it was highlighted how for a binary response the variance estimate, both for 
a proportion and an odds-ratio, does not conform to a chi-squared distribution except for 
large sample sizes. The consequence of this is that the chi-squared asymptotic 
assumption for the estimate of the variance cannot be used to assess the sensitivity of 
the study design.
For binary data however, it is the response rate on the control arm, p A, usually 
estimated from a previous clinical study that is used to estimate a population response, 
to which the study design is sensitive to. This control response rate in turn feeds into 
the estimate of variance used in the calculations. Hence, any imprecision in the 
estimation of the control response rate will impact on the study design.
To investigate the effect the imprecision of the estimate of the control response rate will 
have on the study design a range of plausible values could be obtained through 
construction of a 95% confidence interval (using methods described in Chapter 3). 
From the two tails of this confidence interval a re-estimation of the variance could be 
made. The power could then be assessed using these new variance estimates through 
use of the following equation for proportional differences -  (4.1.4) rewritten in terms of 
power
i - / ?  = o n ( p . 4  ~  P b  ):
[ P a Q ~  P a )  +  P b ^ -  P b ) )
(4.1.9)
and the follow for odds-ratios (4.1.3 rewritten in terms of power)
1 - p  = <s> \n(\ogOR )'
i i
(4.1.10)
These calculations would assess the sensitivity o f the study design to plausible values 
for the control response rate.
4.2.1.7. Worked Example
Suppose now, from the worked example given earlier, that the response rate on control 
was estimated from a study with 50 patients. A Wilson (non-continuity corrected) 95%
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\ - p  = a> "(Pa -  Pb)2 - Z I - a  2
{ P a ( X ~  P a )  +  P b ( \ -  P b ) )
\  • /
and the follow for odds-ratios (4.1.3 rewritten in terms of power)
(4.1.9)
i - / ?  = o
( I—  r — \
nflog OR f ' - £  7,
lv i i j
(4.1.10)
These calculations would assess the sensitivity o f the study design to plausible values 
for the control response rate.
4.2.1.7. Worked Example
Suppose now, from the worked example given earlier, that the response rate on control 
was estimated from a study with 50 patients. A Wilson (non-continuity corrected) 95%
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confidence interval for this point estimate would give the true value as being between 
36.4% and 63.4%. Table 4.3a gives the sensitivity of the study design using the odds- 
ratio to calculate the sample size. One can see from this result that there is only a small 
loss in power of 4% if a response rate of 36.4% was observed and a nominal loss if 
63.4% was observed. For both these calculations the effect was assumed fixed at 1.5.
Table 4-3. Sensitivity analysis for superiority worked example
a. Odds-Ratio scale
95% Confidence Interval
Observed Lower Upper
Control Response 0.50 0.364 0.634
Investigative Response 0.40 0.276 0.536
Power 90% 86% 89%
b. Proportional scale
95% Confidence Interval
Observed Lower Upper
Control Response 0.50 0.364 0.634
Investigative Response 0.40 0.264 0.534
Power 90% 94% 90%
c. Proportional scale -  same effects as the odds-ratio
95% Confidence Interval
Observed Lower Upper
Control Response 0.50 0.364 0.634
Investigative Response 0.40 0.276 0.536
Power 90% 86% 89%
Table 4.3b gives the equivalent calculations assuming the effect was fixed at an absolute 
difference o f 10%. One can see from these results that if  a lower or higher response rate 
than expected was observed the power would actually increase. The reason for this, 
recalling Chapter 3, is that the maximum value the variance could possibly be on the 
proportional scale is when the response rate is expected to be in the middle of the range. 
This is a situation one anticipates to observe here (although the pooled two group 
variance is a little different as it accounts for the anticipated investigative response rate).
As was discussed in Chapter 3 the odds-ratio has the property that the same fixed odds- 
ratio will equate to different differences on the proportional scale -  dependent on the 
anticipated control response. Table 4.3b assumed that no matter what the prevalence 
the same effect (10%) would be o f interest whilst Table 4.2a, by default altered the 
effects of interest on the proportional scale (with a fixed OR). Table 4.3c repeats the 
calculations of 4.3b but using the same effects on the proportional scale as used in 
Table 4.3a. This table concurs with Table 4.3a. The issues o f different responses of
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interest according to the control prevalence will be discussed in greater detail in the 
sections on non-inferiority and equivalence trials.
The worked example here was a special case in that the response was anticipated to be 
toward the middle of the range. Suppose though that the control response was expected 
to be 20% and this was estimated from study with 50 patients on the control arm. The 
sample size required for an odds-ratio o f 1.5 is 900 patients per arm. The equivalent 
calculation on the proportional scale gives a sample size o f 917 (a control response rate 
o f 20% and an odds-ratio of 1.5 equates to an absolute difference of 5.7%).
Table 4-4. Sensitivity analysis for superiority worked example
a. Odds-ratio scale
95% Confidence Interval
Observed Lower Upper
Control Response 0.200 0.112 0.330
Investigative Response 0.143 0.078 0.247
Power 90% 71% 97%
b. Proportional scale
95% Confidence Interval
Observed Lower Upper
Control Response 
Investigative Response 
Power
0.200
0.143
90%
0.112 
0.055 
99%
0.330
0.273
76%
c. Proportional scale -  same effects as the odds-ratio
Observed
95% Confidence Interval 
Lower Upper
Control Response 
Investigative Response 
Power
0.200
0.143
90%
0.112 
0.078  
70%
0.330
0.247
98%
Table 4.4 gives the same sensitivity analysis as conducted with Table 4.3. One can see 
here one gets quite markedly different answers to Table 4.3 with the proportional scale 
being quite sensitive to the assumptions around active response rate.
What these examples highlight is the complexity of investigating the sensitivity of study 
with an uncertain response rate. The sensitivity of the design varies according to the 
anticipated control response rate. The issues raised in this section will be re-addressed 
throughout this chapter.
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4.2.1.8. Optimising the Estimates o f the Population Effects
As described earlier in this chapter, to investigate the sensitivity o f a study with binary 
data it is critical to estimate accurately the response rate on control, p 4, as this control
response rate feeds into the variance estimate. If one has several clinical investigations 
from which one can obtain an estimate of the control response rate then an overall 
estimate o f the response is required. To do this one could follow meta-analysis 
methodologies [Whitehead and Whitehead, 1991]. To obtain an overall estimate across 
several studies one could use
where p s is an estimate of the overall response, p t is an estimate of the response from 
study i, wv is the reciprocal of the variance from study i ( w; = l/var(p;.)) and k is the 
number of studies. Hence, define,
where n  is the control response rate. The variance for p s is defined as
Note that the methodology applied here is that of fixed effects meta-analysis. In the 
dissertation to date what has been accounted for is the variation that arises as a result of 
pure sampling error. Random trial to trial variability in the “true” control group rate has 
not been investigated. The approaches described in this section can allow one to 
undertake this investigation.
k
P s  = (4.1.11)
(4.1.12)
and thus
( k \
(4.1.13)
and hence overall one can define
k
ps = ~ k /V(;z\ var(/r)). (4.1.14)
p s = 1/^T h;. and consequently a 95% confidence interval for the overall estimate can be
obtained from
(4.1.15).
196
One could apply a random effects approach by replacing vv( with w* where w* comes 
from [Whitehead and Whitehead, 1991]
»■; = « ■  + t 2 )_i, 
where t is defined as
k
Z h;(a -p,)2
Z " -. -  Z ^  Z 11'.
/=i V / = i / -1 J
Simply, T  can crudely be thought of as
2 _ Variation in the treatment difference between groups 
Variation in the variation between groups
If T  = 0 then the weighting for the fixed effect analysis is used.
The corresponding (random effects) confidence interval would be given by
The relative merits of fixed versus random effects meta analysis will not be discussed 
here. In this chapter the methodology applied will be that of fixed effects meta analysis.
One thing to highlight here however is that in context with this dissertation it is not so 
much random effects analysis but random effects planning that is of importance. Even if 
the decision is made that a fixed effects analysis will be undertaken - the issue of the 
control group remains. The fundamental assumption, when planning a trial, is that the 
true control group rates are the same from trial to trial and observed rates can only vary 
according due to sampling error. However, if this were the case, could one effectively 
say that one could use historical data to form an augmented control group? The very 
fact that concurrent controls are used is an admission o f the fact that the belief is that 
true control group rates can vary from trial to trial. What this touches on, in fact, is the 
heterogeneity of trials, especially trials conducted sequentially over time or in different 
regions say. This will be discussed in greater detail in Chapter 6.
4.2.1.9. Worked Example
Table 4.5 gives the data from 8 different studies for the control response rate [Stampfer, 
Goldhaber, Yusuf et al, 1982]. As one can see the response rates vary between 8% and 
27% across the different studies. The final two columns give the workings for 
calculations for vr, and \vjp l and hence the calculations for the overall estimates. From
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this one can estimate the overall response to be 14.3% with standard error 0.0086. 
Hence, the 95% confidence interval around the overall estimate is (0.126 to 0.160).
Table 4-5. Table of control data by individual study
Control
Trial d Total Pi P M
1 15 84 0.179 572.66 102.26
2 94 357 0.263 1840.44 484.60
3 17 207 0.082 2746.05 225.52
4 18 157 0.115 1546.72 177.33
5 29 104 0.279 517.18 144.21
6 23 253 0.091 3061.30 278.30
7 44 293 0.150 2295.89 344.78
8 30 159 0.189 1038.68 195.98
Total 270 1614 13618.91 1952.97
The response from each study and the overall response estimate are given in figure 4.1. 
There may be some evidence of heterogeneity across the studies used in this example. 
This may be because certain trials were sampled from "different" populations. As 
mentioned earlier the issue of heterogeneity across studies will be investigated in 
Chapter 6.
Figure 4-1. Plot of point estimates and confidence intervals for individual studies 
and overall
Trial 1 
Trial 2 
Trial 3 
Trial 4 
Trial 5 
Trial 6 
Trial 7 
Trial 8
Fixed
0.0 0.1 072 0.3 0.4 0.5
Control Prevalence
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4.2.1.10. Calculations Taking Accounting of the Imprecision of the Estimates of the 
Population Effects Used in the Sample Size Calculations
4.2.1.11. Odds-Ratio
Earlier in this chapter sample size calculations were given for the case where the 
population effects were assumed known. However, when calculating a sample size the 
population effects are not usually known but are estimated from previous research -  a 
study say of similar design where the control regimen was given.
In Chapter 2 it was shown that for Normally distributed data, where a sample estimate is 
used instead of the population variance, the expected power could be determined from a 
non-central t-distribution. Now if arguments for Normally distributed data could be 
generalised to data which take a binary form the sample size per group would be 
derived from
6[(/«v(l -  p ,  d f , Zl a : ) 2/ ( lo g  O R ) 2
'  X /> ;
' ■-1
where TINV(»,m,a) denotes the (monotonically increasing) inverse function of the 
cumulative distribution of a non-central t distribution with m degrees of freedom and 
non-centrality parameter a. The degrees of freedom (d.f.) in the formula refers to the 
degrees o f freedom about the variance estimate used in the sample size calculation.
For the case of the log(OR) remember the approximate result
6
V a r  (log( O R ) )  = (4.1.17)
/ - I  a ’
V i - i  J
Now, for (4.1.16) to hold, the variance about the estimates should following a chi- 
squared distribution. However, in Chapter 3 it was empirically demonstrated that this 
was not the case for small sample sizes. Also, in Chapter 3 methodologies were 
described for the calculation of confidence intervals for a single proportion. Assume in 
this instance that it is the control response rate, p A , estimated from a previous study
that is random and that the effect size of interest is the odds-ratio and is fixed. Using an 
appropriate confidence interv al methodology an estimate of the 1st, 2nd 3rd percentile, 
say, o f p A can be made based on the previously observed p A . In this instance these 
percentiles will be estimated using the Wilson Score (not continuity corrected) method.
For each percentile the corresponding anticipated response on the investigative arm can 
be estimated from
P s  =
exp log(<9tf) -  log
f  W
P a
(4.1.18)
P
+
■i J )
199
and an estimate o f the variance from (4.1.17). If one took the average across all the 
percentiles then for a given sample size, n, and imprecision around the estimate of p A 
the power can be estimated from
1-/?
1
0.998
I  0.5
perc  -0.001
ioi> o r  y
( r
+ n(  log OR f
i - I .pl .
I  ^ I
1 - t p U
/ 6 -  Z,
/ 6 — Z,
(4.1.19)
(4.1.19) can be iterated on n until the appropriate power has been reached.
4.2.1.12. Comparison of the Two Methods
A comparison of the two methods is given in Table 4.6. The sample sizes are estimated
from (4.1.19) and (4.1.16). From empirical observation of table it seems that if the
anticipated control response rate is 0.20 then (4.1.16) and (4.1.19) agree however, 
overall in comparison to (4.1.19) the results from (4.1.16) can be summarised as follows
0.10 - Underestimation
0.20 - Close agreement
0.30 - - Over estimation
Note there is a symmetry to the results such that the result for an anticipated response of 
0.90 (not given) is similar to 0.10; 0.80 is similar to 0.20 and 0.50 to 0.70 are similar to 
0.30 to 0.40.
The results from Table 4.6 are not surprising when one remembers what was observed 
in Chapter 3. First of all for small sample sizes the variance of the estimated log-odds- 
ratio is not well approximated by the chi-squared distribution. Second through the mid 
range of anticipated observed response rates (between 0.3 and 0.7) the variance is 
relatively flat and does not deviate much. Hence, the over estimation of the sample size 
of (4.1.16), compared to (4.1.19). Finally as the anticipated responses tend towards the 
limits (0,1) there are quite marked deviations in the variance depending the anticipated 
responses. Hence the under estimation of (4.1.16) compared to (4.1.19).
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Table 4-6. Table of sample sizes for a fixed odds-ratio of 2, for different assumed 
control responses and degrees of freedom around the sample variance. Calculated 
using numerical methods and the non-central t-distribution
Degrees Numerical Non-central t 
Control of Sample Sample
Response Freedom Size_______ Size
0.10 10 1694 807
15 1061 738
20 902 707
25 829 688
50 713 653
75 680 642
100 665 637
0.20 10 455 433
15 407 396
20 387 379
25 375 369
50 354 351
75 347 345
100 344 342
0.30 10 286 313
15 271 287
20 263 274
25 259 267
50 250 254
75 247 249
100 246 247
250 243 244
500 242 242
0.40 10 224 259
15 216 237
20 212 227
25 210 221
50 205 210
75 203 206
100 202 205
4.2.1.13. Proportional Difference 
The equivalent formula to (4.1.16) for calculations done on the proportional scale is
n  = fr/nvQ ~ A  df< Z i .. (P.iU -  P.,) +  P A 1 ~ Ps ))  (4 , 20)
(p ., ~ Ps  f
Similar to the case with the odds-ratio, for (4.1.20) to hold the variance about the 
estimates should follow a chi-squared distribution. However, as with the odds-ratio, it 
was shown in Chapter 3 that empirically this assumption does not hold for small sample 
sizes.
Remember that, for the difference in proportions, p 4 -  p B, the variance is defined as
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V a n p A . p , )  = E ^ z l A  + E ^ z P il (4.1.21)
As described for odds-ratio using the Wilson Score method percentiles for p A can be 
estimated from previously observed p 4. Now assuming the effect size, p 4 -  p B, is 
fixed then for each percentile the corresponding anticipated response on the 
investigative arm can be estimated from
P b =  P a + W e c t (4.1.22)
and an estimate o f the variance made from (4.1.21). Correspondingly an estimate of the 
power for a given n and imprecision about p  , can be made from
<t>! ' A p a  p h f
i »■»* i . \  ( / ' , ,  (i p  .
I  / !  '  > '  0 . 5 '  ' '
0 . 9 9 8  „  |  ;
P
ct>! ____________________ p, y___________
-O.x.l, , (1 + / A , . . ...... - P {l,r n . ) )  z , " : i
(4.1.23)
The sample size can be estimated through iteration.
4.2.1.14. Comparison o f the Two Methods
A comparison of the two methods is given in Table 4.7. The final two columns give the 
sample size calculated using (4.1.20) and from (4.1.23) respectively.
From empirical observation of the table it seems that if the anticipated control response 
rate is 0.05 then (4.1.20) and (4.1.23) agree. For the other control responses (4.1.20) 
over estimates the sample size. Responses over 0.25 are not given as between 0.30 and 
0.50 there is no advantage in accounting for the imprecision according to (4.1.23) which 
returns the same sample size for all response. Table 4.7 can be summarised as follows
0.05 Close agreement
0.10 or 0.25 Over estimation
0.30 to 0.50 Over estimation with (4.1.23) returning the same sample size as
standard formula
Again the results from Table 4.7 arc not surprising when one remembers what was 
observed in Chapter 3. First o f all as with the log-odds-ratio for small sample sizes the 
variance around a proportion does not follow the chi-squared asymptotic form. Second 
through the mid range of anticipated observed response rates (between 0.3 and 0.7) the 
variance is relatively Hat and does not deviate much. Also the peak possible variance is 
for when the anticipated response it around 0.50. Hence accounting for the imprecision 
around the estimates of the population effects has no affect in the mid range. Finally as 
the anticipated responses tend towards the limits (0,1) there are quite marked deviations
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in the variance depending the anticipated responses hence the variation in the sample 
size when accounting for the imprecision around the sample variance.
Table 4-7. Table of sample sizes for a fixed proportional difference of 0.10, for 
different assumed control responses and degrees of freedom around the sample 
variance, calculated using numerical methods and the non-central t-distribution
Degrees Numerical Non-Central t
Control of Sample Sample
Response Freedom Size Size
0.05 10
. .  ^
239.1
20 215 209.4
30 207 200.5
40 202 196.2
50 199 193.6
100 192 188.7
0.10 10 298 341.6
20 285 299.2
30 279 286.4
40 276 280.2
50 274 276.6
100 269 269.6
250 266 265.4
500 264 264.0
0.15 10 350 430.5
20 344 377.0
30 340 360.9
40 339 353.1
50 337 348.6
100 335 339.6
0.20 10 393 505.6
20 392 442.8
30 392 423.9
40 391 414.8
50 391 409.4
100 390 398.9
4.2.1.15. Worked Example
An investigator wishes to design a study where the response anticipated on the control 
therapy was 20%. The effect of interest is an odds-ratio o f 2.0 in favour o f the control 
therapy (i.e. the aim is to reduce the number of events) and the investigator wishes to 
design the study with Type I and II errors fixed at 5% and 10% respectively. From 
Table 4.1 one can see that the sample size required would be 333 patients per arm of the 
trial.
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Now suppose this estimate of the control response rate came from a trial with 50 
patients receiving control. To allow for the imprecision in the estimate of the control 
response rate the sample size (from Table 4.6) would need to increase to 354 patients
With a response rate of 20% anticipated on control, an odds-ratio of 2.0 would equate to 
reducing the investigative response rate to 11.11 % or an 8.89% reduction. From (4.1.4) 
one can see that the sample size required to detect this difference is 344 patients. When 
one allows for the imprecision in the control response rate estimate the sample size 
(from (4.1.23)) is increased to 355.
4.2.1.16. Calculations Taking Accounting of the Imprecision of the Estimates Used in the 
Sample Size Calculations -  Bayesian Methods
In Chapter 2 there was a discussion on the use of Bayesian methods for sample sizes for 
non-inferiority and equivalence studies where there was uncertainty about the mean 
difference. The calculations were for data anticipated to take a Normal form. For this 
situation there is no great practical application for this work however.
If the primary endpoint is a binary response then it is the uncertainty in the mean 
(proportional) response which adversely affects sample size calculations. The context 
now is to interrogate sample sizes where a superiority study is be planned and a control 
response, Pr  had previously been observed. In the prospective trial being designed 
inference is to be made about the ‘true’ difference n A- n B- In context with the problem 
here the effect size (whether it be an odds-ratio or a proportional difference), is assumed 
known so that the variance for the odds-ratio and proportional difference can be 
estimated from (4.1.17) and (4.1.21) respectively as before.
For the given sample size what needs to be determined is the probability o f observing a 
given control response, Pi , or greater for o given that Pu has already been observed i.e.
Pr o b { 0 > p A \ p 1t)-
Note, similar to Normal data in Chapter 2, the methodology described in the 
subsections, ( 4 . l . l . l l )  and (4 .1.1.14), could be considered to be sample calculations 
calculated under a Bayesian framework but with a non-informative prior distribution for
0 .
For inference about an unknown binary parameter, 0, what one is interested in is how 
would our belief about 0 change. If the prior is expressed in the density p(0) and if 
subsequently data x arc observed then the posterior distribution is expressed in the 
density, p(0|x), where the Bayes rule for densities is
p(0|x) oc >frx|0) p(0), (4 .1.24)
where X(x|0) is the likelihood function.
For binary data the Beta distribution can be used for the prior responses such that
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PROBBETA(p4,a,b) x p ^  ‘(1-/?^)' (4.1.25)
where p r o b b e t a o  is defined as a cumulative density distribution for a beta distribution. 
The Bayesian updating rules are now described. Although not directly comparable this 
chapter draws on the work of Johnson, Su, Gardner et al [2004].
4.2.1.17. Prior Response
Prior values for pROBBETA{p^.a„.bj (and the corresponding^ a = BETAm\Perc ,a M )
could be derived as follows. For an informative prior one could use the mode (or most 
likely value) and a percentile to build a prior. For a Beta distribution the mode is 
defined by
Hence, the Oo (and consequently bl() could be derived from
P rvnenuu = B ETA I.Xl'(percent i le, a,,, [a -  1] ni -  + 2) ■> ( 4 . 1.26)
if a percentile for the control response can be postulated.
If one wished to use a non-informative prior then a Jeffrey’s prior could be used such
that
PIHrt t = BETA IXI (p e r c , 0 . 5 ,0 .5) ■ (4 .1 .2 7 )
This Jeffrey’s prior has the advantage of being invariant with respect to transformations.
4.2.1.18, Anticipated Response
The anticipated control response (and consequent variance) is defined a sp  ^ . This value
is taken from an objective value observed in a previous clinical trial. The control 
response equates to an observed number of successes ( a<) and failures ( b, )■
4.2.1.19. Posterior Response
With the anticipated and prior responses the posterior distribution can be calculated 
from the following result
P ^ t = BETAISl  \ p e r c ,a, t K  ) • (4 .1 .2 8 )
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These values for p = f l m / . v r ( / ? e / r . « , can be used in (4.1.19) and (4.1.23) to
obtain estimates of the sample size for an odds-ratio and a proportional difference 
respectively accounting for the imprecision in the variance estimate.
4.2.1.20. Worked Example
Repeating the earlier example where an investigator wished to design a study where the 
response anticipated on the control therapy was 20%. The effect size of interest is an 
odds-ratio of 2.0 in favour of the control therapy with the investigator wishing to design 
the study with Type 1 and II errors fixed at 5% and 10% respectively.
Now, again, suppose this estimate of the control response rate came from a trial with 50 
patients receiving control and the investigator wished to allow for this imprecision in 
the estimate of the control response rate in the estimation of the sample size.
If initially a non-informative prior was used then using (4.1.27) in (4.1.19) the sample 
size is estimated to be 354 patients. The sample size is as calculated previously when 
allowing for the imprecision in the sample variance.
Imagine the investigator was sceptical as to the control response being as high as 20% 
such that the belief was that the most likely response was 15% with at least 90% 
certainty that it was greater than 10%. From (4.1.26) estimates of (]{) and /> of 7.899
and 40.094 are obtained. Hence, now using (4.1.28) in (4.1.19) the estimate of sample 
size is now 379.
Now suppose the investigator is more optimistic about the control response believing 
the most like response to be 25% and is at least 90% certain that it was greater than 
20%. From (4.1.26) estimates of and ^  of 25.048 and 73.144 are obtained. Hence,
now using (4.1.28) in (4.1.23) a sample size estimate of 297 is calculated. This is less 
than the sample size calculated not allowing for imprecision in the variance.
Similar calculations could be done if calculations were based around an absolute 
difference in the responses. Here though (in terms of the variance) an optimistic prior 
would be one where the response is lower than 20% and pessimistic prior would be 
where the response is higher than 20%.
4.2.2. Cross-over Trials
When the data are paired, such as in a cross-over trial, there are two main summary 
measures, the difference in proportions and the odds-ratio, that may be used. This 
section will concentrate on these two summary measures in considering sample size 
calculations. Also, the sample size calculations will depend on whether the effect of 
period will or will not be allowed for in the final analysis. The methodologies will now 
be discussed in detail.
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4.2.2.I. Ignoring Period
4.2.2.2. An a lysis
For a cross-over trial with binary data the data could be summarised as per Table 4.8 
and analysed by the McNemar test
( » I 0  ~ " o i ) :  :Xi
",o+"oi
where nlQ and n0l are the number of responses expected in cells '10' and '01'. The data
in the final column and final row give the overall responses for each treatment. These 
overall responses are the outcomes one may consider to be expected in a parallel group 
study.
Table 4-8. Summary table of hypothetical cross-over trial
Treatment B 
1 0
Treatment A 1 n ,i n .o n Al
0 n o, n oo n A0
n Bl n B0 n
In a cross-over trial only discordant responses are of interest for statistical comparisons
i.e. those subjects who respond '10' or '01'. A large proportion of the data are thus 
discarded in constructing a statistical test, as the test is conditional on subjects being 
discordant. This is quite intuitive though, as in a superiority trial concordant responses 
concur with the null hypothesis of no treatment differences. Thus what one is 
determining is whether for those subjects who only respond to one treatment, this 
response is more likely to be in favour of one treatment over the other.
4.2.2.3. Sample Size Estimation
4.2.2.4. Population Effects Assumed Known
Table 4.8 can be rewritten in terms of proportions as per Table 4.9, where /tl0 = nw In  , 
T01 = n()l I n .  Au = nu In and A0() = nl){) In and PA = n n I n and PB -  nB] I n and the 
trial can be summarised with an odds ratio defined as
A,,,
(4.1.29)
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Table 4-9. Summary table of hypothetical cross-over trial
Treatment B
1 0
Treatment A 1 ^  /[]0 PA
0 4,1 !-pA
Pb 1-Pb 1
This odds-ratio is a conditional summary statistic, using just the discordant responses. 
A conditional odds-ratio can be difficult to interpret. To assist in the interpretation the 
odds-ratio can be approximated from the marginal totals [Royston, 1993]
where T10 ^ p A( \ - p B) and A0] ~ p B{ \ -  p A).  Thus, the conditional odds-ratio for a
cross-over trial can be interpreted in terms of the odds-ratio from a parallel group study 
(approximated from the marginal proportions). This is of particular use in the 
calculation of sample sizes, as marginal totals could be used to estimate the conditional 
odds-ratio, which in turn can be used to estimate the discordant sample size.
The discordant sample size, nd , for a cross-over trial can be derived from [Royston,
1993; Julious, Campbell and Altman, 1995; Connett, Smith and McHugh, 1987; Fleiss 
and Levin, 1981; Schesselman, 1982]
which has shown to perform well in simulations [Julious and Campbell, 1998]. To 
calculate the total sample size, the discordant sample size is divided by the proportion 
expected to be discordant [Julious, Campbell and Altman, 1995; Connett, Smith and 
McHugh, 1987] i.e.
There are alternative formulae, which do not require a two-stage approach to calculate 
the total sample size [Julious, Campbell and Altman, 1995; Connett, Smith and 
McHugh, 1987; Conner, 1987; Miettinen, 1968], However, this chapter though will 
concentrate on the two-stage approach.
The equivalent sample size for one arm in a parallel group trial, N  , can be estimated
from (4.1.33) now defined slightly differently as [Campbell, Julious and Altman, 1995; 
Whitehead, 1993]
Odds-ratio= if/ ^ (4.1.30)
(4.1.31)
N (4.1.32)
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N _ 6 { Z \ - a  2 +Z\_fl) / ( \ 0 g 0 R ) 2
Pg
' - I p ,'
1 -u
(4 . 1.33)
where similarly to (4.1.3) p 0 and p x are the responses across treatments for outcomes 0 
and 1 such that p , = ( p + p B) / 2 and /?, = 1 -  p {).
Similar to the situation described earlier in the chapter for the sample size formulae for 
odds-ratios and proportional differences, on the face of it (4.1.31) is quite dissimilar to
(4.1.33). However, (4.1.31) can be re-written as
(Z l a :(4o + 4)1 ) + 2ZI W^uA)! 1 
(^10 +  All )(Ao ~  A I )
(4.1.29)
and in turn re-writing T10 and A01 in terms of the marginal totals (A10 % p 4(\ -  p B) and 
T01 ^ p B( 1 -  p A))  (4.1.34) can be approximated by
N  ^  iZ \-a 2( Pa (1- P b ) + P b (1-P.<)) + 2 Z i- /*Jp A 1- P b )p A 1- P b ) J  (4 J 35)
(p., (1 ~ P b )  +  P b ( 1 ~ P a  )){p A 0  - P n ) - P B < y -  P a  ))2
Also, through the following results p  A{\ -  p B)p  ,(1 -  p B ) = p i  (1 -  p 0)2 and 
P a  (1 ~ P b  ) + P b  0  ~ P t ) ~ - P(1 ~ P)  (4-1 -30) can be re-written as
( Z l - q  2 +  A  / l f - P o(^  ~  Po ) 2 
P o V ~ P o ) ( P a  -  P b ) '
(4.1.36)
Returning back to the case of a parallel group trial where the odds-ratio (OR) is defined 
as OR = (/?.,(! -  p B))/(Pn( 1 -  PA)) and remember
log (OR) *
P q (  1  -  P o  )
(4.1.37)
i - I p ;
V  / - 0  7
P o O -  P o )
(4.1.38)
Substituting (4.1.37) and (4.1.38) back into (4.1.36) one gets 
N  ^ l / .  , . • z  . ! lUnj.()l< I = N
/ / - I p , /
pg '
and the sample size formula for one arm in a parallel group study. Thus, the sample 
size required for a cross-over trial is approximately equivalent to that for one arm of a 
parallel group trial. An alternative way of phrasing this would be to say that the sample
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size required is half that required in total for a parallel group trial. Table 4.10 also gives 
empirical evidence of this fact, giving the sample size required for various expected 
outcome responses for a given treatment and odds-ratios using (4.1.33) and (4.1.34). 
These results demonstrate that if the parallel group formula, (4.1.34), was used, slightly 
smaller estimates of the sample size for a cross-over trial would be obtained compared 
to (4.1.33) but only marginally so. Practically they give the same sample size.
Table 4-10. Sample size estimates for a cross-over trial (nc) and one arm of a 
parallel group trial (nPR) for various expected outcome responses for a given 
treatment (pA) and odds-ratios for a two sided type I error rate of 5% and 90% 
power
Odds-Ratio
1.25 1.50 1.75 2.00 3.00 4.00
Pa n c n c " p* n c " n nc n p . n c " p* n c " ps
0.20 2824 2819 905 900 499 494 339 333 154 146 106 98
0.40 1804 1803 561 560 302 300 201 200 87 87 58 56
0.60 1726 1725 518 517 270 270 176 176 71 70 46 45
0.80 2471 2468 711 709 359 356 226 224 83 71 50 49
Intuitively these results seem reasonable as the analysis one is undertaking in a cross­
over trial, the McNemar test, is simply a one sample x~ -test. For the analogous paired 
t-test, as highlighted in Chapter 2, the estimated sample size from one arm of a parallel 
group study provides an approximately equivalent sample for the paired sample size. It 
is good therefore to see that the same rationale can be applied to binary data.
The practical application of this result is that when designing a clinical trial one could 
use the marginal effects expected for the respective treatments and consequently the 
effect sizes anticipated if the trial was a parallel group investigation. These effects 
could be then used in the parallel group formula -  taking the one arm sample size to be 
the total sample size. Working with the marginal totals may make it easier to formulate 
effects and consequently trials should be easier to design.
From now on in this chapter the approach of using the sample size formula for one arm 
of a parallel group trial as the total sample for a cross-over trials will be the approach 
applied and no great detail will go into the discussion of sample sizes for cross-over 
trials.
Note that although the arguments here concentrated on odds-ratios, as was demonstrated 
earlier in the chapter one can move interchangeably between odd-ratios and 
proportional differences and hence the arguments can be generalised to proportional 
differences with respect to cross-over trials.
Note also that the conditional odds-ratio is not the same as the marginal odds ratio but 
can be an approximation to “all things being equal” . This issue is discussed again later 
in the chapter.
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4.2.2.5. Worked Example
An investigator wishes to design a study where the marginal response anticipated on the 
control therapy is 40%. The effect if interest is 2.0 in favour of the control therapy and 
the investigator wishes to design the study with Type I and II errors fixed at 5% and 
10% respectively.
An anticipated control response of 40% and an odds-ratio of 2.0 would equate to a 
response of 25% on the investigative therapy. Hence, the marginal responses, as per 
Table 4.11, can be completed, as well as the remaining entries in the table through 
multiplying the marginal totals. From this table it is evident that the odds-ratio defined 
through (4.1.29) and (4.1.30) is now the same.
Table 4-11. Summary table of anticipated responses for worked example
Investigative
1 0
Control 1 0.10 0.30 0.40
0 0.15 0.45 0.60
0.25 0.75 1
From Table 4.10 one can see that if (4.1.31) the sample size required would be 201 in 
total and if (4.1.33) were used the sample size would be 200. Practically this is the 
same.
If one wished to base the sample size purely on the discordant sample size, recruiting 
until the discordant sample size is reached, then the sample size would be (using the 200 
per arm result) 200x(0.30+0.15) or 90 patients.
4.2.2.6. Alternative Sample Size Formulae
One aspect of designing cross-over trials with binary endpoints is the diverse array of 
alternative formulae that can be applied. Upon inspection, however, this diversity is 
down not to any technical difference in results but to definition of effect to be inserted 
into the sample size formula.
Here, as an aside, this chapter will briefly describe the different alternative formulae for 
the discordant sample size (two stage approach) and total sample size.
4.2.2.7. Discordant Sample Size 
To calculate the discordant sample size Schesselman [1982] gives the following formula
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n, =
(o.5Z,_a ,+Z, ^ P ( \ - P ) )  
( P - Q . 5 f
(4 .1.39)
where P - ¥
1 + cp
(4.1.40)
and cp is the conditional odds-ratio for binary data defined as
¥  =
01
(4.1.41)
Connett, Smith and McHugh [1987] give a different format to Schesselman’s equation 
simply by putting (4.1.40) into (4.1.39) to get [Royston, 1993; Fleiss and Levin, 1988]
0.5Z. , + Z i-/#-
/  v/
V.
\ ¥  + >j
<p +1 y/ 
y/ +1 y/ + 1
V
n, =
f 2y/ y/ +1 ^
2 ( ^  +  1) 2 ( ^  +  1)
_ (zi-a 2(¥ + 1) + 2z, j2 
(^  -1  )2
(4.1.42)
and (4.1.31) given earlier in this chapter. The results above are comparable to the 
formula given by Julious and Campbell [1998]
4<p(z i a 2 + Z1 -/if , Zf„ :
-  + (4.1.43)
4.2.2.8. Total Sample Size
As discussed earlier in the chapter, to calculate the total sample size one can just divide 
the discordant sample size by the expected discordant proportion to obtain a sample 
size, termed a conditional approach i.e.
n, =
*o. +
(4.1.44)
Alternatively one can adopt a number of unconditional approaches such as that of 
Miettenen [1968]
Z, -,y[r + Z,
f  r -  A' (3 + r ) N 
4 r
\  -
(4 . 1.45)
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where r -  T10 + Am and S  = A]0 -  Am . The Miettinen formula is not dissimilar to the 
formula given by Conner [1987]
( Z 1 - a  2j r  +Z\_p^ r - 8 - )n. = ----------------r—=----------- (4.1.46)
where r and £ are as given for Miettinen. Connett, Smith and McHugh [1987] gives an
alternative format to that for Conner as r = T10 + T01 = (y/ + l)/l0l and
S = Al0 - A ol = {[j/ -1)A01, which if one substitutes into (4.1.41) gives
„ = (Z| " f 1>+ z i n Az +J  ’ “1[v ~ 1 ):A l l  (4 1 47)
II' 11 a _ '
Finally, multiply (4.1.47) top and bottom by (y/ + l)and one obtains the formula of 
Julious, Campbell and Altman [1999]
[Zi-a :(V^ + 0 + Zi -/y V(v7 + 1)~ _ { V  -  I)"7'] (4.1.48) 
( V - !) r
4.2.2.9. Sensitivity Analysis about the Estimates of the Population Effects Used in the 
Sample Size Calculations
Following on from the arguments on equating the one arm sample size of a parallel trial 
with that of the total sample size of a cross-over study, the methodology described 
earlier in this chapter for parallel group studies can be adapted to assess the sensitivity 
of a cross-over trial.
To investigate sensitivity of the study design to the imprecision of the estimate of 
control marginal response rate a range of plausible values could be constructed through 
a 95% confidence interval. The power could then be used assessed through for the two 
tails of this confidence interval, with the effect size fixed, by using the following - 
(4.1.28) rewritten in terms of power
f  I------------ i
/if log o r  y / 6  " Z i « :
u ' 0 J
4.2.2.10. Worked Example
Suppose the marginal response rate on control of 40% given in the earlier worked 
example was estimated from a study with 40 patients. A Wilson (non continuity 
corrected) confidence interval for this point estimate would give the true value as being 
between 26.3% and 55.4% which would equate to powers of 80.2% and 93.3% 
respectively for the fixed sample size of 200 patients and odds-ratio of 2.
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4.2.2.11. Calculations Taking Accounting o f the Imprecision o f the Estimates o f the
Population Effects Used in the Sample Size Calculations
As with assessing the sensitivity of a study, to calculate the total sample size of a cross­
over study to account for the imprecision in the variance estimate used in the sample 
size calculations the results from the parallel group case can be extended to give the 
following result
i o ^
i -  p  = - v  0.5
0.998
<p n( log OR f 6 - Z ,
+ <I>
/ ...............
nf log OR > 1 - Z  / w •0901) / 6 - Z ,
A
J i 1 - )
(4.1.50)
which can be iterated on n until the appropriate power has been reached.
4.2.2.12. Worked Example
Repeating the example gain given earlier of an anticipated marginal control response of 
40% and odds-ratio of 2. If this response rate was estimated from 25 patients from a 
previous study then from Table 4.6 the total sample size is 212 (7% more than before).
4.2.2.13. Calculations Taking Accounting of the Imprecision of the Estimates Used in the 
Sample Size Calculations -  Bayesian Methods
Bayesian methods described for parallel group trials can also be extended to studies 
with a cross-over design. A posterior distribution for a control response can be 
estimated and (4.1.50) can be used for sample size estimation.
4.2.2.14. Accounting for Possible Period Effects
4.2.2.15. Analysis
As well as ignoring concordant data, the McNemar test ignores the fact that subjects 
were assigned to different sequences, i.e. either AB or BA for a two period cross-over 
trial, and thus ignores any possible period effect which may exist. To allow for any 
possible period effect Tabic 4.8 can be re-written as sequence differences as in 
Table 4.12. The numbers in fable 4.12 can, in turn, be re-written in terms of Table 4.8 
as 'd\+<\2=n l0» b|+b2:=«0| an^ n ,\u + n n.\ ^n9-
This approach is analogous to the period adjusted t-test [Senn, 1993]. Sequence 
differences can be used to give a period adjusted estimate of the odds ratio, by taking 
the log-odds-ratio for sequence B-A away from A-B and dividing by 2
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Log\\f =(logy/.,g -log[j/ ^ , )/2=(logai/br logb2/a2)/2=0.5log(aia2/bib2)
=0.51ogORp. (4.1.51)
Where ORp is the period adjusted odds-ratio. From (4.1.51) it is therefore evident that 
the non-period odds-ratio is equivalent to the square rooted odds-ratio from the period
adjusted analysis. Thus, \f/ = ^ O R p and hence a test statistic for the period adjusted 
test can be derived
(4.1.52)
varlog y/
where (4.1.52) is asymptotically equivalent to the McNemar test as well as to alternative 
period adjusted tests such as the Mainland-Gartt test and the Prescott test [Senn, 1993].
Table 4-12. Summary table of period adjusted analysis of hypothetical cross-over 
trial
Treatment Difference
Sequence Difference -1 1 Total
A-B ai bi n AB
B-A b2 a2 *BA
The period adjusted approach described in this paper is an extension of the two group 
described by Whitehead [1993] and by McCullagh [1980]. The advantage of this 
approach is that it gives a measure of treatment effect, the odds-ratio, which is easily 
interpretable. Senn describes a similar approach, although that approach includes 
concordant data in the analysis [Senn, 1993]. The period-adjusted analysis can be 
undertaken via logistic regression, using the sequence difference as the outcome with 
sequence in the model. The log odds ratio derived from this analysis would be the same 
as (4.1.51) and the test statistic would be (4.1.52). To attain an estimate of the odds- 
ratio and confidence interval equivalent to the McNemar test one must exponentiate and 
then square root the log(ORp) from the analysis.
Table 4-13. Summary table of period adjusted analysis of hypothetical cross-over 
trial
Sequence Difference 
A-B
B-A
P-\ P+1
Treatment Difference 
-1 ‘ 1
Pt,,
Pa. Pa.
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If one was to calculate (4.1.52) by hand then one would need to know the variance of 
log(\|/). However, one knows that log\j/=0.51og(ORp) and that the variance of log(ORp)
is
(var[logOR ])“' =
12 1 - X  p' ( P ,I +P , )' - A3i - p \  =-A P,\( l -P^ 1 K (4.1.53)4
where, p t is the mean proportion anticipated in category i, for example, 
P\ ~ (Pai + Pt \ ) 12 (where p a] = a i / n AB and p hl = bx / n 4B ) as described in Table 4.13. 
Thus, one can combine (4.1.51) with (4.1.53) to obtain the test statistic (4.1.52). If there 
is no period effect, then (4.1.48) can be rewritten as
P jL  I 
4 2
a, b ,
\ n AB n BA J \ r , AU
1 n,  1 ( n]l} +
i J
and as var(logv|/)=var(0.51ogORp) and ( /?10 + nin )=n, one attains 
4var 'logO R '  
2 ,
Additionally, for y  close to 1 (0.33 ^ ) ,  log(vj/) can be approximated by
2(  y / - l ) _ 2(«10 - « 01)logf <//
(// + 7 ",o + "ui
and thus, the test statistic (4.1.52) can thus be derived
(logyQ2 = 4 7 ni0- n Ql)2 K , + * Ui ) =  ( ^ i o  — ” o i ) ~ 
var(logyz) (a;10+a;0I): 4 ",0 +"oi Ti'
Therefore, (4.1.52) is approximately equal to the McNemar test algebraically if  there is 
no period effect. The consequence of this result is that if by default one does a period 
adjusted analysis, and there was truly no period effect, then one would obtain equivalent 
results to the McNemar test. This is analogous to the period-adjusted t-test and paired t- 
test described in Chapter 2.
In summary, if a period adjusted analysis were undertaken on data where there is no 
period effect then there would be no effect on the inference. The converse though is not 
true. Imagine there are two treatment sequences AB and BA with the odds-ratios for 
each treatment sequence defined as
ka, kb,  k
WAB = — - = k y /  and <//„, ---• -
£>, a, y/
where k (k< 1.00) is the known period effect. From (3.51) it is therefore evident that for 
the special case of <?, = a, and b] = b, an unbiased estimate of the odds-ratio is obtained
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no matter what the value of the odds-ratio and k. However, if the period difference had 
been ignored with the data simply pooled the data across the sequences the naive 
estimate of the odds-ratio, assuming k and y/ are known, is defined as
^  + * > - ^ ( ¥ * ± 1 ) .  ( 4 . , . 5 4 )
k(ky/  + 1) + {y/ + k)
The bias estimated from (4.1.54) is given in Table 4.14 for different values of k. It is 
evident therefore that by ignoring a possible period effect the results are becoming 
biased towards the null hypothesis, with the bias increasing with increasing effect size 
(in absolute terms but not relatively). Overall though, with the exception of large period 
differences, the bias is relativelv small.
Table 4-14. Bias in estimated odds-ratio through ignoring possible period effects
k
Odds-Ratio
1.00 1.25 1.50 1.75 2.00 3.00 4.00
0.50 1.000 1.220 1.435 1.647 1.857 2.684 3.500
0.60 1.000 1.233 1.463 1.691 1.918 2.818 3.711
0.70 1.000 1.241 1.481 1.721 1.959 2.908 3.853
0.80 1.000 1.247 1.493 1.738 1.984 2.963 3.941
0.90 1.000 1.249 1.498 1.747 1.996 2.992 3.987
1.00 1.000 1.250 1.500 1.750 2.000 3.000 4.000
4.2.2.16. Sample Size Estimation
4.2.2.17. Population Effects Assumed Known
To calculate the discordant sample size, allowing for any possible period difference the 
following formulas can be used
« : + ^, - , ,J - /  2 ( / ,  „ , + Z yf l f / ( \ o &ORp ) :
/ / - I  p : P - iO - p . , )
(4.1.55)
where ORp and p  , are as defined in (4.1.51) and (4.1.53) respectively. For known 
values of y/ and k Table 4.15 can be derived (similar to Table 4.9) and as a consequence 
the requisite discordant and total sample size calculated.
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Table 4-15. Summary table of period adjusted responses expected in hypothetical
cross-over trial
Sequence Difference
Treatment Difference 
-1 1 Total
A-B ¥ k 1
y/ + k y/ + k
B-A 1 y/k 1
y/k +1 y/k +1
Similarly to earlier in the chapter, a table for each sequence, given in Table 4.16, can be 
derived using the marginal totals expected from a parallel group study with the expected 
odds ratio (where y/ = OR ).
Table 4-16. Summary of hypothetical cross-over trial for each treatment sequence
a. Sequence AB
Treatment B
1 0
Treatment A 1 p-
1 A (1 - P A)P,ORk PA
(1 - P A)ORk + PA (1 - P A)ORk + PA
0 AC 1 (1 - P A)2ORk 1 - P A
(1 - P A)ORk + PA (1 - P A)ORk + PA
Pa (1 - P A)ORk 1
( \ - P , ) O R k  + PA (1 -  PA)ORk + PA
a. Sequence BA
Treatment _ A ______
Treatment B 1 ^.p- 0 - ^ * kPA
(\ Pa )OR+Pa (1 - P A)OR + kPA (1 -  Pa)OR + kPA
o pa( \ - p a)OR (1 ~ P , ) :OR (1 - P a)OR
( \ - P A)OR + kPA { \ - P A)OR + kPA (1 -  PA )OR + kPA
i1,  i -  p.
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Table 4.16 can thus be used to estimate the expected proportion discordant so that the 
total sample size can be estimated using the two-stage approach described earlier. 
Therefore, using (4.1.55) and Table 4.16, Table 4.17 can be derived for various values 
of k, pi and the odds-ratio. From this table for k=l it seems that the estimate sample
sizes are slightly smaller compared to equivalent data in Table 4.10. For decreasing 
values of k the sample size is modestly increased.
Table 4-17. Sample size estimates for a cross-over trial for various expected 
outcome responses for a given treatment (p.\), period effects (k) and odds-ratios for 
a two sided type I error rate of 5% and 90% power
Odds-Ratio
k Pa 1.25 1.50 1.75 2.00 3.00 4.00
0.70 0.20 2869 911 496 333 143 98
0.40 1851 570 303 199 82 56
0.60 1773 527 272 175 67 45
0.80 2513 718 358 223 78 49
0.80 0.20 2835 901 492 336 142 94
0.40 1819 560 298 197 81 52
0.60 1741 518 268 172 66 41
0.80 2482 709 354 221 77 44
0.90 0.20 2819 897 489 399 142 93
0.40 1803 556 296 195 80 52
0.60 1725 513 265 171 66 41
0.80 2467 705 352 220 77 44
1.00 0.20 2814 895 489 329 142 93
0.40 1798 554 295 195 80 52
0.60 1720 512 265 171 66 41
0.80 2462 704 351 219 77 44
In summary therefore this section has gone, in detail to recommend ignoring the effect 
of period in the sample size calculations and use (4.1.33).
4.2.2.18. Sensitivity Analysis and Population Effects Assumed Unknown
Following on from the arguments in the previous sub-section the results for assessing 
sensitivity (4.1.49) and allow for the imprecision in the marginal control estimate 
(4.1.50) when period adjustment is not being allowed for in the sample size estimation 
could be extended to period adjusted sample sizes.
4.2.3. Advantages of Cross-over Trials over Parallel Group Designs
As well as the obvious advantage of a well designed cross-over trial potentially 
requiring the same total sample size as just one arm of a parallel group, i.e. half the total
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sample size, cross-over trials also convey another advantage in the estimation of 
treatment effects as illustrated in the hypothetical example in Table 4.18.
Imagine one had a parallel group trial designed to compare the outcome o f two 
treatments, where the outcome takes a binary form. Suppose too that a known 
prognostic factor, gender say, exists but that there is perfect balance with respect to this 
factor and no interaction between the factor and treatment (see Table 4.18a) with an 
odds-ratio equal to 3 in each sub group. If one collapsed the data down and ignored the 
covariate the estimated odds-ratio is biased down to 2.78 (Table 4.18c). However, as a 
cross-over trial assesses an effect within subject the estimate of the treatment effect is 
not intluenced by any between subject factors (if there is no interactions). This is 
evidenced by fable 4.18b (derived from the marginal totals of Table 4.18a) and 
Table 4.18d.
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Table 4-18. Hypothetical data from a cross-over and parallel group trial
A. Parallel group broken down by gender
Males Females
Outcome Outcome
1 0 Total 1 0 Total
Treatment A 225 75 300 Treatment A 150 150 300
B 150 150 300 B 75 225 300
Total 375 225 600 Total 2*>5 375 600
B. Cross over broken down by gender 
Males
Treatment B
1 0 Total
Treatment A 1 112.5 112.5 225
0 37.5 37.5 75
Total 150 150 300
* - there are fractions of subjects in the tabl
C. Parallel group overall
Outcome
1 0 Total
T reatment A 375 225 600
B 225 375 600
Total 600 600 1200
Females
Treatment B
1 0 Total
Treatment A 1 37.5 112.5 150
0 37.5 1 12.5 150
Total 75 225 300
but the table is only for illustration
D. Cross ov er ov erall
Treatment B
1 0 lotal
Treatment A 1 150 225 375
_________________ 0_____ 75 _ _  _150 225_
Total 225 3 "5 600
A caveat should be added here in that this comparison is an "all things being equal" one 
as cross-over trials by their design are prone to biases and problems to which parallel 
group trials are not.
As an aside this hypothetical example nicely illustrates a fallacy quoted for binary data 
that adjusting for covariates inflates the sample si/.e through increasing the standard 
error [Whitehead, 1993; Robinson and Jewell, 1991]. In the example the unadjusted 
log-odds-ratio does indeed have a smaller standard error of 0.119 compared to 0.125 for 
the analysis adjusting for gender. A standard error has increased by 5% through 
covariate adjustment. However, this effect is more than swamped by the bias in the log 
odds ratio, with the unadjusted log-odds-ratio being 1.022 (odds-ratio=2.78) compared 
to an adjusted 1.099 (odds-ratio-3.00) which is a 7.5% increase in the log-odds-ratio by 
adjusting. Thus, bias introduced by not adjusting will always pull the estimate nearer to 
the unity. This issue will be discussed in detail in section (4.6) of this chapter.
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4.3. N on-Inferiority  T rials
Going against the ordering of previous chapters, in this chapter, non-inferiority trials 
will be discussed before equivalence trials. The reason for this is that the issues under 
pinning non-inferiority trials are more established than for equivalence trials. However, 
the points raised in this sub section can be generalised to the later discussions on 
equivalence trials.
Before describing sample size calculations for non-inferiority trials it is pertinent first to 
recall the definition of the null (H()) and alternative (Hi) hypotheses:
Hq: A given treatment is inferior with respect to the mean response ( n  A ^ )■
Hi: The given treatment is non-inferior with respect to the mean response ( n A < ttB ).
These hypotheses can be written in terms o f a clinical difference, d [CPMP, 2000; Chen, 
Tsong and Kang. 2000; Chan, 2003]
H0: 7iA - n B > d .
Hi: n  A -  n B < d .
The issue to highlight here is that under both the null and alternative there is a none zero 
difference between treatments. This issue was first highlighted by Dunnett and Gent 
[1977] the implications of which will now be discussed in detail.
4.3.1. Parallel Group Trials
4.3.1.1. Sample Size with the Population Effects Assumed Known
4.3.1.2. Proportional Difference
From Chapter 1 one requires the following
Where p , is the proportion of responses expected in n subjects on treatment A 
and p H is the expected proportion of responses in nB subjects on treatment B. For the 
special case of n , = n B (4.2.2) can be substituted in to (4.2.1) (replacing A with 
P  t ~ P b ) giving a direct estimate o f  the sample size
l 'a r (S )=  ^
/’
(4.2.1)
and as with superiority Var(S) can be defined as
(4.2.2)
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(pA(\ - pA) + pB{\ - pH)\zx p + z ,  J :
n , = ----------------:------------------- ^  • (4.2.3).
((Pa ~ P h) ~ ^ Y
This equation is similar in form to that of the result for superiority trials given earlier in 
this chapter
(p.4 (1 -  P a  )_+ P « 0 [ -  , • +  z i -  : ^
( ( P a  ~  P h ) ~  d Y
" ,  = ‘ ‘ ' ...... --------------------------- • (4-2.4)
Although not discussed in the section on superiority trials (4.2.4) can actually be written 
as [Machin, Campbell, Payers et al, 1997]
n  = (Z l-a : V 2 p ( l - P >+ /<V' P a  (• "  P a  )  + P A l ~  P b ) )  (4  ,
( ( P ,
where p ~ { p A + p B) <2. Note that under the superiority null hypothesis p A = p B. 
Hence, Z ]_a , is multiplied by the v ariance under the null hypothesis and Z x_p is
multiplied by the variance under the alternative hypothesis i.e. (4.2.5) can be expressed 
as
(z,_a n y/Variance under Null + Z, p, V Variance under the Alternative)  ^ ^
((P ,  P B ) - c l Y
Practically, however, use is made of the following result for superiority trials, 
p A(l -  p x ) + p M(l -  /?,,) = 2p(l -  p ) , which as evidence empirically from Table 4.19
(text in bold highlights differences) holds as a reasonable approximation hence enabling 
(4.2.4) to be used.
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Table 4-19. Variances estimated from two different results for different expected 
treatment responses pA and Pb
a. p > 1 > ) +  P  B U - P b )
P b
P a 0.10 0.20 0.30 0.40 0.50 0.60 0.70 0.80 0.90
0.10 0.18 0.25 0.30 0.33 0.34 0.33 0.30 0.25 0.18
0.20 0.25 0.32 0.37 0.40 0.41 0.40 0.37 0.32 0.25
0.30 0.30 0.37 0.42 0.45 0.46 0.45 0.42 0.37 0.30
0.40 0.33 0.40 0.45 0.48 0.49 0.48 0.45 0.40 0.33
0.50 0.34 0.41 0.46 0.49 0.50 0.49 0.46 0.41 0.34
0.60 0.33 0.40 0.45 0.48 0.49 0.48 0.45 0.40 0.33
0.70 0.30 0.37 0.42 0.45 0.46 0.45 0.42 0.37 0.30
0.80 0.25 0.32 0.37 0.40 0.41 0.40 0.37 0.32 0.25
0.90 0.18 0.25 0.30 0.33 0.34 0.33 0.30 0.25 0.18
b. 2p(l -  p)
P a
 _________________________ P b_____________________________
0.10 0.20 0.30 0.40 0.50 0.60 0.70 0.80 0.90
0.10 0.18 0.26 0.32 0.38 0.42 0.46 0.48 0.50 0.50
0.20 0.26 0.32 0.38 0.42 0.46 0.48 0.50 0.50 0.50
0.30 0.32 0.38 0.42 0.46 0.48 0.50 0.50 0.50 0.48
0.40 0.38 0.42 0.46 0.48 0.50 0.50 0.50 0.48 0.46
0.50 0.42 0.46 0.48 0.50 0.50 0.50 0.48 0.46 0.42
0.60 0.46 0.48 0.50 0.50 0.50 0.48 0.46 0.42 0.38
0.70 0.48 0.50 0.50 0.50 0.48 0.46 0.42 0.38 0.32
0.80 0.50 0.50 0.50 0.48 0.46 0.42 0.38 0.32 0.26
0.90 0.50 0.50 0.48 0.46 0.42 0.38 0.32 0.26 0.18
Note, the practical application of this result will be used further in the section on trials 
for a given precision. Now for non-inferiority trials one requires the following result for 
the estimation of sample sizes.
[z L"_v'r?  ~ P J  + P h (1 -  ?* ) + 5 1 ,t J p A ' ~  P a ) + P bQ - P h))
{(Pa ~ P h) - c1)2
(4.2.7)
where
A A A  ZA + hS] z h ] (4.2.8)
n A n H
is an estimate of the variance under the null hypothesis, which has that p A * p B. As 
the estimates of p  ., and p H affect the estimate of the variance the definition of the null 
hypothesis hence influences the variance under this hypothesis. There are a number of 
ways of estimating (4.2.8) and will be discussed now.
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4.3.1.3. Method 1 -  Using Anticipated Responses
The first method of estimating the variance under the null hypothesis is simply to 
replace p A and p B with anticipated estimates of the response, p  A and p B [Dunnett
and Gent, 1977; Farrington and Manning, 1990], Hence, the variance under the null 
hypothesis becomes
P ^ - P ^  + E j^ lZ P jlI . ( 4 2 .9)
nA nB
The sample size can hence be estimated from
n ^ (Z. ii + Z  „ ^( /M 1 ~ P , )  + P/,<* -  P« >) (4 2 1 0 )
i(P , - P h) -  dY
and the same result as (4.2.3).
4.3.1.4. Method 2 -Using Anticipated Responses in Conjunction with the Non-Inferiority 
Limit
The second method is to estimate p  , and p B from [Dunnett and Gent, 1977]
P a = ( P a + P b
P b = ( P a + P b - d ) ! 2 .  (4.2.11)
where d is the non-inferiority limit. Hence, (4.2.11) can be applied to the estimate of 
the variance (4.2.8) and an estimate of the sample size can be obtained from
( z . +  p J p a I \ - P a )  +  P b Q - p ' b) )  , ,  0n 4 = -----------------------------------   . (4.2.12)
( ( P a  ~  P b ) - c 1 Y
For (4.2.11) to be used the following inequality must hold [Farrington and Manning, 
1990]
m ax{-r/,r/}< p A + p H < 2 + min{- d yd ) . (4.2.13).
Farrington and Manning state that (4.2.13) is "easily violated". Which is true but only if 
one enters stupid values for d, p  , and p B i.e. if one set d^O.20 where one expected a
response rate of 0.90 for both regiment A and B. Patently this is a nonsensical limit for 
such a high response rate (for d^O.10, a more sensible limit, (4.2.13) would not be 
violated). Hence, although "easily violated" (4.2.13) holds for all practical limits of d, 
P a and P b ■
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4.3.1.5. Method 3 -  Using Maximum Likelihood Estimates
The third method is to use maximum likelihood estimates for p  4 and p B [Farrington 
and Manning, 1990; Miettinen and Nurminen, 1985; Koopman, 1984] defined as
p  4 = 2ucos(u) -  —  ,
3c/
P b  = P a  (4.2.14)
to enter into (4.2.8) where d x ~ p A( \ - d ) d .  b -  - ( 2  + p + p B -  3 d ) , a=2,
v = {p2 /  21 tv -  b e / 6a 2 + c/, j l a ), vr = [yr + cos 1 (v/ i d  )J/ 3 , u = s ig n (v ) ^ b 2/ 9  a 2 - c / 3 a  
and c = d~ -  2d { p A + 1) + p A + p H . With (4.2.14) and (4.2.7) an estimate o f  the sample 
size can be estimated from -similar in form to (4.2.12)
{Z e ^ rP A ] -  P a ) + P h( ] -  P b ) + p V  P a ( 1 ~ P  J  +  P  * 0  ~  P  j ) ~
n A = - --------------------------------------------------------------   — ----------------------------------------------------------------------- . (4.2.15)
((P.^ -  P n ) - d )
4.3.1.6. Comparison of the Three Methods o f Sample Size Estimation
As evidenced by their descriptions the three methods for estimating the variances under 
the null hypothesis are markedly different. As a result they give quite different 
estimates of the variance and as a consequence different estimates for the sample size.
To compare the three methods of sample size estimation a simulation was undertaken. 
The simulation was undertaken for different p and p B proportions between 0.70 and
0.90 and non-inferiority limits, d, between 0.05 and 0.20. These values were chosen, as 
they are quite common responses for anti-microbial non-inferiority studies. For each d, 
p A and p B the sample size was iterated until the required power was reached. 100,000 
simulations were undertaken to estimate the power for each n, d, p A and p B . The 
simulation was undertaken in SAS [ 1990],
The simulation was repeated for 4 different methods of calculating confidence intervals: 
Normal approximation; Normal approximation with continuity correction; Wilson's 
score method and Wilson's score method with continuity correction. The different 
methods of calculating the confidence intervals were described in Chapter 3. The 
simulations were stopped when the requisite proportion of simulations (90%) had an 
upper tail of a 95% confidence interval less than d. The Normal approximation with 
continuity correction gave substantially larger estimates o f  the sample size compared to 
the other 3 and are not included here.
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Table 4-20. Sample sizes for a non-inferiority study estimated through 3 
alternative methods for 90% power and a type I error rate of 2.5%
Sample Size Method 
P a P a-P r  Lim it  Method 1 Method 2 Method 3
+0.10 0.15 1556 1540 1534
+0.05 0.10 1466 1452 1471
0.15 366 359 375
0.00 0.05 1346 1342 1369
0.10 337 334 352
0.15 150 147 162
+0.05 0.05 303 303 318
0.10 135 134 149
0.15 76 74 88
+ 0.10 0.05 117 118 130
0.10 66 66 79
0.15 43 42 54
+0.10 0.15 1324 1309 1263
+0.05 0.10 1209 1199 1209
0.15 303 296 312
0.00 0.05 1072 1069 1099
0.10 268 265 287
0.15 120 116 135
-0.05 0.05 229 249
0.10 102 101 120
0.15 58 56 73
+0.05 0.10 915 905 896
0.00 0.05 757 754 791
0.10 190 186 215
Table 4.20 gives the sample sizes for the different methods of sample size estimation 
and Table 4.21 gives summary statistics for the ratio of the estimated sample size of 
over the simulations.
Within the parameters of the simulation it seems that which sample size method to use 
depends on preference. Method 1 gives the closest estimates compared to simulations. 
Method 3 one can at least almost guarantee one would never be underpowered. From 
now on method 1 is the method that will be described.
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Table 4-21. Summary statistics comparing the different methods of sample size 
estimation for a non-inferiority study through simulation and three alternative 
methods (ratio of calculated to simulation)
Cl Calculation Statistic
Method of Sample Size Calculation
Method 1 Method 2 Method 3
Normal Minimum 0.93 0.90 0.95
Approximation Quartile 1 0.99 0.97 1.02
Median 1.00 0.99 1.05
Quartile 3 1.00 1.00 1.15
Maximum 1.01 1.05 1.30
Wilson Minimum 0.82 0.81 0.96
Quartile 1 0.97 0.97 1.03
Median 1.00 0.98 1.05
Quartile 3 1.00 0.99 1.11
Maximum 1.02 1.03 1.28
Wilson with Minimum 0.82 0.81 0.95
Continuity Quartile 1 0.97 0.95 1.02
Correction Median 0.99 0.98 1.05
Quartile 3 1.00 1.00 1.11
Maximum 1.01 1.05 1.28
4.3.1.7. Odds-ratio
Remember the following result for non-inferiority studies the variance of the measure of 
effect must satisfy
f a r  (S) = — ( - - - - - I . . .  , (4.2.16)
< / .
and that the variance about the log-odds-ratio can be approximated by [Whitehead, 
1993]
,'f l r (S ) = _ _ 4  . (4.2.17)
' { 1 ' -
where p t is the average response each outcome category ( p x -  ( p A + p ti) / 2  and 
p 2 = 1 -  p ] ). By equating (4.1.7) with (4.1.6) one requires
n -
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where d in this instance is the non-inferiority limit on the log OR scale. In Chapter 3 
appropriate values were quoted as either log(0.43), log(0.50) or log(0.55) as well as that 
o f log(0.47).
Table 4-22. Sample sizes for different non-inferiority limits on the odds-ratio scale 
and anticipated responses for 90% power and ty pe 1 error of 2.5%
Odds- Limit o f  0.43 Limit o f  0.47 Limit o f  0.50 Limit o f  0.55
Pa Ratio formula Simulation formula Simulation formula Simulation Formula Simulation
0.80 0.70 498 508 745 762 1044 1061 2031 2066
0.80 319 330 435 445 557 567 876 893
0.90 234 244 302 307 369 373 525 530
1.00 185 189 231 235 274 284 368 372
1.10 154 158 187 192 218 228 282 292
1.20 132 137 158 163 181 186 228 233
1.40 105 109 122 127 137 142 167 171
0.85 0.70 612 629 915 933 1282 1317 2496 2530
0.80 396 406 539 549 690 700 1085 1103
0.90 OQ") 302 3 77 387 460 471 655 666
1.00 ">3'> 290 300 344 348 462 466
1.10 194 204 236 247 275 279 355 360
1.20 167 172 200 205 230 240 289 299
1.40 133 138 156 160 175 179 212 217
0.90 0.70 848 873 1268 129 1778 1822 3460 3527
0.80 553 571 7 5 3 771 965 982 1518 1543
0.90 411 421 531 548 648 653 923 940
1.00 328 339 410 421 487 497 654 664
1.10 275 286 336 340 391 401 505 516
1.20 239 249 286 296 328 338 412 417
1.40 191 201 223 234 251 261 304 315
It was on the odds-ratio scale that Dunnett and Gent recommended inference be based 
[Dunnett and Gent, 1977], Not least, as discussed in Chapter 3, because there is a 
sufficient statistic for the odds-ratio, which leads to exact confidence intervals to be 
calculable.
As with assessing non-inferiority on the proportional scale (4.1.18) can be rewritten to 
account for the variability under the null and alternative hypothesis. This is because the 
variance is estimated from p  , and p H , which, as discussed earlier in this chapter, differ
according to the null and alternative hypothesis. However, (4.1.18) gives the most 
conservative estimate of the variance as approaches such as method 3 (if applied to the 
anticipated proportions used to estimate the variance) would reduce the variance 
estimate on the log-odds scale - the opposite to that for the proportional scale (see 
Chapter 3).
A simulation was undertaken to assess (4.1.18) for different p A and p B proportions 
between 0.70 and 0.90 and non-inferiority limits, d, log(0.43), log(0.47), log(0.50) and
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log(0.55). For each d, p  A and p  B the sample size was iterated until the required power
was reached. 100,000 simulations were undertaken to estimate the power for each n, d, 
p A and p B. The simulation was undertaken in SAS [1990]. The simulations were
stopped when the requisite proportion o f  simulations (90%) had a lower tail o f the 95% 
confidence interv al greater than d.
Table 4.22 gives the sample sizes calculated from (4.1.18) along with the equivalent 
sample sizes estimated from simulation. It seems from this table that (4.1.18) 
underestimates the sample size a little compared to the simulations.
4.3.1.8. Proportional Difference Versus Odds-Ratios
The comparison of the odds-ratio and absolute risk is not straightforward for non­
inferiority trials. As discussed in Chapter 3, when setting a non-inferiority limit on the 
odds-ratio scale one has the prime advantage o f a constant margin, which will vary, in 
terms of the absolute difference, depending on the overall response anticipated. This is 
opposed to working with the absolute difference where a stepped margin may need to be 
applied. The issue is debatable however. For modeling purposes the log-odds scale is 
preferable -  not least as it allows for an adjustment for covariates. However for decision 
analysis, the probability scale is probably the most relevant.
Table 4-23. Comparison of sample sizes calculated on the odds-ratio and 
proportional scale - assuming p.\=PB
Anticipated
Sample Size 
Non-Inferiority Limit for the
Response Odds-Ratio
Rate Margin Proportional 0.43 0.47 0.50 0.55
90% -10% 190 328 410 487 654
85% -15% 120 232 290 344 462
80% -15% 150 185 231 274 368
75% -20% 99 158 197 234 314
70% -20% 111 141 176 209 281
Table 4.23 gives the sample size required for different anticipated response rates using 
calculations based on the absolute difference, from (4.2.10), and the odds-ratio, from 
(4.2.18). For the odds-ratio different non-inferiority margins were used.
Table 4.23 highlights one disadvantage of using the odds-ratio in that it consistently 
returns a greater sample size than that for the "equivalent" proportional difference 
calculation.
Note equivalent was put in speech marks, as the exact equivalent odds-ratio to that of 
the proportional difference is not being used. However, by the same token the table 
highlights the disadvantage to working on the absolute scale. Whilst the odds-ratio
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moves smoothly up in terms of sample size (requiring the smallest sample size for a 
response of 0.70 and the greatest for a response o f  0.90) for the proportional difference 
the sample size does not. With the fixed margin of 0.20, an anticipated response rate of 
75% would require a sample size less than that of 70%. However, there is a subsequent 
step up when the response reaches 0.80 and a tighter margin. Working on the absolute 
risk scale therefore leaves one's calculations very sensitive to assumptions about the 
anticipated response rates.
4.3.1.9. Worked Example
An investigator wishes to design a trial where the anticipated response rate on the active 
control is 85%. The investigator also expects an 85% response rate on the investigative 
therapy. Using an odds-ratio of 0.50 for the non-inferiority limit Table 4.22 gives the 
sample size as being 344 patients per arm.
In comparison working on the proportional scale, with the same anticipated responses, 
but with a non-inferiority limit of 15% one requires just 120 patients per arm.
Note here that although the sample sizes here seem quite disparate for the odds-ratio 
scale compared to the proportional scale, one must bear in mind that one is not 
comparing like with like. For an anticipated control response of 85%, an odds-ratio of
0.5 equates to a 11.1% difference a little short of 15%.
4.3.1.10. Sensitivity' Analysis About the Estimates of the Population Effects Used in the 
Sample Size Calculations
As highlighted earlier in this chapter for superiority trials, it is the response rate on 
control, p 4 say, to which the study design is sensitive. This response rate in turn feeds
into the estimate of variance used in the calculations and, for the absolute difference, the 
non-inferiority margin used.
As with superiority trials the sensitivity of the non-inferiority study design to the control 
response rate can be investigated through construction of a 95% confidence interval. 
The power could then be assessed at the two tails of the confidence interval.
The following result for the absolute difference could be used to investigate the 
sensitivity of a study. Note that in this formula the study design will be sensitive to both 
the control response rate (as the non-inferiority margin would change) and the variance,
I -  /? = O
" ( ( / %  ~ p H ) - c l ) '  z
V
(4.2.19)
( P a ^ -  P a )  +  P h ) )
/
The equivalent formula to investigate the sensitivity of study about an odds-ratio is
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( 1 - - - - 1 \
\ n ( \o g {O R ) -d  f ' 2>
IV / / )
4.S. 1.11. Worked Example
Suppose that in the worked example given earlier, the control response rate was 
assessed from a previous study in 100 patients. It is assumed that the investigative 
response rate is correct at 85%. Using the Wilson's score method for calculation, the 
confidence interval indicates that a plausible range for the control response to be 
between 16.1% and 90.7%.
Table 4-24. Sensitivity analysis for non-inferiority worked example
a. Odds-ratio scale
9 5 ° o Confidence Interval
_________________________ Observed Lower Upper
Control Response 0.85 0.767 0.907
Investigative Response 0.85 0.850 0.850
Power 90°o 100.0% 9.4%
b. Proportional scale
95% Confidence Interval
_________________________ Observed Lower________Upper
Control Response 0.85 0.767 0.907
Non-inferiority Margin 0.15 0.15 0.10
Investigative Response 0.90 0.90 0.90
Power 90% 99.7% 17.9%
Table 4.24 gives a breakdown of the sensitivity of the study design to the estimate of the 
control response rate. As one can see from this table it is the upper point of the 
confidence interval to which the study is sensitive. The calculations about the odds 
ratio are more sensitive to this tail (power reduced to 9.4%) than the absolute difference 
(power reduced to 17.9%).
Note that when undertaking the sensitivity analysis here one is simultaneously assessing 
the sensitivity of the study to assumptions both about the anticipated variability 
(( p (1 -  p 4) + p H (1 -  p H)) and the mean difference between treatments ( p A -  p B).
Note also that in assessing the sensitivity on the absolute difference scale it was 
assumed that if one observed a lower than expected control response rate than the 
original non-inferiority would still be used. However, if a higher than expected 
response rate was observed that a tighter limit would be used.
232
4.3.1.12. Calculations Taking Account o f  the Imprecision o f the Estimates o f  the
Population Effects Used in the Sample Size Calculations
As described earlier in this chapter for superiority trials, using appropriate confidence 
interval methodology around the control response rate, p 4, the power, and, hence
iteratively, the sample size can be calculated using numerical methods. By extending 
this methodology the sample size for a non-inferiority trial, where the proportional 
difference is of interest, can be estimated from the following result.
{J> I P j  c/y _y
1 "■*■>» \  ( p .. (I p  ... ) * p „ 0  p .o ) 1 '\ p . —  y  050 40S | , ‘ .. . • ........
> : ,■ i’"K Z|
, \  (/>,..    (I P.. . .     ) ’ / M l  P h ))
(4.2.21)
The equivalent calculation for a non-inferiority study design around the odds-ratio 
would be estimation from
1 - P
1
0.998 I 05pen 0 001
<t>| n( log (OR) -  d )
V \
6 - Z ,
+
, r
n( log (OR) -  df  | I - .0C / 6 -  Z,
(4.2.22)
Tables, which give sample sizes using (4.2.22) and (4.2.21), are given in Tables 4.25 
and 4.26 respectively.
This calculation could be questioned for (4.2.21) as here one is assuming that the 
assumed proportional difference is remaining constant but that the variance is assessed 
imprecisely. However, both in this instance depend on p A and as discussed previously 
in this chapter (and in Chapter 3) the non-inferiority limit also varies depending on p A 
(when working on the proportional scale).
Intuitively the calculations are more robust for (4.2.22) as a fixed odds-ratio varies on 
the absolute scale depending on the anticipated control response rate. Hence, p A could
be considered to only affect the variance.
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Table 4-25. Sample sizes for a non-inferiority study, limit of 0.50, on the odds-ratio 
scale for different precisions around the variance and different anticipated 
responses for 90% power and type I error of 2.5%
Control Odds- Degrees o f  Freedom
Rate Ratio 10 20 30 40 50 100
0.80 0.70 1344 1177 1130 1108 1095 1069
0.80 724 631 605 592 585 571
0.90 484 420 402 393 388 379
1.00 362 313 299 293 289 281
1.10 289 249 238 233 230 224
1.20 242 208 199 194 192 187
1.40 185 158 151 147 145 141
0.85 0.70 1945 1541 1445 1402 1377 1329
0.80 1060 834 781 757 743 716
0.90 715 559 523 506 496 478
1.00 538 419 391 378 371 357
1.10 433 336 313 303 297 286
1.20 364 282 262 254 249 239
1.40 279 215 200 193 189 182
0.90 0.70 4583 2487 2193 2073 2008 1888
0.80 2523 1360 1196 1130 1093 1026
0.90 1713 919 807 761 736 690
1.00 1297 693 608 573 554 519
1.10 1047 558 489 461 445 417
1.20 883 470 411 387 374 350
1.40 681 361 315 297 287 268
Table 4-26. Sample sizes for a non-inferiority study on the absolute difference scale 
for different precisions around the variance and different anticipated responses for 
90% power and type I error of 2.5%
Control Degrees o f  Freedom
Rate Diff Limit" 10 " 20 30 40 50 100
0.80 -0.10 0.15 1561 1565 1564 1563 1562 1559
-0.05 0.10 1495 1485 1479 1475 1473 1468
0.15 374 372 370 369 369 367
0.00 0.10 354 347 344 342 341 339
0.15 158 155 153 152 152 151
0.05 0.10 147 142 140 139 138 136
0.15 83 80 79 78 78 77
0.10 0.10 100 84 75 71 69 67
0.15 57 51 47 45 44 43
0.85 -0.10 0.15 1399 1372 1360 1353 1348 1337
-0.05 0.10 1320 1275 1256 1246 1239 1225
0.15 330 319 314 312 310 307
0.00 0.10 308 291 284 281 278 274
0.15 137 130 127 125 124 122
*0.05 0.10 128 116 112 109 108 105
0.15 71 65 63 62 61 59
0.90 -0.05 0.10 1118 1030 996 977 966 941
0.00 0.10 255 216 210 206 198
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4.3.1.13. Worked Example
Suppose that the investigator wishes to redo the calculation from the worked example 
given earlier to allow for the fact that the control response rate was estimated from 100 
patients.
For the same non-inferiority limit of ORrrO.5 as previously the sample size should be 
increased to 357 patients per arm around a 4% increase in the sample size.
Repeating the sample calculations on the absolute difference scale decreases the same 
size to 122 patients per arm. This is 2 more than the calculation earlier.
4.3.1.14. Calculations Taking Account o f the Imprecision o f the Estimates Used in the 
Calculation of Sample Sizes -  Bayesian Methods
The percentiles for a posterior control response can be calculated as described in 
4.1.1.16. From these percentiles (4.2.21) and (4.2.22) could be used to estimate the 
sample size allowing for the imprecision in the estimate of the control response rate 
[Julious, 2004d].
It is best to highlight the points through worked example.
4.3.1.15. ft orked Example
For the absolute difference scale with a non-informative prior the sample size is 
estimate to be 122 patients per arm. which is the same as calculated before.
With a more pessimistic prior, the most likely response being 80% with 90% certainty 
that it is greater than 75% (from (4.1.26) estimates of «o and ^  of 27.326 and 106.304
are obtained), the sample size estimate is increased to 139 patients per arm.
With a prior that the control response rate observed is about right, the most likely 
response being 85% with 90% certainty it is greater than 80% (from (4.1.26) estimates 
of a0 and b„ o f 18.244 and 98.716 are obtained), the sample size estimate is to 122
patients per arm -  the same as for a non-informative prior.
Similar calculations could be done for the odds-ratio.
4.3.1.16. Calculations Taking Account of the Imprecision of the Estimates of the 
Population Effects with Respect to the Assumptions about the Mean Difference and the 
Variance Used in the Sample Size Calculations
When one is designing a non-inferiority study, as discussed in Chapter 2 for Normal 
data, the imprecision in the mean difference as well as the variance may be of 
importance. This is particularly so for non-inferiority studies (and equivalence studies
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described later in the chapter) where the mean response, assessed by p  A, feeds into the 
assumptions both about the mean difference and the variance.
To allow for the imprecision in the mean difference and variance one could use 
numerical methods to calculate the sample size on the absolute difference scale and the 
following result
; J  "((/>,.. P h ) ' A  )
( J)  I r  . . . . .    . . A /  ■
, : 1 \ [ P  . 0  P ,  ) ’ / M  1 / ' *) )  !
1 -fir ' X 05!
04 4S  ■ "((/>., p H) A  z
\  (p.  . P. ..     ) * / M l  P h ))
(4.2.23)
Note that in this instance, in contrast to non-inferiority calculations given earlier, a 
number of issues need to be additionally considered
1. If any of the percentile values around the control response crosses a step (given in 
Table 4.23) then the non-inferiority margin, d, should be altered accordingly.
2. The investigative response rate. p H, remains assumed fixed calculated from the 
initial/?., but not from individual p .
3. Following on from 2. for instances where p pi.n. ~ P B exceeds the non-inferiority
bound then the power for this percentile (to be averaged across for power 
calculation) is set to 0.
The equivalent calculation for a non-inferiority study designed around the odds-ratio 
would be
(I>i n(  l og O R
i \
f  cDl nf  log O R
l \  ~ #
d f \  / - I / W  ' 6 -Z; < 
- d> ' l ~ / 6 -  Z,
.(4.2.24)
As the odds-ratio does not suffer from the issues of stepped non-inferiority bounds the 
calculations are relatively more straightforward. However, the following two points 
should be considered similar to the proportional difference
1. The investigative response rate, p H, remains assumed fixed calculated from the 
initial/?^ but not from individual p .
2. Following on from 2. for instances where ORpen. = (p perc ((1 -  p  a ))/(p fl(l -  p  perCl))
exceeds the non-inferiority bound then the power for this percentile (to be averaged 
across for power calculation) is set to 0.
Tables 4.27 and 4.28 give sample size calculations using (4.2.24) and (4.2.23) 
respectively. A couple of points are worth noting from these tables.
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Table 4-27. Sample sizes for a non-inferiority study, with a limit of 0.5, on the 
odds-ratio scale for different precisions around the anticipated control response 
rate and variance for 90% power and type I error of 2.5%
Control
Rate
Odds-
Ratio
Degrees of Freedom 
50 100 250 500
0.80 0.90 2971 861 504 430
1.00 1070 500 344 306
1.10 603 348 261 238
1.20 411 266 211 195
1.40 250 183 154 145
0.85 0.90 10717 1424 689 560
1.00 2324 757 461 397
1.10 1103 506 347 308
1.20 691 379 278 253
1.40 388 255 202 188
0.90 0.90 37602 3993 1177 863
1.00 19176 1653 750 601
1.10 4325 988 550 462
1.20 2033 697 435 377
1.40 886 441 312 279
Table 4-28. Sample sizes for a non-inferiority study on the absolute difference scale 
for different precisions around the anticipated control response rate and variance 
for 90% power and type I error of 2.5%
Control D e c rees o f  f reedom ______
Rate Pa-Ph 50 100 750 500
0.80 0.00 0. 15 215 172 148 148
+0.05 0. 15 86 76 75 75
+0.10 0. 15 43 41 41 41
0.85 0.00 0. 15 283 150 126 122
+0.05 0.15 80 64 59 58
0.90 +0.00 0.10 263 214 188 188
The first is that these calculations are only possible if one is optimistic in one’s 
assumptions around the investigative response rate i.e. one should assume the response 
is equal to or better than the control response rate.
The second is that the odds-ratio for these calculations give very large sample size 
estimates. In fact these calculations seem to demonstrate that just because you can do 
the calculation it does not mean you should. Indeed as on the OR scale the margin 
changes as the control response changes (in terms of absolute differences) one could 
seriously question the need for these calculations. The recommendation therefore 
would be simply to use (4.2.22) and Table 4.25 for odds-ratio calculations.
For the absolute difference scale the calculations seem more plausible. This is because 
the assumed absolute difference (and non-inferiority margin) now changes depending
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on the imprecision of the control response. The sample sizes are quite plausible and are 
in the same region as Table 4.25. The recommendation would therefore be to use 
(4.2.24) and Table 4.28 when working on the absolute difference scale.
4.3.1.17. Proportional Difference V ersus Odds-Ratios - Revisited
It seems at first that the calculations on the odds-ratio scale are overly sensitive, 
compared to the absolute difference, to assumptions around the variance. In fact this is 
a function o f  the properties of the odds-ratio -  the fact that a fixed odds-ratio would 
equate to smaller and smaller differences, as the control response gets greater. In 
comparison on the absolute difference scale the margins are relatively fixed (all be it 
stepped) such the same margin could be used, 10%, independent of the anticipated 
response.
Which statistical analysis and consequent sample size calculation, to use depends on the 
robustness of one’s assumptions. If it is reasonable to have relatively fixed margins 
then one can work completely on the proportional scale. If one wishes to have more 
flexible margins then one should work on the odds-ratio scale.
In truth, however, there is no generic answer as to what scale to work on. For example 
an anticipated response of 90% raises far greater questions (should the margin narrow if 
a response rate greater than 90% is observed?) than one of 80%. Thus, it is 
recommended that the decision as to the most calculations be undertaken on a case by 
case basis w ith a thorough investigation made as to the sensitivity of one’s calculations 
to the assumptions inherent in them.
4.3.1.18. Worked Example
Revisiting the worked example again where the investigator had a control response rate 
estimated from a trial with 100 patients.
For the same non-inferiority limit of O R -0.5 as previously the sample size should be 
increased to 757 patients per arm approximately a 2 fold increase in the sample size 
compared to the original calculations.
Repeating the sample calculations on the absolute difference scale increases the same 
size to 150 patients per arm approximately a 20% increase in the sample size.
4.3.1.19. Calculations That Take Account of the Imprecision of the Estimates Effects with 
Respect to the Assumptions about the Mean Difference and the Variance Used in the 
Sample Size Calculations -  Bayesian Methods.
As previously discussed the percentiles for a posterior control response can be 
calculated as in 4.1.1.16 and from these percentiles from (4.2.21) and (4.2.22) can be
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used to give an estimate of the sample size [Julious, 2004d]. Again it is best to 
highlight the points through worked example.
4.3.1.20. Worked Example
For the absolute difference scale with a non-informative prior the sample size is 
estimate to be 152 patients per arm. This is two greater than the sample size calculated 
before.
With a more pessimistic prior (the most likely response being 90% with 90% certainty 
that it is greater than 85%), the sample size estimate is increased to 155 patients per 
arm.
Note that this is more of a pessimistic prior then when just looking at variability as one 
is now calculating the power for instances when the belief is that the mean difference is 
in favour of the control treatment. This will adversely affect the sample size.
With a prior that the control response rate observed is about right (the most likely 
response being 85% with 90% certainty it is greater than 80%) the sample size estimate 
is increased to 126 patients per arm.
4.3.2. Cross-over Trials
There are a number of papers which deal specifically on the topic o f  cross-over 
equivalence trials [Lu and Bean, 1995; Tango 1998, 1999; Nam, 1997; Tang, 2003; 
Tang, Tang and Chan, 2003]. However, these methodologies are simply extensions of 
methodologies for superiority cross-over trials and parallel group non-inferiority trials.
Earlier in this chapter it was highlighted how to estimate the sample size for superiority 
trial one could simply use the sample sizes for parallel group superiority trials and take 
the sample size per arm to be the total sample size for a cross-over trial. This argument 
can be extended now to non-inferiority trials. It is therefore recommended to use the 
parallel group methodologies described in this sub-section of the chapter to estimate the 
total sample size for a non-inferiority cross-over trial
4.4. As G ood as or Better Trials
As discussed in Chapter 2, to calculate the sample size required for an "as good as or 
better" trial one should apply the methodologies described for superiority and non­
inferiority trials.
The big advantage in designing as good as or better trials for binary data is that the non­
inferiority limits (as discussed throughout this chapter and Chapter 3) are more clearly
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defined. Hence, the criteria for the closed testing procedure are also more 
straightforward to define.
Other issues with as good as or better trials are either the same as described for Normal 
data in Chapter 2 or generic and described in Chapter 1. Hence, this chapter will not go 
into detail on these types of trial now.
One issue that may potentially become more open for debate is the choice of analysis 
population. As discussed in Chapter 3, for a superiority trials the primary data set is the 
intention to treat population (ITT); whilst for non-inferiority trials it is both the per 
protocol data set (PP) and the ITT [CPMP, 2000]. Garrett [2003] has recently 
challenged this assertion. Highlighting how for binary data there is no bias in the point 
estimates for the PP population with any conservativeness being down simply to a 
smaller sample size. However, the regulatory guidance currently advocates the joint 
primary population approach [CPMP, 2000] and so any sample size calculation should 
also reflect this.
4.5. Equivalence Trials
For equivalence trials, the null (Ho) and alternative (Hi) hypotheses are defined as:
H0: A given treatment is inferior with respect to the mean response ( n  , * n B).
H i: The given treatment is equivalent with respect to the mean response ( n  A -  n B).
Formally, these hypotheses can be written in terms of a clinical difference, d [CPMP, 
2000]
Ho: 7iA -  n ti > d  or n 4 -  n B < - c l .
Hi \ - d  < n  A-  n H < c l .
The issue to highlight here is that like non-inferiority trials under both the null and 
alternative there is a non-zero difference between treatments [Dunnett and Gent, 1977]. 
The implications are similar to those for non-inferiority trials discussed earlier and will 
now be discussed.
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4.5.1. Parallel Group Trials
4.5.1.1. Sample Sizes with the Population Effects Assumed Known
4.5.1.2. General Case
4.5.1.3. Proportional Difference
Recall from Chapter 1 that the total Type II error (defined as /? = /?,+/?-,) is derived 
from the following result.
true mean difference is not fixed to be zero the sample size cannot be derived directly as 
the total Type II error is the sum of the Type II errors associated with each one-tailed 
test.
As with non-inferiority trials discussed earlier in this chapter there are a number of 
approaches for the derivation of the variance under the null ( p  A{ \ - p  J  + p . O - p , ) )  
and alternative ( p   ^ (1 -  p  a ) + P b (1 ~ P b ) )  hypothesis. The generic solution to 
estimation the power for a given sample size is thus
This chapter will now discuss the different methods for estimation the variances.
4.5.1.4. Method 1 -  Using Anticipated Responses
As with non-inferiority trials the first method of estimating the variance under the null 
hypothesis is simply to replace p  , and p B with anticipated estimates of the response, 
Pj  and p H [Dunnett and Gent, 1977; Farrington and Manning, 1990], Hence, the 
variance under the becomes
' p' = 4 ^ )
As discussed in Chapter 2, for equivalence trials for the general case where the expected
(4.3.1)
P a Q ~  P a ) +  P h 0 ~ P h \ (4.3.2)
and the power for a given sample size can hence be estimated from
To estimate the sample size one iterates (4.3.3) on the sample size until the nominal 
power is reached.
4.5.1.5. Method 2 -  Using Anticipated Responses in Conjunction with the Equivalence 
Limit.
The second method is to estimate p  , and p H from [Dunnett and Gent, 1977]
P a  ~  i P a  +  P b  +  d ) / 2  ,
P b  ~ i P a  + P b  ~ d ) / 2 .  (4.3.4)
where d are symmetric equivalence limits. Applying, (4.3.4) to (4.3.1), an estimate of 
the power for a given sample size can be obtained from
i - / ?  = o " ( ( . P a  - p , ) - d f  Z, . u \ I p a O - P a )  + P b Q - P b )
P a U  -  P a )  +  -  P „ )  - J p  , 0  -  P a )  +  P b (  1 -  P b )
+ d> "{(Pa - P b ) + cI)2 Zi ■ „^ P. A) - P a) + PbO - P b)
(4.3.5)
P.A1 - P a )  +  P b Q - P b )  aJ p .a O -  P a )  +  jC>s(l -  P b )
One uses this result to iterate to find the required sample size. As for non-inferiority 
trials to use (4.3.5) the following inequality must hold [Farrington and Manning, 1990]
max{- d, d]  < p., + p B < 2 + min{- d . d ) .
4.5.1.6. Method 3 -  Using Maximum Likelihood Estimates
The third method, again like for non-inferiority trials is to use maximum likelihood 
estimates for p  , and p 8 [Farrington and Manning, 1990; Miettinen and Nurminen,
1985; Koopman, 1984] defined as
p A = 2^cos(vr) -  —  ,
3 a
P b  =  P a  + 4 ,
to enter into (4.3.1) where r/, = p  , (1 -  d)d  , c = d 2 -  2 d { p A + 1) + p A + p B, 
b = -(2  + p + p H -  3d ), u = [/T + cos '(v/i/' )J/3 , u = s ign(v)Jb2/ 9 a 2 - c / 3 a  ,a=2, and 
v = b2/21a' -  be/ 6a2 + d j l c t . Hence, an estimate of the sample size can be estimated 
from
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Table 4-29. Sample sizes for an equivalence study estimated by and 3 alternative 
methods for 90% power and a type I error rate of 2.5%
 Sampjc Size Method
P a  P a - P b  Limit Method 1 Method 2 Method 3
-0.10 0.15 1556 1540 1534
-0.05 0.10 1461 1451 1471
0.15 366 359 375
0.00 0.05 1664 1660 1690
0.10 416 413 433
0.15 185 182 199
+0.05 0.10 1209 1199 1334
0.15 303 296 350
+0.10 0.15 1051 1035 1330
-0.10 0.15 1324 1309 1263
-0.05 0.10 1209 1199 1209
0.15 303 296 312
0.00 0.05 1326 1322 1356
0.10 332 328 353
0.15 148 144 165
00.05 0.10 915 905 1077
0.15 229 223 289
+0.05 0.10 915 905 895
0.00 0.05 936 933 973
0.10 234 231 262
4.5.1.7. Comparison o f the Three Methods
A similar eomparison to that done earlier in the chapter for non-inferiority trials was 
undertaken to compare the three methods of sample size estimation through simulation. 
The simulation was undertaken for different p , and p B (between 0.70 and 0.90) and 
non-inferiority limits, d (between 0.05 and 0.20). For each d, p A and p B the sample 
size was iterated until the required power was reached. 100,000 simulations were 
undertaken to estimate the power for each n, d, p A and p H . The simulation was
undertaken in SAS [1990].
Note though that for equivalence trials there is a greater limitation on the calculations as 
p  A - p 8 cannot now exceed either d or d. For non-inferiority trials there is just one
bound.
As with non-inferiority trials earlier the simulation was repeated for 4 different methods 
of calculating confidence intervals: Normal approximation; Normal approximation with 
continuity correction; Wilson's score method and Wilson's score method with continuity 
correction. Again though the Normal approximation with continuity correction gave 
substantially larger estimates of the sample size compared to the other 3 and are not 
included.
The simulations were stopped when the requisite proportion of simulations (90%) had a 
95% confidence interval wholly contained within (-d, d). Table 4.29 gives the sample 
sizes for the different methods of sample size estimation and Table 4.30 gives summary 
statistics for the ratio of the estimated sample size of over the simulations.
With the parameters of the simulation for the equivalence trial comparison methods 1 
and 2 give closer estimates of the sample size compared to simulations than for non­
inferiority trials described earlier in the chapter, with method 1, being the closest to the 
simulations. Again method 3 seems over-estimate the sample size when compared to 
the simulated results.
Through the remainder of this section it will be method 1 that will be method described.
Table 4-30. Summary statistics comparing the different methods of sample size 
estimation for an equivalence study through simulation and 3 alternative methods 
(ratio of calculated to simulation)
Met hod of Sample Size Calculation
Cl Calculation Statistic Method 1 Method 2 Method
Normal Minimum 0.98 0.95 0.95
Approximation Quartile 1 1.00 0.98 1.01
Median 1.00 0.99 1.04
Quartile 3 1.00 0.99 1.11
Maximum 1.01 1.00 1.31
Wilson Minimum 0.95 0.93 0.95
Quartile 1 1.00 0.98 1.01
Median 1.00 0.99 1.06
Quartile 3 1.01 1.00 1.11
Maximum 1.03 1.00 1.31
Wilson with Minimum 1.00 0.99 0.96
Continuity Quartile 1 1.01 1.00 1.04
Correction Median 1.02 1.01 1.09
Quartile 3 1.04 1.02 1.16
Maximum 1.08 1.05 1.32
4.5.1.8. Odds-Ratio
Remember again that the variance about the log-odds-ratio can be approximated as 
[Whitehead, 1993]
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Var (S) =
' - I *
V / I
(4 .3 .7)
where p .  is the average response on each outcome category ( p x = ( p A +  p B ) / 2  and 
p 2 = 1 ~ P \ ) -  Consequently an estimate of the sample size for a given power can be 
estimated from
\ - p  = o I - I p; (log( O R ) - J f  6 - Z ,  „ f ct>
V l
' - i * (\og(OR) + d f  / 6  - z,_„ - 1 , ( 4 . 3 . 8 )
where d in this instance is the symmetric equivalence limit on the log scale. For non­
inferiority trials discussed earlier suggested values for d were given as: log(0.43), 
log(0.47), log(0.50) or log(0.55). The rational for their use in non-inferiority trials can 
be generalised to equivalence trials.
Table 4-31. Sample sizes for different equivalence limits on the odds-ratio scale 
and anticipated responses for 90% power and type I error of 2.5%
Odds- Limit of 0.43 Limit of 0.47 Limit of 0.50 Limit of 0.55
pA Ratio Formula Simulate Formula Simulate Forumula Simulate Formula Simulate
0.70 498 509 745 756 1044 106 2031 2057
0.80 319 330 435 446 557 568 876 881
0.90 243 254 311 316 377 388 532 543
1.00 229 240 285 296 339 344 455 466
1.10 254 265 323 328 391 402 546 557
1.20 318 323 424 429 532 543 804 815
1.40 564 582 829 847 1141 116 2124 2142
0.70 612 623 915 933 1282 130 2496 2531
0.80 396 407 539 550 690 701 108 1096
0.90 303 314 388 399 471 482 663 674
1.00 287 298 358 369 425 436 571 582
1.10 320 331 407 425 492 503 688 699
1.20 403 421 536 547 673 684 101 1028
1.40 717 735 1054 1080 1452 147 2703 2729
0.70 848 874 1268 1286 1778 1823 3460 3505
0.80 553 579 754 772 965 983 151 1536
0.90 427 445 547 565 663 681 934 952
1.00 406 424 507 525 602 620 808 826
1.10 455 473 580 598 700 718 979 1005
1.20 575 593 766 792 962 988 145 1478
1.40 1030 1075 1514 1559 2085 2141 3883 3939
As with designing non-inferiority trials (4.3.8) can be rewritten to account for the 
different variabilities under the null and alternative hypothesis. However, as with non­
inferiority trials, (4.3.8) gives the most conservative estimate of the variance.
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A simulation was undertaken to assess (4.1.8) for different p 4 and p B proportions
between 0.70 and 0.90 and symmetric (on the log scale) equivalence limits, d, log(0.43), 
log(0.47), log(0.50) and log(0.55). For each d, p A and p B the sample size was iterated
until the required power was reached. 100,000 simulations were undertaken to estimate 
the power for each n, d, p  4 and p B . The simulation was undertaken in SAS [1991].
The simulations were stopped when the requisite proportion of simulations (90%) had a 
95% confidence interval wholly contained within (-d,d).
Table 4.31 gives the sample sizes calculated from (4.1.8) along with the sample sizes 
estimated from simulation. From this one can see that (4.1.8) gives sample size 
estimates close to the simulation, although under estimating little, all be it consistently.
4.5.1.9. Proportional Difference Versus Odds-Ratios
The issues raised in comparing the proportional difference and the odds-ratio for non­
inferiority trials can be generalised to equivalence trials and so this comparison of odds 
ratios and proportional differences will not be made here.
4.5.1.10. Special Case of No Treatment Difference
As with equivalence trials discussed for Normal data in Chapter 2 when the assumption 
is made of no true difference between treatments the calculations are greatly simplified 
with a direct estimate of the sample size now possible. This sub-section will now 
briefly discuss these calculations
4.5.1.11. Proportional Difference
The three methods below are as described earlier for the general case.
4.5.1.12. Method 1 -  Using Anticipated Responses
For the special case of no anticipated treatment difference the power can be estimated 
from
1 - /7  =  2 0  -   /
P a ( ] -  P a ) +  P b 0 ~  P h )
However, as p ,  = p B (4.3.9) can be rewritten as
- 1 .  (4.3.9)
246
\ - P  = 2 0 nAd 2
2p{] -  p)
Z I - a - 1 . (4.3.10)
where p  = (/?4 + p B)i 2 interpreted in this instance as the anticipated overall response. 
Equation (4.3.10) can in turn be rewritten to give a direct estimate of the sample size 
[Machin, Campbell; Fayers et al, 1997]
n,  = 2(z , d z  + z , a f  p Q - p ) (4.3.11)
4.5.1.13. Method 2 -  Using Anticipated Responses in Conjunction with the Equivalence 
Limit
Following on from the arguments for method 1 the power is estimated from
\ -  P  -  2 0 nd'
m - P )
Z \ a d P A 1 -  P a )  +  P s O -  P b )  
P i } ~  P )
- 1, (4.3.12)
where p A - p  + d / 2  and p B = p - d / 2 and the inequality turn hence now becomes 
max{- d , d)  < 2p  < 2 + min{- d. d) .  From (4.3.12) for a direct estimate of the sample 
size one gets
J p . i O - P , , )  + P b (1 -  Pb ) + Z 1 -p. 2 ^ 2 p ( \ - p )  )~
d
(4.3.13)
4.5.1.14. Method 3 -  Using Maximum Likelihood Estimates 
For method 3 p  , and p B are now a little different 
bp  A - 2 u cos(vv)
3 a
where d { = p ( \ ~ d ) d ,  c = d~ -  2(d(p  + 1) + p) ,  b = -(2(1 + p)  -  3d ), a=2,
v = b2/21a* -  be/6a2 + d j 2 a  , u -  s ig n ( \ j^ b 2/9 a 2 -  c/3a and w,= [/t + cos_i(v/m;,)J/3.
However, given these definitions the formula for the power
\ -  p  -  2 0 n d 2 Z, a -  P a )  + P b O  ~  P B )
p O - p ) yTpi ^ - p)
- 1, (4.3.14)
and the sample size
247
n . = (Z l~a > I P a ( 1 - P a )  +  P b ( ] - P h ) +  Z 1 - p  2 V 2 / ^ "  P ) )
d 2
4 .3 . 15)
take similar forms to (4.3.12) and (4.3.13) respectively.
4.5.1.15. Odds-Ratio
With the assumption of no true difference between treatments (equivalent to OR=l) the 
power can be estimated from
(
\ - / 3  = 2<X> i - I p ] d 2 /6 — Z, (4.3.16)
whilst a direct estimate of the sample size can be obtained from
+ Z \-a fn =
i - ± p ! d~ ■ (4.3.17)
i - /
4.5.1.16. Worked Example
An investigator wishes to design an equivalence trial where the anticipated response rate 
on the active control is 85%. The investigator also expects a 85% response rate on the 
investigative therapy. Using an odds-ratio of 0.50 for the symmetric equivalence limit 
Table 4.31 gives the sample size as being 425 patients per arm.
In comparison, working on the proportional scale, with the same anticipated responses, 
but with an equivalence limit of 15%, one would require (from Table 4.30) just 148 
patients per arm.
4.5.1.17. Sensitivity Analysis About the Estimates of the Population Effects Used in the 
Sample Size Calculations
As with superiority and non-inferiority trials discussed earlier in this chapter the 
sensitivity of an equivalence study design to the control response rate can be 
investigated through construction of a 95% confidence interval. The power could then 
be used assessed at the two tails of the confidence interval.
This confidence interval could then be used with (4.3.3), for an absolute difference, and 
(4.3.8), for an odds-ratio to interrogate the sensitivity of the study to the control 
response rate.
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4.5.1.18. Worked Example
Suppose the control response rate was assessed from a previous study in 100 patients 
and it is assumed that the investigative response rate is fixed at 85%.
Using the Wilson's score method for calculation, confidence interval indicates that a 
plausible range for the control response to be between 76.7% and 90.7%.
Table 4.32 gives a breakdown of the sensitivity of the study design to the estimate of the 
control response rate. As is evidenced from this table this equivalence study is sensitive 
to both the lower and upper points of the confidence interval -  as these both bring the 
point estimate closer to the equivalence boundary.
Table 4-32. Sensitivity7 analysis for equivalence worked example
a. Odds-ratio scale
Observed
95% Confidence Interval 
Lower Upper
Control Response 0.85 0.767 0.907
Investigative Response 0.85 0.850 0.850
Power 90% 13.6% 10.7%
b. Proportional Scale
95% Confidence Interval
Observed Lower Upper
Control Response 0.85 0.767 0.907
Non-inferiority Margin 0.15 0.15 0.10
Investigative Response 0.90 0.90 0.90
Power 90% 31.2% 19.1%
For the odds ratio calculation the lower and upper tails of the confidence interval have 
powers of 13.6% and 10.7% respectively. Whilst for the absolute difference the lower 
and upper tails have 31.2 and 19.1 % power respectively.
Note that the same assumptions were made here as for non-inferiority trials earlier in 
this chapter w ith respect to the simultaneous assessment of the sensitivity o f the study to 
both increases in anticipated variability (p  ,(1 -  p A) + p B{\ -  p B)) and the mean 
difference between treatments (/>.,- p H ). Another consideration is that if  a higher than 
expected response rate was observed then a tighter limit would be used.
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4.5.1.19. Calculations Taking Account o f the Imprecision o f the Estimates o f the
Populations Effects Used in the Sample Size Calculations
As for non-inferiority and superiority trials, by using appropriate confidence interval 
methodology around the control response rate, p  4, the power, and hence the sample
size can be calculated using numerical methods for equivalence trials. Hence, where the 
proportional difference is of interest, the sample size can be estimated from the 
following result,
\ - p = — y  
0.008  . ,  2 (4.3.18)
where X4 and k H are defined as
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The equivalent calculation for an equivalence study designed around the odds-ratio 
would be,
1 0 99s
\ - p = — —  y
0.998
T1:
1 (4.3.19)
where rj 4 and r)B are defined as
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Tables 4.34 and 4.33 give sample sizes using (4.3.18) and (4.3.19) respectively. As 
with non-inferiority trials discussed earlier in this chapter, intuitively the calculations 
are more robust for (4.3.19) where a fixed odds-ratio varies on the absolute scale 
depending on anticipated control response rate.
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Table 4-33. Sample sizes for an equivalence study, limit of 0.50, on the odds-ratio 
scale for different precisions around the variance and different anticipated 
responses for 90% power and type I error of 2.5%
Control
Rate
Odds-
Ratio
Degrees of Freedom
10 20 30 40 50 100
0.80 0.70 1344 1177 1130 1108 1095 1069
0.80 726 631 605 593 585 571
0.90 526 442 419 408 402 389
1.00 494 406 382 371 364 351
1.10 558 463 437 425 418 404
1.20 723 615 585 572 563 548
1.30 1028 881 840 821 810 787
1.40 1536 1314 1253 1224 1207 1174
0.85 0.70 1945 1541 1445 1402 1377 1329
0.80 1069 836 782 757 743 716
0.90 807 600 552 530 518 494
1.00 774 560 510 487 474 449
1.10 867 637 583 559 545 518
1.20 1101 836 775 748 732 702
1.30 1551 1196 1113 1075 1054 1012
1.40 2322 1791 1665 1608 1575 1513
0.90 0.70 4584 2487 2193 2073 2008 1888
0.80 2635 1368 1200 1132 1095 1027
0.90 2159 1020 872 812 779 718
1.00 2132 973 821 758 724 660
1.10 2350 1097 933 866 830 762
1.20 2850 1411 1223 1147 1105 1030
1.30 3838 2005 1751 1647 1590 1487
1.40 5682 3006 2625 2469 2384 2228
4.5.1.20. Worked Example
Suppose the control response rate was estimated from 100 patients. Repeating the same 
calculations from earlier for the same equivalence limit of OR=0.5 the sample size 
should be increased to 449 patients per arm around a 6% increase in the sample size.
Repeating the sample calculations on the absolute difference scale increases the same 
size to 156 patients per arm. This is an increase in the sample size of 5%.
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Table 4-34. Sample sizes for an equivalence study on the absolute difference scale 
for different precisions around the variance and different anticipated responses for 
90% power and type I error of 2.5%
Control Degrees of Freedom
Rate P a - P r Limit 10 20 30 40 50 100
0.80 0.10 0.15 1564 1569 1564 1564 1564 1560
-0.05 0.10 1495 1487 1480 1480 1474 1469
0.15 374 374 370 370 370 367
0.00 0.05 1852 1782 1753 1728 1717 1698
0.10 469 450 442 435 429 424
0.15 211 198 198 193 193 189
+0.05 0.10 1327 1273 1262 1243 1243 1228
0.15 337 322 316 311 311 307
+0.10 0.15 1220 1154 1127 1104 1094 1077
0.85 -0.10 0.15 1400 1377 1367 1358 1350 1337
-0.05 0.10 1327 1285 1262 1252 1243 1228
0.15 337 322 316 316 311 307
0.00 0.05 1649 1534 1477 144 1415 1379
0.10 421 385 366 358 358 345
0.15 182 174 167 161 161 156
+0.05 0.10 1144 1049 1004 991 968 949
0.15 293 263 255 248 242 237
0.90 -0.05 0.10 1123 1033 1004 979 968 941
0.00 0.05 1399 1234 1144 1105 1070 1012
0.10 352 310 287 277 268 253
4.5.1.21. Calculations that take Account of the Imprecision in the Estimates of the Effects 
Used in the Sample Size Calculations -  Bayesian Methods
As discussed previously in this chapter the percentiles for a posterior control response 
can be calculated as described in 4.1.1.16 to give an estimate of the sample size. As 
previously it is best to highlight the points through worked example.
4.5.1.22. Worked Example
For the absolute difference scale with a non-informative prior the sample size is 
estimate to be 153 patients per arm. This is 3 less than the sample size calculated 
before.
With a more pessimistic prior (the most likely response being 80% with 90% certainty 
that it is greater than 75%), the sample size estimate is increased to 173 patients per 
arm.
With a prior that the control response rate observed is about right (the most likely 
response being 85% with 90% certainty it is greater than 80%) the sample size estimate 
is increased to 152 patients per arm.
Similar calculations could be done if equivalence is defined in terms of an odds-ratio
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4.5.1.23. Calculations Taking Account o f the Imprecision o f the Populations Effects With
Respect to the Assumptions about the Mean Difference and the Variance Used in the
Sample Size Calculations
To allow for the imprecision in the assumptions about both the mean difference and 
variance numerical methods could be used to calculate the sample size on the absolute 
difference scale from.
I " ' Wh 2  ♦ 2i_/7 =  y
0 . 9 9 8  2
where k A and AB are defined as
f r - pHi  ciy
2, = <t>| J-r—   ■ -  ■ - ■- V -Z,
\ ( / V .  T  p  . ) • p h0  p H)f
d,I j. . .. - p j - d j  z 
' \  , . , o - p p Hi y - p h ) \
(4.3.20)
r P h )
P, ) + / M 1 - p H))
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(1 -  P h ( } -  P h ) )
Note that, similar to non-inferiority calculations given earlier, a number issues need to 
be additionally considered
1. If any of the percentile values around the control response crosses a step (given in 
Table 4.23) then the non-inferiority margin, d, should be altered accordingly.
2. The investigative response rate, p B, remains assumed fixed, calculated from the 
initial p A, and not from individual p  .
3. Following on from 2. for instances where p  -  p B exceeds an equivalence bound
then the power for this percentile (to be averaged across for power calculation) is 
set to 0.
The equivalent calculation to estimate the sample size for an equivalence study design 
based around the odds-ratio would be
1
1 I  /L
0.998 P, ^ UI0] 2
where p t and p B are defined as
(4.3.21)
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As the odds-ratio does not suffer from the issues of stepped equivalence bounds, the 
calculations are more straightforward. The following two points should be considered 
however
1. The investigative response rate, p B, remains fixed and is estimated from the initial
P a -
2. Following on from 2. for instances where ORfvn Pb))/(p*Q- Pi**,)) exceeds an 
equivalence bound then the power for this percentile (to be averaged across for 
power calculation) is set to 0.
Tables 4.35 and 4.36 give sample size calculations using (4.3.21) and (4.3.20) 
respectively. As with non-inferiority trials discussed earlier in this chapter the 
calculations for the odds-ratio give, what could be considered to be, unfeasibibly large 
sample size estimates. Following on from the same arguments for non-inferiority trials 
the recommendation therefore is to use (4.3.18) and Table 4.33 when working on the 
odds-ratio scale and (4.3.20) and Table 4.36 when working with absolute differences.
Table 4-35. Sample sizes for an equivalence study, with a limit of 0.5, on the odds- 
ratio scale for different precisions around the anticipated control response rate 
and variance for 90% power and type 1 error of 2.5%. The true odds-ratio is fixed 
at 1.00
Control
Rate
Degrees of Freedom
50 100 250 500
0.70 1031 464 321 287
0.75 1486 563 369 325
0.80 2833 758 452 389
0.85 12510 1242 614 507
0.90 NE 3524 1034 776
NE -  Not estimable
4.5.1.24. Worked Example
Repeating the worked example from earlier where the control response rate was 
estimated from 100 patients the sample calculations on the absolute difference scale 
increases the sample size to 194 patients per arm.
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Table 4-36. Sample sizes for an equivalence study on the absolute difference scale 
for different precisions around the anticipated control response rate and variance 
for 90% power and type I error of 2.5%
Control Degrees of Freedom
Rate _ Pa'Pb Limit 50 100 250 500
0.80 -0.10 0.15 11554 11554 4075 2400
-0.05 0.10 1460 1460 1460 1460
0.15 1014 583 417 365
0.00 0.05 1663 1663 1663 1663
0.10 415 415 415 415
0.15 269 199 184 184
* 0.05 0.10 1208 1208 1208 1208
0.15 349 302 302 302
+0.10 0.15 1050 1050 1050 1050
0.S5 -0.10 0.15 1 1322 1 129 2640 1842
-0.05 0.10 11207 1208 1208 1208
0.15 10301 465 345 323
0.00 0.05 1325 1325 1325 1325
0.10 356 331 331 331
0.15 356 194 165 157
+0.05 0.10 914 914 914 914
0.15 418 330 290 262
0.90 -0.05 0.10 10913 2797 1363 1067
0.00 0.05 935 935 935 935
0.10 324 246 233 233
4.5.1.25. Calculations Taking that take Account o f the Imprecision of the Populations 
Effects With Respect to the Assumptions about the Mean Difference and the Variance 
Used in the Sample Size Calculations -  Bayesian Methods
In the following worked example the calculations are repeated using Bayesian methods 
to estimate posterior percentiles to use in (4.3.21).
4.5.1.26. Worked Example
For the absolute difference scale with a non-informative prior the sample size is 
estimated to be 201 patients per arm. This is 7 greater than the sample size calculated 
before.
With a more pessimistic prior (the most likely response being 90% with 90% certainty 
that it is greater than 85%), the sample size estimate is increased to 233 patients per 
arm.
With a prior that the control response rate observed is correct (the most likely response 
being 85% with 90% certainty it is greater than 80%) the sample size estimate is 168 
patients per arm.
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4.5.2. Cross-over Trials
As with non-inferiority trials discussed earlier in this chapter the arguments for 
superiority and non-inferiority trials can be extended to equivalence trials. Although 
there are a number o f  paper which deal specifically on this topic [Tango 1998, 1999; 
Nam, 1977; Tang, Tang and Chan, 2003], it is recommended to use the parallel group 
sample size methodologies per arm in this sub section o f the chapter to estimate the total 
sample size for an equivalence cross-over trial
4.6. E stim ation  to a G iven Precision
4.6.1. Parallel Group Trials
4.6.1.1. Sample Sizes with the Population Effects Assumed Known
4.6.1.2. Proportional Difference
In a two-group study where the primary outcome is binary and the objective is to 
estimate the possible population difference such that
d = P , ~  P b -
where p A and p B are sample proportional responses on treatment groups A and B 
respectively. As discussed in Chapters 1 and 3 a ( l - a ) l 0 0 %  Normal approximation 
confidence interval for f (//) has half-width
/ ,  (4.4.1)
where var(S) is defined as
, ar(S) = ML" <’ 7 M  , (4.4.2)
n
which can in turn be approximated from
I ' ar(S) = : , ' (l P) . (4.4.3)
n
where p - ( p  , + p B) 2 i.e. the mean proportion expected across both the treatments.
Remember from earlier in the chapter that from Table 4.19 it seems that this 
approximate variance formula holds for proportional responses ( p A and p B) that are
within +/-0.30 of each other and thus covers most practical situations. For trials based 
on precision considerations, therefore, it may be optimal to use an estimate o f  the mean 
overall response for the variance and subsequent sample size calculations (given that it 
is probably the aim of the study to estimate possible treatment responses). However, if 
one has reasonable estimates for each treatment response then these should be used in 
calculations.
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Therefore, for a given half confidence interval width, w the following condition must be 
met to obtain the sample size per group
2p(l -  p ) Z 'n = . (4.4.4)
u*
From (4.4.4) Table 4.37 is derived. Table 4.37 gives the sample size required for 
different values o f  the expected mean response across treatment groups, p , and widths
w. Two sided 95% confidence intervals are assumed to be planned to be constructed. 
The mean responses, p , given in the table vary from 0.10 to 0.50. Values greater than 
0.50 are not given as the sample size required for p =  0.60 is equivalent to p  =0.40, the 
sample size for p  ^0.70 is the same as p  -0 .30 etc.
Table 4-37. Sample sizes required per group for two sided 95% confidence 
intervals for different v alues of width, w, for various expected mean proportional 
responses
w
p 5 10 15 20 25
0.10 277 70 31 18 12
0.20 492 123 55 31 20
0.30 646 162 72 41 26
0.40 738 185 82 47 30
0.50 769 193 84 49 31
4.6.1.3. Odds-Ratio
For binary data the difference in the sample proportions may also be expressed terms o f 
an odds-ratio (OR)
ci -  OR / M 1 P h) 
P h0 - P a )
A ( l -o r )  100% confidence interval for log(d) can be derived using the following 
variance estimate [Whitehead, 1993]
I V//‘(log(c/)) =
/ - 2 > :
Therefore, as for binary data for a given half confidence interval width, w, around the 
odds-ratio the following condition must be met to obtain the sample size per group
6 Z l at : (4 .4 .5)
(log(l -  w))‘
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where p t are the expected mean responses. Remember that for binary data
P\ — ( P a + P b ) ^ = p  , say, and p 2 = 1 -  p, = 1 — p  and thus correspond to p  given 
earlier in this chapter.
Note that in this instance w is on the log scale and so w=0.60 would equate to a 
confidence interval for a given odds-ratio, OR, being within (l-w)OR to OR/(l-w) i.e. 
0.40OR to 2.50R. Also note that log(l-w) is on the arithmetic scale i.e. 
log( 1 -w)—-log[ 1 (1 -w)]
Table 4.38 gives sample size required for different values o f  the mean response across 
treatment groups, ~p , and widths w estimated using (4.4.5). Two sided 95% confidence 
intervals are again assumed. As with fable 4.36 the mean responses, p , given in the 
table vary from 0.10 to 0.50. To obtain a sample size for p  >0.5 look up 1 - p  .
Table 4-38. Sample sizes required per group for t>vo sided 95% confidence 
intervals for different values of width w around the odds-ratio for various expected 
mean proportional responses
w
p 0.25 0.30 0.35 0.40 0.45 0.50
0.10 1032 672 461 328 239 178
0.20 581 378 259 185 135 100
0.30 443 288 198 141 103 77
0.40 387 252 173 123 90 67
0.50 372 242 166 118 86 64
A feature of Table 4.38 that is different to Table 4.37 but which is consistent with the 
other types of trial described in this chapter, is that as p  approaches 0.5 the smaller
sample size that is required for equivalent values of w. Table 4.39 further illustrates 
this. For different mean response rates and values of w around the odds ratio the 
equivalent widths on the proportional scale are given. For example for a w=0.50 on the 
odds-ratio scale an equivalent width would be 0.173 on the proportional scale for 
p=0.50. Details of the derivation o f  Table 4.39 are given in the next sub-section.
4.6.1.4. Equating Odds-Ratios with Proportions
As with superiority trials discussed earlier (4.4.4) and (4.4.5) can be approximately 
equated. If one redefined the half widths around the confidence intervals of the odds- 
ratios ( \vot ) and proportional differences ( \vp ) in terms o f odds-ratios and proportional
differences one obtains respectively
= ( P a ~ Ph ) ~  iP a, -  Ph, ) '
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1 -  wor = OR/  OR,  = p A x p A  j  P ’> (1 P »< ?
p A ' - p . , ) /  P h, 0 ~ P a , )
Thus, (4.4.4) and (4.4.5) can be re-written as
2p(l -  p ) Z ; a :n =
[ (P. <- P„) ~( Pa, ~ P h, )? '
n > 6 '/-I „ , / ( log OR -  log OR. /
/ - £ p :
(4 .4 .6 )
(4.4.7)
Remembering that, 
6 2
■ - I  P,‘
V i=i J
p o - p )
(4.4.8)
and \og(OR) ^  2(OR -1 )i(OR + /) , which holds for odds-ratios within 0.33 ^ ) R ^ . 00, 
hence,
2 ( O R - l )  ^ p A ~ p B 
OR + 1 p(l -  p)
(4.4.9)
and
log OR, P .. “  Pr: 
P i } ~ p )
(4.4.10)
Assuming /;(1 -  p)  ^ p [ (1 -  p.  ) where p t = ( p 4 + p B ) / 2 and substituting (4.4.8), 
(4.4.9) and (4.4.10) into (4.4.5) one obtains
n > Z:
p 0 - p )
. . . . .  p ( ] p ) _______
(p., ~ Ph) - ( P  I, -  Ph. )
2p(l - m l a  ,
- P b) -  (Pa, -  Pb, )f
Thus, similarly to superiority trials, (4.4.4) and (4.4.5) can be used interchangeably 
depending on preference. Due to this property one therefore has
2p(l -  p)Z{ (t , 
.........
  ..., 2  X L  : _____  _
(log(l -  vv^))?p(l -  p)
and thus
U- ~ | l0g ( l - u oj l ( p ( l - p ) ) . (4 .4 . 11)
Using (4.4.11) Table 4.39 can be derived.
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Table 4-39. Table of widths on the absolute difference scale that are equivalence to 
the widths, w, around the odds-ratio for various anticipated expected mean 
Proportions
w
p 0.25 0.30 0.35 0.40 0.45 0.50
0.10 0.026 0.032 0.039 0.046 0.054 0.062
0.20 0.046 0.057 0.069 0.082 0.096 0.111
0.30 0.060 0.075 0.090 0. 107 0.126 0.146
0.40 0.069 0.0S6 0.103 0. 123 0.143 0.166
0.50 0.072 0.089 0.108 0. 128 0.149 0.173
4.6.1.5. W orked Example
A pilot study is planned to estimate the odds ratio between comparator and control 
regimens. The expected mean response rate is 50% across the two treatments and the 
wish is to quantify the odds ratio within ±55% (i.e. w=55%). This means that if a odds 
ratio o f 0.70 was observed, one would be able to say that the true odds-ratio is likely to 
be between 0.32 and 1.56. Therefore, from Table 4.38 the sample size required is 49 per 
group.
Following from the example from Table 4.39 w=0.55 on the odds ratio scale is 
equivalent to proportional half confidence width of 20% for a mean response rate of 
50%. From Table 4.38 a width of 20% and a mean proportional response o f  50% gives 
49 subjects per group again.
4.6.1.6. Sensitivity' Analysis About the Estimates of the Population Effects Used in the 
Sample Size Calculations
Extending the arguments for other types trial discussed earlier in this chapter the 
sensitivity o f  a precision based can be investigated through construction o f a 95% 
confidence interval around the anticipated overall response rate. For each tail o f this 
confidence interval one can re-investigate the precision of the trial to give a 
quantification of its sensitivity.
4.6.1. 7 .  Worked Example
Suppose the expected response rate o f  50% for the worked example earlier was 
estimated from a trial with 50 patients. The 95% confidence interval for this would be 
between 33.2% and 66.8%.
On the absolute difference scale these lower and upper tails would give precision of 
19%. A slight improvement over the previous calculations -  due to 50% giving the 
maximum variance estimate.
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On the odds ratio scale the precision for each tail would be 57%, which is a little worse 
than that previously observed.
4.6.1.8. Calculations Taking of Account the Imprecision o f the Estimates o f the 
Population Effects Lsed in the Sample Size Calculations
Adapting the formula for superiority trials the following result could be used to 
calculate sample sizes to account for the imprecision in the sample variance on the 
odds-ratio scale
1
0.998 I  0-5
f : J  : ' ' 1 "
<I>j >i( log (1 -  u ) )' j / - p'"" 6 -  Z, u „
+ <t>| n( log (1 - u ) /  | /  - ....
I \ l ■ ;
6 -  Z,
> 0 .5
(4.4.12)
Table 4.40 gives the sample sizes using (4.4.12) for difference precisions around the 
sample variance. For trials based on estimated it seems that the imprecision around the 
sample variance has little impact on the sample size estimate.
Table 4-40. Sample sizes for a precision based study, for precision of width, w, of 
0.50, on the odds-ratio scale for different precisions around the variance and 
different anticipated overall responses for a 95% confidence interval
Overall Degrees of Freedom __
Rate 10 20 30 40 50 100
0.10 186 179 177 177 177 177
0.20 108 104 104 104 101 101
0.30 84 80 80 80 80 77
0.40 75 71 71 71 68 68
0.50 72 68 68 68 68 65
Nominally the equivalent result if working on the absolute difference scale would be
•■>: , "{r‘ p- y , . . I., \ (/' (l /’ > • /' 0 /' >) I■ v ,15 ........
0 . 9 9 S  , V'
  i ’- ] ............................ ..
\ I/’ . ,0 f>, . . ) ’ P.,..: /^ ,   I >)
(4.4.13)
> 0.5
however, accounting for the imprecision in the variance has no effect on the sample size 
when working on this scale and so no tabic is given and this result can be ignored.
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4.6.1.9. Worked Example
Suppose an investigator wished to design a trial where the anticipated overall response 
rate is 50% and the investigator wished to quantify the odds ratio with precision o f  0.5. 
From Table 4.40 the sample size required is 64 patients per group.
Now supposing the overall response was estimated from a trial with 30 patients. 
Accounting for this would increase the sample size to 68 patients.
4.6.1.10. Calculations that take Account o f the Imprecision in the Estimates Used in the 
Sample Size Calculations -  Bayesian Methods
As discussed earlier in this chapter the percentiles for a posterior control response can 
be calculated as described in 4.1.1.16 to give an estimate of the sample size. As 
previously it is best to highlight the points through a worked example.
4.6.1.11. Worked Example
If initially a non-informative prior was used then the sample size is estimated at 67 
patients per arm. A sample size 1 short of calculated previously.
Supposing the investigator was sceptical as the control response being as high as 50% 
such that the belief was that the most likely response was 40% with at least 90% 
certainty that it was greater than 30%. The estimate of sample size is now 66.
4.6.2. Cross-Over Trials
As with the other types of trial discussed it is recommended that the total sample size 
for a cross-over precision based trial be taken from the one arm sample size for a 
parallel group trial. There are a number papers that discuss issues with confidence 
intervals for cross-over trials [Tango, 1998, 1999; Newcombe, 1998c; May and 
Johnson, 1997],
4.7. D esign C onsiderations
4.7.1. Inclusion of Baselines or Covariates
As discussed in chapter 2 in the analysis of the results of a clinical trial, the effects of 
treatment on the response of interest are often adjusted for predictive factors, such as 
demographic or clinical covariates by fitting them concurrently with the treatment 
variable. It was highlighted in this chapter how when adjusting for a highly predictive 
covariate, such as baseline, the sample size can be dramatically reduced due a reduction 
in the variance estimate.
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It has previously been reported that for the case o f  binary data when adjusting for a 
baseline or other predictive covariate the variance estimate increases [Whitehead, 1993; 
Robinson and Jewell, 1991]. The inference from this is that for binary data variance 
adjustment increases the sample size and not decreases it as for Normal data. This point 
will now be challenged.
Suppose one is designing a trial to compare two treatments where a binary baseline 
covariate has been assessed. The relationship between the covariate and outcome is 
assumed to be an odds-ratio, OR( . While the relationship between the treatment, and
the outcome, the treatment effect, is assumed to be ORr .
Assuming that final analysis is to be through a logistic regression the model would be 
defined as
log
f  \
P,
1 - P ,
= Constant + Bx covariate(0or 1) + C x treatment(0or 1), (4.5.1)
or
log
r \ 
P,
v 1 -  P. y 
Hence,
P
P, = \ + e 1'
(4.5.2)
Now, for the case o f the covariate taking level 0 the probability of observing outcome 
level 1 for each treatment (A and B say for levels 0 and 1 respectively) can be defined 
as
i i o r ;p   and p R. = ---------------------------
1 + 4 1 + OR.,A a + o r ;
(4.5.3)
Note A = e (Vns,u" . Remember, that the variance for the log-odds-ratio is defined as
var(log(6W))
X/>: -  p P
(4.5.4)
where p t is defined as the average response across treatments for each outcome 
category ( /?, = {p n + p H])/ 2 and p ? = 1 - /? , ) .  Hence,
2 + 4 (0 /^  +1)
2(1 + 4)(1 + OR, A)
(4.5.5)
and
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P \ l \ - P \ )  =
((1 + 2A)ORr + 1)H Y 2 + A{ORt +\ )  
2(1 + .4)(1 + OR, A) 2(A + 1)(1 + ORrA) (4.5.6)
Equivalently, for the case where the covariate takes level 1 the probability o f  observing 
outcome level 1 for each treatment can be defined as
P a i =
ORc , OR OR.
and p Hl =
A + OR, A + OR( OR, (4.5.7)
Hence,
-  -  OR<iA + OKt ° K, )_+(-'< + ORc )ORcOR, 
P] 2(OR( + A)(A + OR( OR,  )
(4.5.8)
and
p ( \ -  P)  =
OR( (A + OR, OR, ) + (A + ORc )ORc OR,
2 (OR, + A)(A + OR,.OR,.)
A(2A + ORcORr +ORc ) 
{ 2(A + ORc )(A + ORr )
.(4.5.9)
To obtain an overall estimate of effect across the two levels o f  the covariate one could 
use
£  u- log (OR, ) 
log(0/?) = —-—  -----------
I -
(4.5.10)
where OR( is an estimate of the response from covariate level 1 and w is the reciprocal 
o f the v ariance from covariate level i ( w = l/var(log(CW())) and k is the number of 
levels for the covariate. Consequently, an overall estimate of the variance is defined as
I
(4.5.11).
U '
Hence, for the case of a two level covariate described here one has
8(/l + l) : (,l + 6 ;/^ )
IV,
{(A + OR,  ) + (/! + 1)OR, )A(2A + OR,  + 1) ’
(0RC A((20R( A f  1 )OR, t 1))(2 +_ORcA(\ + OR, )) 
8{OR, A -+ l)2 (1 f ORcOR, A)2
(4.5.12)
This can be put into (4.5.11) to obtain an overall estimate of the variance. Note that for 
the special case of ORc = 1 one has u 0 = vv,. Note that in all o f  these calculations the
assumption is that there is no interaction between treatment and the covariate i.e. the 
effect of treatment is independent of covariate.
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Table 4-41. Bias and variance inflation for unadjusted logistic regression for various odd-ratios for the covariate and treatment
Covariate
OR
Treatment
OR
Pooled
OR*
SI: Pooled 
OR
Unadjust
OR
Unadjust 
SE OR
SE ratio Bias 
Unadj:Pool Unad:Pool
Pooled
Standard
Unadjust
Standard
0.60 0.50 0.50 0.2098 0.5051 0.2084 0.9929 0.9854 3.3032 3.2779
0.60 0.60 0.2077 0.6046 0.2062 0.9926 0.9849 2.4595 2.4405
0.70 0.70 0.2061 0.7038 0.2045 0.9924 0.9846 1.7308 1.7173
0.80 0.80 0.2048 0.8028 0.2033 0.9922 0.9844 1.0893 1.0808
0.90 0.90 0.2039 0.9015 0.2023 0.9921 0.9842 0.5167 0.5126
0.70 0.50 0.50 0.2072 0.5025 0.2064 0.9965 0.9927 3.3458 3.3330
0.60 0.60 0.2053 0.6023 0.2045 0.9963 0.9925 2.4887 2.4791
0.70 0.70 0.2039 0.7019 0.2031 0.9962 0.9924 1.7496 1.7428
0.80 0.80 0.2028 0.8014 0.2021 0.9961 0.9923 1.1001 1.0958
0.90 0.90 0.2021 0.9007 0.2013 0.9961 0.9922 0.5213 0.5193
0.80 0.50 0.50 0.2052 0.5010 0.2049 0.9986 0.9971 3.3775 3.3723
0.60 0.60 0.2035 0.6009 0.2033 0.9985 0.9970 2.5096 2.5058
0.70 0.70 0.2024 0.7008 0.2021 0.9985 0.9970 1.7626 1.7598
0.80 0.80 0.2015 0.8005 0.2012 0.9985 0.9969 1.1072 1.1055
0.90 0.90 0.2010 0.9003 0.2007 0.9985 0.9969 0.5242 0.5234
0.90 0.50 0.50 0.2038 0.5002 0.2038 0.9997 0.9993 3.4006 3.3995
0.60 0.60 0.2024 0.6002 0.2023 0.9997 0.9993 2.5243 2.5234
0.70 0.70 0.2014 0.7002 0.2013 0.9997 0.9993 1.7711 1.7705
0.80 0.80 0.2007 0.8001 0.2007 0.9997 0.9993 1.1116 1.1112
0.90 0.90 0.2003 0.9001 0.2003 0.9997 0.9993 0.5259 0.5257
1.00 0.50 0.50 0.2028 0.5000 0.2028 1.0000 1.0000 3.4173 3.4173
0.60 0.60 0.2016 0.6000 0.2016 1.0000 1.0000 2.5341 2.5341
0.70 0.70 0.2008 0.7000 0.2008 1.0000 1.0000 1.7764 1.7764
0.80 0.80 0.2003 0.8000 0.2003 1.0000 1.0000 1.1140 1.1140
0.90 0.90 0.2001 0.9000 0.2001 1.0000 1.0000 0.5266 0.5266
Stan Ratio 
Unadj:Pool
n Qcm  
n 9 9 7 3  
0 9 9 7 ?  
0 9 9 7  1 
0 9 9 7  1
0 99<S7 
0 9961 
0 9961 
0 9961 
0 9961
0 9 98S  
0 998S  
0 99X5 
0 99X5 
0 99X5
0 9 9 9 7  
0 9 9 9 7  
0 9 9 9 7  
0 9 9 9 7
0 9 9 9 7
1 0000 
1 0000 
1 0000 
1 0000
-L0000
The pooled OR is the odds-ratio estimated through combining the ORs from each sub-group (which are equal)
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Unadjusted estimates of the overall effects can be obtained from averaging the estimates of 
P a\ a°d P M from (4.5.3) and (4.5.7) -  note here one is assuming equal sample size for 
each level of the covariate. Hence, one has
Pm 2 {1 + A + OR( A + 1 J 2(1 + /f)(l + ORcA)j ) (\ + ORcA) + (A + \)
P h i =   ------------------------- +
2 ^ 1 +  <? /? , . • !  1 + OR, OR, A
) (1 ) OR( OR, A) -t- (1 +  OR7 A)
J ’  2 ( 1  +  OR, . 1 ) (1  +  ORcORr A ) (4.5.13)
Obviously, an unadjusted estimated of the log-odds-ratio can be estimated from (4.5.13) 
from
log(O/0 = —A l z J l l l l  (4.5.14)
P ui^ - P ai)
The variance for which can be estimated through putting (4.5.13) into (4.5.4)
Using (4.5.14) for unadjusted estimates of the overall response and (4.5.13) with (4.5.4) for 
unadjusted estimates of the variance and (4.5.10) and (4.5.11) for adjusted estimates of the 
overall response and variance respectively Table 4.41 was constructed (note A was fixed at 
1) with the sample size fixed at 100 per group. The first column gives the OR estimate for 
the covariate effect with respect to outcome and the second column gives the OR estimate 
for the treatment effect with respect to outcome.
Column three gives the adjusted point estimate from (4.5.10) and column four its 
corresponding standard error. Column 5 and 6 give the corresponding unadjusted point 
estimates with their standard errors. It seems from inspection of these results that the 
variance estimate is indeed bigger when adjusting and is confirmed in column 7, which 
gives the ratio of the standard errors. However, this result should be put into context with 
the next column, which gives a ratio of the log-odd-ratios. From this column it seems that 
although the unadjusted estimates have smaller errors the point estimates are biased and 
this bias is towards the "null" hypothesis. The bias in not adjusting for covariates has 
previously been commented on [Gail, Wieand and Paintadose, 1984] and from these results 
it seems that the bias gets bigger the bigger the effect of the covariate.
Columns 9 and 10 further confirm these points as these give the Z-statistic of the point 
estimate (log-odds-ratio) divided by it standard error. From this one can see that the Z- 
statistic is consistently smaller for the unadjusted estimates compared to the adjusted (as 
evidenced by the final column which gives the ratio of the of the Z-statistics).
From the results of Table 4.41 it is evident that relative to the point estimate (the Z-statistic) 
adjusting for a covariate does not increase the variance. In fact through adjusting for 
covariates one is obtaining unbiased estimates of the treatment effect. Practically what
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these results highlight is that adjusting for covariates does not (relatively) increase variance 
estimate and so one does not need to increase the sample size to account for any planned 
covariate adjustment.
Note in the hypothetical example in Table 4.18 the unadjusted log-odds-ratio has a smaller 
standard error o f 0.119 compared to 0.125 for a logistic regression analysis in PROC 
LOGISTIC in SAS adjusting for gender. Hence, the standard error has increased by 5% 
through covariate adjustment. However, this effect is more than offset by the bias in the 
log odds ratio, with the unadjusted log-odds-ratio being 1.022 (odds-ratio=2.78) compared 
to an adjusted 1.099 (odds-ratio=3.00). A 7.5% increase in the log-odds-ratio by adjusting. 
Using (4.5.1) to estimate the standard error for Table 4.18 gives an estimate o f 0.119 for the 
adjusted analysis and (4.5.4) gives an estimate of 0.116 both a little lower than using PROC 
LOGISTIC. The estimates from (4.5.10) and (4.10.14) match exactly the point estimates 
from PROC LOGISTIC
As an aside it may be worth noting what ICH E9 [1998] says for the case where one is 
unsure of the effect of a covariate a priori
"When the potential value of an adjustment is in doubt, it is often advisable to nominate the 
unadjusted analysis as the one for primary attention, the adjusted being supportive"
Given the direction of the bias this advice may be true for superiority trials with binary data 
as the bias is towards the "null" and would be against the investigative treatment. 
However, for non-inferiority and equivalence trials the aim is to demonstrate no effect and 
so an unadjusted analysis would be biased in favour of the investigative treatment. The 
biased estimate would also have a smaller standard error too which would be most optimal 
for demonstrating a confidence interval is contained within a bound. The advice in E9 
should therefore take the opposite standpoint for binary non-inferiority and equivalence 
trials i.e. the adjusted should be the primary analysis.
The situation of what is conservative for superiority trials being counter conservative for 
equivalence or non-inferiority trials is recognised in other aspects of study conduct -  for 
example whether the pre protocol or intent to treat population is the primary analysis set -  
but to date no recognition with respect to covariates and logistic regression.
4.7.2. Post Dose Measures Summarised by Summary Statistics
There have been a number of articles written on the topic of repeated binary data [Nixon 
and Thompson, 2003; Liu, 1991, 2001], however, here all that will be highlighted is how, 
for the special case where the post dose measures are analysed using summary statistics, the 
form of the data changes.
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For the simple case of two post dose measurements, by taking a simple average of the two 
measures the scale moves from a two-point scale to a three-point scale. The data has thus 
been transformed from binary to ordinal in form. The advantage with reference to the 
sample size can be observ ed in Table 4.42. From this table it is evident that if there are 
several post dose measurements the sample size can be reduced by up to a third (compared 
to a simple binary response).
Discussion of Table 4.42 will be made in greater detail in Chapter 5 in context with an 
ordinal response.
Table 4-42. Correction factors to use w hen the number of categories is less than or 
equal to 5
Number of Correction
Categories Factor
2 1.333
3 1.125
4 1.067
5 1.042
4.8. Summary of Chapter 4
For cross-over trials it is recommended that the standard parallel group methodologies 
described in this chapter be used to calculate the sample size, taking the sample size per 
group from these calculations as the total sample size. It is recommended that the effect of 
period be accounted for in any statistical analysis but that there is no need for it to be 
considered when calculating a sample size.
For parallel group trials it was highlighted how not allowing for a predictive covariate in a 
statistical analysis could bias one's results and it was demonstrated how when adjusting for 
these covariates that it did not inflate one's sample size. It was highlighted that an 
unadjusted analysis was a conservative analysis for a superiority trial but not for a non­
inferiority or equivalence trial.
When designing a study with a binary response one should account for the imprecision 
around the estimated control response rate. This recommendation is particularly important 
for either high or low anticipated response rates. It is recommended numerical methods 
derived in this chapter be used to account for the imprecision in the control response over 
the results described for Normal data in Chapter 2.
For binary data simple Bayesian procedures can considerably enhance the estimates of the 
sample size. As well as using empirical observation, beliefs about the results that are
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anticipated can be used in sample size calculations. The use of a priors provides an 
opportunity to the explore robustness (sensitivity) of calculations. For example one may be 
more sceptical in one's priors than results previously observed. This more sceptical prior 
could be used to calculate posterior probabilities and hence sample size calculations.
The non-Bayesian methods have the advantage of being able to provide generic sample size 
tables for a given imprecision around the proportional response. The Bayesian approach 
does not provide a generic solution -  each clinical trial would require specific priors and 
hence a specific sample size estimate. Given this however, it is recommended that 
Bayesian methods described here be considered for all calculations when the primary 
response is binary.
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5 . C H A P T E R  5  - S A M P L E  S I Z E  C A L C U L A T I O N S  F O R
C L I N I C A L  T R I A L S  W I T H  O R D I N A L  D A T A
This chapter will discusses the calculations for clinical trials where the expectation is that 
the data will take an ordinal form. The main type of ordinal data that this chapter will 
concentrate on, are data that is from quality of life type outcomes. The rationale for this is 
that quality of life (QoL) endpoints have become an increasingly important endpoint in 
clinical trials [de Haes and van Knippenberg, 1985; Fayers and Machin, 2000]. QoL is 
particularly valuable in cancer trials where an assessment of the palliative effect of 
treatments can be made in situations where the size of any survival advantage for a new 
treatment is, at most, modest.
To highlight the issues of designing a trial with a QoL outcome this chapter will use data on 
QoL outcome scores from a palliative clinical trial in lung cancer patients [Medical 
Research Council Lung Cancer Working Party, 1996]. It will be demonstrated how sub- 
optimal calculations can impact on sample size calculations. Finally, this chapter will 
describe how if one is using data from earlier trials, this impacts on sample size 
calculations.
In describing sample size methodologies this chapter will concentrate on methodologies 
that rely on the assumption of proportional odds-ratio [McCullagh, 1980; Whitehead, 1993] 
-  using an odds-ratio to quantify a difference between treatments -  and will draw heavily 
on the work of Julious et al [Julious, George and Campbell, 1995; Julious, George, Machin 
et al, 1997; Julious, Walker, Campbell et al. 2000; Campbell, Julious, Walker et al, 2000].
The chapter will be briefer than other chapters extending either the work from Normal data 
from Chapter 2 or the work from binary data from Chapter 4.
5.1. Aims of the Chapter
The main issues discussed in the chapter are as follows;
• To describe calculations for the estimation of sample sizes where the primary 
endpoint is ordinal.
• To investigate how issues such as dichotomisation can impact on sample size 
calculations
• To interrogate how effect sizes for parallel group studies can be generalised to 
cross-over trials.
• To investigate the asymptotic properties of data anticipated to be ordinal in form 
and how non-parametnc bootstrapping methods can be used in sample size 
calculations.
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• To assess how the conservative nature o f non-inferiority and equivalence trials can 
impact on sample size calculations.
5.2. The Quality o f  Life Data
The data in this chapter are taken from a randomised parallel group controlled trial of a 
standard treatment against a less intensive treatment in 310 patients with small-cell lung 
cancer and poor prognosis [Medical Research Council Lung Cancer Working Party, 1996]. 
The standard treatment (.1) consisted of a four-drug regime (etoposide, cyclophosphamide, 
methotrexate and vincristine) while the new less intensive treatment (B) under investigation 
contained just two of these compounds (etoposide and vincristine). The two treatment 
schedules were the same, comprising three cycles o f chemotherapy at the same dosage. 
Each cycle was given on three consecutive days at three-week intervals.
The two Health Related Quality of Life (HRQoL) questionnaires used in this trial were the 
Hospital Anxiety and Depression Scale (HADS) [Zigmond and Snaith, 1983] and the 
Rotterdam Symptom Checklist (RSCL) [de Haes; van Knippenberg and Neijt, 1990].
The Hospital Anxiety and Depression Scale was developed by Zigmond and Snaith [1983]. 
It was designed to measure two psychological dimensions of QoL, those of anxiety and 
depression, in patients who were physically ill, and therefore it excluded somatic symptoms 
that might be due to illness. It is a self-rating questionnaire, which a patient completes in 
the waiting room before meeting a doctor in order to reflect how they have felt during the 
past week. It has 14-items which split equally into the two sub-scales and provides scores 
in the range 0-21 in two dimensions: anxiety and depression. Moorey, Greer, Watson et al 
[1991] reported that HADS is a useful instrument for measuring these dimensions in cancer 
patients.
The HADS has three clinically pre-defined categories for each dimension: a total score 0-7 
is defined as a ‘normal', 8-10 as a ‘borderline-case’ and 11-21 as a ‘case’ suggesting 
significant anxiety or depression.
The RSCL has two main scales, physical symptom distress and psychological distress, in 
addition to the scales for activity and overall evaluation. It was developed to measure the 
symptoms of cancer patients participating in clinical research. Patients indicate how much 
they have experienced particular symptoms over the last week. The RSCL psychological 
dimension, for example, has scores ranging from 0 to 24, where high scores constitute 
psychological distress. It has two clinically pre-defined categories where a total score of 0- 
10 is considered a *non-case' and 1 1-24 is a ‘case’ considered to constitute psychological 
distress.
In the case study in this chapter setting both HRQoL questionnaires were completed 
together. The 310 patients’ baseline scores prior to randomisation are used in this chapter
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for expository purposes as the outcome for the control therapy. Two hundred and sixty six 
patients completed a baseline response.
Figure 5-1. Distribution of HADS anxiety scores at baseline
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HADS Anxiety Score at Baseline
Figure 5.1 displays the distribution of the HADS anxiety scores at baseline. It is negatively 
skewed. Figure 5.2 shows the equivalent distribution of the RSCL psychological 
dimension scores. It is positively skewed. In both cases the scores do not seem to take an 
approximate Normal distributional form. It therefore seems that the usual mean and 
standard deviation are not adequate to summarise the distributions. As a consequence, in 
the context of this chapter, it is recommended that distribution-free techniques should be 
used for testing treatment differences.
Note in practice transformations such as a log transformation may be considered for such 
data with inference then made on the transformed scale. For the purposes of this chapter, 
however, transformations will not be considered.
272
Figure 5-2. RSCL psychological scores at baseline
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5.3. Superiority Trials
5.3.1. Parallel Group Trials
5.3.1.1. Sample Sizes that are Estimated Assuming that the Population Effects are Known
Most QoL scales have categories that can be ordered, but the scores should not be treated as 
meaningful numbers, for example, a change in HADS from 5 to 10 is not the same as a 
change from 10 to 15. However, methods have been developed for sample size calculations 
for ordered categorical (ordinal) data [Whitehead, 1993].
As discussed in Chapter 1, in general terms for a 2-tailed, a -level test one requires the 
follow ing for the variance if the test is going to have the correct power
Var (S)=-------- ---------- T, (5.2.1)
(Z,/(+Z, „ O'
Here d is the effect size of interest (assessed through a log-odds— ratio) with the sample 
variance, var(S), about the log-odds-ratio for an ordinal response estimated from 
[Whitehead, 1993; McCullagh, 1980; Jones and Whitehead, 1979, Campbell, Julious and 
Altman, 1995]
1,1/ (.S j . '• (5.2.2)
/ - i; />:
Here k is the number of categories on the QoL instrument, p.t is the mean proportion 
expected in category /, that is, p t = (p.v + p B, ) /2 ,  where p /V and p Bi are the proportions
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anticipated in category i for the two treatment groups A and B respectively and a  and P are 
the overall type I and type II errors respectively with Z,_a2 and Z,_p denoting the
percentage points of a standard Normal distribution for these two errors. Here n is the 
sample size per group. Note that in this chapter, as for binary data, the issue of allocation 
ratios between treatments will be ignored.
Now by equating (5.2.1) with (5.2.2) one has [Julious, George and Campbell, 1995; 
Julious, George, Machin et al, 1997; Julious, Walker, Campbell et al.2000; Campbell, 
Julious, Walker et al, 2000; Whitehead, 1993; Dark, Bolland and Whitehead, 2003; Lee, 
Song, Kang et al, 2002; Rabbee, Coull, Mehta et al, 2003; Campbell, Julious and Altman, 
1995]
6[Zi-/; + Zi-a :f''flog OR f
*
(5.2.3)
Equation (5.2.1) is based on the Mann-Whitney (7-test for ordered categorical data. It 
estimates the sample size based on the odds ratio (OR) of a patient being in a given 
category or less in one treatment group compared to the other group.
Note that a form of this equation was used in Chapter 4 for binary data - a binary response 
being a special case of (5.2.3). For an analysis under the assumption of proportion odds the 
anticipated effect size is expressed as an odds ratio defined as:
or  = £ i ^ z £ s , l .
P s , 0 - P j
This is a measure that is not immediately straightforward to interpret for binary data and, as 
a consequence, is more difficult for an ordinal response. It is best to discuss the application 
of (5.2.3) through a worked example.
There are alternative ordinal methodologies [Hilton and Mehta, 1993; Lachin, 1977; 
Noether, 1987] for sample size calculation for ordinal data. Indeed the methodology of 
Noether [1987] is of particular interest as it is written simply in terms of the probability of 
one group being greater than the other. However, this chapter will concentrate on (5.2.3) as 
it has the advantage of being thought of as generalised from binary methodology and as a 
result (as will be highlighted later) has a measure of effect that can be interpreted in terms 
of the binary response.
274
5.3.1.2. Worked Example
5.3.1.3. Full Ordinal Scale
When designing a clinical trial to estimate the odds ratio one can utilise the predefined 
clinical cut points that the HADS and RSCL each provide. For example, 27.1% of patients 
at baseline are dehned as borderline cases or better on the HADS Anxiety dimension score 
at baseline (see Table 5.1), that is, 27.1% record values resulting in a score of <10. This 
one could take, for expository purposes, as what one would expect on standard therapy (S). 
The odds with S is thus 0.271/(1-0.271)=0.372. Suppose a new therapy (T) is to be studied 
and the investigator decided that a clinically meaning effect is one that would increase the 
proportion of non-cases to 40.0% or a postulated odds of 0.40/(l-0.40)=0.67. The ratio of 
these odds gives 0/^=0.372/0.667=0.56 in favour of T. This value can then be used as the 
basis for the sample size calculation.
Equation (5.2.3) makes no assumption about the distribution of the data, but it does assume 
proportional odds between the treatments across the QoL dimension. This implies that the 
odds ratios are identical for each pair of adjacent categories throughout the scale. What this 
means practically can be highlighted by extending the example given above. When using 
the pre-defined clinical cut point for 'non-cases’ the investigator anticipated the OR would 
be 0.56. The assumption of proportional odds implies that, if instead of using <10 as the 
definition of a 'non-case'. <9 had been used, one would nevertheless obtain ORq=0.56. and 
so on for OR$, OR? etc. Thus, although the actual observed odds ratios might differ from 
each other across the scale, the corresponding population values are all equal which implies 
that OR\=OR2 =OR\=...^ORz\ =0.56. However, the calculations of sample size using
(5.2.3) are robust to departures from this ideal, provided all the odds ratios indicate an 
advantage to the same treatment [Julious, George, Machin et al, 1995; Julious, Walker, 
Campbell et al, 2000].
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Table 5-1. Frequency of responses on the HADS anxiety scores as baseline for patients
with small-cell lung cancer
C ategory Score Number of
Patients
Normal 0 0
1 0
2 1
3 0
4 2
5 3
6 5
7 10
Borderline 8 12
9 15
10 24
Clinical Case 11 41
12 49
13 36
14 23
15 34
16 9
17 2
18 0
19 0
20 0
21 0
Total 266
Normal 0 - 8 21 (7.9%)
Borderline 9 -  10 51 (19.2%)
Clinical Case 11-21 194 (72.9%)
Mean 11.70
SD (a) 2.66
Median 12
Using the odds-ratio of 0.56 the anticipated new therapy responses can be derived as per 
Table 5.2. From these anticipated responses an estimate of the variance can be made from 
(5.2.2) which when placed in (5.2.3) with the odds-ratio gives an estimate of the sample 
size of 188 patients per arm (for 90% power and two sided Type I error rate of 5%).
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Table 5-2. Anticipated percentages of response on the HADS anxiety scores for
standard treatment (S) and new treatment for patients with small-cell lung cancer
Standard Therapy (S)  New Therapy (7)
Category Score* Percentage Cumulative Percentage Cumulative
(Ps,) percentage
( 0 S i )
Or,) percentage
( 0 i / )
Normal 0 - 3 0.4 0.4 0.7 0.7
4 0.8 1.2 1.4 2.1
5 1.1 2.3 1.9 4.1
6 1.9 4.2 3.2 7.3
7 3.8 8.0 6.2 13.5
Borderline 8 4.5 12.5 6.9 20.4
9 5.6 18.1 8.0 28.4
10 9.0 27.1 11.6 40.0
Clinical Case 11 15.4 42.5 17.0 57.0
12 18.4 60.9 16.6 73.6
13 13.5 74.4 10.3 83.9
14 8.6 83.0 5.8 89.8
15 12.8 95.8 7.8 97.6
16 3.4 99.2 1.9 99.6
17 -2 1  0.8 100.0 0.4 100.0
*Note The 22 categories of Table 1 are reduced to k = 15.
The application of proportional odds therefore allows that, if the distribution of one of the 
treatment groups can be specified, then the anticipated cumulative proportions for the other 
treatment can be directly deriv ed. Hence, with prior knowledge of the distribution of just 
one treatment group and an anticipated OR, obtained about any cut point on the QoL scale, 
an estimate of the sample size can be obtained.
5.3. /. 4. Effects o f Dichotomisation
An advantage of the HADS and RSCL instruments for the process of anticipating the effect 
size and consequent sample size is that they both have predefined definitions of what 
constitutes a ‘case' and which can then be used to obtain a value of a readily interpretable 
effect size. This effect size, here expressed as an odds ratio, ean thus be extended across 
the full QoL scale and an estimate of the sample size made.
These cut-offs, however, ean encourage some researchers to dichotomise QoL scales to 
calculate sample sizes. For example, with the HADS Anxiety dimension, one of the cut­
offs can classify subjects either as a 'clinical ease' or ‘borderline’ or better. For this, now 
binary, situation (5.2.3) can still be used to estimate a sample size but ignoring the full 
ordered categorical nature of the data, may result in a substantial over-estimation of the
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sample size. For example, if a clinically meaningful difference was set again at 0.56 
around the cut off ol non-cases/clinical cases on the HADS Anxiety score then by 
dichotomising (5.2.3) gives an estimate of the sample size of 277 compared to only 188 
when all k — 22 categories are used in the calculations. This is a potential over-estimate of 
47% in the necessary sample size if the data was analysed using all 22 categories.
Obviously, it the intention is to analyse the scale as a dichotomous endpoint then the 
sample size may be appropriate although this approach may be questioned also as wasting 
patients.
5.3.1.5. Effects of A dditional Points
It may not be necessary to use the full categorical scale. For example, with HADS there is 
an additional category of ‘normal’ for subjects with a score of <8 and just under 8% of 
patients are classified as such on the anxiety dimension. If one then calculated the sample 
size using the k= 3 groups of ‘normal’, ‘borderline-case’ and ‘clinical-case’ as the 
categories, the estimated sample size, trom (5.2.3), is Ar3=267 subjects - only a marginally 
closer estimate. However, if one identified an additional category of ‘severe-clinical-case’ 
for subjects with a HADS score >14 [Julious, George, Machin et al, 1997; Julious, Walker, 
Campbell et al, 2000] and based the sample size calculations on the 4 categories, the 
estimated sample size is of 210 patients is now quite close to the optimal 188.
Dichotomising the QoL scale in order to estimate a sample size, and consequently 
analysing the data as ordinal, should be avoided if possible as sample sizes could be 
unnecessarily inflated. However, knowledge of anticipated responses in only a handful of 
categories can give sample size estimates that are more precise for only a modest increase 
in the complexity of the calculations.
Table 5-3. Correction factor to be used when the number of categories is less than 5
Number of 
Categories
Mean Proportions Anticipated Correction
Factor
2 “^3
1 II II O 1.333
3 > II II II O 1.125
4 > II II II >> 
i II O ‘to 1.067
5 P\ = P 2 = P> = Pa = P * =  ° - 2 1.042
The reason why ignoring the ordinal scale substantially increases the sample size is due to 
the increase in variance estimated from (5.2.2). Table 5.3 illustrates this point. The 
minimum the variance can be for any number of categories on a scale is for the special case
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where the anticipated mean responses for each category are equal i.e.
P \  -  P i  -  P }  - • ■ ■ ■ P k - 1 = P k  ■ ^ ^ is  result is placed into (5.1.1) one can obtain the
anticipated relative variances for different numbers of categories for the most optimal 
responses. The ratio of these variances can in turn give inflation factors for the sample size 
for different numbers of categories relative to the optimum number of categories i.e. a
k
continuous scale where / - p'  = l .
i i
From Table 5.3 one can see that for the optimum mean responses one would anticipate a 
33% increase compared to a continuous response as opposed to just 5% for 5 categories 
[Campbell, Julious and Altman, 1995]. Thus, what these results show is that dichotomising 
could lead to a serious inflation of the sample size. Even using only a little extra 
information (from extra categories) can substantially improve a sample size estimate.
Note also that another common way to calculate sample sizes for ordinal responses is to use 
the Normal data methodology described in Chapter 2. Julious et al demonstrated that 
assuming the data takes a Normal form might also give misleading results [Julious, George 
and Campbell, 1995; Julious. Walker, Campbell et al, 2000]. This is mainly due to the fact 
that the distributional form of an ordinal response may be asymmetric. This would lead to 
asymmetric sample size estimates depending on the sign of the effect of interest. In 
comparison, however, for Nonnal data a mean shift in either direction would give the same 
size due the symmetric form of the data.
5.3.1.6. Sensitivity Analysis about the Estimates o f the Population Effects Used in the 
Sample Size Calculations
5.3.1. 7. Extending the Results from Normal Data
In Chapter 2 it was described how, for data that take a Normal form, the sensitivity of a trial 
design to the variance could be investigated using the degrees of freedom of the variance 
estimate used in the calculations. Using the degrees of freedom for the variance, and the 
chi-squared distribution, the sensitivity ol the study can be investigated for high plausible 
values for the variance, taken from the upper 95th percentile for the variance using the 
following formula
,1 4 5 . -  v . (5.2.4)
Xo.vyjf
Where ,v: is a sample variance from the trial(s) being used for planning purposes. To 
generalise this result to ordinal data (5.2.2) could be used in (5.2.4) to obtain an upper 
estimate of the v ariance.
Next one can rewrite (5.2.3) to be written in terms of power i.e.
279
f r k1 II eIf ( \ ogOR f  / 6 - Z ,  a :vV ' > )
With this result an upper estimate of the variance could be used to assess the sensitivity of 
the study to assumptions around the sample variance being used in the planning. However, 
for binary data discussed in Chapters 3 and 4 the equivalent result to (5.2.4) does not hold, 
as the variance for these data does not follow a chi-squared distribution. The assumptions 
around the result (5.2.4) will now be interrogated for ordinal data.
5.3.1.8. Simulation Investigation of the Ordinal Variance
Ordinal data to an extent fall between binary data and Normal data. Thus, to investigate the 
appropriateness of using (5.24) with (5.25) a simulation was undertaken for different 
sample sizes, number of categories (of the ordinal response) and expected mean responses. 
It is not anticipated that the variance for ordinal data (described in the context of this 
chapter) will follow a chi-squared distribution, as this requires Normality and hence the 
simulations are undertaken for interest. The simulation was done in SAS [1990]. For 
investigation 10,000 simulations were undertaken.
For each simulation the ratio of the ‘sample’ variance over the ‘population’ variance was 
calculated which would be plausibly expected approximated to follow a chi-squared 
distribution i.e.:
("-1 )s~ , M ;—  = (« -  1)
a
6 n 
6/z,
M
.
' 1
1
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:
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where p t are the estimated mean responses from the simulation and ni are the population 
mean responses from which each simulation w as drawn.
Figures 5.3 to 5.5 give some indicative simulations for 3, 4 and 5 category responses. One 
can see from these simulations that the approximation to the chi-squared gets better the 
more categories one has and also the greater the sample size. Overall, however, the 
simulations indicate a reasonable approximation to the chi-squared distribution in this 
instance, although not great.
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Figure 5-3. Chi- probability plots for a 3 category variable for anticipated responses
of 0.4, 0.3 and 0.3 for the 3 categories
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Figure 5-4. Chi- probability plots for a 4 category variable for anticipated responses 
of 0.3, 0.3, 0.2 and 0.2 for the 4 categories
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Figure 5-5. Chi- probability plots for a 5 category variable for anticipated responses
of 0.3, 0.2, 0.2, 0.15 and 0.15 for the 5 categories
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Figures 5.6 to 5.8 give alternative simulations (again for 3, 4 and 5 category responses) but 
here one category is expected to dominate. In this instance, except for large sample sizes, 
the approximation to the chi-squared is weak. These results are, as one would anticipate for 
with one category dominating the data, similar in parametric form to that o f a binary 
response. As discussed in Chapters 3 and 4 the variance for binary responses does not 
follow a chi-squared distribution.
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Figure 5-6. Chi- probability plots for a 3 category variable for anticipated responses
of 0.8, 0.1 and 0.1 for the 3 categories
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Figure 5-7. Chi- probability plots for a 4 category variable for anticipated responses
of 0.7, 0.1, 0.1 and 0.1 for the 4 categories
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Figure 5-8. Chi- probability' plots for a 5 category variable for anticipated responses
of 0.6, 0.1, 0.1, 0.1 and 0.1 for the 5 categories
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5.3.1.9. Bootstrapping
What the results illustrate in this sub section is that the variance for an ordinal response 
does not follow a chi-squared distribution (although other distributional forms can not be 
ruled out. A number of authors have described how non-parametric bootstrapping can be 
applied [Efron and Tibshirani; Hall, 1993; Julious, 2001; Keene, 2002]. These arguments 
can be extended to the situation here. Hence, a solution to the problem is to form a 
bootstrap distribution for the sample variance for a particular example and from this take a
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95th percentile. This one tailed bootstrap upper percentile could be used to investigate the 
sensitivity o f a study. An example is the best way to illustrate the solution.
5.3.1.10. Worked Example
5.3.1.11. Full Ordinal Seale
Re-visiting the worked example from earlier where a trial was designed based around an 
eflect size of OR=0.56. The calculated sample size was 188 patients per arm. The estimate 
ol the variance used in the sample size calculation was 6.089. Through a bootstrap sample 
of 10,000 drawn with replacement from the original data the 95th percentile was estimated 
as 6.119, which if put into (5.2.5) would give power of 89.9%. Hardly a fall at all.
In comparison, through applying (5.2.4) an upper estimate of the variance is given as 6.983, 
which would equate to a power reduction to 85.7% if this were nearer to the true variance. 
In this instance through applying the chi-squared assumption a more conservative 
assessment of sensitivity would be given.
Table 5-4. Sensitivity analysis for worked example superiority study assuming all 
categories are used in the calculations. The estimated 95th percentiles for the 
variance are calculated through bootstrapping and approximation to the chi-squared 
distribution.
______ Bootstrap_____ _______ Chi-squared
Sample 95th Power 95th Power
Size Percentile Percentile
50 6.296 0.891 8.244 0.797
100 6.156 0.898 7.580 0.829
266 6.125 0.899 6.983 0.857
1000 6.101 0.900 6.545 0.879
Table 5.4 gives a summary of the sensitivity assessment along with repeated calculations 
assuming the same distribution of responses was observed but drawn from sample sizes of 
50, 100, 266 (the actual sample size) and 1000. For each case assuming a chi-squared 
distribution gives a more conservative assessment.
5.3.1.12. Four Point Scale
In the same example earlier for the same ellect size the 22 point scale was reduced to 4 
(using clinical cut-offs) for ease o f calculations. The estimated variance as a result was
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increased to 6.796, which as a result increased the sample size to 210 patients. A bootstrap 
95th percentile for the variance is estimated as 7.041 which if was nearer the true variance 
would mean the powered reduced to 89.1 %.
The corresponding variance estimate from (5.2.4) is 7.795 would mean a reduction in 
power to 85.8%.
Table 5.5 gives a summary of the sensitivity assessment along with repeated calculations 
for different sample sizes. A couple o f points are worth highlighting from this table. The 
first is that although the bootstrap estimates are now nearer those estimated from a chi- 
squared, the chi-squared estimates are still a little conservation. The second point is that 
although, in terms of the initial sample size calculation, discarding categories does not have 
a major effect, comparing Table 5.5 with Table 5.4 it does seem in this instance that one's 
calculations do become more sensitive to the assumptions about the variance.
Table 5-5. Sensitivity analysis for worked example superiority study assuming 4 
categories are used in the calculations. The estimated 95th percentiles for the 
variance are calculated through bootstrapping and approximation to the chi-squared 
distribution.
Bootstrap    Chi-squared
Sample
Size
95th
Percentile
Power 95th
Percentile
Power
50 8.522 0.826 9.202 0.797
100 7.251 0.882 8.461 0.829
266 7.041 0.891 7.795 0.857
1000 6.911 0.896 7.206 0.879
5.3.1.13. Calculations Taking Accounting of the Imprecision of the Estimates of the 
Population Effects Used in the Sample Size Calculations
If the results from Chapter 2 could be extended to ordinal responses then to account for the 
imprecision in the variability the following result could be applied
_ 6[tinv(\ -  [3. df. Z, u ,)
k
/ - I * '
i i
/ ( log o r  y (5.2.6)
where TlNV(»,m,u) denotes the (monotonically increasing) inverse function of the 
cumulative distribution of a Students non-central t distribution with m degrees of freedom 
and non-centrality parameter a. The degrees of freedom (d.f.) in the formula refers to the 
degrees of freedom about the variance estimate used in the sample size calculation.
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In Chapters 3 and 4 it was highlighted how an equation of the form of (5.2.6) could not be 
applied to binary data as the assumption of the variance following a chi-squared 
distribution does not hold. It was recommended instead that an equation o f the form
1 (I ^ 8
\ ~ / j  = —  y  0.5
0.998 r e r 7 7 u m
4>LWlog(<9/?) / /[var(log(<9/?))] -  Z,
f ®Un<  log (OR)  f  ''[var(log(0/?))] -  Z,.„ 2
(5.2.7)
be applied and the sample si/e be estimated through numerical methods. Remember that 
for binary data values for [var(log(0/O)] were estimated through the percentiles from the
control prevalence from which the variance and sample size were base.
For ordinal data there seems also to be a similar issue with the variance about the log(OR) 
also seeming not to following a chi-squared distribution as a general rule. To assess 
sensitivity it was recommended that a bootstrap distribution be built around the variance 
and a 95th percentile taken from this. It is now recommended that the same arguments be 
extended to provide values for [var(log(CM?))] to be put into (5.2.7). To do this, follow the
following steps
1. Generate an empirical bootstrap distribution for [var(log(0/?))] through sampling with 
replacement from the original distribution.
2. Rank the empirical distribution of [vur(log(0/?))] in order of size.
3. Take the smallest value as the 1st percentile, 2nd smallest as the 2nd percentile etc
4. Use these empirical percentiles in (5 .2 .7 ) and calculate the average power across these 
for a given sample size.
5. Iterate the sample size to the required power is reached.
It is again best to highlight the calculations through worked example.
5.3.1.14. Worked Example
5.3.1.15. Full Ordinal Scale
Remember the worked example from earlier where a trial was designed with a calculated 
sample size of 188 patients per arm. The variance of 6.089 was estimated from a trial of 
266 evaluable patients. Forming an empirical bootstrap distribution of 10,000 drawn with 
replacement from the original data for the percentiles for the variance (5.2.7) also gives 188 
patients per arm.
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In comparison using (5.2.6) gives a sample size of 190 per arm - a slight increase in the 
required sample size.
Table 5.6 gives a summary o f the sample size calculations along with repeated calculations 
assuming the same distribution of responses was observed but drawn from sample sizes of 
10, 15, 50, 100 and 266 (the actual sample size). For each case assuming (5.2.6) gives a 
more conserv ative sample size.
Table 5-6. Sample sizes for worked example superiority study assuming all categories 
are used in the calculations. The sample sizes were estimated taking percentiles for 
the variance calculated through bootstrapping and approximation to a non-central t- 
distribution.
Calculated Sample Size 
Original Bootstrap Non-central t 
Sample Size _______ _______________ _
10 196 251
25 191 209
50 189 198
100 189 193
266 188 190
5.3.1.16. Four Point Scute
Reducing the scale to a 4 point one increases the sample size estimate to 210 patients. 
Taking into account the original variance was estimated from 266 patients, through 
bootstrapping, and (5.2.7) also gives a sample size of 210. In comparison (5.2.6) gives a 
sample size of 212.
Table 5-7. Sample sizes for worked example superiority study assuming 4 categories 
are used in the calculations. The sample sizes were estimated taking percentiles for 
the variance calculated through bootstrapping and through approximation to the chi- 
squared distribution.
Calculated Sample Size_
Original Bootstrap Chi-Squared
Sample Siz e _________  __ _____
10 234 "281
25 218 234
50 214 224
100 212 215
266 210 212
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Table 5.7 gives a summary of the sample calculations along with repeated calculations 
assuming the bootstrap sample was taken from different sample sizes. It is worth noting 
that in comparison to Table 5.6 that imprecision of the variance estimate (assessed through 
the original sample size the estimate was drawn from) has greater effect on the 4 point 
scale.
When using all the categories, accounting for the imprecision has little effect on the sample 
size calculations (for the case study described) and so this chapter will now concentrate on 
the 4-point scale.
5.3.1.17. Calculations Taking Accounting of the Imprecision o f the Estimates of the 
Population Effects Used in the Sample Size Calculations -  Bayesian Methods
As the effect size (with respect to the odds-ratio) is fixed the binary methods described in 
Chapter 4 could be extended to ordinal data when there is a cut off. If there is a prior 
belief, expressed by the mode and a percentile, of the response around the cut off for a 
control treatment arm. From previously observed trial data and the fixed odds-ratio a 
posterior response distribution can be built for the investigative arm. This could be used in 
(5.2.7) to estimate sample sizes.
Alternatively the work with beta distribution could be generalised to a multinomial 
direchlet distribution, which could be used for priors [Ferguson 1973, 1974; Escobar 1994, 
1995],
5.3.2. Cross-over Trials
5.3.2.1. Sample Sizes that are Estimated Assuming that the Population Effects are Known
Remember from Chapter 4 how the methodology for parallel groups could be generalised 
to that for cross-over trials when the data is binary. The practical consequence was that 
equivalent effect sizes could be used and the sample size for one arm of a parallel group 
trial could be taken as the total sample size for a cross-over.
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Table 5-8. Summary table of hypothetical cross-over trial
Treatment B
1 2 3 4
Treatment A 1 * „ *,= * , 3 * , 4 P A .
2
* 2 , * 3 3 * ’ 4 P A 2
3
* 3 3 * 3 3 * 3 4 P A 3
4
* 4 , * 4 3 * 4 3 * 4 4 P A 4
P,„ P 132 P B 3 P „ 4 1
The same principals as applied to binary data can be extended to ordinal data through 
applying the results of Agresti [1993, 1999], Table 5.8 gives a table of hypothetical cross­
over data where each cell of the 4x4 table is derived from the marginal totals.
Table 5.9 gives the 2x2 tables around each cut off on the ordinal scale corresponding to 
Table 5.8. Under the assumption o f proportional odds the odds ratios from each of these 
tables should equal each other. Also extending the work from Chapter 4 the odds-ratios 
from each of these tables will also approximately equal the equivalent odds-ratios 
calculated from the marginal totals i.e. those expected from a parallel group trial.
Table 5-9. Summary table of hypothetical cross-over trial revisited
a. First cut off
Treatment B
1 2+3+4
Treatment A 1 Pn P|2 * P|3 P|4 o AI
2 13.4 P:|-Pi,'P41 P22 * P2, ' P24 r P ,, * P43+P44 + P4CP43+P44 + o A,
Qb, 1-0 1
b. Second cut off
Treatment B
1 -2 3+4
Treatment A 1^ 2 P,.'P,3*P?rP:: P,,’P,4+P!..+P24 Q.«
3*4 P*| P3^  P41 ’ P43 P„'P,4'P4«'P44 + o A!
P 1-PB 1
b. Third cut off
Treatment B
1+2+3 4
Treatment A 1+2’3 P,,, P,UP,3+P:, •P;,'P,,,P,l'P,,fP„ P41 + P42 + P4J 0,33
4 P41 f P42 "* P43 P44 '-0AJ
^ 3 3 '•Ob, 1
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To obtain an overall estimate of the odds-ratio Agresti [1993, 1999] gave the following 
result
Z O ' - ' H
OR = > < j (5.2.8)
where and i and j are the row and column numbers respectively and XtJ are the cell counts 
corresponding to the cell counts (see Table 5.8). The variance for (5.2.8) is defined as
var[log(<9/?)] =
Zo-'TX Z
+  -
Z ('-M, Z
(5.2.9)
which can be rewritten in terms of the cell probabilities, p u, as follows
Z o -<)■>, Z o
var[log(0/?)] = +
Z Z'/ i|/>
(5.2.10
By definition this odds-ratio would equate to that one would expect from a parallel group 
study which is a useful result. To calculate the required sample size one could equate 
(5.2.8) and (5.2.10) with (5.2.1) to give a sample size estimate for the total sample size of 
the form
n —
[z,,/y + Z,_a 2]  var(log(Q/?))
[iog(o/oF (5.2.11)
Again it is best to highlight the calculations through a worked example
Note to undertake such a period-adjusted analysis similar to described for binary data in 
Chapter 4 (5.2.8) would need to be applied to each sequence and the average (on the log 
scale) taken to obtain a period adjusted effect. However, generalising the results for binary 
data, whilst period-adjusted analyses are important it is not an important issue when 
designing a trial.
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53.2.2. Worked Example
Suppose an investigator wishes to design a trial where the outcome is a four point ordinal 
response. Whilst the anticipated responses on the control treatment (treatment A) are given 
in the final "overall" column of Table 5.10. The effect size of interest is an odds-ratio of 
0.56. From this odds-ratio the anticipated responses for the investigative treatment are 
given the final row -  assuming proportional odds of the marginal responses. The Type I 
and Type II errors are set at 5% and 10%.
Table 5-10. Summary table of cross-over trial for worked example
Treatment B 
1 2 3 4 Overall
Treatment A 1 0.011 0.021 0.035 0.013 0.080
2 0.026 0.051 0.084 0.031 0.191
3 0.064 0.125 0.208 0.076 0.473
4 0.034 0.068 0.113 0.041 0.256
Overall 0.134 0.265 0.439 0.162
The individual cells are derived through multiplying the marginal totals. From these 
individual cells and through using equation (5.2.11) the total sample size is estimated as 
229 patients. There are anticipated to be 31.1% concordant responses (from the diagonal) 
and so from this the discordant sample size could be estimated as 161 patients
In Chapter 4 the methodology for a parallel group trial was extended to that for cross-over 
trials where the sample size per arm calculated for a parallel group study was taken as the 
total sample for a cross-over study. Applying the same arguments to the ordinal case, using 
the marginal totals as the basis for the sample size calculation and (5.2.3) the sample size is 
estimated to be 213 patients in total or 149 discordant patients. This approach gives a 
sample size around 7% lower than through using (5.2.11).
Julious and Campbell [1998] highlighted that one can simplify one's calculations by 
ignoring the ordinal nature of the data; dichotomising the overall responses around the 
direction that subjects are discordant i.e. either just -1 or 1 and then using a discordant 
sample size formula from Chapter 2 [Connett, Smith and McHugh, 1987]
n _ (Z‘ ■“ 2(1/7 i l U  2 /; [  (5.2.12)
( v - 1 )2
Here, the odds-ratio, 1//, is the ratio of positive to negative responses.
Before applying (5.2.12) one must first estimate y/ . For 43% of the patients the responses
on the control therapy are expected to be higher than on the investigative whilst for 26% of 
patients the responses are expected to be lower on the control. Thus, y/ could be estimated
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as 0.60 (approximately the same as 0.56 -  the treatment effect from the initial calculations) 
and an estimate o f the discordant sample size from (5.2.12) is 164 patients. A little higher 
than from (5.2.11).
It is worth noting that Julious and Campbell [1998] highlighted that for many instances the 
discordant sample size (5.2.12) would give would be quite similar to the total sample size 
from (5.2.11). The reason is that by ignoring the ordinal nature of the data, there is an over­
estimation of the discordant sample size. This over-estimation is of a magnitude such that 
the discordant sample size for a binary response approximately can equate to the total 
sample for an ordinal. It does not, in this instance, as the response has 4 categories with 1 
predominant category.
5.3.2.3. Sensitivity Analysis about the Estimates of the Population Effects Used in the 
Sample Size Calculations
Similarly to parallel group data to assess the sensitivity o f a trial to the estimate of the 
variance bootstrapping can be applied to the get an estimate of an upper percentile for the 
sample variance. This plausibly high value for the variance can be put into -  (5.2.11) 
written in terms of power
1 -  (3 = 0>{ jn ( \ogOR f  / var(log(O /0) -  Z, a 2)^  (5.2.13)
to get an assessment of the sensitivity of the study.
5.3.2.4. Worked Example
In the worked example from earlier suppose that the original data, which produced a 
variance estimate of 7.30, had been estimated from a trial with 100 patients. Bootstrapping 
on the observed data produced a bootstrap 95th percentile estimate of 7.90. A plausible 
high estimate of the variance - 8.2% higher than used in the sample size calculation. If this 
value were applied to (5.2.3) then the power would be reduced 87.7%. Hence, the study 
seems reasonably robust to assumptions about the variance used in the calculations.
5.3.2.5. Calculations Taking Accounting of the Imprecision of the Estimates of the 
Population Effects Used in the Sample Size Calculations
To account for the imprecision of the sample variance in the estimate of the sample size, 
similarly to parallel group trials, the following result can be applied
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0.998 I  0-5pen - 0  0 0 1
Q>\^n(\og{OR) /  / [var(log(0/?))L . ~ z i-«--2
+ <D(v;//f log {OR) f  /[var(log(0/?))] -  Z,.„ ,
where the percentiles for the var(log(OR)) are estimated from an empirical bootstrap 
distribution derived from the original data on which the variance estimate was based.
5.3.2.6. Worked Example
For the same example as described previously. To allow for the fact that the variance was 
estimated from a hundred subjects the sample size would need to be increased by 2 to 231 
patients in total.
5.4. N on -In feriority  T ria ls
Although this chapter will discuss sample size calculations for non-inferiority, and later 
equivalence, trials, for ordinal data for such trials these calculations are not recommended. 
The reason for this is that although the data, as collected, are ordinal in form, in many ways 
for non-inferiority and equivalence trials this is the wrong scale on which to base one's 
inference. The rationale for this is due to the objective of the trial.
For a superiority trial the objective is to assess whether two populations differ. This 
assessment is done primarily done through a P-value. When analysing ordinal data there 
are a number of ways of determining this P-value. In this chapter the concentration has 
been on methodologies based upon the assumption o f proportional odds. Remember here 
one assumes that that the odds-ratio for each cumulative 2x2 are equal across all k 
categories i.e. OR\=OR2-O R s~ ..= O R ^  In practice the individual observed ORs will 
deviate slightly around the overall OR. However, the overall estimate, and inference, will 
hold.
For non-inferiority, and equivalence, trials one wishes to determine whether two 
populations do not differ. This assessment is primarily done through a confidence interval 
where, for a non-inferiority trial, one wishes to determine whether the lower bound is 
greater than some pre-specified non-inferiority margin. As discussed in previous chapters, 
this is operationally the same as doing a one sided test. However, it is the determination 
and interpretation of this non-inferiority margin, which is the issue here. In previous 
chapters the issues with determining non-inferiority margins was highlighted and in this 
chapter it was also highlighted how pre-specified cut-offs could be used to determine a 
treatment effect for designing a superiority trial.
Extending these arguments one can determine non-inferiority limits for ordinal data. This 
is when the crux of the problem is encountered, however, as for a non-inferiority trial if a
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cut-ofl is used to determine the non-inferiority limit then it is about this that interpretation 
would need to be made. Obviously one can assume proportional odds and that 
OR\=OR2=ORi= .. =ORk however, as highlighted previously in practice individual observed 
ORs will deviate at different cumulative cut-offs around an overall effect. This could be 
sub-optimal if the observ ed OR around the clinically meaningful cut off is approaching the 
non-inferiority limit.
Both the HADS and the RSCL highlight this point. For the former a score of 0-7 would 
indicate that a patient is assessed as 'Normal'. Whilst for the latter a score of 0-10 would 
indicate that a patient is a 'Non-case'. For both scales there would be no point 
demonstrating non-inferiority with an overall assessment of the odds-ratio if it cannot be 
proven at the clinically meaningful cut-offs.
To resolve such a problem obviously one could do some form of step down procedure. 
First test the overall odds-ratio and if non-inferior test the odds-ratio around a cut-off for 
non-inferiority. However, such an approach would be driven by the least efficient 
comparison i.e. the one on the dichotomous cut off.
In a roundabout, way, therefore, what one is saying is that for non-inferiority trials it is 
operationally easier to design and analyse them as if they were binary, using the methods 
described in Chapter 3, about the clinically meaningful cut-offs (or several dichotomous 
cut-offs simultaneously as for HADS). This has an obvious adverse effect on the sample 
size, as highlighted in the discussions on superiority trials, however, non-inferiority trials 
are conservative by nature and one's approach should reflect this.
The remainder of this section will briefly describe the calculations as if the trial will be 
designed and analysed on the ordinal scale.
5.4.1. Parallel Group Trials
5.4.1.1. Sample Sizes that are Estimated Assuming that the Population Effects are Known 
Remember the following result for non-inferiority studies from Chapter 1.
V ar(S) = — ^ Z ^ - - .  (5-3.1)
( Z , « + Z .  „ Y
Here d here is the non-inferiority limit of interest, A is the anticipated mean difference and 
var(S) is the estimated sample variance for the log-odds-ratio for an ordinal response.
An estimate o f the variance for the log-odds-ratio can be made from [Whitehead, 1993]
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Var (5) ( k \ 
' 7 - 1  p.v i /
(53.2)
where p , is the average response each outcome category. By equating (5.3.1) with (5.3.2) 
one requires
6|Z|-/y + Z, a p
(5.3.3)
where d is the non-inferiority limit, k is the number o f categories and log(OR) is an 
estimate of the difference between treatments
5.4.1.2. Sensitivity Analysis about the Variance that is used in the Sample Size Calculations
To assess the sensitivity of the study to the variance used in the calculations (5.3.3) could 
be re-written in terms of power as
l - / ?  = 0
The power could then be assessed a priori to a high plausible value of the variance, 
determined through bootstrapping, to determine the studies sensitivity to the assumptions 
about the sample variance.
Hog O R -c l/  / 6 — Z, (5.3.4)
5.4.1.3. Calculations Taking Account o f the Imprecision o f the Variance Used in the Sample 
Size Calculations
To account for the imprecision in the variance estimate used in the sample size calculations 
the following result could be used
i 0 908
i - / * = ■ -  y  o
0 .9 9 8
//flog ( 0 / 0 -  d / / [var(lo  g(O/0)],„„ -  Z, ,
-Z ,
(5.3.5)
<l>(vWlog (OR) -  dr  /[var(log(0/?))]A 
The percentiles for var(logOR)) are estimated through bootstrapping.
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5.4.2. Cross-over Trials
5.4.2.1. Sample Sizes that are Estimated Assuming that the Population Effects are Known
To calculate the sample size for a cross-over non-inferiority trial for ordinal data the 
following result could be used
[Zi/y +zi-„f var(log(<9tf))
n  = ----_—   --------------------------------------------
[log(0 /f)-« /]- • (5-3.6)
where OR and var(log(OR)) are as defined by (5.2.8) and (5.2.10) respectively.
5.4.2.2. Sensitivity Analysis About the Variance that is used in the Sample Size Calculations
To assess the sensitivity of the study to the variance used in the calculations (5.3.6) could 
be re-written in terms of power as
1 -  p  = O^yWlog O R - d f  / var(log(Otf)) -  Z, a ) (5 3 7)
with a plausibly high value used, estimating from bootstrapping, to assess the studies 
sensitivity.
5.4.2.3. Calculations Taking Account o f the Imprecision o f the Variance Used in the Sample 
Size Calculations
To account for the imprecision in the variance estimate used in the sample size calculations 
the following result could be used
1 - / 7  = ------- Y  0.:
0 .998
4>vV l o g ( 0 t f ) d  / / [ v a r ( l o g ( -  Z,  a
cDU/iflog (OR)-  df  4var(log(0/?))] -  Z, u
(5.3.8)
where the percentiles for var(logOR)) are estimated through bootstrapping.
5.5. As G ood  as or B etter T ria ls
The issues of as good as or better trials were discussed in detail in previous chapters and 
these arguments can be extended to ordinal data. The one issue to highlight is that in 
designing such trials one may be undertaking two different types of sample size calculation.
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One assuming the data is binary in form for the non-inferiority calculation and one 
assuming it is ordinal for superiority calculations.
5.6. E q u iva lence T ria ls
The same issues for non-inferiority trials discussed in earlier this chapter generalise to 
sample size calculations lor equivalence trials with ordinal responses. Where practical it is 
recommended that the data be treated as a binary response around an ordinal cut off (such 
as lor HADS and RSCL discussed earlier) and the methodologies described in Chapter 4 
for binary data be used.
5.6.1. Parallel Group Trials
5.6.1.1. Sample Sizes that are Estimated Assuming that the Population Variance is Known
5.6.1.2. General Case
Remember again that the variance about the log-odds-ratio can be defined as [Whitehead, 
1993]
r flr ( s ) = T - 4 - ^ r  (5-5-,)
" '  - X  P- I
v ■■ I J
where p t is the average response on each outcome category and k is the number of
categories. Consequently an estimate of the sample size for a given power can be estimated 
from
] - p  = cpf j / i |  I -Y  n ‘ j(loe(0/?)- (if '6 - Z, i -t 0>! (J J-Y  ~n■ \{\og(OR)idY 6 - Z, 1 - 1 ,  (5.5.2)
111 ; \ , \ i ]  ; ^  / 1
where d is the equivalence limit, k is the number of categories and log(OR) is an estimate 
of the difference between treatments
5.6.1.3. Special Case o f No Treatment Difference
As with equivalence trials discussed in previous chapters when an assumption is made of 
no true difference between treatments the calculations are simplified - with a direct estimate 
of the sample size possible. With the assumption of no true difference between treatments 
(equivalent to OR=l) the power can be estimated from
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r k /  ^e<NIII
f
d 2 / 6 - Z  ,.a
A / J ( 5 .5 .3)
whilst a direct estimate o f the sample size can be obtained from
- p  +  - a  ?n =
i - Z p ! d-  • (5.5.4)
5.6.1.4. Sensitivity Analysis About the Variance that is used in the Sample Size Calculations
As with superiority and non-inferiority trials discussed earlier to assess the sensitivity of a 
study to assumptions about the sample variance the power, for the same sample size, could 
be assessed from (5.5.2) using a plausibly high value of the variance. This high plausible 
value for the variance could be taken as a 95th percentile from a bootstrap sample.
5.6.1.5. Calculations Taking Account o f the Imprecision o f the Variances Used in the 
Sample Size Calculations
The sample size for an equivalence study accounting for the imprecision of the sample 
variance can be estimated from
\ (3= 1 y  rh+n'
0 .9 9 8  , h , .  2  . ( 5 . 5 . 5 )
where r\ ^  and rjH are defined as
71\ = l°g ) ”  ll > [var('og( <9/0 -  Z, „ )+ cD^'Vlog {OR[Hn ) + d )‘ /[var(log(0/?))]/HTi -  Z, _a ) -  1
'1: = ^Vlog(<9tf.,,, ) - 9  /  [var(log((;/f))j.........   -  Z, „ )+ 4>(v'Vlog ( O R ^  ) + <///[var(log(0/?))]^„.+„(Mll -Z ,.„ )- l
As discussed previously in this chapter the percentiles for the variance used in the 
calculation are estimated through bootstrapping.
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5.6.2. Cross-over Trials
5.6.2.1. Sample Sizes that are Estimated Assuming that the Population Variance is Known
5.6.2.2. General Case
An estimate of the sample size for a given power can be estimated from
\ - p  = (&y(\o£(OR) -</j*7 [ \a r ( lo g (6W))] / ,  , 1 - ^  v'Oog (OK) * ; / )7 [var(log(6>/?))] -  1 ,(5.5.6)
where OR and var(log(OR)) are as defined by (5.2.8) and (5.2.10) respectively.
5.6.2.3. Special Case o f No Treatment Difference
For the special case of no true difference between treatments (equivalent to OR=l) the 
power can be estimated from
(5.5.7)1 -  P  = 2o(V</: /[var(log (O/?))] -  Z ,. J - 1 >
whilst a direct estimate of the sample size can be obtained from
^ _ ^[Zi. p  + Z , _ a  j2
[var(log(0/?))}7“ • (5.5.8)
5.6.2.4. Sensitivity Analysis About the Variance that is used in the Sample Size Calculations
As described through this chapter the sensitivity of a study to its variance estimate can be 
determined through bootstrapping (from the original data the variance is estimated from) to 
calculate a high plausible value for the variance. This power of the study could then be 
determined through (5.5.6) to assess the sensitivity of the study.
5.6.2.5. Calculations Taking Account o f the Imprecision o f the Variances Used in the 
Sample Size Calculations
The sample size for an equivalence study accounting for the impression in the sample 
variance can be estimated from
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1 0 w s  n +  nl - /? = —1— y  U i l h .
0.998 ptrt -_(jo()i 2 (5  5 9 )
where rjA and rfH are defined as
= ® (/« n o g (C W „ „  W  /,[v a r (lo g (0 /< ))],.„  - 7 ,  „ )+ log (OR„.n > + < //'/[ v a r ( lo g (0 /f ) ) ]„ „ .-Z ,.„ ) - l
log ) -  d /  ■ [vanlog < « » ] , ,    -  Z, „ )+ ®(V/W log (O/f,.,, ) + <//’ ■hr(log(OK»]<„ , -  Z,.„ ) -  I
where the percentiles for [var(log(OR))] are estimated through bootstrapping.
5.7. E stim ation  to a G iven Precision
5.7.1. Parallel Group Trials
5. 7.1.1. Sample Sizes that are Estimated Assuming that the Population Variance is Known
Earlier in this chapter detailed sample size derivation for efficacy trials with ordered 
categorical endpoints were given [Campbell, Julious and Altman, 1995; Julious, Walker, 
Campbell et al, 1997; Julious, George, Machin et al, 1997]. This work can be extended to 
trials based on precision. For ordered categorical data the difference between two regimens 
may also be expressed terms of an odds-ratio (OR)
d  = OR = P a V - P b )  
P b ( ] ~  P a )
(5.6.1)
A (l -  a )  100% confidence interv al for log(d) can be estimated using the following variance 
[Whitehead, 1993]
Vcir(\og((l)) =
i - T p '
i I
(5.6.2)
Therefore, for a given half confidence interval width, w, around the odds-ratio the 
following condition must be met to obtain the sample size per group
6 Z;n -
(log(l -  \v)f / - I  P',
(5.6.3)
where p t are the expected mean responses for each of the categories on the scale. In fact it
is an advantage to have the variance estimated from the mean responses here. This is 
because for estimation trials the objective is to estimate possible differences between
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treatment and as such a priori it is reasonable to assume that the response on each treatment 
to be unknown. What is more likely to be known is the anticipated mean response.
5.7.1.2. Worked Example
A pilot study is being planned to estimate the odds ratio between comparator and control 
regimens where the primary endpoint is an ordered categorical outcome with 4 points on 
the scale. The wish is to quantify the odds ratio within ±55% (i.e. w=55%). It is 
anticipated that the mean responses across the scale are equal i.e. that 
P \ ~ P i ~  Py  ~  Pa = ^-25 ■ Thus, the sample size required is 39 patients per arm.
5. 7.1.3. Sensitivity Analysis About the Y'ariance that is used in the Sample Size Calculations
In assessing sensitivity of a precision based trial instead of interrogating the power of the 
study to high plausible values for the variance one instead interrogates the loss in precision. 
This could be done through re-writing (5.6.3) in terms of precision (assuming w <l)
,og(1 _  w ) = (5 6 4 ) .
As with other calculations in this chapter the high plausible value for the variance is 
calculated through bootstrapping.
5.7.1.4. Worked Example
The estimated variance used in the earlier worked example was 6.4. Suppose that this was 
based on data from just 25 patients. Bootstrapping produces an estimate for the 95th 
percentile for the variance of 6.87, a 7.4% increase. This will equate to the precision in the 
point estimates reducing to 56.1%.
5. 7.1.5. Calculations Taking o f Account the Imprecision o f the Variance Used in the Sample 
Size Calculations
To account for the imprecision in the variance estimate for sample size calculations one 
could use the following result
i 0 90S
I  05
O^.'/jflog (OR) -  <J f  [var(log((9tf))]/Jt.,( Z, a 
+ ®[yjn( log (OR) df [var(log((7/0)]ptr< -  Z, u ,
>0.50 (5.6.5)
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where the percentiles for var(log(OR)) are estimated through bootstrapping.
5 .7 .1.6. Worked Example
Accounting for the fact that the original variance was estimated from 25 patients in the 
sample size calculation would increase the sample size to 40 patients from the 39 
previously calculated.
5.7.2. Cross-Over Trials
There is a big issue in the calculation of sample sizes for precision based cross-over trials in 
that the results from (5.2.8) and (5.3.10) require information on individual cell counts -  
which a priori one would not be expected to know but would in fact be trying to estimate.
Earlier in this chapter it was highlighted how to estimate the sample size for other types of 
trials (superiority, non-inferiority and equivalence) one could use the sample size for 
parallel group trials and take the sample size per arm to be the total sample size for a cross­
over trial. This would potentially under estimate the sample size a little (empirically 
between 3-7%). However, as precision based trials are quite small, in absolute terms the 
under-estimation would be quite small and could be circumvented by adding 2 say to the 
calculated sample size. It is therefore recommended to use the parallel group 
methodologies described in this sub-section of the chapter to estimate the total sample size 
for a precision based trial.
5.8. Sum m ary o f C hapter 5
This chapter demonstrates how simplifying calculations through dichotomisation for 
superiority trials can adversely impact on the sample size. However, for non-inferiority and 
equivalence trials, due to their conservative objectives, it is recommended that 
dichotomised calculations be used.
When assessing sensitivity it was demonstrated that assuming a chi-squared distribution for 
the variance provides a conservative assessment of sensitivity. However, simulations 
demonstrated the approximation to the chi-distribution does not hold so well for small 
sample sizes - particularly if one category dominates making the response practically a 
dichotomous response. The recommendation therefore would be to use bootstrapping 
developed in this chapter to assess sensitivity to the variance, as this is a generic solution 
that makes no assumption about the parametric form of the data.
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Extending the results of Chapter 2 to use a non-central t-distribution to calculate the sample 
size it was shown would provide a conservative estimate of the sample size. However, this 
chapter also demonstrated that bootstrapping developed in this chapter provide a solution to 
estimate the sample size that makes no assumption about the distribution of the variance. 
The recommendation is to use bootstrapping to calculate the sample size to account for the 
imprecision in the sample variance used in the calculations.
When designing a cross-over trial it was demonstrated that although a common effect size 
can be shared between a parallel group trial and a cross-over trial for ordinal data as for 
binary data unlike for binary data one can not use the parallel group results to calculate the 
sample size as this would lead to a potential underestimation of the sample size. It is 
recommended therefore that the more complicated cross-over ordinal methodology 
introduced in this chapter be used for sample size calculations.
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6 . C H A P T E R  6 - I S S U E S  A S S O C I A T E D  W I T H  C L I N I C A L
T R I A L S
6.1. Introduction
This chapter will describe a number of applied case studies that highlight issues associated 
with the design of clinical trials. The areas that will be covered are:
1. Adaptive Designs
2. Heteroscadicity of trials
3. Computer intensive methods
4. Designing based on a surrogate or novel endpoint
5. Individual clinical trials in context with wide clinical plans
In each case the objective of the chapter is not to give a definitive review of the 
methodologies but to show how their application can assist in the design of clinical studies 
pertinent to the issues described in the dissertation to date. For each case study in turn an 
introduction and summary will be given.
6.2. A daptive Designs
6.2.1. Introduction to Adaptive Designs
When NASA launches a rocket to Mars it does not point the rocket in the general direction 
of its target and launch it with their fingers crossed with a vain hope that in 2 years time it 
w'ill hit the red planet. It continuously monitors the course of the rocket tinkering and 
modifying its route to optimise the chances of success. Analogously in clinical trials why 
should one set up the study and then hope that the assumptions upon which the trial was 
designed were correct?
Throughout this dissertation the trial design assumption most investigated has been the 
assumption about the trial's variability. One solution to the problem of having an uncertain 
estimate of the variability is to be adaptive. The advantage of being adaptive is that it 
allows one to alter or stop the course of a study during its actual conduct such that 
unexpected occurrences are not encountered for the first time when the study has stopped 
and the final analysis undertaken. There are three approaches that one can adopt for 
adaptive designs [Julious 2004b],
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1. Apply a group sequential design where the sample size in each group is fixed but 
interim analyses are undertaken to investigate the null hypothesis with a decision made 
at each analysis to stop the trial for success or failure or to enrol another cohort.
2. A design is applied where at fixed interim analyses the parameters used in the 
estimation of the sample size are re-estimated, such as the variance for Normal data, 
and the sample size is adjusted accordingly. The null hypothesis is not investigated.
3. A combination of 1. and 2. where at the interim analyses both the null hypothesis is 
investigated and the sample size is re-estimated -  conditional on whether the trial is 
stopped for success or failure.
The first two approaches are relatively straightforward but the third is more complex, as the 
sample size re-estimation depends on a decision on the null hypothesis. This section will 
concentrate on group sequential designs and worked example will be introduced: a recently 
conducted two stage group sequential drug interaction study. There is a developing 
literature on this topic [Julious, 2004b, 2004e; Day, 2000; Browne, 1995; Zucker and 
Denne, 2002; Zucker, Wittes, Schabenberger et al, 1999; Proschan, Liu and Hunsberger, 
2003; Friede and Kieser, 2001; Liu, Proschan and Pledger, 2002; Gould 1992, 1995a, 
1995b, 2001; Gould and Shih 1992, 1998; Birkett and Day, 1994; Kieser and Friede, 2000; 
Wittes and Brittain, 1990]
6.2.2. Case Study
Recall from Chapter 1 a worked example was given of a bioequivalence study which failed, 
primarily, it was thought, due to an observed variance over twice as high about which the 
study was designed. This study led to the motivation of this dissertation, in particular the a 
priori investigation of the sensitivity of a study's design to assumptions about the variance 
used in the sample size calculations and the allowance for the imprecision of this variance 
used in the sample size calculations.
Another research area that dove tailed from this one study was an investigation of 
appropriate adaptive methodologies for critical path studies. Critical path studies being 
studies upon which the start or full implementation of other studies are dependent. The 
case study described here followed soon after the worked example described in Chapter 1 
and is described by Julious [2004b]
In this case study, a priori it was believed that an investigative compound might interact, 
from a pharmacokinetic point of view, with desipramine, leading to the plan to conduct an 
in vivo study prior to the start of phase III. For this case study the no effect criteria, used to 
determine if the investigative compound had any effect on the drug exposure of the probe 
drug desipramine (jnDtl) compared to desipramine alone ( p D), was 24% on the log scale.
Thus, the null and alternative hypotheses for the trial were:
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H0: Mt /Mr -  0-76 or p T/ p R ^ 1 -30.
Hi: 0.76 < f iTj n R <1.30.
Here, the "standard" 20% bioequivalence limits were not used as a priori because it was 
believed that the wider margin of (0.76, 1.30) was sufficient to declare no effect. Likewise 
it was believed that only the AUC had to fall within the no effect margin for no effect to be 
declared. The study followed the drug regulatory guidelines for drug interaction studies 
[FDA, 1999; CPMP, 1997],
One issue that became apparent w hen designing the study was that the variability observed 
in the pharmacokinetics of desipramine in previous studies varied quite markedly with three 
studies on file having within subject coefficient of variations (CVw) for AUC of 14%, 27% 
and 39%. There was no apparent rational for the diverse variabilities observed and so none 
of them could be discounted in calculations. This led to the issue of what variance to use to 
estimate the sample size as the CVw of 39% would lead to a sample size estimate 
approaching 5 times that a CVw of 14% would require.
To overcome this particular problem a tw o-stage group sequential design was applied. The 
advantage of this approach is that group sequential methodologies allow an interim analysis 
to be carried out on data from one cohort of subjects - w’here a decision can be made 
whether to stop the trial for success or failure or to enrol a second cohort of subjects. To 
allow for the fact that an interim analysis is made the overall type I error rate of the study 
should be maintained at 5% by the use of appropriate statistical methods. The concept of 
the group sequential trial is captured in Figure 6.1.
One issue to highlight with such trials is that it is essential that the stopping rule applied at 
the interim analysis be pre-specified.
For the case study therefore calculations were based on two one-sided tests, a type I error 
rate of 5% and a no effect range of 24% i.e. (0.76, 1.30). The group sample sizes were 
calculated assuming a true mean ratio of unity and CVw's of 27% and 39%, which gave a 
sample size of 30 subjects in each cohort. To ensure 30 subjects completed the study it was 
planned to have 34 subjects start in each cohort.
An equal allocation, 2.5%, of the type 1 error was spent in each cohort using a simple 
Bonferoni correction. This alpha spending allocation is a little conservative but it was a 
pragmatic allocation given the equal cohort sample sizes. With the Bonferoni correction 
"adjusted" 90% confidence intervals were presented such that the overall Type I error was 
maintained at 5% i.e. in the calculation of the confidence intervals a /2  and not a  was
used. Operationally, this is equivalent to undertaking the two one-sided test procedure but 
then doubling the P-values calculated.
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Another pragmatic decision was the choice of CVw's for sample size calculations. The 
pooled estimate of the CVw from the previous three studies was 28.5% however for this 
study it was decided just to use the two observed CVw's of 27% and 39%.
Table 6-1. Sample size and sensitivity of the sample size to assumptions about the 
variability and mean ratio.
CVw Cohort N True Ratio
1.00 1.05 1.10
14% 1 30 99% 99% 99%
2 60 99% 99% 99%
27% 1 30 90% 83% 60%
2 60 99% 99% 90%
39% 1 30 42% 38% 28%
2 60 90% 82% 60%
Figure 6.1 gives a description of the study design and Table 6.1 gives the breakdown of the 
sensitivity of the study to deviations in the assumptions about the variability and the mean 
difference. This table appeared in the protocol of the study. As one can see the study was 
quite robust to most deviations.
Figure 6-1. Concept of a group sequential trial
1st c o h o r t  
n 3 0
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i n c r e a s e d  f r o m
2 6  to  3 0
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I f  T . a c k  o l  I n t e r a c t i o n '  t h e n  
S T O P
II c l e a r l v  I n t e r a c t i o n  t h e n  S T O P  
I f  i n c o n c l u s i v e .  C O N  P IN U P .
   . ]
a d j u s t e d  O ° o  C l  
n = 3l)
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a n d  0. 0 5 -  I r u e  ra t i o  ■ 1 1)3
2nd c o h o r t  
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The following stopping rules were applied at the interim analysis
1. Lack of interaction; the adjusted 90% confidence interval for the ratio 
(S+I):S of AUCs for desipramine falls within (0.76, 1.30)
2. Clear interaction: the ratio (S+I):S of AUCs for desipramine falls outside 
(0.76, 1.30)
3. Otherwise: recruit a further 30 subjects.
A total of 34 subjects were included in the interim analysis. In the actual study at the 
interim analysis the adjusted 90% confidence interval for the ratio was (D+I)/D=0.94 
(0.89, 1.00) with CVw=11.7 % - a lower than expected variability. Therefore ‘lack of 
interaction’ of the compound on desipramine was demonstrated and the study stopped.
Had the study continued to a second cohort, the plan was to perform a “fixed sample size” 
analysis in each cohort separately and then to combine the two cohorts using the method 
described by Gould [ 1995b].
6.2.3. Sample Size Re-estimation - Extending the Work of the Dissertation
It is worth noting that adaptive designs and the methodologies developed in this dissertation 
can be married to give sample size re-estimation methodologies.
Zucker and Denne [2002] give the following sample size re-determination formula for an 
interim analysis
where sj is the variance estimated from the interim analysis, d is the effect size of interest, 
Z |.u : and Zi.fj are the corresponding percentiles for the standard Normal distribution for a 
significance level a  and power 1-/3 and IF is the "Inflation Factor" that accounts for the 
imprecision in .v;. This correction factor is estimated through numerical methods [Zucker 
and Denne, 2002; Zucker, Wittes, Schabenberger et al, 1999]. However, Julious [2004e] 
highlighted that the inflation factor can be derived directly without the need to use 
numerical methods (see Chapter 2).
The direct derivation is relatively straightforward. First re-consider the "standard" way of 
estimating a sample size through using an equation of the form
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2(^1-/* + z, a : )2^ /
n  =  -  -— - — ' . ( 6 .2 . 2 )  
d 2
To account for the fact that .v; is an estimate of the population variance instead of using 
(6.2.2) (6.2.3) below (as given in Chapter 2), should be used to allow for the uncertainty in 
the sample variance used in the calculations (as assessed by its degrees of freedom)
„ / , . . ) ]
d '
where TINV(*,m,a) is an (monotonically increasing) inverse function of the cumulative 
distribution function of a Students non-central t distribution with m degrees of freedom and 
non-centrality parameter a. Here, m is the degrees of freedom of the variance estimate, s j , 
used in the calculations. Now' the ratio of (6.2.2) and (6.2.3) depends only on a, P and m 
and not on s or d. Thus, by taking the ratio of (6.2.3) over (6.2.2) an inflation factor (IF) 
can be derived directly that adjusts the interim sample size recalculation for the uncertainty 
in the interim variance estimate
I F j T I N V ( l - f l , m . Z  ff (6 2 4 )
\ Z l -a - 2  +  Z \ - p )
Table 6.2 gives the inflation factors for different degrees of freedom calculated from
(6.2.4). Equation (6.2.4) agrees with the numerical methods described by Zucker and 
Denne [2002] to 2 decimal places.
Table 6-2. Table of correction factors for different degrees of freedom assuming a 2 
tailed type I error rate of 5% and power of 90%
Degrees of Calculated 
Freedom Inflation Factors
10 1.30
15 1.19
20 1.14
25 1.11
30 1.09
40 1.07
50 1.05
Note that if one multiplies (6.2.1) by (6.2.4) one obtains (6.2.3), the direct estimate for the 
sample size, allowing for the degrees of freedom of the sample variance that was given in 
Chapter 2.
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6.2.4. Summary of Adaptive Designs
Group sequential and adaptive methodologies can overcome the problems associated with 
imprecise estimates of variability. Although the design in the case study did not allow for 
sample size re-estimation the sensitivity analysis highlighted that the study was robust to 
deviations in the assumptions made in the sample size calculation.
Why do people not use adaptive methods more often? One reason is that it is not routine 
from an operational perspective to implement. In the phase I drug interaction case study 
described it was straightforward to implement the group sequential methodologies as the 
investigators conducting the trial controlled the recruitment rate. Hence, it could be fixed 
for subjects to arrive in a group sequential manner. For later phase trials this is not the case 
and the recruitment of subjects is not, usually, in the direct remit of the investigator.
There are a number of other operational issues associated with applying adaptive 
methodologies.
One may find that the recruitment rate may be so fast that by the time sufficient subjects 
have enrolled (and then had there data entered, cleaned and analysed) for interim 
assessment of the primary endpoint, recruitment may have completed. This point could be 
overcome to a degree by having a proven surrogate for the primary endpoint that would 
allow for adaptive decisions to be made.
Another issue is that upon starting a trial all centres do not immediately start recruiting - it 
may take over 6 months to initiate all centres. Thus, an early sample size review may be 
conducted on an unrepresentative sub sample of the current trial population, which may 
impact on calculations. See discussion later on heteroscadicity.
6.3. Investigating H eteroscad icity
6.3.1. Introduction to Heteroscadicity
As highlighted throughout this dissertation one of the most important components in the 
sample size calculation is the variance estimate used. This variance is usually estimated 
from retrospective data sometimes from a number of studies. To adjudicate on the relative 
quality of the variance, as discussed in Chapter 1, Julious [2004a] recommended
considering the following aspects of the trial(s) from which the variance is obtained.
1. Design: is the study design ostensibly similar to the one you are designing? On the 
basic level are the data from a randomised controlled trial - observational or other 
data may have greater variability. If you are undertaking a multi-centre trial is the 
variance estimated too from a similarly designed trial? Were the endpoints similar 
to those you plan to use -  not just the actual endpoints but were the times relative to 
treatment of both the outcome of interest and the baseline similar to you own?
313
Table 6-3. Baseline demographics and variances from 20 randomised controlled trials placebo data
Study HAM D
Entry
Criteria
N um ber Duration Y ear Population 
o f
Centres
Region Phase Sam ple 
Size
D egrees
o f
Freedom
V ariance
1 18 1 6 1984 Adult N orth A m erica II 25 22 41.59
2 18 1 6 1985 A dult/G eriatric North Am erica II 169 160 59.72
3 18 6 6 1985 A dult/G eriatric North A m erica III 240 232 57.11
4 21 3 6 1986 A dult/G eriatric North A m erica III 12 9 62.97
5 18 10 6 1985 A dult/G eriatric North Am erica III 51 49 58.32
6 18 28 12 1991 A dult/G eriatric North A m erica III 117 109 42.51
7 18 23 12 1991 Adult/G eriatric North Am erica III 140 133 68.98
8 18 12 8 1992 A dult/G eriatric North Am erica III 129 121 51.81
9 18 1 6 1982 Adult Europe III 21 19 62.44
10 15 1 6 1983 A dult/G eriatric Europe III 10 8 44.71
11 15 12 12 1994 A dult/G eriatric North A m erica III 85 80 38.81
12 13-18 12 8 1994 Paediatric North A m erica III 87 85 46.09
13 15 18 10 1994 Adult North A m erica IV 43 41 60.01
14 15 20 12 1996 Adult North Am erica III 101 99 61.42
15 20 20 12 1996 Adult North Am erica III 110 108 61.65
16 18 29 12 1996 Geriatric North A m erica III 109 105 45.54
17 20 40 8 2001 A dult/G eriatric North Am erica III 146 140 58.36
18 18 1 4 1983 Adult Europe III 23 20 43.64
19 18 1 4 1983 Adult Europe III 3 1 19.32
20 18 1 4 1989 Adult Europe II 4 2 43.9
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2. Population: is the study population similar to your own? The most obvious 
consideration is to ask is whether the demographics were the same but if  the trial 
conducted was a multi centre one was it conducted in similar countries? 
Different countries may have different types of care (e.g. different concomitant 
medication) and so may have different trial populations. Was the same type of 
patient enrolled the same (same number of mild, moderate and severe cases)? 
Was it conducted covering the same seasons (relevant for conditions such as 
asthma)?
3. Analysis: was the same statistical analysis undertaken? This means not just the 
question o f whether the same procedure was used for the analysis but were the 
same covariates fitted into the model? Was the same summary statistics used?
The quality o f the variance estimate will obviously influence the sensitivity o f a trial to 
the assumptions made about the variance and will obviously influence the strategy o f an 
individual clinical trial. Depending on the quality o f the variance estimate (or even if 
one has a good variance estimate) it may be advisable, as discussed earlier, in this 
chapter, to have some form of variance re-estimation during the trial.
Even if one has a good estimate o f the variance what guarantee is there that the trial 
population from which the population is taken will be the same as the one the 
prospective trial will be drawn? One could perform two apparently identical trials 
(same design, same objectives, same centres) but this is not a guarantee that each trial 
will be drawn from the same population. For example concomitant medicines may 
change over time. In addition the technologies associated with the trials may change, 
from technologies associated with study conduct to the technology used to actually 
assess subjects.
The question being raised here is the heteroscadicity of trials. Empirically this can often 
hold for example McClung, Quessey, Julious et al [2004] observed that in COX-2 
inhibitor trials in rheumatoid arthritis there was a 10% difference in placebo response 
for the primary endpoint of proportion of subjects being an ACR20 responder in North 
America (29.3%) compared to the rest of the world (40.0%). If all trials were indeed 
drawn from different populations then it would be problematic to base one trial design 
upon another. For the rheumatoid example quoted different response rates would need 
to be used depending on the region where the study is to be conducted.
Recommendations as to how to investigate heteroscadicity will be made through a case 
study.
6.3.2. Case Study
In designing a clinical trial for depression variability data were collated from a number 
o f trials. The primary endpoint for the prospective trial was the Hamilton Depression 
Scale (HAMD) [Hamilton, I960], An appropriate estimate o f the variance was thus 
required to use in the design of the prospective study.
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63.2.1. The Data
The placebo data from 20 randomised controlled trials were collated for the primary 
endpoint o f the HAMD 17 Item scale. The data sets were based on the Intent to Treat 
data set as this will be the primary analysis population in the future trial.
A summary o f the top-level baseline demographic data for each trial is given in Table
6.2. The data span 18 years from 1983 to 2001. The studies are conducted in the two 
regions o f Europe and North America in a number of populations. The duration of the 
studies varies from 4 weeks through to 12 weeks.
63.2.2. The Methodology
As discusses in Chapter 2 to get an overall estimate o f the variance across several 
studies one can use the following result
± d f / ;
s 2„ = —t------- , (6.3.1)
z #1=1
where k is the number of studies, sj is the variance estimate from study i (estimated 
with dft degrees of freedom) and s 2p is the pooled estimate of variance.
To test the heterogeneity between the study variances Bartlett's test can be applied and 
compared to the chi-squared distribution [Bartlett, 1937; Armitage and Berry, 1987]
M / C (6. 3. 2) 
where
k \
Z #/ = ! )  /-I
C = l + -
J___
3(*^7) z
z * .
Armitage and Berry [1987] recommended using C in the test statistic only in marginal 
cases as it is usually close to 1.
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6.3.2.3. The Results
The pooled estimate o f the variance is 55.03, which is estimated with 1543 degrees of 
freedom. However, there does seem to be some heterogeneity in the sample variances 
in the different sub-populations, given in Table 6.4, with the variability overall in the 
paediatric population 46.09 (on 85 degrees of freedom) and in the geriatric population 
45.54 (on 105 degrees o f freedom). Also, albeit on smaller populations in Europe, there 
seems to be a difference between the two regions of North American and Europe.
Table 6-4. Baseline dem ographics and variances from 20 randomised controlled  
trials placebo data
O verall_________ Europe_______ N orth  A m erica
Population d f  r . 2
P
d f
%
d f
All 55.03 1543 50.48 50 55.19 1493
A dult 58.59 312 51.58 42 59.70 430
A dult/G eriatric 55.66 1041 44.71 8 55.74 1033
P adiatric 46.09 85 46.09 85
G eria tric 45.54 105 45.54 105
These differences, potentially, are not trivial either with differences in variances o f 20% 
knocking on to consequent 20% difference in the sample size estimate.
Note though that this investigation o f the heterogeneity ignores factors like HAMD 
entry criteria at baseline and study duration, which may also impact on the 
heterogeneity o f the studies. There is no evidence of any trends by time.
For an overall test of heterogeneity, however, the Bartlett test returns a P-value o f 0.561 
(excluding C in the calculation) and 0.519 (including C). Thus, although the seems to 
be some evidence o f differences in the different demographic populations the Bartlett 
test statistic infers that the individual studies themselves are drawn from the same 
population (and thus the demographic differences may be down to chance).
The data can also be examined pictorially. Data taken from a chi-squared distribution 
can be approximated to a Normal distribution with mean yj2df -  1 and variance 1. This
result only technically holds for large n (and there are some small sample sizes in the 
case study), however, most of the studies are reasonably large. Hence, by taking away 
y]2df\ -1  from each study (and dividing by 1) one can convert each of the variances to
a scale, which approximates to the standard Normal. From these amended variances a 
Normal probability plot can be constructed.
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Figure 6-2. Normal probability plot of the observed variances across the 20 studies 
in the heteroscadicity case study
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Figure 6.2 gives the Normal probability plot for the data. The bounds around the line 
are confidence bounds calculated using the methodologies o f Friendly [1991], Thus, 
this figure pictorially supports the result from the Bartlett test.
6.3.2.4. Summary' o f Heteroscadicity
This case study is good in that at first, with 20 studies, it seems that one has ample data 
upon which to estimate a variance for a sample size calculation. However, by definition 
the reason why there are so many studies is to interrogate different populations. Once 
one drills down into the data to optimise calculations for the prospective trial: same 
population; same study design and same region, there was fewer data to rely upon.
When assessing the data at a global level, however, there seemed to be no 
heteroscadicity between the studies. The evidence seems to suggest that the assumption 
that each study was drawn from the same population holds and that a global, pooled 
estimate, of the variance should be sufficient to power the prospective study.
6.4. D esign in g  B ased  on a S u rrogate  or N ovel E n d poin t
6.4.1. Introduction to Designing on a Surrogate or Novel Endpoint
In the calculation of a sample size one of the most important steps is the quantification 
o f an effect size to use in the sample size calculations. This is not straightforward for a 
conventional established endpoint. However, for a novel (or surrogate) endpoint it is 
particularly difficult as the clinical experience with using the endpoint has not been 
established to evaluate what a clinically meaningful difference is.
What may assist in establishing a clinically meaningful difference for a novel endpoint, 
however, is the association the novel endpoint may have with more established 
endpoints. If a clinically meaningful difference is known for these established
endpoints then the association may be used to quantify an effect for the novel endpoint.
N o r r r ' a l  G u a r v l l e
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The case study below describes the calculations for quantifying an effect size in a stroke 
trial using a novel endpoint, the 16-question version o f stroke impact scale (SIS-16) 
[Duncan, Lai, Bode et al, 2003; Duncan, Wallace, Lai et al, 1999]
6.4.2. Case Study
The SIS-16 assessed at three months was being considered as the primary endpoint for a 
stroke trial. It was felt to have advantages over conventional scales which we 
considered to lack sensitivity to detect possible clinical effects. For example the Barthel 
scale, often used as a primary endpoint, could have people with quite different 
disabilities getting the same score. As the SIS-16 is a comparatively novel endpoint 
designing a study with it as the primary endpoint led to the issue of quantifying a 
clinically meaningful difference. However, for other health outcomes used commonly 
in stroke trials, Barthel, NIHSS and Rankin, a clinically meaningful difference may be 
known and these have an association with SIS-16. Thus, the association between the 
other health outcomes and SIS-16 can be used to estimate a clinically meaningful 
difference for SIS-16 [Julious and Khandker, 2003],
6.4.2.1. The Methodology
The estimated treatment effect for each established health outcome was taken as an 
odds-ratio. A previous empirical distribution for the health outcome scores at three 
months was assumed to be the prospective placebo response. The health outcome score 
distribution on active was estimated from the placebo response under the assumption of 
proportional odds [Campbell, Julious and Altman, 1995; Julious, Walker, Campbell et 
al, 2000; Julious, George, Machin et al, 1997; Julious, George and Campbell, 1995].
To estimate an effect size for the SIS-16 following four steps were applied.
1. For each health outcome category the mean SIS-16 response was calculated.
2. Using the methods described above the expected proportions on active and placebo 
were estimated.
3. By multiplying the mean response for each response by the expected proportion and 
then summing an expected mean response was obtained for both active and placebo.
4. The difference in the mean overall responses on active and placebo were taken as an 
estimate of treatment effect for SIS-16 equivalent to the effect of interest for health 
outcomes.
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Table 6-5. Worked example of the effect size estimation through associating SIS-16
with Rankin - dichotomised scale
Step 1. Calculate mean score for each Rankin category
Rankin SIS-16
Mean
0-1 90
2-5 51
Step 2. Estimate active and placebo proportions
Rankin SIS-16 Observed Placebo Anticipated Active
Mean Proportion Proportion
0-1 90 0.33 0.43
2-5 51 0.67 0.57
Step 3. Multiply mean score with corresponding sample proportions and sum  
across categories
Rankin SIS-16 Observed Mean x Anticipated Mean x
Mean Placebo Proportion Active Proportion
Proportion (placebo) Proportion (active)
0-1 90 0.33 29.7 0.43 38.7
2-5 51 0.67 34.2 0.57 29.1
Expected overall mean 63.9 67.8
Step 4. The difference taken between active and placebo means 
treatment effect for SIS-16.
to estim ate the
Rankin SIS-16 
Mean
Observed
Placebo
Proportion
Mean x
Proportion
(placebo)
Anticipated
Active
Proportion
Mean x
Proportion
(active)
0-1 90 0.33 29.7 0.43 38.7
2-5 51 0.67 34.2 0.57 29.1
Expected overall mean 63.9 67.8
Treatment Effect 67.8-63.9 =3.9
6.4.2.2. Worked Example
6.4.2.3. Dichotomised Response
For expository purposes to highlight the calculations the worked example will be first 
undertaken first dichotomising each of the scales around the clinically meaningful cut­
offs.
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Different treatment effects sizes were investigated on Barthel, Rankin and NIHSS to 
determine the associated effects with SIS-16:
• NIHSS - to increase the proportion of subjects classed as mild stroke (0-5%) at
three months by 10%
• Rankin - to increase the proportion of subjects with Rankin score 0-1 or a Rankin
score 0-2 by 10%
• Barthel - to decrease the proportion of subjects with a Barthel score 0-60 by 10%
To illustrate the calculations the calculations associating SIS-16 with increasing the 
proportion of subjects with Rankin score 0-1 are given in Table 6.5. The four sub-tables 
of Table 6.5 give the 4 steps of the calculations described in the methodology section 
earlier.
Table 6-6. Treatment effects for S1S-16 associated with effects on the Rankin, 
NIHSS and Barthel - dichotom ised Scale.
Mean Bootstrap
______________ Difference 95% Cl __
Rankin 0-1 T85 3.51 to 4.28
Rankin 0-2 4.36 3.99 to 4.74
NIHSS (0-5) 4.16 3.67 to 4.72
Barthel 0-60 6.54 _______ 4.82 to 6.25__
Table 6.6 gives a summary of the effect sizes on SIS-16 associated with the three health 
outcomes. The confidence intervals are calculated using bootstrapping and give a 
measure of precision for the point estimates [Efron and Tibshirani, 1993]. Basically to 
do the bootstrapping repeat samples were taken with replacement from the data. For 
each sample an effect size was estimated and across the bootstrap sample an empirical 
"bootstrap" distribution was formed of effect sizes. From this bootstrap distribution the 
appropriate percentiles for the confidence interval were taken.
Decreasing the proportion of subjects by 10% on Barthel seems to be associated with 
the largest effect on SIS-16. This is probably down to the fact that in relative terms an 
absolute difference on this scale is quite large. It seems from these simple calculations 
that a mean effect of around 4 on SIS-16 would be associated with meaningful effects 
on the other health outcomes.
6.4.2.4. Ordinal Response
As Table 6.7 highlights by dichotomising a scale one is throwing away a fair amount of 
information. This is illustrated by the different mean responses in the categories 
collapsed into 0-1 and 2-5 in the dichotomised example earlier.
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Table 6-7. Worked example of the effect size estimation through associating SIS-16
with Rankin - ordinal scale
Rankin SIS-16
Mean
Observed
Placebo
Proportion
Observed Placebo
Cumulative
Proportion
Anticipated
Active
Proportion
Anticipated Active
Cumulative
Proportion
0 92 0.13 0.13 0.19 0.19
1 85 0.19 0.33 0.23 0.43
2 76 0.19 0.52 0.19 0.62
3 63 0.20 0.72 0.18 0.80
4 38 0.21 0.93 0.15 0.95
5 15 0.07 1.00 0.05 1.00
The same effect size is used as for the dichotomised scale but here the absolute 
difference is converted to an odds-ratio, which is then applied across the full scale to 
estimate the anticipated active response.
Table 6-8. Treatment effects for SIS-16 associated with effects on the Rankin, 
NIHSS and Barthel - ordinal scale.
Mean
Difference
Bootstrap 
95% Cl
Rankin 0-1 5.20 4.78 to 5.68
Rankin 0-2 4.97 4.57 to 5.43
NIH 5.19 4.68 to 5.64
Barthel 0-60 6.63 6.04 to 7.35
Table 6.8 gives a summary of the effect sizes, and confidence intervals for these effect 
sizes, on SIS-16 associated with the three health outcomes. It seems that a 5-point 
increase in SIS-16 across the scores is associated with effects on Rankin, NIHSS and 
Barthel. The association with Barthel again gives the largest estimate of treatment 
effect.
It is reassuring that the ordinal calculations are consistent with those for the more 
simpler dichotomised approach. However, because of the additional information used 
in the calculations it is recommended that the ordinal approach be used for effect size 
estimation.
Although not covered in detail here the calculations can be extended for multiple 
calculations. In the worked example absolute differences were used to estimate odds- 
ratios, which were then used as a basis o f effect size estimation. However, if  only odd- 
ratios were used a variety off odds-ratios could be examined to determine different 
effect sizes. Figure 6.3 illustrates this point. The mid-line is the point estimate o f effect 
size for different odds-ratios. The lower and upper lines are the bootstrap confidence 
intervals about this effect estimate line.
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Figure 6-3. Treatm ent effect sizes on SIS-16 against different effects on the Rankin  
(odds-ratios)
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6.4.3. Summary of Designing on a Surrogate or Novel Endpoint
The calculations in this case study highlight how simple calculations can enable one to 
estimate effect sizes for a novel endpoint if one has information on established 
outcomes. The same calculations could be extended to provide effect sizes for a 
surrogate associated with a primary outcome.
In the case study it seemed that a 5 point in improvement on SIS-16 would be 
associated with clinically meaningful effects on the more established outcomes.
Note though that here we are associating means with means. What one is saying is that 
on average if one increased the mean SIS-16 by 5 this would be associated with a mean 
increase in the proportion of subjects with mild stroke by 10%. No inference is being 
made on individual data and individual predictivity.
6.5. C om p u ter  In ten sive  M eth od s
6.5.1. Introduction to Com puter Intensive M ethods
Throughout this dissertation computer intensive methods have been used either to 
validate the sample size calculations or to undertake the sample size calculations. In 
Chapter 2 simulations were performed to validate the methodologies recommended; in 
Chapter 4 computer intensive methods were used to calculate sample sizes; while in 
Chapter 5 bootstrapping was applied to estimate the sample size.
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In a case-by-case basis computer intensive methods can be a valuable too. If one has 
data from a prior, similarly designed, study then one could use these data to 
prospectively design future studies.
At the simplest level one could bootstrap, say, from these data to calculate the sample 
size. This strategy is particular useful if  one is undertaking a statistical analysis for 
which there is no easy methodology for the calculation of the sample size. Alternatively 
one could use simulation-based methodologies to investigate such things as hierarchical 
testing strategies to minimise the Type I error.
As well as computer intensive methods to design a study one could use them to analyse 
the study. For example in Chapter 3 bootstrapping was recommended as way of 
calculation confidence intervals for the number needed to treat.
In the case study below it will be highlighted how simulations at the design stage could 
assist in both the design of the study and in the final statistical analysis - as well as the 
decision as to the most appropriate statistical analysis [Julious, 2001],
6.5.2. Case Study: Change Point Regression
When people exercise they need to produce energy and there are different metabolic 
pathways by which this energy is obtained (aerobic and anaerobic). For a given 
individual it is important to know whether a given pathway changes during exercise 
and, if so, when. One way of detecting this is through examining the relationship 
between the two metabolic variables over time while the person is exercising. In this 
case study a rower was to be connected to measuring equipment that reads physical 
responses over time. The workload was increased over time; that is, the resistance of 
the rowing machine to the rower was increased.
The variables considered here are those of volume of oxygen inhaled and carbon 
dioxide exhaled in a minute. The measurements were taken every thirty seconds up to a 
maximum of 17.5 minutes. What is of interest is whether there is an approximately 
linear relationship between the two variables or whether there is a change in slope once 
a critical level of oxygen inhalation is reached. The change-point represents the point at 
which a subject switches metabolic pathways, from aerobic to anaerobic.
The change-point regression problem was described by Quandt [1958, 1960] since 
when there has been an extensive literature [Shaban, 1980; KLrisnaiah and Miao, 1988]. 
It can be applied to physiological situations where the regression slope is not expected 
to be constant but to change suddenly at a given point. It is this "change-point" which is 
o f primary interest, as it may be a marker for a change in some physiological response, 
such as age o f the menopause in a plot of bone density against age in a study of female 
bones [Lees, Molleson, Arnett et al, 1983], or, as here, anaerobic thresholds in subjects 
exercising to exhaustion [Bennett, 1988].
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If the location of the change-point is known then the estimation of the parameters in the 
model is straightforward; however, if  it is not known an extra parameter (the change- 
point) has to be estimated. Furthermore, the problem is no longer linear and the only 
way to estimate the parameters is through numerical optimisation.
This rowing model is a pharmacology model that can be used in healthy volunteers in 
early phase drug development, to investigate the possible pharmacological activity o f a 
new chemical entity. More than one subject would undertake the challenge, maybe in a 
cross-over trial with a number o f regimens or doses. New chemical entities that could be 
investigated in this pharmacological model are therapies that increase glycogenolysis, 
increasing hepatic and muscle glycogen stores, or therapies that reduce lactic acid 
production, such as creatinine containing products. These types of therapies would be 
expected to delay the change-point from aerobic to anaerobic production.
6.5.3. Location of C hange-point Known
Although for the data in this planned study the location of the change-point could not be 
assumed to be known it is informative to discuss this special case first.
6.5.3.1. Estimation o f Model
For any interval (Xo, X \ ) on the real line the problem is defined as follows
f(x ,) = f| (X| ;/?,) X0 < x, < S
= f,(x , ;/? ,) i5< x : < X, ’
such that f ,(5 ;P ,)  = f, (5 ;p ,) ;  i.e. the slope of the relationship between y and x is
constant until a point along the x-axis, 5, when it suddenly changes with no 
discontinuity in the regression relation. For a simple two-line linear regression this is 
equivalent to
f(x,) =Gti+p|Xj 
=a:+p2X,
X0<x,<5,
5<x,<X|
where the parameters are constrained so that «/+/?/<5= a?+/??£, such that the function 
f(x) is continuous, although not differentiable at the change-point. The least-squares 
estimates of the regression parameters can be derived from normal equations or 
alternatively the parameters for each half of the model can be estimated from [Hudson,
1966]
• , (  * ^
i±
k j
5 n -1 -C  q ,
t
(6.5.1)
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where
k  =  {X\_ X , / ‘ X l Y j ,
*
P \ = ( X [  X^ ) 1 X^Y:,
the unconstrained maximum-likelihood estimates of p, and (3, i.e. a two-line model
that is not constrained to meet at a known change-point in the range of the data. It is 
evident therefore that one way o f deriving the least-squares estimates of the parameters 
is to first estimate the parameters o f the two-line model where the lines are not 
constrained to meet at a known change-point, and then adjust these unconstrained 
estimates so that the two lines are constrained to meet at a known change-point.
6.5.3.2. Testing fo r  a Regression Change when the Location o f  the Change-Point is 
Known
A two-line regression model will have residual sums of squares not larger than those 
for the corresponding one-line model. Therefore, to test whether the two-line model has 
a statistically better fit the total residual sum of squares can be used to see whether the 
more complicated two-line model significantly reduces the error. This leads to an F-test
f = . .R.s s ‘.: R S S - . ( 6 . 5 . 2 )
RSSz /  (T - 3 )
Here the RSSi and RSS2 are the residual sums of squares for the one- and two-line 
models respectively and T is the number of observations. The statistic has an F- 
distribution with 1 and T-3 degrees of freedom.
6.5.4. Location of Change-point Unknown
The more general case is the situation o f unknown change-point which will now be 
described.
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Figure 6-4. Algorithm to obtain an estimate of the change-point
Yes No
Fit all possible unconstrained two-line models.
Is the smallest RRSS <the smallest URSS?
If two lines meet such that xt <6 <  xt+i then calculate total 
restricted residual sums of squares (RRSS), else calculate 
total unrestricted residual sums o f squares (URSS)._______
Take the smallest RRSS as the best model and its parameters 
as the least squares estimates for the slopes and change-point.
Constrain the unrestricted model with the smallest URSS to 
meet first at x, and then xm Select the model which has the 
smallest RRSS, and add to the RRSS models.
6.5.4.1. Estimation o f  Model
When the location of the change-point is unknown the problem is no longer linear. The
only way to estimate the parameters is through numerical optimisation and an algorithm
should be used derived (Figure 6.4) to estimate all the parameters in the model [Julious,
2001 ].
This algorithm works as follows.
1. All unconstrained two-line models are fitted and the algorithm determines if  each o f 
these models meets within the required region on the x-axis (x,, xt+i).
2. The unconstrained models that meet within the required points are re-coded as 
constrained models. The algorithm then determines whether the residual error from 
the best fitting constrained model is smaller than the residual error from the best 
fitting unconstrained model. If so, then the algorithm stops and takes the 
constrained model with the smallest residual sums of squares as the least squares 
estimates. If not, then the best fitting unconstrained model is constrained, using
(6.5.1) to meet at either x, or xt,| and added to the constrained models.
3. This process is repeated until one obtains the least squares estimates.
Figure 6.4 more clearly explains the iterative process.
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6.5.4.2. Testing fo r  a Regression Change when the Change-Point is Unknown - An F- 
statistic
An F-statistic can be derived [Worsley, 1983] that again uses the ratio o f the sum of 
squares between the one- and two-line models,
r  ( RSS\ ’ R S S i ) / 2b  -------------------------. (6.5.3)
RSS2 /  (T  - 4  )
If the change-point has to be estimated, this no longer has an exact F-distribution under 
the null hypothesis [Hinkley, 1988], if the statistic had an exact F-distribution it would 
be with 2 and T-4 degrees o f freedom.
6.5.4.3. Simulation Comparison o f  the Asymptotic F-Test
To investigate how well the distribution of the "F" statistic from (6.5.3) is approximated 
by the F-distribution, simulations were performed using the Interactive Matrix 
Language (IML) in SAS [SAS, 1985]. Simulated F values were generated by fitting a 
two-line model to a set of data simulated from a one-line model. The null model was 
assumed to have a common slope of 2 (intercept o f 0), with a variance of 100. The 
simulation was repeated 1000 times.
If regular asymptotic theory could be applied then the "F" statistic would have an F- 
distribution on 2 and T-4 degrees of freedom. There were 100 points fitted by each 
model (xi = 1, x^=2,...x ” 100), giving an F on 2 and 96 degrees of freedom. Figure
6.5 gives a probability plot of simulated F values, against ranked deviates distributed as 
F on 2 and 96 degrees of freedom. This plot looks fairly straight, except that there is a 
slight kink in the straight line at the beginning and at the end of the plot, although the 
slope does not seem to be unity.
328
Figure 6-5. Probability plot of ranked simulated F-values against ranked deviated 
distributed as F on 2 and 96 degrees of freedom
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An F-distributed random variable with m and n degrees o f freedom has expected mean 
and variance [Mood, Graybill and Boes, 1974]
mean = —- — for n > 2 , 
n - 2
2n2(m + n - 2 ) _variance =     for n > 4.
m ( n - 2 ) 2( n - 4 )
Therefore, for an F-test on m=2 and n=96 degrees o f freedom the expected mean and 
variance are 1.021 and 1.088 respectively. The mean and variance of the simulated F 
values were 1.687 and 1.405, 65% and 30% bigger than expected. Thus, the probability 
plot and the deviation from the expected mean and variance suggests that asymptotic 
theory cannot be applied to the F-test.
6.5.4.4. Testing fo r  a Regression Change when the Change-Point is Unknown - 
Bootstrapping
The F-test mentioned previously relies on assumptions regarding the distribution o f the 
parameters. It is these assumptions, which caused the tests to fail. Efron and Gong 
[1983] proposed non-parametric bootstrap methods to overcome problems when using 
parametric tests. Bootstrap methods have been recommended for linear regression 
analysis [Bunke and Droge, 1984; Wu, 1986] and the extension o f linear regression, 
change-point regression, [Hinkley, 1988; Julious, 2001] as well as a situation analogous 
to change-point regression, mean shift models [Hinkley and Schechtman, 1987].
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The methodology in applying bootstrap methods to the change-point problem is quite
straightforward:
1. For a given set o f data obtain the best-fitting two-line and one-line models and 
calculate the F-statistic
2. Calculate the residuals for the two-line case.
3. Using the original x values, recalculate the new y values, by using the values from 
the best fitting one-line model and adding an error term, sampled with replacement 
from the set o f residuals from the best fitting two-line model.
4. To this new set of data, fit a two-line and a one-line model and calculate the F- 
statistic.
5. Repeat steps 3 and 4 a large number o f times, each time using the one-line 
parameters and two-line residuals from the original data.
A bootstrap distribution for the F-test can be derived and a P-value can thus be
calculated. The methodology is quite computer intensive although the algorithm in
Figure 6.4 speeds up the estimation of the parameters.
6.5.4.5. Simulation Assessment o f  Bootstrapping
To investigate the properties of the bootstrap for the change-point regression problem a 
simulation exercise was undertaken. Simulated results were again generated using the 
Interactive Matrix Language (IML) in SAS (SAS Institute, 1985).
Simulations were initially undertaken to investigate the influence of the location o f a 
change-point on the x-axis on the power o f a test for various changes in slope. The data 
were simulated for regression changes at all the points along the x-axis from X2 to X49 on 
a fifty-point scale. A hundred simulations were carried out for each point on the x-axis 
to estimate the empirical power. For each simulation a bootstrap distribution o f 100 
points was generated and a bootstrap significance level of 5% was chosen (thus 
48x100x100 simulations were done). Figure 6.6 gives the empirical power from the 
simulations of regression changes at various points along the x-axis, for various values 
of a standardised difference d, where d is defined as d = (P rP 2)/a, i.e. the difference in 
slopes before and after the change-point, standardised by dividing by a, the standard 
deviation about the two-line model. The lines are jagged due to the noise in the 
simulations. The power is greatest for a change-point near the centre of the x-axis and 
falls towards each end of the range. The power also increases with increasing sizes of 
the standardised difference, d. The implication of these results is that when designing a 
study to investigate a possible regression change, if possible, it should be ensured that 
there are the same number o f points before as after the change-point, to guarantee the 
appropriate power.
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Figure 6-6. Plot of Empirical Power against Location of Regression Change for
Various Slope Differences
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An equivalent simulation was undertaken to assess the effect the number o f points in the 
regression analysis had on the power. Data were simulated for regression changes at the 
mid-point along the x-axis for different numbers o f points in the regression (from 10 to 
50) for various standardised differences, d. A hundred simulations were carried out for 
each number o f points to estimate the empirical power. For each simulation a bootstrap 
distribution o f 100 points was generated and a bootstrap significance level o f 5% was 
chosen (thus 40x100x100 simulations were done). Figure 6.7 gives the empirical power 
for a regression change for various numbers o f points. From these results it seems that 
for a large regression change at the midpoint o f the x-axis the number o f points required 
is quite small (14 for d=l at 80% power) with an increasing number o f points required 
for smaller standardised differences.
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Figure 6-7. Plot of empirical power against number of points in the regression
change for various slope differences
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6.5.4.6. Worked Example
The data for the worked example are given in Table 6.9 and are plotted in Figure 6.8. 
From observation of the data it seems that the variables increase over time and that there 
is some fluctuation due to random variation.
The best fitting single-line model with a Residual Sum Squares (RSS) o f 1.072 for 
Carbon Dioxide Exhaled ( Y j )  against Oxygen Inhaled ( X j )  is
Yj=-0.659+0.067Xi>
and the best fitting two-line model with a RSS o f 0.389 is 
Y j=0.076+0.042Xj 12.5 5X, 539.46,
Yj=-1.659+0.086Xi 39.46 5Xj 5351.8. (6.5.4)
The comparison o f the two- and one-line models gives an F-statistic o f 
[(1.072-0.389)/2]/[(0.389/31)]=27.21. If the statistic had an exact F-distribution it would 
be with 2 and 31 degrees of freedom. The bootstrap P-value (on 1000 simulations) is
0.001. The two-line model o f best fit is highlighted in Figure 6.8. Visual inspection of 
this figure gives the impression that this model well represents the data. Although there 
is more than a two-fold increase in the slope between the two halves o f the model, the 
standardised difference, at just 0.070 ((0.086-0.042)70.624), is quite small.
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Table 6-9. Data collated from measurements over time, volume of oxygen inhaled 
per minute (O millilitres per minute) and volume of carbon dioxide exhaled (C 02  
litres per minute)
Time
ordering
Volume of 
Oxygen(X)
Volume of Carbon 
Dioxide (Y)
1 12.5 0.75
2 26.2 1.12
3 24.8 0.98
4 27.4 1.13
5 31.1 1.31
6 34.6 1.47
7 21.5 0.93
8 27.9 1.34
9 29.2 1.36
10 35.2 1.60
11 32.6 1.47
12 34.9 1.57
13 34.9 1.59
14 37.6 1.73
15 36.3 1.68
16 40.1 1.88
17 42.7 2.01
18 43.4 2.07
19 44.2 2.12
20 47.9 2.35
21 49.9 2.50
22 48.1 2.48
23 48.4 2.49
24 51.7 2.71
25 51.8 2.74
26 55.5 3.00
27 54.9 3.02
28 57.0 3.21
29 57.9 3.30
30 58.3 3.37
31 58.2 3.42
32 59.5 3.53
33 59.7 3.55
34 61.8 3.76
35 48.4 2.96
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Figure 6-8. Plot of volume of carbon dioxide exhaled (C 02  litres per minute) 
against volume of oxygen inhaled per minute (O millilitres per minute)
There is thus strong evidence to suggest that the linear relationship between the amount 
o f carbon dioxide exhaled and oxygen inhaled changes once the amount o f oxygen 
exceeds about 39 millilitres per minute.
6.5.5. Summary of Computer Intensive Methods
This case study highlighted the value compute intensive methods can add when 
designing study. They may allow one to interrogate both how to design and analyse a 
study.
The main theme o f this dissertation is the importance of investigating a priori a clinical 
trial's robustness to the assumptions made in its design. Computing intensive methods, 
such as simulation, can be a valuable tool in such assessments.
6.6. Individual Trials In C ontext w ith W ider C linical Plans
6.6.1. Introduction to Clinical Development Plans
No study is an island. In a pharmaceutical setting an individual study would form part 
o f a clinical development plan, which will incorporate a number of studies from Phase I, 
pharmacology studies, through to Phase III pivotal studies. Statisticians too often 
concentrate on optimising individual studies but the same principles to optimise 
individual studies, can be extended to optimise a clinical development plan.
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The following case study highlights how the application of decision sciences can 
optimise clinical plans [Julious and Swank, 2005]. The example given is a novel 
compound being developed for the acute treatment of stroke.
As with other sections in this chapter this example is not intended as a definitive review 
of the decision science methodologies but an indication o f how decision science can 
assist drug development. A more detailed exposition of the theoretical work available 
from other work [Enas and Anderson, 2001; Burman and Senn, 2003; Senn, 1997].
6.6.2. Case Study
A project team was established charged with the development of a novel compound for 
the treatment of acute stroke. Developing a stroke asset is viewed as being unusually 
risky as
1. Only one product for acute stroke had succeeded in making it to the market to date -  
acteplase [NINDS rt-PA Stroke Study Group, 1995]
2. The costs o f development were expected to be high relative to the commercial value.
The challenge presented to the project team was to put in place a development plan that 
optimised asset value whilst mitigating and controlling the risks.
6.6.2.1. Methodology
The team employed decision science techniques to create and objectively evaluate 
alternative different clinical development plans. The process was a team effort that 
required the committed involvement of representatives from marketing, project 
management, and clinical in addition to statistics. After alternative plans were framed, 
the team then evaluated the alternative plans using classic decision tree analysis 
[Clemen and Reilly, 2001]. The tree and the associated financial model used took into 
account differences in the probabilities of success for each stage of development, study 
costs, and launch dates.
A detailed exposition of the methodologies used in the decision analysis is beyond the 
scope of this dissertation. However, a brief description of the methodologies will be 
given.
6.6.2.2. Assessing the Value o f  the Asset fo r  Different Plans
Expected net present value is the probability weighted average of the net present values 
(NPV) of all the possible development outcomes [Clemen and Reilly, 2001]. Net 
present value is the total (net) value of current and future costs and revenue expressed in
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today's (present) currency. It is quite a common term used in the evaluation of assets 
(not just pharmaceutical) and is in fact a function in SAS.
The criteria for evaluation of the different clinical development plans are intertwined. 
For example, launch date can be important in its own right, but it also significantly 
impacts the value o f a successful drug, and hence, significantly impacts eNPV.
6.6.2.3. Assessing the Probabilities o f  Success fo r  Different Plans
A somewhat non-traditional approach was taken to obtain the probabilities of success 
assessments required for the decision tree. This approach allows for more accurate 
comparison of alternative development plans and makes it easier to incorporate 
statistical information about the ability of studies to distinguish between a successful 
and unsuccessful drug candidate. The process involves first assessing the team's 
confidence (expressed as a probability) that the drug will truly meet the safety and 
efficacy targets for success. This probability is the same for all the alternative 
development plans. Once the probability that the drug will really work has been 
assessed, the team then assesses the probability that each phase in the alternative clinical 
development plans will correctly indicate the drug works (sensitivity) or does not work 
(specificity).
Figure 6-9. Example of probability of success calculations
Confidence of
S u c c e s s  P hase Outcom e Go No Go
0.850G o
0.300S u ccess
Nln On \  0-150
0.700G o
0.700Failu re
N o G o  |  0 300
< 3  0.255
P robability  of "Go" from  p h ase  stud ies=  
Probability  of "No Go" from  p h ase  stud ies=  
R ev ised  c on fidence  of su ccess  P (G |S ) /P (G )=
0.490
0.045
0.210
Tru e
S uccess
F a lse
N eg ative
F a lse
Positive
T ru e
Fa ilu re
0.745
0.342
0.255
Figure 6.9 illustrates an example of the approach used to assess the probabilities of 
success for just one single phase’s outcomes in a clinical development plan. In this 
example, the team's confidence the drug will really work is 0.300. The probability that 
the studies in this phase o f development will correctly indicate "Go" to the next phase of
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development when the drug really works was assessed at 0.850. The probability o f a 
“false negative” from this phase of development is, therefore, 0.150. The probability 
that the studies in this phase of will correctly indicate "No Go" when the drug does not 
work is 0.300. The probability o f a “false positive” for this phase o f development is, 
therefore, 0.700. These probabilities might be typical o f a Phase IIA or IIB study. The 
probability o f success for each stage o f development is then calculated as illustrated in 
the Figure 6.9. The probability o f success ("Go" Outcome) is 0.745 (sum of true 
success and false positives).
The revised (or posterior) confidence o f success is calculated through the use o f Bayes' 
Theorem as 0.342 (0.255/0.745), a slight increase from the confidence o f success prior 
to this study. This confidence o f success would be the starting point for calculating the 
probability of success for the next phase o f development.
6.6.3. Evaluation of the Clinical Development Plans
The team considered over 20 different alternative clinical development plans before 
selecting the most attractive options. So many plans were evaluated in fact that the tool 
the team was using had to be expanded to allow us to further evaluate alternatives. In 
truth though most of these plans were variations of three themes. However, there was 
not a clear and distinct trichotomy o f plans with the team working to accentuate the 
strengths and to mitigate the weaknesses of individual plans. Decision Science 
techniques then assisted in assessing the impact of any changes.
It took a great deal of time for the team to come up with the inputs for the first few 
plans. However, the decision tree format for the output allowed for easy interpretation 
o f the results. Before long the team was using the tools in real time to explore "what 
ifs" to see how changes in the plan would impact value, hence the number of 
development plans.
The focus now will be on three representative plans. Plan A is a development plan that 
utilises limited Phase II studies before starting two large Phase III studies.
Plan B utilises a powered imaging study in Phase II prior to the Phase III studies to 
reduce the risk of Phase III failure. Finally, Plan C uses an adaptive Phase II/Phase III 
study to reduce risk and speed development. Details of each of the plans follow. The 
actual numbers given in the case study have been changed to protect the innocent.
6.6.3.1. Plan A - Limited Phase II
This clinical development plan, excluding the Phase I enabling studies, consisted of two 
Phase II studies conducted sequentially followed by two Phase III studies conducted in 
parallel. The plan was of the form:
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Phase IIA -  A relatively small dose escalation safety study where the asset would be 
administered for the first time to stroke patients to establish a target dose. The team did 
not expect the drug to fail this study.
Phase IIB - A study primarily focussed with establishing a safety database at the chosen 
dose. Some preliminary efficacy data would also be obtained although the study would 
not be powered for this objective. Again, because o f the study design and the expected 
"go/no go" criteria, the team expected the drug to succeed in this study.
Phase III - Two pivotal studies to assess the efficacy of the asset in a stroke population.
The rationale for this development plan was that it speeded up the entry of the asset into 
Phase III. This was considered desirable, as it is only in Phase III that an asset can 
"truly" be assessed. By design, this development plan has the lowest probability o f a 
false negative. However, it has a high probability o f an expensive Phase III failure.
Figure 6-10. Results of decision analysis for Plan A -limited Phase II
Figure 6.10 gives the decision tree analysis for Plan A. The probabilities in the figure 
were calculated using Bayesian methods described in section 6.6.2. The probabilities 
come from the team’s confidence the compound will work in conjunction with the 
team’s assessment of the sensitivities and specificities of the individual studies. The 
comparison o f the different plans will be made in section 6.6.3.4.
6.6.3.2. Plan B - Powered Imaging Assessment in Phase II
Phase IIA -  same as Plan A except more patients would be included in the IIA study to 
allow for better decision making prior to the start o f Phase IIB. The probability of 
success from this study was slightly lower than the Phase IIA study in Plan A because 
o f the higher number o f patients enrolled.
Phase IIB -  a study powered to assess the effect o f the asset in reducing stroke infarct 
volume assessed through imaging. When designing the study, the team had choices 
about what "go/no go" criteria to use for this study. The team chose a "go/no go"
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criteria that was designed to minimise the probability o f a false positive (progressing a 
drug that will fail in Phase III). Thus, a high "Go" hurdle was set for this study. 
However, this had the impact of increasing the probability o f a false negative 
(terminating a drug that works). During the actual analysis, a sensitivity analysis was 
done to determine the impact o f different "go/no go" choices on the balance o f false 
negative and positives from this study.
Phase III -  The team postulated that the PIIB powered imaging study could be pivotal 
such that only one PIII pivotal trial would then be required. This possibility was 
allowed for in the assessment o f costings etc. The sensitivity of the eNPV to this 
assumption was explored separately. The probability of success for Phase III was 
higher in this plan than in Plan A because of the risk removed by the Phase IIB imaging 
study.
The rationale for this development plan was that it mitigated the risk for late phase 
failure through assessing the asset using a surrogate in IIB -  imaging. In the context of 
the clinical development plan this imaging study would be relatively small (requiring a 
fraction of the sample size of a Phase III study) although it would relatively slow in 
recruiting.
Figure 6-11. Results of decision analysis for Plan B 
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Figure 6.11 gives the decision tree analysis for Plan B. The NPV for success is much 
lower in Plan B because it was expected the launch date would be approximately 12 
months after the launch date in Plan A.
6.6.3.3. Plan C -  Adaptive Phase I IB/I I  I Study
Phase IIB/III -  An adaptive study design initially starting with two active doses (which 
may be altered at pre-specified interim analyses) and placebo before one dose is 
selected to enable the study to continue enrolment with this dose powered against 
placebo. The interim analysis where the dose was selected would be considered to be 
IIB.
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Phase III - A second pivotal study would start dependent on the IIB/III study. It would 
start early if  the interim analysis when the dose was selected was sufficiently 
encouraging (interim analyses to be undertaken independent of the sponsor with the 
sponsor remaining blind to the results). Otherwise the decision to start second Phase III 
would be made once the IIB/III study completes.
The rationale for this development plan was that it both allowed for a dose ranging 
assessment (which it was felt would reduce late phase risk) and an assessment in IIB of 
efficacy using the same outcomes as used in Phase III. It was felt also that the risk 
would be spread more evenly across Phase II and III.
Figure 6-12. Results of decision analysis for Plan C - an adaptive Phase Ilb/III 
Study
0.070
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Figure 6 .12 gives the decision tree analysis for Plan C. The value of success depends 
on the path taken to success. If the results from the PIIB/PIII are positive enough to 
justify starting the second PIII early, the drug can launch approximately 3 months 
earlier than in Plan A. However, if we must wait for the entire PIIB/PIII to complete 
before starting the second PIII, the launeh date is approximately 4 months later than 
Plan A.
6.6.3.4. Results o f  the Evaluation
Table 6.10 and Figures 6.10-6.12 summarise the results o f the decision analysis. Some 
figures in the table have not been previously introduced. “Probability False Negative” 
is simply the difference between the team ’s confidence (probability) the drug actually 
works (0.300) less the overall probability o f success divided by the team ’s confidence
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the drug actually works. “Relative Launch Month” is the expected launch date relative 
to Plan A. Plan C has a range o f “Relative Launch Dates” depending on the likelihood 
the second pivotal study is started at the completion o f PIIB or waits until after the end 
o f PIIB/PIII. “eCost” is the probability weighted average (expected) development cost 
for each plan.
Table 6-10. Summary of clinical development plans
Plan
A B C
Limited Pll
P h ase  II 
Imaging
Adaptive
PIIB/III
Probabilities of S u c c e ss
PI IA 0.883 0.845 0.883
PIIB 0.831 0.201 0.411
PIII 0 .228 0.520 0 .516
Overall 0 .167 0 .088 0.187
Summary of Plans
Probability PIII Failure 0.566 0.082 0 .176
Probability False Negative 0.345 0.654 0.267
Relative Launch Month 0 +13 -3 to +4
NPV given su c c e ss £300M £224M £303M
eNPV £36M £ 1 1M £45M
eC ost £19M £10M £16M
Based on the results of the analysis the team chose Plan C as the best plan. It has the 
highest expected net present value (eNPV) by over £9M, a significant amount for a 
project this early in development. It also has the highest overall probability o f success 
(nearly twice that of Plan B), the potential for the earliest launch (which significantly 
impacts eNPV), and a reasonable expected development cost (eCost) when compared 
with the alternatives. Plan B would have had a lower eNPV and higher eCost if  we had 
assume the powered PIIB imaging study could not be pivotal.
The most surprising result for the team was how poor Plan B appeared to be for this 
particular asset. Prior to the decision analysis, this plan had been the plan preferred by 
the team. Indeed Plan B may still be optimal for other assets but there were issues 
particular to this asset not covered in this dissertation, which impacted on Plan B (hence 
the high hurdle etc). However, in Plan B, it was felt by the team in this instance that 
there was a high probability (approximately 0.25) that a "no go" might actually have 
terminated a valuable therapy. In addition, the study was not a particularly “fast” nor 
“cheap” kill because of the difficulties associated with enrolling patients in an 
adequately powered study.
Before settling on its final recommended plan, the team performed a sensitivity analysis 
to confirm the robustness of the recommendation. The quality o f the subjective 
probabilities assessed by the project team is always a worry. In truth there is a degree of 
"rubbish in, rubbish out" here. If the initial assessments are off the mark then so will be 
the different probabilities. However, the team felt relatively comfortable comparing the
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assessments across the plans and thus, although the probability values may be off the 
team was confident o f the relative ordering. When the team completed their sensitivity 
analysis, they found that Plan C was robust.
6.6.3.5. Where Should Statisticians Focus to Optimise Value
It is clear that the process for optimising clinical development plans described above 
offers a number o f key areas where statisticians can facilitate the process and help 
optimise project value.
E ndpoin t se lec tio n : Identifying the most appropriate endpoint is critical to ensure that 
objectives of individual studies, and consequently the clinical plan, are met. For this 
case study statisticians utilised literature and existing in-house data to assist in the 
selection of the most appropriate endpoint(s) for the Phase III studies [Duncan, Lai, 
Bode et al, 2003; Khandker and Julious, 2003]. In a similar manner, they were able to 
provide additional insights on the use o f the powered imaging study utilised in Plan B.
S tudy  design: Individual study designs must be evaluated within the context o f the 
overall development plan. In the case study described, the statisticians on the team 
introduced the concept adaptive designs to be used in Plan C to spread the risk more 
evenly.
B udgetary  C onsidera tions and  Im plica tions: Selection of endpoints and design impacts 
on sample size, which in turns impacts on budgets and timelines. Statisticians need to 
design all the facets of an individual development plan to assist in assessing its 
budgetary and time implications. In the adaptive design proposed in Plan C, the 
statistician also helped the team understand how many additional patients might be 
enrolled before the results from the interim are available to determine if an adaptive 
design would be feasible and practical.
A ssess in g  Innova tive  Technologies: When new technologies come to the fore, the entire 
team needs to determine the positive impact the new technologies would have. For the 
case study described, Bayesian Decision Theory (not covered in this chapter) was used, 
through the use of priors, to help the team choose appropriate futility and early Phase III 
starting rules for safety and efficacy endpoints within the adaptive study.
C om m unication  o f  C oncepts: Some of the probabilistic concepts used in Decision
Science maybe unfamiliar to certain members and would require clear explanation. 
This is a skill that statisticians will already have. For the case study statisticians 
enabled the team to determine meaningful probability assessments by illustrating the 
power of different studies to distinguish between successful and unsuccessful drugs.
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6.6.3.6. Summary o f Clinical Development Plans
In this section three different plans were discussed that were considered by the team: 
one which placed most of the risk in Phase III (Plan A); one which placed most o f the 
risk in Phase II (Plan B); and one which spread the risk more evenly (Plan C). It 
highlighted how in the context o f full clinical development plan no study is an island 
and how using decision sciences one can adjudicate on different options and, in this 
case study, give a rational for adaptive trial design methodologies over more 
conventional approaches.
In truth what is described in this chapter is not rocket science. However, what this 
decision sciences case study highlights is that "it ain't what you do it's the way that you 
do it" as a way to get optimal results. The process and comparisons walked through in 
this section were made as a consensus through optimal team working and information 
sharing. Through working as a team each development option was rationally assessed 
to come up with objective comparisons that formed the team decision.
Such decision science approaches can add considerable value to the drug development 
process.
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7 .  C H A P T E R  7  -  S U M M A R Y  A N D  C O N C L U S I O N S
This dissertation has reviewed the current situation with respect to sample size 
estimation for clinical trials. It has described the basic methodologies for sample size 
calculations for the most common types o f trial and extended these calculations to 
account for the imprecision in the estimates used in the calculations.
7.1. Background
In Chapter 1 of the background to randomised clinical trials along with the basic 
concepts for clinical trial design were described. The most common types o f clinical 
trials, i.e. those for superiority, equivalence, non-inferiority
7.2. Background
In Chapter 1 o f the background to randomised clinical trials along with the basic 
concepts for clinical trial design were described. The most common types o f clinical 
trials, i.e. those for superiority, equivalence, non-inferiority, bioequivalence and 
precision, were introduced and it was highlighted how the different null and alternative 
hypotheses impact on the calculations. The chapter then went on to explain the 
limitations of the conventional calculations and how, through a real world worked 
example, these limitations can have a severe impact on the design of a study. The 
concepts o f sensitivity analysis and allowing for the imprecision of the estimates used in 
the calculations were first described.
The background to clinical trials given in this chapter was published [Julious and 
Zariffa, 2002] as well as the description of the different types of trial [Julious, 2004a] 
and the rational for trials based on precision [Julious and Patterson, 2004]. For the latter 
also the use of confidence intervals around individual means to interpret statistical 
significance between means has also been published [Julious, 2004c]. The concepts of 
sensitivity analysis and allowing for uncertainty o f the estimates used in the trial have 
been published [Julious, 2004b] and presented twice at conferences at plenary invited 
sessions [Julious, 2001, 2002].
7.3. Norm al data
In Chapter 2 standard calculations for data anticipated to take a Normal form were 
given. It was highlighted that the assumption that the variance used in the sample size 
calculation is the population variance and not a sample variance was a major 
assumption. The calculations for assessing the sensitivity of a trial to assumptions 
about the variance were given. Recommendations were also provided on obtaining the 
most relevant variance estimate, pertinent to the study being designed, and the
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methodology was given to combine different variance estimates across several studies 
to get an optimal variance estimate.
A new sample size formula was given which allows for the degrees of freedom of the 
sample variance estimate when calculating the sample size. Initially this result was 
given for superiority trials. Inflation factors were provided which show the increase in 
sample size required for different levels of imprecision of the variance estimate (as 
assessed through its degrees of freedom) compared to standard calculations. If one has 
few degrees of freedom the inflation factors can be quite large -  30% for a study with 
90% power, 5% two sided significance level and 10 degrees o f freedom for the variance 
estimate -  although falls the with greater precision. The results were compared to 
simulations and shown to be in agreement. With 200 degrees o f freedom or more then 
it was shown that standard results can be used.
The chapter extended the work to other types o f study. For non-inferiority and 
equivalence studies Bayesian methods were also introduced for the situation where as 
well as imprecision in the variance, imprecision in the mean difference was o f interest.
For trials based around imprecision the work was compared to an alternative solution 
from Grieve [1991] and found to be comparable. Finally in this chapter the impact of 
covariates and repeat post dose measures on sample size estimation was assessed.
The standard calculations given in this chapter have appeared as a tutorial article 
[Julious, 2004a]. The work on investigating sensitivity have been presented at 
conference [Julious, 2001, 2002] and has been published [Julious, 2004b]. The solution 
that allows for the imprecision in the sample variance when estimating the sample size 
has been presented at conference [Julious, 2001, 2002] and is published [Julious and 
Owen, 2006]. Additionally the standard sample size calculations for precision-based 
trials have appeared [Julious and Patterson, 2004], as has a note on the impact of 
repeated post dose measures [Julious, 2000],
7.4. B inary Data
In Chapter 3 an overview of inference for binary data was given. A discussion was 
given as to the different types o f summary statistics that could be used for binary data. 
It was recommended that only odds-ratios and absolute differences be used to 
summarise a binary response - although it was highlighted that the odds-ratio had the 
better mathematical properties.
For the results of Chapter 2 to be generalised to binary data the distribution for the 
variance around the response should follow a chi-squared distribution. It was 
highlighted that this was only the case for large sample sizes, which prevented the 
results from Chapter 2 from being extended.
Chapter 4 described the standard calculations for sample size estimation. For cross-over 
trials it was demonstrated that when designing a trial the parallel group sample size
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methodology could be generalised to cross-over trials with the sample size per arm for a 
parallel group trial being used as the total sample size for a cross-over trial. It was also 
demonstrated that a treatment effect for a cross-over trial could be equated to a the 
treatment effect for a parallel group trial to assist in study design.
In addition for cross-over trials an assessment of the effect of period on sample size 
calculations was made. It was concluded that although possible period effects should be 
allowed for in any analysis their effect was small and so sample sizes could be 
calculated assuming there was no period effect.
For non-inferiority and equivalence studies a review of the standard calculations 
highlighted three quite different methods for calculations. A simulation was undertaken 
to compare the three approaches. From this work the it was recommended that simpler 
calculations [Machin, Campbell, Fayers et al, 1997] be used over the more complicated 
methodologies [Dunnett and Gent, 1977; Farrington and Manning, 1990; Miettinen and 
Nurminen, 1985; Koopman, 1984],
For binary data the factor that it was assumed to impact most on sample size calculation 
was a poorly estimated control response. A methodology was developed in Chapter 4 
that estimated the sample size required, accounting for the imprecision in the control 
response, using numerical methods. The numerical methods were then extended 
through the use of Bayesian methodologies. It was highlighted how simple Bayesian 
techniques can be used to add considerable value to the calculations - particularly for 
non-inferiority and equivalence studies.
Finally the chapter discussed how covariates and repeated post dose measures impacted 
on the sample size. It was highlighted that it was a fallacy that inclusion o f covariates 
increased sample sizes -  despite increasing the variance -  due to the factor their 
inclusion removed bias from the estimates. A bias that pulled the estimate o f treatment 
effect towards to the null hypothesis (assuming a superiority study is being designed).
The work discussing the merits of the number needed to treat [Julious, 2002b] and the 
work describing calculations for non-inferiority trials [Julious, 2004d] were both given 
at a conference. Notes on number needed to treat and on exact confidence interval 
calculations are published [2005b, 2005c]
7.5. Utility o f Bayesian M ethods
Throughout the dissertation, but in particular in Chapter 4, a mixed approach has been 
undertaken whereby Bayesian methods were used in the derivation of sample sizes for 
clinical trials where the intention was to undertake a classical frequentist analysis. The 
restriction o f using frequentist methods for the final analysis comes from the restriction 
o f the work being set in a regulatory pharmaceutical setting where as discussed in 
Chapter 1 quantification of effect is undertaken through P-values and confidence 
intervals.
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Given that the motivation of the PhD was to account for the imprecision o f previous 
observed estimates in the current sample size calculation an application it was logical to 
investigate possible Bayesian solutions. In the context o f the PhD these Bayesian 
methods were used as a methodology as opposed to philosophy and lent in particular to 
a solution to the problem of sample sizes for non-inferiority trials with a binary 
response where the investigators beliefs as to the anticipated control response differ to 
what has been seen empirically. Bayesian approaches allow for the combination of 
these prior beliefs with the observed data to form a posterior distribution to be used in a 
sample size calculation that allows for the imprecision of the estimates. In turn these 
simple Bayesian methods can be used to assess the sensitivity o f the calculations to the 
assumptions made both in terms o f the imprecision of estimates and also to one’s priors.
7.6. Ordinal Data
In Chapter 5 the sample size calculations for ordinal data were discussed. The context 
of the work was with respect to assessing quality of life o f treatments in clinical trials. 
The concentration of the chapter was on trials where an assessment o f treatment effect 
would be made through an odds-ratio through a proportional odds assumption 
[Whitehead, 1993].
Similarly to binary data it was demonstrated empirically that the variance around a log- 
odds-ratio does not follow a chi-squared distribution. Hence, the methodologies 
introduced in Chapter 2 could not be extended to ordinal data.
It was proposed in this chapter that bootstrapping be undertaken to both assess the 
sensitivity of the study to assumptions about the variance and to estimate sample size 
estimates accounting for imprecision in the estimate o f the variance.
As with binary data it was highlighted for cross-over trials that it was possible to have 
estimates o f treatment effect that could be thought o f in terms of parallel group effects. 
However, unlike for binary data, the parallel group methodology could not be extended 
to cross-over trials as there would be an underestimation of the sample size. The more 
complicated results were instead recommended to be used.
Although sample size methodologies were given in this chapter for trials where the 
objective was to assess non-inferiority or equivalence trials it was recommended that 
ordinal scales be dichotomised and binary methodologies be used. The reason for this is 
due to the conservative nature of these trials and which hence would require a 
conservative hurdle to demonstrate the primary objectives.
7.7. Issues A ssociated w ith C linical Trials
In Chapter 6 issues associated with clinical trials pertinent to the dissertation were 
discussed.
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The dissertation has talked of issues associated with designing a trial when one has 
imprecise estimates and how this impacts on the sample size calculations. In Chapter 6 
it was highlighted that if up front one believes the estimates to be poor then one solution 
could be to be adaptive in the prospectively planned trial. The adaptive design 
methodology was described through an applied case study.
It was also highlighted in the discussion on adaptive designs how the Normal data 
methodologies described in the dissertation to allow for the imprecision in the sample 
variance could be extended to provide sample size estimates in an interim analysis of a 
clinical trial.
The discussion as to the use of adaptive designs has been published [Julious, 2004b] and 
has been presented twice at conferences [Julious, 2001, 2002]. The result on extending 
the work in the dissertation to interim analyses has appeared as a note [Julious, 2004e].
Through the dissertation discussion has been made around the issues associated with 
designing a clinical trial based on estimates in a preceding trial. The assumption 
throughout has been that and study-to-study variation was purely random. However, 
there may be instances when the study-to-study is not random but is due to 
heteroscadicity of clinical trials. In Chapter 6 there was some discussion on this issue 
and a case study was given where possible heteroscadicity was explored. In truth the 
issues around heteroscadicity are complex with discussion appropriate on a case-by-case 
basis. This will be discussed again in the later section on areas for further work.
Chapter 6 then discussed the issue of designing a trial with an innovative or novel 
endpoint. The assumption in the dissertation has been that although you have imprecise 
estimates you at least know what clinically meaningful difference to design the study 
around. This chapter discussed the situation where the clinically meaningful difference 
is not known due to the fact a novel or surrogate endpoint is being used. The chapter 
described how an effect size could be estimated through its association with a 
previously used endpoint, which has known treatment effects. The work was illustrated 
through a case study from the stroke therapeutic area. This work was presented at a 
conference [Julious and Khandker, 2003].
Although numerical methods and simulation have been used throughout the dissertation 
these were used in conjunction with or to complement distributional approaches. For 
example in Chapter 2 simulations were performed to confirm the result accounting for 
the imprecision of the variance and in Chapter 4 numerical methods were used to 
estimate the sample size allowing for the imprecision in the control response but for 
each percentile used in the numerical integration the power was calculated using 
Normal approximation. Chapter 6 discussed how a design and analysis maybe 
performed if no asymptotic assumptions could be made, such that the final analysis 
would be performed through bootstrapping. The work was illustrated through a case 
study where a change-point regression was the planned analysis in a pharmacology 
study. This work has been published [Julious, 2001].
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Finally, Chapter 6 discussed the issues where instead of considering optimising an 
individual study; one is considering optimising a series o f studies put together into a 
clinical development plan. It was highlighted how simple statistical concepts such as 
false positive and false negatives, used regularly in individual trials, can be generalised 
when working to optimise a clinical plan. It was highlighted how these concepts can be 
framed through elementary decision science techniques. The work was highlighted 
through a case study for a stroke compound and is due to be published [Julious and 
Swank, 2005].
7.8. Areas for Further W ork
7.8.1. Survival Data
In this dissertation methodologies have been described where the primary endpoint was 
anticipated to take a Normal form; be binary or be ordinal. Survival type data are 
common primary endpoints in trials concerned with the survival experience o f the 
patients. Usually this survival experience is expressed in terms of survival status (e.g. 
alive or dead; recurred or recurrence free) and survival time (time to death; time to 
recurrence).
If the event of interest was observ ed in all subjects then the analysis, and hence design, 
would be relatively straightforward with a continuous primary endpoint with continuous 
methodologies applicable. However, studies usually finish some fixed time after start 
o f study (e.g. 1 year) such that the event of interest is not observed in all subjects. The 
effect of this is that applying conventional methods for continuous endpoints would 
ignore subjects in whom the event was not observed.
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Figure 7-1. Graphical Illustration of Survival Data.
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Conversely if the data was treated as binary with the primary analysis based on a 
comparison o f survival status by treatment time would be ignored. A survival analysis 
therefore accounts for the survival experience o f subjects not just by investigating 
whether or not the event o f interest has been observed in subjects but also the time to 
this event. Subjects where the event has not observed (the study may have stopped 
before the event was observed or subjects may have left before the end but not due to 
the defined endpoint), are treated as censored with the last observed value used in the 
analysis. Figure 7-1 gives a graphical illustration of survival described through a 
Kaplan-Meier plot [Collett, 1994].
A discussion o f the generalisation of the results o f the dissertation to studies where a 
survival endpoint feeds into the primary analysis will now be made. The emphasis will 
be on parallel group superiority trials although the methodologies can be extended to 
other designs and objectives.
A survival analysis, and hence the design o f studies where there will be a survival 
analysis, depends on whether the event o f interest is negative (e.g. death) where a 
proportional hazards approach will be applied or positive (e.g. cure) where an 
accelerated failure time approach will be applied. A series of papers by Bradbum, 
Clark, Love and Altman [Bradbum, Clark, Love and Altman, 2003a; Bradbum, Clark, 
Love and Altman, 2003b; Clark, Bradbum, Love and Altman, 2003] provide a 
comprehensive introduction to the analysis o f time-to-event data in the context o f cancer 
trials. They include a discussion of the relative merits o f the proportional hazards and 
accelerated failure time model types.
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7. 8.1.1. Event o f Primary Endpoint is Negative
Suppose the event of interest is a negative: such as death or recurrence such that the 
primary objective o f the trial is to delay the event of happening. The primary analysis 
for such a response would be a log-rank test [Collett, 1994]. Now suppose the survival 
distributions for the two arms o f the trial have instantaneous death rates o f A.a for 
treatment A and XB for treatment B. Now from this the hazard ratio (HR) is defined as
where wA and 7Tb are two survival proportions at some fixed time point. An alternative
When calculating the sample sizes at the simplest level the calculations described in 
Chapter 4 for binary could be applied. However, this approach would ignore the 
survival times. A more plausible approach would be to use the methodologies in 
Chapter 2 for Normal data for the (probably logged) survival times. This approach 
would ignore the censored subjects meaning the sample size would be just for the 
number of events and not the total sample size. The issues allowing for the imprecision 
of estimates with these approaches are discussed in Chapters 2 and 4.
Alternative approaches are discussed in Machin, Campbell, Fayers and Pinol [1997]. 
Let T be the survival time random variable such that for treatment A one has
HR = XA/XB (7.7.1)
If the hazard ratio does not change with time then it can be estimated by
(7.7.2)
formula for the Hazard ratio is to derive it in terms o f the median survival terms for 
each treatment
log M A
(7.7.3)
where MA and Mb are the median survival times on A and B respectively.
7.8.1.2. Sample Size Calculations
7.8.1.3. Method 1 -  Assuming Exponential Survival
S{t) = P(T > t) = e A11, (7.7.4)
where XA is constant and does not change with t. From (7.7.4) one gets
Ma=\o%q2!Xa. (7.7.5)
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A similar result for Mb can be derived for where and hence from (7.7.3) the hazard 
ratio can be derived such that the number of events, E, required in each patient group is 
approximately
2(Z, +Z , „)2E  =---------- ------- . (7.7.6)
(log HR)'
Note (7.7.6) involves specifying the HR only. If HR was derived from a previous trial 
then its imprecision could be accounted for using numerical methods described in 
Chapter 4. Most likely though the effect size for log(HR) would take account o f other 
observed trials but would be based on judgment. The result (7.7.6) therefore does not 
use any imprecisely estimated responses.
7.8.1.4. Method 2: Proportional Hazards Only
An alternative for sample size estimation is one that assumes neither that the 
exponential survival or that ^ A(t) and XB(t) are constant over time, t. However, it does 
assume that there is a constant hazards ratio, HR=^A(t)/^B(t), over time, t, such that the 
number of events, E, required in each patient group is approximately [Machin, 
Campbell, Fayers and Pinol, 1997]
(///? + l )2(Z, a , +Z, J 2E = ----------— L (7. 7. 7)
2 ( H R - \ y
Note as with (7.7.6) this involves specifying HR only. As this approach makes fewer 
assumptions than (7.7.6) it will return slightly larger sample size estimates.
7.8.1.5. Total subjects
The results (7.7.6) and (7.7.7) give sample sizes for the number o f events that are 
independent o f the anticipated event rare in the trial. If these results were applied then 
the study would recruit to a specified number of events have been observed. There are 
obvious advantages to this approach. However, for planning purposes: for budgets; for 
timescales; an estimate o f the total sample size would also be required.
The total sample size, n, in each group can be approximated from [Machin, Campbell, 
Fayers and Pinol, 1997]
I F
 , (7.7.8)
^ 71A 71B
which as well as requiring the hazard ratio specifying also requires the anticipated 
response rates 7tA and ttb- From (7.7.2) (7.7.8) can be rewritten as
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2 E
n ~ 2 _ e " ^ * *  - nA ( 7 .7 .9)
The result (7.7.9) is similar to the problem as described in Chapter 4 for binary data. 
An estimate o f the anticipated response on one arm of the trial, tca, could be available 
from previous studies. Using the effect size the anticipated response for the other arm, 
tib, can hence be estimated. If nA was estimated imprecisely then the sensitivity o f the 
total sample size to this estimate could be assessed as in Chapter 2 and a sample size 
calculated allowing for this imprecision.
7.8.1.6. Event o f Primary Endpoint is Positive
In a survival analysis sometimes the objective is to speed the event up (if the event is 
good). Positive events that could be investigated include: time to cure; time to 
remission or time to target level.
Keene [2002] describes a trial where the primary objective was time to alleviation of 
symptoms in an influenza trial. Figure 7.2 gives a Kaplan Meier plot from this trial. 
For these data the actual event rate by the end of the trial was the same for both 
treatments but one treatment had a faster onset o f action. For trials where the objective 
is to speed time to event up the primary analysis would be a Generalised Wilcoxon Test 
[Collett, 1994].
Figure 7-2. Time to alleviation of symptoms.
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For the data summarised in Figure 7.2 Keene presented the results as median survival 
times, which were 6.0 days for placebo and 4.5 for active. These equated to a median 
reduction o f 1.5 days with corresponding confidence intervals (calculated through 
bootstrapping) o f 0.5 to 2.5.
An alternative approach would be to model the data through an accelerated failure time 
model, an approach applied by different authors for similar data [Patel, Kay and Rowell, 
2006]. For data from Keene if they were expressed in terms o f “acceleration factors” 
which are equivalent to median ratios then the estimate o f effect would be 4.5/6.0=0.75. 
The performance of different AFT models is also evaluated in a series of examples by 
Kwang and Hutton [2003].
7.8.1.7. Sample Size Calculations
For data where the objective is to speed time to event there is no unique solution. If one 
has pre-existing data one could remove the censored subjects and applying the 
following methods
The method Whitehead [1993] as described in Chapter 5. The methodologies in 
Chapter 5 could also be applied to investigate the sensitivity o f the trial to the estimates 
used and also to allow for the imprecision of the estimates. The disadvantage o f this 
approach is that the calculations depend on defining an odds-ratio which is not how the 
data will be analysed.
The method of Noether [1987] as briefly discussed in Chapter 5. For continuous data it 
has the advantage of method of being distribution free, although it does not have too 
easily interpretable estimates of treatment effect. For discrete data, which often survival 
data are in trials as subjects are assessed at fixed times; there can be limitations to the 
method.
Probably the best method, and certainly the simplest, would be to log the survival times 
and assume the data take a Normal. The results from Chapter 2 could then be applied.
If there is a need to account for censoring in the sample size calculation then 
bootstrapping could be considered as an approach. This was discussed briefly in 
Chapter 6 and was used to assess sensitivity o f the calculations in Chapter 5. The main 
advantage of this approach is that the sample size calculation may more accurately 
reflect the analysis. This approach should also be applied if bootstrapping is to be done 
in the analysis.
On a case by case level it may be optimal to use one o f the methods, depending on the 
study, and then use another approach or two to interrogate the robustness o f the sample 
size estimate
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7.9. C luster R andom ised Trials
In the dissertation there has been a focus on pharmaceutical based regulatory trials. In 
such trials subjects are randomised at the individual level to receive treatment. For 
health technology assessments it may not always be possible to randomise at the 
individual level due to pragmatic considerations. Instead subjects are randomised at the 
level o f hospital; primary care practice or practitioner level that the trial is cluster 
randomised.
Cluster randomised trials are therefore experiments in which intact social units rather 
than independent individuals are randomly allocated to intervention groups. Examples 
include: communities selected as the experimental unit in trials evaluating mass 
education programs; schools selected as the experimental unit in trials evaluating 
smoking prevention programs and families selected as the experimental unit in trials 
evaluating the efficacy of dietary interventions.
The reasons for adopting a cluster randomisation include administrative convenience; to 
enhance subject compliance and to avoid treatment group contamination. The latter is 
o f particular importance as if say an education initiative was being given in a primary 
care setting it may not be feasible to give the intervention to one subject without subject 
another also being exposed. Also, if it is at the practitioner level that the intervention is 
being applied then it may not then be possible to individually randomise subjects and so 
a cluster randomisation is applied. Clustering is also an issue even in individually 
randomised trials where the subjects are randomised, say, to a surgical technique or to 
an intervention such as acupuncture. Subjects may be individually randomised but due 
to the finite number of practitioners there is in fact clustering. This is particularly an 
issue where only one arm as the cluster. Even in the pharmaceutical setting there may 
be a degree o f clustering. If a trial had a central randomisation (i.e. not stratified by 
centre) but had a large number of centres relative to subjects there may be centres where 
subjects receive just one treatment and hence clustering.
There are disadvantages of cluster randomised trials particularly if there is a between 
cluster variation the presence o f which as the effect of reducing the effective sample 
size. The extent o f the problem depends on degree of within-cluster correlation and on 
average cluster size. There are a number o f possible reasons for between-cluster 
variation for example: subjects frequently select the clusters to which they belong e.g. 
patient characteristics could be related to age or sex differences among physicians; 
important covariates at the cluster level affect all individuals within the cluster in the 
same manner e.g. differences in temperature between nurseries may be related to 
infection rates; individuals within clusters frequently interact and. as a result, may 
respond similarly e.g. education strategies or therapies provided in a group setting and 
finally; a tendency of infectious diseases to spread more rapidly within than among 
families or communities.
A consequence of the issues associated with cluster randomised trials is that standard 
approaches for sample size estimation and statistical analysis do not apply as standard 
sample size approaches would lead to an underpowered study and applying standard
355
statistical methods would generally tend to biased liberal -values i.e. could lead to 
spurious statistical significance. Cluster randomised trials also lead to the question of if  
you have 1000 subjects in 10 clusters for the analysis do you have a sample size of 1000 
or 10? For a more complete discussion of issues associated with cluster randomised 
trials see Donner and Klar (2000) and Eldridge (2005).
7.9.1. Normal Data
7.9.1.1. Intra Cluster Correlation
An important consideration in designing cluster randomised clinical trials is the 
estimation of the intra-cluster correlation coefficient, g . In terms o f variance
components the overall response variance cr may be expressed as the sum of two 
components, i.e.
cr2 = a 2B+ a ; ,  (7.8.1)
where cr2B is defined as the between-cluster component of variance and cr2 as the 
within-cluster component of variance now
g =  , • ( 7 -8 . 2 ) .
a ~B +
Note that cr w = c f ( \ -Q .
7.9.1.2. Quantifying the Effect of Clustering
Consider a trial in which k clusters of size m are randomly assigned to each o f an 
experimental and control group. Also assume the response variable Y is Normally 
distributed with common variance a 2. The study is being designed as a superiority trial 
with the objective to test H0:|Ua=Pb-
Appropriate estimates of pA and pB are x 2 and x 2B the sample means which have the 
common variance
[1 + ( m - \ ) c ] c r 2
 ---------  — -, (7.8.3)
km
where g is the intra-cluster correlation coefficient (ICC), k is the number of clusters 
and m the sample size per cluster.
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7. 9.1.3. Sample Size Requirements for Cluster Randomised Designs
Suppose k clusters of size m are to be assigned to each o f two intervention groups. 
Recall from Chapter 2 under the Normal approximation assumption the sample size for 
an individually randomised trial can be estimated from
To account for the effect o f clustering the sample size for the number of subjects per 
intervention from (7.8.4) and (7.8.4) can be estimated from [Donner and Klar, 2000]
From taking the ratio of (7.8.5) over (7.8.4) an inflation factor (IF) can be estimated
to account for the cluster randomisation. Alternatively, in terms of clusters the sample 
size is estimate to be
Actually, the results from (7.8.5) and (7.8.4) and not too dissimilar. Remember in 
Chapter 2 discussion was made as to the effect o f covariates on the sample size such 
that if a single baseline was collected which was correlated with outcome by p  the
sample size could be estimated from
The result (7.8.8) is seldom used as for individually randomised trials a variance is used 
for sample size calculations from that is appropriate for the study being planned. In 
Chapter 1 a discussion was made as to how to assess the variance such that if  the 
design, population and analysis from the study it is taken are similar to the one being 
planned then (7.8.4) could be applied. Similar principles should be considered for 
cluster randomised trials as if variance estimates are from trial ostensibly similar to the 
trial being planned then (7.8.4) and the subsequent results in Chapter 2: to assess 
sensitivity and to account for imprecision, can be applied.
A more detailed discussed on estimation of the intra-cluster correlation will be made in 
the discussion of binary data.
d 2
(7.8.4)
n — (7.8.5)
d 2
(7.8.6).
k = (7.8.7)
m d2
n = (7.8.8)
357
7.9.2. Binary Data
It is less straightforward for binary data to allow for the imprecision in the intra-cluster 
correlation. Recall from Chapter 4 an estimate of the sample size when one has a binary 
response can be estimated from
where the main determining factor in the estimate o f the variance (and hence sample 
size) is the estimate of the control response rate tt4 which, with effect size fixed, 
determines the anticipated response on the investigative arm nB .
In comparison the sample size for a cluster randomised trial the sample size can be 
estimated from [Donner and Klar, 2000]
where now on has n A and the intra-cluster correlation £ influencing the sample size. A 
number of authors have discussed the impact the intra-cluster correlation has on the 
design and conduct of trials [Campell, 2000; Campbell and Grimshaw, 1998; Campbell, 
Grimshaw and Steen, 2000]. Pertinent to the problem of allowing for the imprecision of 
the estimated of the intra-class in the sample size calculation is the estimation of 
confidence interval. Methodologies include parametric and exact methodologies 
[Donner and Wells, 1986; Fisher, 1925; Swiger, Harvey, Everson et al, 1964; 
Ukoummunne, 2003; Turner, Omar and Thompson, 2006] through to non-parametric 
bootstrap [Uloummunee, Davison, Gulliford et al, 2003]. While Bayesian methods 
have also been discussed for interval estimation [Thompson, Warn and Turner, 2004; 
Turner, Omar and Thompson, 2006].
The imprecision of the estimate of the intra-class correlation and its impact on sample 
size calculations have been discussed by a number of authors with solutions 
recommended from numerical approaches [Turner, Prevost Thompson, 2004] through 
to Bayesian [Turner, Omar and Thompson, 2001; Turner, Prevost Thompson, 2004; 
Spieglehalter, 2001] through to simulation [Feng and Grizzle]. While, with approaches 
similar to those discussed in Chapter 6, Lake, Kammann and Klar [2002] suggested 
adaptive sample size re-estimation approaches as a solution to imprecisely estimated 
intra-correlation coefficients.
In context with the dissertation the problem now in hand is to allow for imprecision in 
both the control response zr, and the intra-cluster correlation £ (with fixed effect size
here). The solution in the context of this dissertation is o f the form
(7.8.9)
n = k < 0 - ”• . < ) + : + Zi / t f r  + (m - l ) £ ]
( *4 - KbY
(7.8.10)
\ - f i =
10000 )][("+ (m -  \)gr,„^  J
(7.8.11)
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where p (ranperc1)( is a random percentile for the estimated control response p A estimated
using methods discussed in Chapters 3 and 4 -  for example Wilson Score or Bayesian 
approaches. Likewise %ranperc-, is a separately estimated percentile for £ estimated using
an appropriate methodology. By calculating many iterations for the percentiles for p A 
and £ and taking the average one is effectively applying a numerical percentile method; 
forming a distribution for the variance (accounting for the imprecision in £ ) and then 
numerically integrating across this to obtain the power for a given n. To obtain n for a 
given power one would need to iterate on n to the required power is reached. If the 
solutions are unstable then one would need to increase the number o f permutations.
If p 4 and are correlated then (7.8.11) would not be appropriate. If one has actual 
individual data however one could bootstrap to obtain percentiles for the overall 
variance estimate [^ ( l  -  k a ) + /rfl(l -  7rB) \ z i_a + Zx_f^ f\[ + (m -  l)<j] and the
methodologies in Chapter 4 could be generalised. In fact this approach could be 
considered anyway for all trials where one has individual data.
7.9.3. Ordinal Data
The solution for ordinal data would be similar to that for binary data although as 
discussed in Chapter 5 bootstrapping may be required to obtain percentiles for the 
variance .
7.10. H eteroscadicity o f Trials
As highlighted earlier in this chapter one of the main assumptions that has been made in 
the development of methodologies in this dissertation is that any study-to-study 
variation is random and that, in terms of the variance say, any imprecision in the 
estimates is down purely due to insufficient degrees of freedom. However, there is 
reason to believe that study-to-study variability may not be random but due to trial 
heteroscadicity. There could be a number of possible sources o f heteroscadicity such as
The technology of trials improving the more experience gained in conducting trials in 
a given populations passes on learnings that enable better future trial conduct
The technology within trial improving - innovative endpoints when initially used may 
have greater variability than subsequent trials. An example here is imaging where but 
the tools of the trade and the technicians using the tools have improved -  in terms of 
repeatability and reliability -  over time
Trials being conducted in different populations -  different populations could be 
different demographic populations or different geographic regions. Different 
populations may equate to heterogeneous results.
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Protocol populations changing over time -  the most obvious aspect here is that 
concomitant therapies allowed within a trial change over time as health interventions 
and technologies improve. Hence, a subject on placebo may be receiving different 
adjunct therapies in a trial designed today than 5 years a go. A consequence o f this 
could be improved responses for subjects receiving placebo than previously would have 
been anticipated. This sometimes is referred to as placebo creep. There are also other 
factors that may also influence the heteroscadicity of trials.
An investigation as to likely heterogeneity should be undertaken prior to designing any 
trial, as any evidence of heteroscadicity would impact on the trial design. If there is 
evidence of heteroscadicity then the trial being planned would need to allow for it. 
Practically there would need to be an initial the sample size estimate -  based on the 
“best guess” for the variance, say -  but it would be a recommended that a sample size 
re-appraisal be then prospectively planned.
7.11. Contributions to C linical Research
This dissertation has highlighted a flaw in conventional sample size calculations in that 
standard calculations make an assumption that the estimates uses in the calculations, 
such as the variance, are really known population effects. The dissertation introduced 
results that allowed for the imprecision in the sample estimates when estimating the 
sample size. For Normal data a result using the non-central t-distribution was 
introduced whilst for binary and ordinal data results using numerical methods were 
introduced.
The application o f the results of the dissertation is that they provide they provide 
methodologies that allow for the imprecision in the estimates used in the sample size 
calculations. For Normal data tables of inflation factors are calculated for the main 
types of trial which can be used to inflate the sample size to allow for the imprecision in 
the variance used in the sample size calculations. For binary and ordinal data the 
dissertation provided solutions which are computer intensive but relatively 
straightforward.
When writing the sample size section for a new protocol using the methodologies from 
this t dissertation the assumptions made in the calculations should be clearly stated. A 
separate section should be included to investigate the sensitivity of the trial to these 
assumptions. Finally if the trial is sensitive to the assumptions actions, such as an 
adaptive design, should be described in the protocol to overcome these concerns.
While issues highlighted in this dissertation are particularly pertinent to innovative early 
phase clinical development, where, by definition, there is often little information 
available to design a trial the work can also be generalised to later development. For 
example a compound may be late in development but it may be going into a study 
where the primary endpoint is a novel one or alternatively but it could be going into a 
new patient population.
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The methodologies developed in the dissertation will allow a study to be designed to 
allow for any possible random uncertainty in the nuisance parameters as well as 
allowing an investigation into any assumptions made in the design o f the trial.
The work is currently being extended in particular in the area o f non-inferiority trials 
where the trials are particular sensitive to the estimates used in calculations. The 
sensitivity is compounded by the fact that for active controlled non-inferiority studies 
the comparison to placebo is at best indirect and at worst indirect and retrospective. It is 
not unknown over time for placebo response to increase over time and so any indirect 
comparisons would need to account for this placebo creep. In this context the prior 
beliefs above the control response could also incorporate the beliefs of the control 
response over placebo to help define non-inferiority margins in the design of the trials. 
This is important to protect the efficacy that is observed (or has the potential to be 
observed) in the current active control over placebo.
The work is further being considered outside o f pharmaceutical trials into health 
technology assessments such as in role replacement studies e.g. nurse practitioners 
replacing medical doctors particularly with binary responses. These are usually 
designed as non-inferiority trials but have the additional factor o f having to allow for 
the imprecisely estimated intra-cluster correlation and control response rates. 
Bootstrapping is being considered both to combine estimates across several studies for 
the intra-cluster correlation and for the numerical integration when estimating the 
power.
A final area o f extension is into there are of time to event data where the outcome is a 
positive event. A number of approaches are being considered for sample size 
calculations for example: Normal approximation; bootstrapping and Weibull each of 
which tie into the work undertaken in the dissertation.
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